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Summary.
Schizophrenia is a severe psychiatric disorder with a lifetime risk of about 1%. 
It affects almost all domains of mental function, including perception, emotion, 
cognition and social performance. Evidence from family, twin and adoption studies 
has shown the disorder to have a high genetic component.
The aetiology of schizophrenia remains obscure but over the last decade there 
has been increasing evidence that abnormal oligodendrocyte function and/or 
myelination might play a part. The main strands of evidence that provide support for 
this hypothesis have been compiled from neuropathological studies, brain imaging, 
symptom overlap with demyelinating diseases, age related changes in myelin and 
evidence from micro-array studies. In this thesis, I investigated several genes of 
importance to oligodendrocyte function and/or myelination as candidate genes for 
influencing susceptibility to schizophrenia. Genes were primarily selected for study 
based upon their reports of altered expression in micro-array studies of post-mortem 
schizophrenic brain. In many cases, their potential involvement was supported by 
positional evidence from linkage studies and a putative functional role in the 
neurobiology of schizophrenia.
In total thirteen genes were studied: CNP, NOGO, NgR, OMG, NGFR, GFAP, 
MOG, SOX 10 and APOL 1-5. During my studies I detected, modest evidence for 
association with three genes (CNP, NOGO and MOG). I also showed that the 
expression of these genes is under the influence of cis-acting polymorphisms. Whilst, 
the results for these genes are modest and require independent replication, they do 
provide some support for the general hypothesis that oligodendrocyte and/or 
myelination abnormalities play a role in schizophrenia aetiology.
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Chapter 1. General Introduction:
1.1 Schizophrenia -  General Description:
The concept o f ‘schizophrenia’ and the term itself emerged in the early 1900s, 
where it was first used by Eugen Bleuler in his book Dementia Praecox or the Group o f  
Schizophrenias (Bleuler 1911). His book followed the earlier work of Emil Kraepelin 
who had previously established a distinction between manic depressive insanity and what 
he called ‘dementia praecox’ (Kraepelin 1896). Bleuler, although agreeing with most of 
Kraepelins core symptoms (e.g hallucinations and delusions), instead saw the disorder as 
comprising a range of different conditions. The acceptance of this refined definition can 
be seen by the decline of the term ‘dementia praecox’ and the rise of the word 
‘schizophrenia’.
Schizophrenia is a common mental illness with a lifetime prevalence of about 1% 
(Jablensky 1997; McGrath, Saha et al. 2004). The typical age of disease onset is in 
adolescence or early adulthood (between 15 and 30 years of age), although in some cases, 
onset can occur in childhood or old age. The risk is the same for both sexes although the 
average age of onset for males is 3-4 years earlier than for females (Murray and Van Os 
1998). The incidence of disease has been shown to be similar across a range of different 
countries and cultures in both the developing and developed world (Jablensky, Sartorius 
et al. 1992). There are however pockets of populations where the risk of schizophrenia is 
higher, for example the Afro-Caribbean population in the UK (Sharpley, Hutchinson et 
al. 2001; Cantor-Graae and Selten 2005), the risk being greater for second generation 
rather than first generation migrants or the general UK population. This argues against a
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selective migration of people early in the course of disease and indicates a possible gene- 
environment interaction (Sharpley, Hutchinson et al. 2001; Cantor-Graae and Selten 
2005). There is also a higher incidence in urban compared to rural areas, with the risk 
increasing depending on the duration of urban dwelling as a child (Mortensen, Pedersen 
et al. 1999). There have also been other environmental factors associated with 
schizophrenia including: winter and spring birth, pregnancy and birth complications, 
delayed childhood development and cannabis use (Murray 2002).
Within the spectrum of psychiatric disorders schizophrenia is the most disabling 
and requires the highest level of support and intervention by the mental health services. 
For instance schizophrenia has been estimated to account for around 50% of admissions 
to psychiatric hospitals and schizophrenic patients occupy roughly 25% of psychiatric 
hospital beds (Mueser and McGurk 2004). The outcome for schizophrenia sufferers is 
variable even with treatment; some patients do well and appear to make a full recovery, 
but for most, the outcome is not so good and is typically one of repeated relapses 
requiring medication for the remainder of their lives and leading to lasting social and 
occupational impairment (Andreasen 1995).
Schizophrenia is characterised by a diverse group of symptoms affecting almost 
all domains of mental function, including disturbances of emotion, cognition and social 
performance. These symptoms vary between patients, creating very different patient 
profiles. The symptoms can include delusional beliefs, auditory hallucinations, catatonia, 
disorganised thought and speech patterns, apathy, blunted affect, cognitive impairment 
and social withdrawal. These symptoms generally lead to impaired functioning in work, 
school, self-sufficiency, interpersonal relationships and social interaction.
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Because the signs and symptoms of schizophrenia are so heterogeneous, efforts 
have been made to subdivide the disorder into broad categories. The most commonly 
used approach is to divide the symptoms into groups classed as ‘positive’ and ‘negative’. 
Positive symptoms present as a distortion or excess o f ‘normal’ function (e.g delusions 
and hallucinations). Negative symptoms are conceptually a deficit or loss of normal 
functions (e.g apathy, flattening of affect, poverty of speech and social withdrawal). In 
general the presence and severity of positive symptoms tend to be episodic over time, 
whereas negative symptoms are more pervasive fluctuating less over time and are 
therefore strongly associated with poor psychosocial functioning (Hafner 2003).
The lack of a known pathogenesis or biological marker of disease means that the 
diagnosis of schizophrenia is based entirely on clinical presentation. This has led to 
researchers questioning whether the disease could be diagnosed with enough reliability to 
be useful for genetic research. However, the use of structured and semi-structured 
interviews for the identification of symptoms and operational diagnostic systems does 
allow reliable diagnosis. The two major diagnostic systems currently in use are the Tenth 
Revision o f the International Classification o f Diseases (ICD-10) (WHO 1992), and the 
Diagnostic and Statistical Manual, Fourth edition (DSM-IV) (ASP 1994). Although both 
systems objectively define symptoms and characteristic impairments in similar ways, 
there are some important differences. The DSM-IV system requires evidence of social or 
occupational dysfunction (not included in ICD-10) and a 6-month duration of symptoms 
(versus a 1 month duration in ICD-10), thereby resulting in a narrower definition of the 
disease in the DSM-IV system (Andreasen 1995).
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1.2 Neurodevelopmental hypothesis of Schizophrenia:
The results of the various and diverse areas of research in schizophrenia, have led 
to the formulation of numerous theories about the biological origin of schizophrenia. 
However, over the past two decades schizophrenia has increasingly been viewed as a 
neurodevelopmental disorder. The ‘neurodevelopmental hypothesis’ proposes that 
schizophrenia is the result of abnormalities that occur in the brain during development; 
that the abnormalities occur before the onset of schizophrenic symptoms and are caused 
by a combination of genetic and environmental factors (Weinberger 1987).
Support for the hypothesis has been drawn from the imaging studies that have 
been performed in schizophrenia. The best replicated anatomic abnormality in 
schizophrenia revealed by different forms of imaging is that of lateral ventricular 
enlargement. Shenton and colleagues (Shenton, Dickey et al. 2001) reviewed the results 
of 193 MRI studies from 1988 to 2000 and reported that over 80% of the studies showed 
significant lateral ventricular enlargement in schizophrenia. The degree of enlargement in 
schizophrenics has been calculated to be around 30% on average with a slightly greater 
enlargement in male patients compared to females (Lawrie and Abukmeil 1998). Studies 
of other ventricle systems in the brain support a more general ventricular enlargement in 
schizophrenia. Shenton and colleagues (Shenton, Dickey et al. 2001) reported that 73% of 
the MRI studies they reviewed, that had studied the third ventricle showed enlargement 
of this region in schizophrenics. It should be noted that the range of ventricular size in 
schizophrenics, overlaps with the range in the normal population and thus the ventricular 
size of a particular schizophrenic patient may still fall within this normal range (Pearlson 
and Marsh 1999).
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In addition to ventricular abnormalities, MRI studies have also reported limbic 
and temporal lobe abnormalities in schizophrenia in the amygdala, hippocampus, 
parahippocampal gyrus and the superior temporal gyrus (Liddle 2003). There is some 
evidence of a general volume reduction in the temporal lobe in schizophrenia (Liddle 
2003). However, there is also evidence for more pronounced effects on specific regions 
within the temporal lobe. For instance of the MRI studies reviewed (Shenton, Dickey et 
al. 2001), 74% showed volume reductions in the medial temporal lobe structures, 
including the amygdala-hippocampal complex and parahippocampal gyrus.
Some studies have tried to assess the role of genetic and environmental factors in 
causing the brain abnormalities by studying discordant mono and dizygotic twins. These 
studies have shown reduced whole brain, parahippocampal and hippocampal volumes in 
affected twins regardless of the zygosity e.g (Suddath, Christison et al. 1990; Baare, van 
Oel et al. 2001), indicating the presence of an environmental contribution to these 
features. However, several studies have reported larger lateral and third ventricles and 
smaller temporal lobe volumes in the unaffected relatives of schizophrenic patients, 
compared to healthy matched control subjects from families without a history of 
schizophrenia (Lawrie, Whalley et al. 1999; Baare, van Oel et al. 2001). This would 
indicate that the brain abnormalities observed in schizophrenia appear to be determined at 
least in part by familial, possibly genetic factors.
The findings of ventricular enlargement and temporal lobe reductions may be 
explained by either a developmental or degenerative hypothesis. However, these brain 
abnormalities are observed in first episode patients before drug treatment, and before 
symptoms have been present for a significant length of time, arguing against the brain 
abnormalities being the result of illness progression or drug treatment and indicating they
are in some way related to the disease aetiology itself (Harrison 1999; Wong and Van Tol
2003) rather than being secondary effects of psychosis. Additionally, studies including 
longitudinal follow ups have shown that there is no correlation between ventricular 
enlargement and the progression of illness, a finding which would be expected if the 
pathological process responsible for the enlarged ventricles was degenerative and 
advanced during the course of the illness (Raz and Raz 1990; Jaskiw, Juliano et al. 1994), 
providing support for the neurodevelopmental hypothesis of schizophrenia. Although, it 
should be noted that two recent studies have demonstrated that ventricular enlargement is 
progressive during the very early stages of schizophrenia (Cahn, Hulshoff Pol et al. 2002; 
Ho, Andreasen et al. 2003).
A second source of support for the developmental hypothesis comes from 
neuropathological data. The search for the neuropathology of schizophrenia has been a 
major but elusive goal of biological psychiatry for over 100 years. However, within the 
last twenty years a number of more robust structural differences have been observed in 
the brains of schizophrenics. Post-mortem studies of schizophrenic brain have reported 
ventricular enlargement, brain weight and volume reductions (Brown, Colter et al. 1986), 
and decreased temporal lobe volume (Bogerts, Meertz et al. 1985; Bogerts, Falkai et al. 
1990), findings which have since been corroborated by more recent imaging studies. The 
changes have been shown to be present in first episode patients, meaning that the 
pathology cannot be explained as an artefact of chronic illness or drug treatment 
(Harrison 1999). The presence of reliable structural brain abnormalities in schizophrenia 
has encouraged further neuropathological research.
Some of the most reliable and important histological findings have been negative, 
and have been interpreted to indicate that the pathology of schizophrenia is not one of
brain degeneration. First there has been no evidence of lesions, tangles or plaques 
detected in schizophrenic brain, and secondly there has been no reliable evidence of 
gliosis being present in schizophrenia, all of which would have indicated the presence of 
a degenerative process (Harrison 1999). Consequently, in the absence of evidence for a 
degenerative process, to account for reduction in the size of brain structures, the 
pathology of schizophrenia has been assumed to be a neurodevelopmental process 
resulting from alterations in the normal maturation of the brain (Weinberger 1987). 
Additionally, the lack of gliosis has been used to predict that the developmental deficits 
in schizophrenia occur in the middle stages of gestation. This is because defects in 
development during early gestation (neurogenesis) would be expected to lead to major 
abnormalities of the cerebral cortex (a symptom not present in schizophrenia), whilst the 
lack of gliosis is interpreted to mean that the abnormalities in development must have 
occurred before the third trimester of pregnancy (Harrison 1999).
With the pathology of schizophrenia likely to be one of neurodevelopment, recent 
neuropathological research in schizophrenia has examined the cortical cytoarchitecture of 
the brain, focusing mainly on the limbic system especially the hippocampus and 
dorsolateral prefrontal cortex (DLPFC) (Harrison 1999). The findings have included 
neuronal disarray in the hippocampus of schizophrenics (Kovelman and Scheibel 1984; 
Conrad, Abebe et al. 1991), irregular neuronal clustering in the entorhinal cortex (Jakob 
and Beckmann 1986; Arnold, Hyman et al. 1991; Arnold, Ruscheinsky et al. 1997), a loss 
of neuronal density in the hippocampus and DLPFC of schizophrenics, as well as 
evidence of disorganised positioning of interstitial neurons in the frontal and temporal 
cortex of schizophrenic patients (Akbarian, Bunney et al. 1993; Akbarian, Vinuela et al. 
1993). All of these findings would implicate an abnormality that occurred in the predicted
period of gestation and involved a disruption in neuronal maturation and development. 
However, the support for the hypothesis is made much weaker by the lack of reliable 
replications of these findings. All of the findings mentioned above have failed to be 
replicated in at least one study, and in the case of the irregular neuronal clustering present 
in schizophrenics at least four studies have failed to replicate this finding (Akil and Lewis 
1997; Krimer, Herman et al. 1997).
Evidence for a neurodevelopmental process also comes from the many studies 
which have looked at the relationship between obstetric complications and schizophrenia. 
Several studies have reported that schizophrenic patients have an increased frequency of 
obstetric complications. A recent meta-analysis (Cannon, Jones et al. 2002) reported that 
three groups of complications were significantly associated with schizophrenia. These 
were: 1) complications of pregnancy (bleeding, diabetes, pre-eclampsia), 2) abnormal 
fetal growth and development (low birth weight, reduced head circumference, congenital 
malformations), and 3) complications of delivery (asphyxia, emergency caesarean 
section). Based on meta-analysis, the effect of obstetric complications on the risk for 
schizophrenia seems genuine but small, with the odds ratio of the effect of exposure to 
obstetric complications estimated to be about 2 (Geddes, Verdoux et al. 1999; Cannon, 
Jones et al. 2002). However, it can not be assumed that obstetric complications have a 
causative effect on schizophrenia as they might be caused themselves by some other 
underlying causal process. For example low birth weight and head size are markers of 
fetal growth retardation, but any factors which adversely affect the fetal development are 
likely to retard its growth and could therefore account for the lack of growth (Rapoport, 
Addington et al. 2005).
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There have also been studies reporting a variety of other prenatal factors with 
increased risk for schizophrenia. These include schizophrenics having about 5% higher 
frequencies of winter and spring births than controls (Torrey, Miller et al. 1997), leading 
some to propose that the higher likelihood of maternal infections in winter and spring 
might affect development. There is also evidence of a higher incidence of schizophrenia 
with urban birth (Mortensen, Pedersen et al. 1999). This was originally thought to be due 
to people with schizophrenia moving into more deprived inner city areas as a 
consequence of their illness, but recent work suggests that urban residence during 
upbringing independent of place of birth is associated with a higher risk of developing 
schizophrenia (Pedersen and Mortensen 2001). There has also been some evidence that 
severe maternal malnutrition during pregnancy is associated with higher rates of 
schizophrenia (Susser, Neugebauer et al. 1996; Wahlbeck, Forsen et al. 2001; St Clair, 
Xu et al. 2005).
If the basis of schizophrenia is neurodevelopmental then one might expect organs 
other than the brain to show defects or for there to be other abnormalities of the nervous 
system to be present. There is some evidence of an increased incidence of physical 
abnormalities in schizophrenics, particularly of the craniofacial variety. Lane and 
colleagues (Lane, Kinsella et al. 1997) reported that by using 12 variables of cranial 
morphology they were able to correctly classify 90% of patients with schizophrenia and 
80% of controls. There is also evidence of developmental delays in children who later go 
on to develop schizophrenia, including motor, cognitive, social and educational defects 
(Marenco and Weinberger 2000). For instance, Jones and colleagues (Jones, Rodgers et 
al. 1994) who studied a cohort of children all bom in the same week in 1946, reported 
that the individuals who went on to develop schizophrenia achieved motor development
goals, particularly walking, later than expected. In the same study the children who 
developed schizophrenia were rated by teachers to be more likely to play alone, be less 
socially confident and more anxious in social situations. Done and colleagues have 
replicated this finding (Done, Crow et al. 1994), reporting that the children in their cohort 
who later developed schizophrenia were more likely to exhibit inappropriate social 
behaviour. There is also some evidence of lower IQ in people who later develop 
schizophrenia compared to controls, with the lower the IQ the greater the risk of 
developing schizophrenia. Evidence for this finding is provided by two studies of army 
conscripts (David, Malmberg et al. 1997; Davidson, Reichenberg et al. 1999), which both 
showed that the IQ of conscripts who later developed schizophrenia was lower than that 
of conscripts who did not. This would indicate that intellectual performance was impaired 
before the onset of schizophrenic symptoms and could be due to earlier developmental 
defects.
The different strands of evidence for a neurodevelopmental hypothesis of 
schizophrenia as discussed above are strong and while much of the evidence can still be 
seen as circumstantial, controversial or inconclusive, when taken together, does suggest 
that neurodevelopmental defects play at least a part in the aetiology of schizophrenia. 
Many modified versions of the hypothesis have been proposed with abnormalities in 
additional processes such as cell adhesion, synaptic pruning, oligodendrocyte function 
and myelination also being proposed to play an important role in the aetiology of 
schizophrenia. The recent interest in the myelination process and a postulated role of 
oligodendrocytes in schizophrenia forms the basis of this thesis and will be discussed in 
more detail in section 1.5 of this chapter.
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1.2.1 Neurochemical hypotheses of schizophrenia.
In addition to the neurodevelopmental hypothesis of schizophrenia there have also 
been several neurochemical hypotheses proposed. These originated following the 
development of antipsychotic medications for schizophrenia, and led to the hypothesis 
that the brain dysfunction associated with schizophrenia was at least in part caused by a 
disturbance in brain biochemistry and neurochemical imbalances. These hypotheses were 
also supported by the observation that psychosis could be induced through the 
administration of certain drugs, such as amphetamines and LSD. It was assumed that the 
neurotransmitters influenced by these drugs would reflect the biological abnormalities 
observed in schizophrenia. This led to extensive study of the various neurotransmitter 
systems and to the formation of many hypotheses for their involvement in schizophrenia.
One of the first and still one of the most widely held hypotheses is the dopamine 
hypothesis of schizophrenia, which proposed that the symptoms of schizophrenia were 
due to dopamine over-activity. This hypothesis was based initially on pharmacological 
evidence showing that dopamine agonists such as amphetamines, which are known to 
increase dopamine release, induce or exacerbate psychosis with schizophrenic like 
symptoms, as well as the fact that the potency of all of the typical antipsychotic drugs 
varies with their affinity for the D2 subtype of dopamine receptor (van Rossum 1966; 
Carlsson 1978).
Another neurotransmitter hypothesised to be implicated in the aetiology of 
schizophrenia is glutamate. Interest was initially created by reports of reduced glutamate 
levels in schizophrenic patients (Kim, Komhuber et al. 1980). The hypoglutamatergic 
hypothesis of schizophrenia was further supported by the discovery that the 
administration of antiglutamatergic drugs such as phencyclidine (PCP) and ketamine,
which act by blocking the NMDA subtype of glutamate receptors, induced psychotic 
symptoms characteristic of schizophrenia (Moghaddam 2003). Moreover, the 
administration of PCP induced not only psychotic positive symptoms like amphetamine 
but also negative symptoms and cognitive dysfunction in healthy controls, and it 
therefore may provide a better model of schizophrenia (Reynolds 2002).
A further neurotransmitter that has been implicated with the aetiology of 
schizophrenia is serotonin. Interest in serotonin was initially generated by the discovery 
that atypical antipsychotics block certain subtypes of the serotonin receptor. The 
involvement of serotonin is further supported by the psychotomimetic properties of drugs 
such as LSD which act upon the serotonin receptor. Subsequent post-mortem studies have 
failed to find consistent changes in the serotonin system or its receptors in schizophrenia 
(Tamminga and Holcomb 2005). However, as serotonin is known to interact with other 
neurotransmitter systems including the dopaminergic, the involvement of serotonin in the 
aetiology of schizophrenia may not be simple and may involve the interaction of several 
neurotransmitter systems (Tamminga and Holcomb 2005).
Detailed discussion of all the proposed neurochemical hypotheses are beyond the 
remit of this thesis, but proponents exist for a contribution from all major 
neurotransmitter systems including those mentioned above, GABA, Acetyl choline and 
noradrenaline.
1.3 Genetic Epidemiology of Schizophrenia:
Genetic epidemiology studies of schizophrenia provide strong evidence for the 
involvement of genetic factors in the diseases aetiology. The numerous family studies
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which have been performed over the last century clearly show that the risk of 
schizophrenia is increased in the relatives of schizophrenic patients (Shih, Belmonte et al.
2004). In comparison to the 1% risk of schizophrenia in the general population, there is a 
modest increase to about a 2-3% risk observed in second and third degree relatives of 
schizophrenics, whilst the risk increases further to about 10% in first degree relatives 
(McGuffin, Owen et al. 1995). However, family studies do not allow us to differentiate 
the genetic vs environmental components of schizophrenia. In order to try and distinguish 
these factors investigators have used further twin and adoption study designs.
The basis of twin studies is to compare concordance rates for the disease between 
members of monozygotic (MZ) twin pairs and dizygotic (DZ) twin pairs. As MZ twins 
share 100% of their alleles, whereas DZ twins share 50%, under the assumption that each 
type of twin pair share the environment to a similar extent, a higher concordance in MZ 
than DZ twins indicates the presence of a genetic aetiology (McGuffin, Owen et al.
1995). In a recent study (Cardno and Gottesman 2000) examined the five most recent 
twin studies. The authors reported a monozygotic concordance estimate of 41-65%, 
compared with a dizygotic concordance estimate of 0-28%. They then used the data to 
estimate a broad genetic heritability for schizophrenia of 85%, with the remaining 15% 
being attributed to environmental factors.
Adoption studies also provide evidence that the increased risk of schizophrenia in 
the relatives of affected patients is not due to shared environmental factors. Individuals 
adopted into families containing an affected individual do not show an increased risk of 
schizophrenia, whereas an adoptee from a family with an affected individual, who is 
adopted by a family with no history of the disease, does carry an increased risk of 
schizophrenia (McGuffin, Owen et al. 1995; Shih, Belmonte et al. 2004).
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Although the epidemiological studies of schizophrenia prove that genes play an 
important role in the disease, environmental factors are still important. This is shown by 
the fact that the concordance of schizophrenia in MZ twins is around 50% and the 
estimated heritability of schizophrenia is less than 100%. What is inherited is not 
schizophrenia, but rather an increased susceptibility to developing the disease.
1.4 Molecular Genetic approaches to Schizophrenia:
It is clear from the genetic epidemiology studies described above that there is a 
significant genetic contribution to schizophrenia. However, studies looking at different 
family relatives of schizophrenic individuals have shown that the relative risk of 
developing schizophrenia decreases too rapidly with increasing genetic distance from the 
affected individual for schizophrenia to be a single gene disorder or a collection of single 
gene disorders. It appears more likely that the mode of transmission of schizophrenia is 
complex, involving the action of several, perhaps many genes which each account for a 
small increase or decrease in susceptibility for the disease. In fact (Risch 1990; Risch 
1990) calculated that the data is incompatible with the existence of any single locus 
conferring a relative risk in siblings (A*) of more than 3, and that models with several loci 
of As< 2 were more likely. It is however still possible that there are some rare genes of 
larger effect operating in certain schizophrenic pedigree families or subpopulations. To 
date there have been three main genetic approaches used to try and identify schizophrenia 
disease genes in human populations: Linkage studies, association studies and the 
identification of chromosomal abnormalities in schizophrenic patients.
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1.4.1. Linkage Studies:
The object of linkage studies is to try and identify regions of the genome 
containing genes that predispose to disease. This is done by studying related affected 
individuals and looking for areas of the genome that are co-transmitted along with disease 
in these individuals. The main assumption behind this approach is that a gene involved 
with a trait of interest is located physically close to the marker locus being studied whose 
location is known in the genome. The nearer two loci are together on a chromosome, the 
less likely it is that a recombination event will separate them during meiosis, and hence 
the more likely it is that they will co-segregate. The probability of a recombination event 
occurring between two markers during meiosis can be calculated to give the 
recombination fraction (0). If two genetic loci are on separate chromosomes or are far 
apart on the same chromosome the recombination fraction (0) will be 0.5, indicating that 
there is an even chance of the two markers being separated during meiosis (independent 
assortment). Two loci are ‘linked’ if during meiosis, recombination occurs between them 
with a probability (recombination fraction) of less than 50% (0 = <0.5), a departure from 
independent assortment. If there is non-independent assortment between a disease and a 
genetic marker, this indicates that a gene responsible for causing the disease is located in 
the region of the genome containing that particular marker. Using the linkage method it is 
possible to screen the whole of the genome for co-transmitted regions using a relatively 
small number of evenly spaced genetic markers (around 200-300 micro-satellites). 
Linkage can potentially identify the chromosomal position of disease related 
regions/genes without any prior knowledge of the disease aetiology (Owen, Williams et 
al. 2004). In order to use parametric statistical methods that have been successful for 
simple genetic disorders a genetic model describing the mode of inheritance of the
disease is required and ideally there is a strong correlation between genotype and 
phenotype. Unfortunately as I have mentioned above schizophrenia appears to be either 
polygenic or oligogenic involving multiple genes of moderate to small effect and the 
power of linkage to detect these genes is limited as a consequence by the reduced 
correlation between any single locus and the phenotype.
Although it does not seem that simple genetic forms are the rule many early 
linkage studies of schizophrenia were performed in the hope that at least some multiply 
affected schizophrenic families would be caused by inheritance of alleles of large effect 
which once identified could then further inform researchers of the possible gene 
pathways and systems involved in the disease. Unfortunately, the negative results of these 
early studies suggested that individual largely monogenic forms of schizophrenia are at 
best extremely rare. However, recently with the introduction of international 
collaborative studies and the availability of larger sample sizes, linkage studies have 
started to provide evidence of loci for schizophrenia, which have then been replicated in 
other samples. The linkage studies have been performed in samples consisting of large 
multiply affected families and also samples of affected sib-pairs, with both types of 
analysis providing positive evidence of loci for schizophrenia. For instance the putative 
susceptibility gene NRG1 was detected following the evidence of linkage to 8p 12-21 
detected in large multiply affected families (Stefansson, Sigurdsson et al. 2002), whilst 
the putative susceptibility gene DTNBP1 was detected following evidence of linkage to 
6p24-22 in samples of affected sib-pairs (Schwab, Albus et al. 1995; Straub, MacLean et 
al. 1995).
Some of the best-supported regions of the genome include: 6p24-22 (Schwab, 
Albus et al. 1995; Straub, MacLean et al. 1995), 10q25-26 (Williams, Norton et al. 2003),
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lq21-22 (Brzustowicz, Hodgkinson et al. 2000), 13q32-34 (Blouin, Dombroski et al. 
1998; Brzustowicz, Honer et al. 1999), 8p21-22 (Blouin, Dombroski et al. 1998; Gurling, 
Kalsi et al. 2001) and 6q21-25 (Martinez, Goldin et al. 1999; Lindholm, Ekholm et al.
2001), with further promising findings for regions like 22q 11-12 (Gill, Vallada et al. 
1996; DeLisi, Shaw et al. 2002; Williams, Norton et al. 2003), 5q21-q33 (Schwab, 
Eckstein et al. 1997; Straub, MacLean et al. 1997; Gurling, Kalsi et al. 2001), lOpl 5-pl 1 
(Schwab, Hallmayer et al. 1998; Straub, MacLean et al. 1998), lq42 (Blackwood, 
Fordyce et al. 2001), and 17pl 1-25 (Williams, Norton et al. 2003). It is likely that some 
of these results represent false positives. However, it is difficult to distinguish the true 
from false positives on the basis of replication because in the context of the expected 
small effect sizes of the genes being sought, the sample sizes are not large enough to be 
able to reliably replicate any single finding. A method that has been proposed to 
circumvent the problems with replication of linkage studies is the use of meta-analysis, 
which merges the results of many separate studies together, thus providing an increased 
power to detect the genes that influence schizophrenia susceptibility. Recently, two 
research groups have performed meta-analysis of the schizophrenia linkage studies. Both 
of these studies have used different methods and reported contrasting but overlapping 
findings. Lewis and colleagues (Lewis, Levinson et al. 2003) looked at 20 linkage studies 
and reported genome-wide significant evidence for a susceptibility locus on chromosome 
2q. The authors also reported evidence for the presence of susceptibility loci on 
chromosomes 5q, 3p, 1 lq, 6p, lq, 22q, 8p, 20q and 14p, with lesser evidence for several 
other chromosomal regions including 16q, 18q, lOp, 15q, 6q and 17q. In the second 
study, Badner and Gershon (Badner and Gershon 2002) reported evidence for the 
existence of susceptibility loci on chromosomes 8p, 13q and 22q. The only regions
receiving support from both meta-analyses were 8p and 22q. The study by Lewis and 
colleagues (Lewis, Levinson et al. 2003) was based upon a larger and more complete data 
set and it is probably reasonable to assume that some of the additional significant regions 
identified in the study might represent genuine susceptibility loci that were not detected 
in the other meta-analysis.
1.4.2. Cytogenetic Abnormalities:
Another method which has been used to try and identify the location of 
schizophrenia susceptibility genes has been the identification of chromosomal 
abnormalities in affected patients. The hope was that cytogenetic abnormalities occurring 
in a specific region of the genome such as translocations, inversions, deletions or 
duplications would either exist in greater frequency in schizophrenics than in the general 
population, would disrupt a region previously implicated by linkage analysis, or would be 
inherited along with schizophrenia in affected families. Any abnormalities detected could 
be pathogenic through various mechanisms such as the direct disruption of a gene or 
genes, the formation of an aberrant gene product by fusing together two previously 
separate genes, by indirectly disrupting the function of a neighbouring gene by modifying 
its expression, or by altering the expression of the gene in the case of deletions or 
duplications.
There have been many studies reporting the association of chromosomal 
abnormalities and schizophrenia. However, only two findings have provided convincing 
evidence for the possible location of a susceptibility gene. Velo-Cardio Facial Syndrome 
(VCFS), which is associated with small chromosome 22ql 1 deletions, have a high risk of 
schizophrenia (Bassett, Hodgkinson et al. 1998), with later studies (Murphy, Jones et al.
1999; Murphy 2002) estimating the relative risk to be around 25-30%. The prevalence of 
VCFS in the general population is too low for the disease to account for more than about 
1% of schizophrenia cases (Owen, Williams et al. 2004), and therefore from the 
schizophrenia genetics point of view, the most interesting question to try and answer is 
whether the high rate of schizophrenia in VCFS patients can provide a clue to the location 
of a susceptibility gene or genes involved in schizophrenic patients without chromosome 
22 deletions. There is some support for this theory from the results of linkage studies 
which have previously reported evidence for the location of a susceptibility locus for 
schizophrenia within a broad region of chromosome 22 (Gill, Vallada et al. 1996; DeLisi, 
Shaw et al. 2002; Williams, Norton et al. 2003). Indeed in the meta-analysis (Lewis, 
Levinson et al. 2003) the 22pl l-q21 region was one of the most significant results.
Several candidate genes in the region (COMT, ARVCF and PRODH) have been studied 
for association with schizophrenia, but so far none have been convincingly implicated 
with disease (Williams, Glaser et al. 2005).
Another result of interest was the discovery of a (1:11) (q42;ql4.3) balanced 
reciprocal translocation which was found to co-segregate with schizophrenia and major 
mood disorders in a large Scottish family (St Clair, Blackwood et al. 1990; Blackwood, 
Fordyce et al. 2001). This translocation has been reported to disrupt two genes on 
chromosome 1, called disrupted in schizophrenia 1 and 2 (Disc 1 and Disc 2) (Millar, 
Wilson-Annan et al. 2000; Blackwood, Fordyce et al. 2001). There have subsequently 
been several association studies published reporting that variation within Disci is 
associated with schizophrenia and bipolar disorder in the general population (Hennah, 
Varilo et al. 2003; Hodgkinson, Goldman et al. 2004; Callicott, Straub et al. 2005; 
Thomson, Wray et al. 2005).
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1.4.3. Association Studies:
Association studies aim to detect a relationship between two variables. In the case 
of a genetic association study it is usually a relationship between a genetic 
polymorphism(s) and a specific trait, such as a particular phenotype or a disease that is 
being tested. A polymorphism is said to be associated with a trait if a genotype or allele 
occurs more often than would be expected by chance in people with that particular trait. 
For instance an allele that is significantly over represented in a disease population when 
compared to the frequency in the general population would be said to be significantly 
associated with the disease.
The genetic loci that are thought to be involved with complex diseases such as 
schizophrenia are likely to be of moderate to small effect size (Risch 1990). Compared 
with linkage, association studies provide an alternative and more powerful means of 
identifying moderately cbmmon alleles of modest to small effect in realistically attainable 
sample sizes compared to linkage studies (Risch and Merikangas 1996). As an example 
Risch and colleagues (Risch and Merikangas 1996) calculated that to detect a gene with a 
genotype relative risk (GRR) of 2.0 with a disease allele frequency of 0.5 using a linkage 
study design would require around 2500 families. In contrast, they calculated that to 
detect the same allele using an association study design would require only around 200 
families.
Unfortunately, studies based upon association do have a major disadvantage 
compared to linkage. It has been estimated that association studies in normal populations 
(no significant inbreeding) would require at least several hundreds of thousands of 
markers to be genotyped in order to screen the whole genome by association (Gabriel,
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Schaflfner et al. 2002; Carlson, Eberle et al. 2004; Hirschhom and Daly 2005). This large 
number of markers initially made the prospect of whole genome association studies 
economically impracticable, even for the most highly funded research laboratories. 
However, recently with the advent of new technology allowing genotyping on an 
extremely large scale, the prospect of whole genome association studies is now feasible.
The basic and most commonly used form of association study is a case control 
study involving comparing the frequency of alleles in a sample of individuals from a 
disease population (cases) against the frequency in a sample of unaffected individuals 
from some form of control population. By doing this it is possible to test for a statistically 
significant difference between the two populations and hence determine whether a 
particular genotype or allele is associated with an increased risk for a disease.
1.4.3.1. Previous association studies in schizophrenia:
Given that the numbers of markers required prohibited genome wide studies until 
recently, association studies of schizophrenia have been required to select specific 
candidate genes or relatively small regions for investigation by association. The selection 
of these genes has been based upon evidence that the gene is a functional candidate on 
the basis of its putative involvement with schizophrenic neurobiology, on the basis that 
the gene is located in a region of the genome implicated by schizophrenic linkage studies, 
or alternatively based upon a combination of the two criteria. Despite the restrictions on 
the scope of association studies they have still been successfully used to identify genes of 
minor effect in various complex genetic disorders, including Alzheimer’s (Corder, 
Saunders et al. 1993; Strittmatter, Saunders et al. 1993), dyslexia (Francks, Paracchini et 
al. 2004; Cope, Harold et al. 2005), schizophrenia (Chumakov, Blumenfeld et al. 2002;
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Stefansson, Sigurdsson et al. 2002; Straub, Jiang et al. 2002), type 1 diabetes (Vella, 
Cooper et al. 2005) and type 2 diabetes (Grant, Thorleifsson et al. 2006).
Hundreds, possibly thousands, of association studies on candidate genes have 
been published in schizophrenia. The results and quality of the data produced by these 
studies has been variable and the results inconsistent and unconvincing, due possibly to 
the small sample sizes and power of the studies to enable detection or replication of 
associations with genetic variants of moderate to small effect size (Owen, Williams et al. 
2004), and incomplete marker coverage of the genes. The positive associations that have 
been reported have often failed to replicate, associations have also been reported with 
different alleles of the same variant, or associations have been reported with different 
variants in the same genes.
However, recently there have been a few genes reported to be associated with 
schizophrenia which have subsequently received strong evidence from replication 
studies, indicating the genes may be putative susceptibility loci for schizophrenia. Three 
of the most compelling are Neuregulin 1 (NRG1), Dysbindin (DTNBP1) and D-amino 
acid oxidase activator (DAOA; also known as G72). All three of these genes were 
initially selected for study on the basis of their location within regions of the genome that 
has been previously linked to schizophrenia.
Neuregulin (NRG1) was first reported to be associated with schizophrenia by 
Stefansson and colleagues (Stefansson, Sigurdsson et al. 2002), who following up their 
earlier linkage findings on chromosome 8p 12-21, detected an association with 
schizophrenia for a single marker and also a more significant association with a seven 
marker haplotype at the 5’ end of NRG 1. This initial result was replicated in an 
independent Scottish case control sample, with association being reported individually for
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three of the markers in the original Stefansson (2002) seven-marker haplotype and again 
a more significant association with the haplotype itself (Stefansson, Sarginson et al.
2003). A further study (Williams, Preece et al. 2003) also supports NRG1 as a putative 
schizophrenia locus by reporting association with the haplotype, although at a moderate 
level of significance. Further positive results have been reported in various populations 
including Irish (Corvin, Morris et al. 2004), Chinese (Yang, Si et al. 2003; Tang, Chen et 
al. 2004; Zhao, Shi et al. 2004), South African (Hall, Gogos et al. 2004) and Portuguese 
(Petryshen, Middleton et al. 2005), with different haplotypes. Recently two meta-analyses 
of the NRG1 association data have provided further support for the genes involvement in 
schizophrenia (Li, Collier et al. 2006; Munafo, Thiselton et al. 2006).
Dysbindin (DTNBP1) was initially implicated in schizophrenia by Straub and 
colleagues (Straub, Jiang et al. 2002) who analysed their previously reported linkage 
region on chromosome 6p22, and detected association to schizophrenia with several 
individual markers in DTNBP1 and also significant association with several three-marker 
haplotypes across the gene. The initial result was supported by the findings of Schwab 
(Schwab, Knapp et al. 2003) who reported association between DTNBP 1 and 
schizophrenia in two separate samples. They reported association with a single marker in 
both their samples and also increased association with various two and three marker 
haplotypes. Additional support has been provided by the results of several large studies 
from the UK (Williams, Preece et al. 2004), Bulgaria (Kirov, Ivanov et al. 2004),
America (Funke, Finn et al. 2004), China (Tang, Zhou et al. 2003) and Japan 
(Numakawa, Yagasaki et al. 2004). All studies have reported associations with different 
haplotypes in DTNBP 1 and schizophrenia. Interesting complementary evidence has also 
been reported by Bray and colleagues (Bray, Preece et al. 2005) who demonstrated that
the associated risk haplotypes in DTNBP 1 tag one or more cis-acting variants responsible 
for a relative reduction in the expression levels of the dysbindin gene.
D-amino acid oxidase activator (DAOA; also known as G72) was first shown to 
be associated with schizophrenia by Chumakov and colleagues (Chumakov, Blumenfeld 
et al. 2002), after following up on their earlier linkage findings on chromosome 13q22- 
34. Replication studies have subsequently reported positive association between DAOA 
and schizophrenia in the German (Schumacher, Jamra et al. 2004), Chinese (Wang, He et 
al. 2004; Zou, Li et al. 2005), Palestinian (Korostishevsky, Kaganovich et al. 2004; 
Korostishevsky, Kremer et al. 2006) and American (Addington, Gomick et al. 2004) 
populations. It is of note that positive association has also been reported between DAOA 
and Bipolar disorder (Hattori, Liu et al. 2003; Chen, Akula et al. 2004b; Schumacher, 
Jamra et al. 2004; Williams, Green et al. 2006). Interestingly when Williams and 
colleagues (2006) analysed their schizophrenic and bipolar data across the traditional 
diagnostic boundaries they detected a significant association between variation within 
DAOA and patients suffering from major mood episodes, but not in those schizophrenics 
with no history of mood disorder.
It is important to remember that the detection of a positive association between a 
marker and a disease does not always mean that you have detected the specific variant 
which is responsible for causing increased risk for the disease. Positive association 
between a genetic polymorphism and a trait can be detected in a particular population for 
several reasons:
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1.4.3.2. Direct association:
Association analysis based on known functional SNPs or complete mutation 
discovery are termed ‘direct’ studies. Here the aim is to test variants directly responsible 
for modifying gene function and hence influencing disease risk. Unfortunately, it is not 
thought that all the causal variants responsible for complex diseases will be located 
within coding sequence, since variation located within non-coding sequence could also 
alter a genes function by affecting the expression, regulation or splicing of the gene. The 
unknown functional boundaries of genes makes complete mutation discovery impossible 
and it is therefore difficult to specify a subset of markers for direct studies.
1.4.3.3. Spurious association:
Association can also be caused by confounding factors such as population 
stratification which can lead to the detection of a false positive association. Population 
stratification occurs when a population is made up of several genetically distinct 
subgroups (e.g different ethnic backgrounds). If the ascertained cases and controls in a 
study have a different proportion of individuals from each genetic background any alleles 
that differ in frequency simply by genetic background can result in a false positive 
association. This type of association is termed ‘spurious’ association as there would not 
be a true positive association between the two variables detected within any of the 
individual genetic subgroups (Sham 2003). These same confounding factors can also 
result in ‘false negative’ association findings by masking the effect of a true association 
signal.
The phenomenon of ‘spurious association’ is obviously of major concern and 
molecular geneticists employ several steps in an attempt to avoid the problem. The first
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step is to ensure that association studies are performed in samples selected from well 
mixed, out-breeding populations, and that the case and control samples are carefully 
‘matched’ for all factors except their disease status. This includes matching the samples 
for traits such as their ethnic origin, age, sex and geographical region.
The use of family based studies has also been strongly advocated to avoid the 
problem of stratification. This is preferably achieved through the use of affected-parent 
trio samples or, where it is not possible to collect parental samples (e.g diseases with late 
onset); samples consisting of affected and non-affected sibling pairs can be used. In order 
to test for potential association, the alleles of the parents that have been transmitted and 
non-transmitted to the affected probands are determined at the locus to be analysed and 
statistical tests are used to determine whether a particular allele is transmitted more 
frequently to affected individuals than expected by chance. The transmission frequency 
analysis is usually performed using either the haplotype based, haplotype relative risk 
(HRR) method (Terwilliger and Ott 1992), or the transmission disequilibrium test (TDT) 
(Spielman, McGinnis et al. 1993). However, family based association studies do have 
some disadvantages compared to more traditional case-control studies. Firstly they are 
more expensive as they require more genotyping due to the trio design, and secondly 
there are often problems with sample collection due to the availability of the parents. For 
example in diseases with a late age of onset, or diseases with strong social stigma and 
high rates of family disruption (e.g schizophrenia) the collection of family based samples 
is very difficult.
Additionally it has also been proposed that the use of genomic controls can help 
to avoid the problem of stratification. This method proposes that by genotyping a large 
number of unselected genetic markers across the genome the extent to which allelic
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variance is influenced by population stratification can be estimated and then the threshold 
required for statistical significance subsequently adjusted in order to reduce the level of 
false positive associations detected.
A further cause of false positive association findings is type I error (statistical 
chance) as a result of sampling variation. If the level of statistical significance adopted in 
a study is p=0.05, then for every twenty markers tested for association one will appear to 
be statistically significant by chance. A high rate of type I error in published data may 
result from the inadequate correction of association findings for the total number of 
markers tested at a locus. One method proposed for dealing with type I error is the use of 
the Bonferroni correction, where the corrected threshold for significance is set at 0.05 / 
the total number of independent association tests performed. However, since association 
studies of complex traits are likely to require the testing of large numbers of markers, 
correcting p-values using the Bonferroni correction is likely to require an initial level of 
statistical significance several orders of magnitude greater in order to remain significant 
after correction. Such levels of significance are extremely difficult to achieve, and 
therefore by applying such a conservative correction it is possible that true association 
findings may be missed. A further problem with the use of the Bonferroni correction is 
the existence of LD between markers. The presence of LD leads to non-independence of 
markers and thus results in the threshold of significance being over corrected. The answer 
to the problems discussed above is not simple. The best answer to the problem of type I 
error is the robust independent replication of positive findings in suitably powerful 
association samples. In order to allow for the problems associated with the non­
independence of markers, the use of permutation testing provides a means to take into 
account the presence of LD.
1.4.3.4. Indirect association:
The final reason for a positive association being detected in a population is termed 
‘indirect’ association. This occurs when a polymorphism being tested for association with 
a disease is actually a surrogate marker for the true causal variant. This situation occurs 
due to the existence of a phenomenon known as ‘linkage disequilibrium’ (LD). In this 
case the polymorphism detected to be showing association with a disease has no direct 
effect on susceptibility, but is instead in linkage disequilibrium (LD) with another 
polymorphism that is the actual true causal variant, and the association is therefore 
termed ‘indirect’.
LD refers to the non-random population association of alleles. This arises when an 
allele at one locus occurs more frequently with a specific allele at a second locus than 
would be expected if the two loci were segregating randomly during recombination 
(Ardlie, Kruglyak et al. 2002). Normally after a mutation event the rearrangement of 
alleles during recombination events rapidly destroys the relationship between alleles at 
the mutated site and those on the chromosome on which the mutation occurred. However, 
if two alleles are very tightly linked the chance of them being separated during meiosis is 
low, and the level of LD between the markers will decay slowly. This may result in the 
persistence of relatively strong levels of LD between the markers for many generations. 
That strong LD can exist between two or more tightly linked markers allows ‘indirect’ 
association to be detected with a marker that is not itself the causal susceptibility variant 
for disease, but is instead displaying association due to strong LD with the true causal 
variant. The fact that association to a disease can be detected with markers other than the 
causal variant by virtue of LD is crucial to association study design. It provides
geneticists with the ability to screen genes or genomic regions for association by only 
testing a selection of the genetic variation within that region, a technique which is termed 
‘linkage disequilibrium mapping’.
1.4.4. Linkage Disequilibrium (LD) mapping:
1.4.4.1. Measurement of linkage disequilibrium:
In order for geneticists to be able to use the phenomenon of LD to their advantage 
they need to be able to measure the strength of the LD which exists between two loci. 
There have been many methods developed over the years to assess the level of LD 
between markers but the two most commonly used statistics are D’ and r2 (Ardlie, 
Kruglyak et al. 2002). Both are based upon one of the earliest measures of disequilibrium 
to be developed, termed the population genetic parameter (symbolised by D). The 
statistic D quantifies disequilibrium as the difference between the observed frequencies of 
two marker haplotypes and the frequencies of the haplotypes that would be expected to 
occur if the alleles at the two loci were segregating randomly. However, although the 
statistic D represents the concept of LD, its numerical value is not very useful for 
comparing and determining the strength of LD between markers, due to its reliance on 
allele frequencies. This limitation led to the development of alternative measures, the two 
most common of which are D’ and r2. These two statistics both range from 0 (no 
disequilibrium) to 1 (complete disequilibrium), although the interpretation of the statistics 
is slightly different.
The statistic of D’ is derived by dividing the population genetic parameter D by 
its maximum possible value, thereby adjusting for the allele frequencies at the two
29
markers being tested. The way that D’ is calculated means that D’=l only if there has not 
been any recombination present between the tested markers during the history of the 
population. This is often called ‘complete LD’ (note that formally, D’ can have values 
ranging from -1 to 1 but the sign is usually dropped in modem practice). Where D’=l, at 
most, three of the possible four two locus haplotypes are present in the sample. A value 
of D’=<1 indicates that the markers have been disrupted by recombination and represents 
the presence of all four of the possible two locus haplotypes in the population. While a D’ 
value of 1 or 0 is relatively easy to understand (either complete or no disequilibrium), 
intermediate values are more difficult to interpret. This difficulty is caused in part by the 
finding that values of D’ can be inflated in small sample sizes, particularly when the 
markers being analysed have rare allele frequencies. It has been suggested that 
intermediate D’ values should not be used to compare the strength of LD between 
samples (Ardlie, Kruglyak et al. 2002).
The second commonly used statistic of LD is r2 and represents the square of 
correlation (r) of the alleles at the two loci being tested. The statistic is complementary to 
D’ and has recently become for many the LD measure of choice for comparing the 
strength of LD between markers and samples, r2 is derived by dividing D2 by the product 
of the four allele frequencies at the two loci being tested. A value of r =1, which is 
termed ‘perfect LD’ only occurs if the markers being tested have not been separated by 
recombination and also have the same allele frequency. In this case only two of the four 
possible two-locus haplotypes are present in the sample. When two markers are in perfect 
LD, genotype observations that are made at one marker provide the complete set of 
information about the other marker, therefore making genotyping of the second marker
redundant. Compared to the D’ statistic, intermediate values of r2 are easier to interpret as 
the value of r2 is directly related to the amount of information provided by one marker 
about another, as well as the sample size required to detect an association (Wall and 
Pritchard 2003). For example consider two markers, one of which (A) is involved with 
susceptibility to disease, and a second nearby marker (B) in LD with the susceptibility 
locus. It has been calculated that in order to provide the same power to detect an 
association that would be provided by genotyping the susceptibility locus (A) itself, 
marker (B) would need to be genotyped in a case control sample whose size has been 
increased by a factor of 1/ r2 (Wall and Pritchard 2003). This has been shown to be an 
oversimplification (Terwilliger and Hiekkalinna 2006), though on average it is correct. 
Similar to the D’ statistic, the value of r2 takes into account the differences in allele 
frequencies at the markers being tested, but additionally has the significant advantage 
over D’ that the value of r2 shows less inflation in small sample sizes (Weiss and Clark
2002). Due to the r2 statistics greater stability in smaller sample sizes and the ability to 
interpret intermediate values, the statistic has been proposed as the LD measure of choice 
for use in association studies (Pritchard and Przeworski 2001).
1.4.5. Extent of LD in the human population:
The extent of linkage disequilibrium within the human genome is not purely 
determined by the genetic distance between the markers being tested. As a consequence, 
markers that are tens or even hundreds of kilobases apart may be in strong linkage 
disequilibrium, whereas markers that are close together on the genome might be in weak 
LD (Wall and Pritchard 2003). Large differences in the extent of LD exist for different
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regions of the genome (Abecasis, Noguchi et al. 2001; Reich, Cargill et al. 2001). This 
variable extent of LD observed across the genome is explained by several factors.
I.4.5.I. Factors influencing LD diversity:
Mutation age/rate and recombination probably have the most obvious impact on 
the extent of LD across the genome, but there are other factors which are also important.
Genetic drift: This results in changes in gene and haplotype frequencies caused by 
random sampling of gametes. This is of particular importance in small populations where 
it can result in the loss of some haplotypes from the population and therefore lead to 
increased levels of LD (Ardlie, Kruglyak et al. 2002).
Population growth: Rapid population growth decreases the extent of LD by 
reducing genetic drift (Ardlie, Kruglyak et al. 2002).
Population bottlenecks: During a population bottleneck the size of a population is 
significantly reduced leading to a loss of haplotypic diversity within the population and 
hence resulting in an increase in the extent of LD within the population (Pritchard and 
Przeworski 2001).
Migration (gene flow): This occurs when two genetically distinct populations 
migrate or admix together and create a ‘hybrid’ population, which can result in the 
generation of LD. Recently admixed populations can have very strong levels of LD 
across large genetic distances (Pritchard and Przeworski 2001). The rate at which the 
level of LD breaks down in these populations is determined by the size of the hybrid 
population and whether the population continues to mix with the original populations 
(slow rate of LD decay) or whether the population becomes isolated (fast rate of LD 
decay) (Pfaff, Parra et al. 2001).
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Natural selection: Selection can affect the extent of LD through two mechanisms. 
The first is where a haplotype which flanks a (selected) favourable mutation becomes 
highly frequent in a population, thus inflating LD (Ardlie, Kruglyak et al. 2002). The 
second selection mechanism which can affect LD is through the epistatic selection of 
combinations of alleles at two or more loci on a chromosome thereby increasing the level 
of LD (Ardlie, Kruglyak et al. 2002).
Gene conversion: This is a phenomenon where a stretch of one copy of a 
chromosome is transferred to the other copy during meiosis. This is very similar to two 
very close recombination events and can result in the breakdown of LD in a manner 
similar to recombination and mutation (Ardlie, Kruglyak et al. 2002).
Variable recombination and mutation rates: Recombination and mutation rates are 
known to vary across the genome. As the breakdown of LD is thought to mostly depend 
on recombination and mutation rates the extent of LD is thought to be related to these 
rates. It has even been suggested that recombination might be restricted to certain regions 
of the genome (hotspots) resulting in the breakdown of LD in these regions, whilst 
recombination might be almost missing in other areas of the genome resulting in high 
levels of LD (Ardlie, Kruglyak et al. 2002).
1.4.6. Studies of the extent of LD across the genome:
It is generally accepted that LD declines with increasing genetic distance, but as I 
discussed there are several factors that can also influence LD and result in LD variation 
across the genome, between genes and also between different populations. This variation 
has led to an increasing number of studies examining the patterns of LD across the 
genome and between different populations:
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One of the earliest of these reports (Kruglyak 1999), was based on a simulation 
study and predicted that useful levels of LD (suitable for association studies) were 
unlikely to span distances of more than 3kb in a general outbreed population. The authors 
then suggested that taking this into consideration roughly 500,000 markers would be 
required to be genotyped in order to perform whole genome association studies.
However, the prediction that useful LD only extends over regions of 3kb or less has been 
rejected by several empirical studies (Abecasis, Noguchi et al. 2001; Reich, Cargill et al. 
2001; Stephens, Schneider et al. 2001).
1.4.7. The block structure of LD:
Recent studies have suggested that the pattern of LD across the genome can be 
structured into blocks of high and low LD, termed ‘haplotype blocks’. Two early studies 
(Daly, Rioux et al. 2001; Jeffreys, Kauppi et al. 2001) reported that LD in the genome 
was highly structured and broken up into ‘blocks’ of high LD with low haplotypic 
diversity (recombination coldspots) interspersed by genomic regions with high levels of 
recombination (recombination hotspots). These initial studies were performed on 
relatively small regions of the genome of about 500kb, but a more recent study has been 
performed on a larger 13Mb region of the genome and demonstrated that a region of this 
size could also be defined into distinct blocks of high LD separated by recombination 
hotspots (Gabriel, Schaffner et al. 2002). There have since been several other LD studies 
performed which have examined large chromosomal regions and again reported that the 
genome can be divided into ‘haplotype block’ structures of high LD separated by 
hotspots of recombination (Dawson, Abecasis et al. 2002; Phillips, Lawrence et al. 2003).
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1.4.8. The use of haplotvpe blocks in LD mapping:
The existence of often high levels of LD throughout the genome has led to the 
prospect of using ‘tag’ SNPs to reduce the number of markers that are required to be 
genotyped in order to perform a whole genome association study (Johnson, Esposito et al. 
2001; Cardon and Abecasis 2003). The term ‘tag’ SNP refers to a SNP that when 
genotyped individually or as part of a multi-marker haplotype, captures a high proportion 
of the common haplotypic information surrounding a gene or genomic region. In order to 
determine which tag SNPs capture the genetic information of a region, initially a highly 
dense set of SNPs needs to be genotyped in a representative panel of individuals 
(Kruglyak 2005). Using the data the minimum number of SNPs required to be genotyped 
in order to capture all or a user defined proportion of the genetic variation within that 
region by LD (either individually or through multi-marker haplotypes) can be calculated. 
This technique therefore reduces the amount of genotyping required to cover a region, 
whilst maintaining the power to detect at least the common known variants present.
The possibility of using tag SNPs to screen a genomic region for susceptibility 
variants for common disease inspired the foundation of the international HapMap 
consortium. This project has obtained genotype information for more than six million 
SNPs (roughly one SNP every lkb) across the genome in 269 individuals from four 
different ethnic populations (Consortium. 2005). The project therefore allows genetic 
researchers to determine the tag SNPs within a region without the need to perform an 
initial dense SNP genotyping study in their own sample. However, the use of the 
HapMap does rely on the assumption that the LD structure in the population of interest is 
the same as in the populations studied by the HapMap consortium, an assumption which
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is less reliable in populations of African origin, as these populations generally contain 
more genetic variation and less LD (Hirschhom and Daly 2005).
Support for the HapMap project is provided by the results of a large genotyping 
study (Hinds, Stuve et al. 2005). The authors presented genotyping data for more than 
1500000 SNPs across the genome (~1 SNP every 1.8kb) in 71 individuals from three 
different populations of European-American, African-American and Asian-American 
ancestry. Using the genotype data the authors calculated the LD structure across the 
genome and then used this to determine blocks (bins) of SNPs where each block had at 
least one tag SNP with an r2 of at least 0.8 with all of the other SNPs in that block. Using 
this pairwise r2 method to define blocks and then select tag SNPs, the authors showed that 
in order to capture the common genetic information would require 30% of the overall 
SNPs to be genotyped in the European-American population, 28% of the SNPs to be 
genotyped for the Asian-American population and 50% of the SNPs to be genotyped in 
the African -American population (Hinds, Stuve et al. 2005). Although the results of this 
study indicate that by using tag SNPs the quantity of genotyping required to perform a 
whole genome association study can be significantly reduced, the authors concluded that 
at best a comprehensive whole genome study will still require genotyping of at least 
several hundreds of thousands of SNPs for each individual in the association sample 
(Hinds, Stuve et al. 2005). Indeed in a recent study (Barrett and Cardon 2006) assessing 
the coverage of the phase II HapMap data it was reported that nearly all common 
variation in the European-American and Asian-American populations can be captured 
with ^>0.8 using approximately 500000 carefully selected SNPs. However, to capture 
nearly all the common variation in the African-American population would require more 
than twice as many SNPs. The authors also reported that in all cases the gain in coverage
achieved with increasing numbers of markers showed a diminishing level of return. For 
example, although 500000 SNPs are required to capture the common variation in the 
European-American population, a set of 250000 SNPs would capture 85% of the 
variation present (Barrett and Cardon 2006). A consequence of this effect is that a large 
proportion of the tag markers are capturing ‘singleton’ SNPs that are not in strong LD 
with any other SNPs.
In an effort to reduce the number of SNPs required to be genotyped further 
methods of tagging the genetic information across the genome have been proposed. The 
most common of these alternatives is the use of multi-marker haplotypes in order to tag 
the genetic variation across the genome (Stram 2004; de Bakker, Yelensky et al. 2005). 
The basis of this method is that a specific multimarker combination (haplotype) can serve 
as a proxy for several individual tag SNPs, and thus make the genotyping of these tags 
individually redundant. Using this method each individually typed tag as well as each 
specific haplotype is tested for association.
Recently de Bakker and colleagues (de Bakker, Yelensky et al. 2005) using the 
available HapMap genotyping data have calculated that by using a pairwise r2 method to 
select tag SNPs reduced the number of genotypes required by 65% in the European 
population compared with testing all of the common SNPs directly. The subset of tag 
SNPs maintained the same level of relative power as would be achieved by testing all of 
the available genetic variation. The authors then went on to calculate whether the use of 
multimarker haplotypes would improve the genotyping efficiency any further. They 
reported that by using a haplotype tagging technique the number of tag SNPs required to 
be genotyped was reduced by a further 30% compared to the number required using the
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pairwise r2 method, whilst still maintaining the same relative power (de Bakker, Yelensky 
et al. 2005).
1.5 Oligodendrocytes, Myelination and Schizophrenia:
Over the last decade there has been increasing evidence suggesting that abnormal 
oligodendrocyte function and/or myelination plays a role in schizophrenia aetiology. The 
main strands of evidence that provide support for this come from studies of 
neuropathology, imaging analysis, symptom overlap with demyelinating diseases, age 
related changes in myelin and evidence from micro-array studies.
Oligodendrocytes are the myelinating glial cells in the central nervous system and 
are essential for the development of the neuronal system and for maintaining the function 
of mature neurons. Oligodendrocytes are the predominant cell type in the white matter of 
the brain where their main known function is the myelination of axons. Satellite 
oligodendrocytes also exist which are involved in regulating the microenvironment 
around neurons (Baumann and Pham-Dinh 2001).
During myelination oligodendrocytes create highly branched membrane processes 
that target and ensheath the axons of neurons in multiple layers of myelin to form the 
myelin sheath (Baumann and Pham-Dinh 2001). The myelin sheath is a highly organised 
multi-lamellar membrane structure, consisting of a specialised set of lipids and proteins. 
The presence of the myelin sheath around axons is essential for the rapid conduction of 
action potentials along axons by the process of saltatory conduction (Sherman and 
Brophy 2005). Proper myelination of the axons of the central nervous system by
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oligodendrocytes is therefore critical to normal neuronal function, a fact demonstrated by 
the involvement of abnormal myelination in diseases such as leukodystrophies and 
multiple sclerosis (MS) in the central nervous system (Baumann and Pham-Dinh 2001).
Oligodendrocytes and myelin have also been proposed to play other functions in 
the CNS. Oligodendrocytes influence neuronal maturation. For example they trigger the 
clustering of sodium channels around the nodes of Ranvier on axons (Sherman and 
Brophy 2005). It has also been suggested that oligodendrocytes are able to promote the 
radial growth of axons, an important process, as conduction velocity has been shown to 
be correlated with axonal diameter (Baumann and Pham-Dinh 2001). Additionally there 
is also evidence that oligodendrocytes secrete factors that promote axonal maintenance 
and survival although the molecular mechanism is still to be determined (Baumann and 
Pham-Dinh 2001; Sherman and Brophy 2005). Finally there is evidence that the 
inhibition of axonal growth and regeneration in the CNS is in part caused by myelin 
proteins on the surface of the myelin sheath (see Chapter 4, section 4.1).
Abnormalities in the myelination process and/or factors that affect myelination 
and the deposition of myelin such as the function of oligodendrocytes could all therefore 
have a profound effect on brain function.
1.5.1. Oligodendrocyte and mvelin related gene expression in schizophrenia.
Some of the strongest evidence for the existence of an oligodendrocyte and/or 
myelination abnormality in schizophrenia comes from micro-array studies of 
oligodendrocyte and myelin related (OMR) gene expression. The study of global mRNA 
expression levels offers a complementary approach to the traditional strategy of selecting 
candidate genes and/or biological pathways for association study in the absence of any
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prior functional or positional evidence linking those genes to the disease aetiology 
(Williams, O'Donovan et al. 2002). Although there are several potential methodological 
as well as experimental and sampling hurdles to overcome with the use of complex post 
mortem tissue, the results of recent studies have suggested that reliable and robust 
changes in gene expression can be detected in human post mortem brain tissue. For 
example one of the earliest micro-array studies to be performed (Hakak, Walker et al.
2001) reported the downregulation of ErbB3 in schizophrenia, a result that has since been 
independently replicated (Tkachev, Mimmack et al. 2003; Aston, Jiang et al. 2004). The 
altered expression of ErbB3 becomes more aetiologically relevant in light of the evidence 
strongly implicating variation in the gene encoding one of its ligands, Neuregulin 1 
(NRG1), with susceptibility to schizophrenia (Stefansson, Sigurdsson et al. 2002; 
Stefansson, Sarginson et al. 2003; Owen, Craddock et al. 2005; Li, Collier et al. 2006). 
Other less compelling examples include the identification of the G protein receptor kinase 
3 gene as a candidate gene for bipolar disorder (Niculescu, Segal et al. 2000) and the 
regulator of G protein signalling 4 (RGS4) as a candidate gene for schizophrenia 
(Mimics, Middleton et al. 2001) findings that have received supportive evidence from 
follow up genetic studies (Chowdari, Mimics et al. 2002; Barrett, Hauger et al. 2003). In
f
the case of RGS4 and GRK3, each gene was selected for genetic analysis because as well 
as displaying altered expression, each mapped to a putative region of linkage for the 
relevant disorder. Therefore each candidate was supported by data from two non­
hypothesis based methods, an approach that has been termed ‘convergent functional 
genomics’ (Niculescu, Segal et al. 2000).
One of the earliest micro-array studies of schizophrenia suggested that 
oligodendrocyte and myelin related (OMR) dysfunction might play a role in
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schizophrenia (Hakak, Walker et al. 2001). The authors assayed over 6000 gene 
transcripts and detected 89 genes that displayed significant altered expression levels in 
post-mortem dorsolateral prefrontal-cortex brain samples of schizophrenic patients 
(n=12) compared to matched controls (n=12). All of the gene expression was 
predominantly up-regulated, except for a series of six genes related to oligodendrocyte 
and myelin function that were down-regulated in schizophrenic brain. The genes that 
were down-regulated were: myelin and lymphocyte protein (MAL), gelsolin (GSN), 
myelin associated glycoprotein (MAG), 2’-3’-cyclic nucleotide 3’-phosphodiesterase 
(CNP), transferrin (TF), and ErbB3. The altered expression of several of these genes has 
subsequently been replicated using independent post-mortem brain samples and different 
global expression assaying techniques, see table 1.1 for a summary of the OMR gene 
expression results.
The first of these replication studies (Tkachev, Mimmack et al. 2003) reported 
down-regulation of genes encoding major oligodendrocyte and myelination proteins, 
along with various oligodendrocyte transcription factors in post-mortem pre-frontal 
cortex brain of schizophrenic patients compared to controls. The authors validated their 
micro-array findings by quantitative PCR experiments to confirm the reductions in 
expression observed for the genes in schizophrenic brain. The genes reported to be down- 
regulated included the oligodendrocyte related genes; myelin associated glycoprotein 
(MAG), transferrin (TF), ErbB3, myelin basic protein (MBP), proteolipid protein 1 
(PLP1), myelin associated oligodendrocyte basic protein (MOBP), claudin 11 (CLDN11) 
and myelin oligodendrocyte glycoprotein (MOG) as well as the oligodendrocyte lineage 
transcription factors Oligl, 01ig2, and Sox 10.
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A further micro-array study (Aston, Jiang et al. 2004) reported significant 
decreases in the expression levels of the myelin related genes MAG, plasmolipin (PLLP), 
PLP1 and ErbB3 in the post mortem temporal cortex of schizophrenic subjects compared 
to controls. The authors also observed reduced expression of three further myelin related 
genes (MAL, TF and CNP) that had been previously reported to be under-expressed in 
schizophrenics (Hakak, Walker et al. 2001).
The altered expression of OMR genes is additionally supported by the results of a 
cDNA micro-array study (Sugai, Kawamura et al. 2004) where the genes MOBP, MBP 
and MAL were all reported to be significantly down regulated in post mortem 
schizophrenic brain. The authors also reported that genes involved in oligodendrocyte 
and myelin processes had the highest frequency of expression alterations in schizophrenic 
patients compared to controls in their study. Further support is provided by the results of 
another micro-array and qPCR study (Iwamoto, Bundo et al. 2005a) reporting the 
decreased expression of OMR genes including; SOX 10, OHg2, MAG, PLP1, MOBP and 
MOG in the prefrontal cortex of schizophrenic brain. Finally a recent micro-array 
analysis studying expression patterns of 15 different regions of post mortem 
schizophrenic brain compared to controls, with expression differences being subsequently 
confirmed by follow-up qPCR analysis in independent samples (Katsel, Davis et al. 
2005b) reported the down regulation of a large number of OMR genes in schizophrenia 
across multiple brain regions. The study reported down regulated expression results for 
the genes QKI, TF, MAG, CLDN5, PMP22, Sox 10, CNP, GSN, ErbB3, MAL, MOG, 
CLDN11 and 01ig2, in multiple regions of schizophrenic brain (Katsel, Davis et al. 
2005b).
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Recently two large studies by the same group (Katsel, Davis et al. 2005a; Katsel, 
Davis et al. 2005b) have reported that the largest expression differences and the greatest 
number of dysregulated OMR genes were observed in the cingulate cortex, the superior 
temporal gyrus and the hippocampus of schizophrenic brain. Most recently from the same 
group (Dracheva, Davis et al. 2006) has also reported region specific expression patterns 
of OMR genes in schizophrenic brain. The authors reported that the expression of MAG, 
CNP, SOX 10, CLDN11, and PMP22 was reduced in the hippocampus and anterior 
cingulate cortex but not in the putamen of the post mortem schizophrenic brains that they 
studied. It is interesting to note that the altered expression of OMR genes is not exclusive 
to schizophrenia but has also been observed in post-mortem brain from other psychiatric 
diseases including bipolar disorder (Tkachev, Mimmack et al. 2003; Iwamoto, Bundo et 
al. 2005a) and unipolar depression (Aston, Jiang et al. 2005).
It should be noted that not all of the global expression assays performed have 
reported the altered expression of OMR genes in schizophrenia. Some of the early studies 
(Mimics, Middleton et al. 2000; Middleton, Mimics et al. 2002; Vawter, Crook et al.
2002) did not detect expression differences in schizophrenic post-mortem brain which 
have subsequently been reported in multiple later studies. It has been pointed out that the 
variable reproducibility of the data may be attributable to methodological artefact, as the 
different arrays available in these studies may not have included probes for identical 
genes, or may have included probes for different gene transcripts (Katsel, Davis et al. 
2005c). Indeed it has been shown that different micro-arrays may produce different 
results even when the same samples are compared across platforms (Hollingshead, Lewis 
et al. 2005).
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Table 1.1 Summary of expression results for OMR genes in schizophrenia.
Table summarising the reported altered expression of oligodendrocyte and myelin related 
genes in schizophrenia. Showing the study, number of patients and controls studied, the 
brain regions studied and the OMR genes displaying altered expression.
Author Patients / Controls Brain region studied OMR genes displaying altered expression
Hakak et al, 
2001 12/12
Dorso-lateral pre­
frontal cortex
MAL, CNP, MAG, TF, GSN, ErbB3 (down- 
regulated)
Tkachev et al, 
2003 15/15 Pre-frontal cortex
MAG, TF, ErbB3, MBP, MOBP, CLDN11, 
MOG, PLP1, Oligl, 01ig2, Sox 10 (down- 
regulated) MPZL1, GFAP (up-regulated)
Aston et al, 
2004 12/14 Temporal gyrus
MAG, PLLP, PLP1, ErbB3, MAL, TF, CNP 
(down-regulated)
Sugai et al, 
2004 6 /6
Dorso-lateral pre­
frontal cortex MOBP, MBP, MAL (down-regulated)
Iwamoto et al, 
2005 13/15 Pre-frontal cortex
SOX 10, Ohg2, MAG, PLP1, MOBP, MOG 
(down-regulated)
Katsel et al, 
2005 30/25
Superior temporal 
cortex, Cingulate 
cortex, Hippocampus
QKI, TF, MAG, CLDN5, PMP22, CNP, Sox 
10, GSN, ErbB3, MAL, MOG, CLDN11, 
OHg2 (down-regulated
Dracheva et al, 
2006 13/13
Anterior cingulate 
cortex, Hippocampus
MAG, CNP, SOX 10, CLDN11, PMP22 
(down-regulated)
1.5.2. Neuroproteomic analysis:
There have currently not been many studies which have examined 
oligodendrocyte or myelin related genes at the protein level in schizophrenic brain. 
However, Flynn and colleagues (Flynn, Lang et al. 2003) reported that CNP protein 
levels were significantly reduced in the prefrontal cortex of schizophrenic brain. The 
reduction of CNP protein in schizophrenic brain has been subsequently replicated by two 
further independent groups in the prefrontal cortex (Prabakaran, Swatton et al. 2004) and 
also the anterior cingulate cortex (Dracheva, Davis et al. 2006).
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There is also further evidence for the potential involvement of OMR genes in 
schizophrenia pathology provided by the results of animal knockout studies. Lappe- 
Siefke and colleagues (Lappe-Siefke, Goebbels et al. 2003) produced a CNP knockout 
mouse which displayed both oligodendrocyte and axonal defects. The authors 
additionally reported that these CNP null mice displayed features of central nervous 
system pathology (reduced brain volume, enlarged ventricles and corpus callosum 
atrophy) consistent with some pathological features observed in schizophrenia (Harrison 
1999).
1.5.3. Imaging techniques provide evidence of white matter abnormalities;
Following the development of imaging techniques like magnetic resonance 
imaging (MRI), there is now a strong basis of evidence for white matter abnormalities in 
schizophrenia.
A meta-analysis of the MRI studies up till 1998 suggests reduction in the overall 
white matter volume in schizophrenic brain (Wright, Rabe-Hesketh et al. 2000). 
Reduction of white matter in the prefrontal cortex of schizophrenics has been reported 
(Buchanan, Vladar et al. 1998; Sanfilipo, Lafargue et al. 2000; Sigmundsson, Suckling et 
al. 2001), and this has additionally been shown to be associated with the negative 
symptoms of the disease. The use of MRI to study white matter changes has recently 
been complemented by the advent of other imaging techniques, including magnetic 
transfer imaging (MTI) and diffusion tensor imaging (DTI) which provides greater levels 
of resolution and detail on the white matter changes present.
MTI allows the indirect visualisation of protons bound to macromolecular 
structures, such as myelin and cell membranes in white matter (Foong, Symms et al.
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2001). These structures are essentially invisible to conventional MRI because of their 
very short relaxation times (Kubicki, Park et al. 2005). The exchange of magnetization 
between bound protons and free water is represented by the magnetization transfer ratio 
(MTR), which provides a quantitative measure of both the amount and structural integrity 
of the macromolecules in the tissue (Kubicki, Park et al. 2005). Thus MTI does not 
visualise myelin directly, but is instead interpreted as providing an index of the integrity 
of myelin. One of the earliest MTI studies of schizophrenia demonstrated a decrease in 
the myelin or axonal membrane integrity in the temporal regions of schizophrenic brain, 
as well as other widespread cortical regions (Foong, Symms et al. 2001). A more recent 
MTI study looking at first episode schizophrenic patients found reduced myelin integrity 
in the prefrontal cortex and other regions of the frontal lobe (Bagary, Symms et al. 2003). 
The existence of white matter integrity deficits at the onset of schizophrenia suggests that 
the abnormalities involving myelin may be of aetiological relevance rather than a 
consequence of disease progression or medication.
DTI measures the sum of the vectors of water diffusion. This sum represents the 
anisotropy of the particular tissue, which in turn is thought to represent the coherence of 
structures within that particular tissue or region. Tissue that is uniform and aligned along 
a similar axis will have a high anisotropy, whereas tissue that is disorganised and less 
uniform will have a lower anisotropy. DTI data are generally thought to reflect both the 
coherence of white matter bundles and also the degree to which myelin is wrapped 
around axons, and therefore normal axons and myelin which are aligned in the same 
plane have a higher anisotropy than disorganised structures which are aligned in multiple 
planes. The observation of lower anisotropy within white matter is thought to be due
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either to a loss of coherence in white matter fibre tracts, to changes in the number/density 
of interconnecting fibre tracts or to changes in myelination.
Recently there have been around 18 DTI studies on schizophrenia with most 
reporting white matter abnormalities (Kubicki, McCarley et al. 2005). Decreased 
anisotropy along white matter tracts have been found in numerous regions of 
schizophrenic brain including the prefrontal cortex, temporal lobes and the various 
regions connecting these regions such as the anterior cingulum (Lim, Hedehus et al.
1999; Agartz, Andersson et al. 2001; Wang, Sun et al. 2004). Although not providing 
conclusive proof, the decreases in anisotropy seen in many regions of the schizophrenic 
brain are consistent with the theory that a myelin and/or oligodendrocyte abnormality 
plays a part in schizophrenia aetiology, probably leading to a functional or structural 
deficit in connectivity.
Kubicki and colleagues (Kubicki, Park et al. 2005) performed both DTI and MTI 
analysis on the same brain regions of schizophrenic patients to try and define better what 
sort of abnormalities were present in schizophrenia. DTI displayed decreased anisotropy 
of white matter in widespread brain regions, with MTI analysis also displaying 
myelination alterations in many of the same brain regions. However, the authors also 
reported regions that were altered only in DTI analysis or MTI analysis. This was taken 
to be an indication that the white matter abnormalities observed in schizophrenia are 
likely to be caused by a combination of abnormal coherence, disorganisation of white 
matter fibre tracts and also myelin disruption, rather than just one type of abnormality. 
Whilst, DTI and MTI studies of schizophrenic brain are consistent with the presence of 
myelin abnormalities in schizophrenia, it should be noted that the findings do not 
definitively prove the existence of such abnormalities. The reduced anisotropy observed
in schizophrenic brain can also be explained by other processes such as changes in the 
number/density of interconnecting fibre tracts.
The majority of DTI studies have looked at chronic schizophrenic patients making 
it difficult to exclude the possibility that reduced anisotropy might result from ongoing 
medication and illness progress. However, recently several studies have tried to resolve 
this problem. Szeszko and colleagues (Szeszko, Ardekani et al. 2005) looking at first 
episode schizophrenic patients reported reduced white matter anisotropy in the frontal 
and temporal gyrus of schizophrenic brain, suggesting that the white matter abnormalities 
observed in schizophrenics are present at the onset of illness and are not the result of any 
secondary factors. A further study (Kumra, Ashtari et al. 2004) looking at early onset 
schizophrenia in adolescents reported lower anisotropy in frontal lobe white matter. This 
would suggest that the white matter abnormalities are present in schizophrenics at a 
young age and are not due to age or illness progression.
There are a few further interesting findings from DTI studies that have been 
reported, such as the correlations between white matter anisotropy and both negative 
disease symptoms and the level of performance when undertaking executive function and 
memory tasks (Kubicki, McCarley et al. 2005). Finally there have been decreases in 
anisotropy reported in several demyelinating diseases such as multiple sclerosis and 
various leukodystrophies, suggesting that DTI does in fact provide a true indication of 
myelin integrity and further supporting the involvement of a myelination deficit in 
schizophrenia (Davis, Stewart et al. 2003).
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1.5.4. Symptom overlaps with demyelinating disease:
If the evidence of white matter abnormalities observed in both schizophrenia and 
demyelinating diseases are due to similar defects in myelination one might expect to see 
some evidence of shared symptoms between the various diseases.
Metachromatic leukodystrophy (MLD) is a disease caused by an accumulation of 
sulfatides in the nervous system, which leads to widespread demyelination usually 
beginning in the frontal lobes of the brain. The rare late-onset form of MLD which 
develops during adolescence to early adulthood often presents with acute symptoms of 
schizophrenia, before leading to progressive mental deterioration (Davis, Stewart et al. 
2003; Stewart and Davis 2004). Psychotic symptoms have been shown to occur in about 
53% of late-onset cases of MLD, and possibly more importantly psychotic symptoms are 
only reported in cases presenting in adolescence and early adulthood which is the 
developmental period during which schizophrenia usually presents (Hyde, Ziegler et al. 
1992). The psychotic symptoms in MLD patients are only present during the early stages 
of the disease when the demyelination is restricted to the frontal lobes. As the 
demyelination spreads through the brain the psychotic symptoms disappear and are then 
replaced by neurological deficits and dementia (Hyde, Ziegler et al. 1992).
Multiple sclerosis (MS) is characterised by patches of demyelination throughout 
the central nervous system. The diverse locations lead to a wide variety of disease 
presentations and symptoms. Psychiatric symptoms are frequently reported in MS, 
although psychotic symptoms are rarely observed. The most interesting finding with 
regard to schizophrenia is the relationship between the location of demyelination in MS 
brain and the associated symptoms. For instance an MRI study (Honer, Hurwitz et al. 
1987) showed that although MS patients with psychiatric symptoms had the same number
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of overall lesions as MS patients with no psychiatric symptoms, their lesions were more 
abundant in the temporal lobe of the brain. A further study (Reischies, Baum et al. 1988) 
demonstrated that the severity of the psychotic symptoms observed in MS patients was 
correlated with the amount of demyelination in the frontal lobe rather than any other 
brain regions.
The differences between MLD and MS symptoms are of relevance to 
schizophrenia. The timing of the myelination defect appears to be important. In MLD if 
the disease presents in early adulthood or adolescence, the same age of onset period as 
schizophrenia, then the MLD patients often present with schizophrenic symptoms, indeed 
they are often misdiagnosed as schizophrenic (Hyde, Ziegler et al. 1992). However, MS 
has a later age of onset than schizophrenia and is rarely seen to present with psychotic 
symptoms (Davis, Stewart et al. 2003). Secondly, the location of the defect in 
myelination appears to be important. In MLD cases displaying psychotic symptoms the 
demyelination begins in the frontal lobes, however, when the demyelination expands to 
the rest of the brain there is an accompanied loss of psychosis (Hyde, Ziegler et al. 1992). 
MS on the other hand rarely presents with psychotic symptoms, but on the rare occasions 
that it does the majority of the demyelination lesions are found in the frontal and temporal 
lobes of the brain (Honer, Hurwitz et al. 1987; Reischies, Baum et al. 1988). These 
observations would suggest that defective connectivity in the frontal lobes of the brain 
caused by abnormalities in myelination is of relevance to the development of psychotic 
symptoms and possibly schizophrenia.
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1.5.5. Age related white matter changes:
The involvement of a myelination abnormality in schizophrenia aetiology would 
be additionally supported if the brain areas that have been previously implicated in 
schizophrenia such as the frontal lobe underwent developmental myelination events at the 
same time as the onset of schizophrenia. The expansion of white matter and the 
myelination process actively proceeds from childhood until the early twenties (Giedd, 
Blumenthal et al. 1999). Connections between the cortex and hippocampus have been 
shown to be actively myelinating during childhood, adolescence and adulthood (Benes, 
Turtle et al. 1994), whilst the frontal and temporal lobes are the last cortical regions to 
complete the myelination process (Goldman-Rakic and Selemon 1997). It is interesting 
that myelination processes occurring during late adolescence to early adulthood, the 
normal age of onset in schizophrenia, are concentrated in the frontal and temporal lobes 
of the brain, both regions which have been implicated in the aetiology of schizophrenia. 
This observation supports the possible involvement of these brain regions along with a 
white matter abnormality in the aetiology of schizophrenia. However, the association 
between the timing of myelination in the brain regions associated with schizophrenia and 
the typical age of onset in schizophrenia can only be seen as speculative.
1.5.6. Evidence of mvelin dysfunction and abnormalities in schizophrenia:
Direct examination of myelin sheaths in the brains of schizophrenia patients has 
demonstrated several ultrastructural abnormalities, including alterations to the myelinated 
fibres between the prefrontal cortex and caudate nucleus, along with a reduction in the 
compactness of the myelin sheath lamellae (Stewart and Davis 2004).
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An electron microscopy study (Uranova, Orlovskaya et al. 2001) looking at post­
mortem tissue from the prefrontal cortex and caudate nucleus of schizophrenic brain has 
demonstrated evidence of apoptosis and necrosis of oligodendroglial cells along with 
damaged myelin sheath lamellae, leading to the formation of concentric lamellar bodies 
(indicators of damaged myelinated fibres). The authors also reported that these dramatic 
changes in myelin ultrastructure could not be accounted for by the effects of any 
confounding factors such as post-mortem delay or neuroleptic medication.
Oligodendrocyte clustering and density have been reported to be significantly 
reduced in the white matter of the superior frontal gyrus of schizophrenic brain compared 
to controls (Hof, Haroutunian et al. 2002; Hof, Haroutunian et al. 2003). The authors of 
these two studies reported that oligodendrocyte clustering in schizophrenic subjects was 
30% lower than in control brain, and proposed that this reduced oligodendrocyte 
organisation might contribute to the reduced white matter tract coherence observed in 
schizophrenia. The authors additionally reported that the density of oligodendrocytes was 
28% lower in schizophrenics compared to controls. Finally the total number of 
oligodendrocytes present in the cortical layer III and white matter of Brodmans area 9 
(superior frontal gyrus) was also shown to be significantly reduced in schizophrenic brain 
(average reduction of 27%) compared to matched control subjects (Hof, Haroutunian et 
al. 2003).
There have also been further reports of reduced oligodendrocyte density in other 
regions of the brain. Uranova and colleagues (Uranova, Vostrikov et al. 2004) 
demonstrated a significant reduction (average reduction of 25%) of oligodendrocyte 
density in the prefrontal cortex of schizophrenic brain samples compared to controls. 
Stark and colleagues (Stark, Uylings et al. 2004) also reported a significant reduction
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(33%) in the number of glial cells observed in the anterior cingulate cortex of 
schizophrenic brain compared to healthy controls, although it should be noted that not all 
of the glial cells are oligodendrocytes.
Finally in the anterior thalamic nucleus of schizophrenic brain, Byne and 
colleagues (Byne, Kidkardnee et al. 2006) reported an average reduction of 17% in the 
volume of both neurons and oligodendrocytes. The authors also reported a significant 
40% reduction in the total number of oligodendrocytes along with a significantly reduced 
ratio of oligodendrocytes to neurons in the post-mortem schizophrenic brain studied.
1.5.7. Association analysis of oligodendrocyte and mvelin related genes:
As described above there is now evidence consistent with the presence of 
oligodendrocyte and/or myelination abnormalities in schizophrenic patients. However, 
the molecular mechanisms responsible for these defects are still uncertain, and it is not 
known whether the abnormalities are a cause or effect of schizophrenia. Whilst, the 
neuropathological and imaging studies support the presence of oligodendrocyte and/or 
myelin abnormalities in schizophrenia, the neuropathological evidence is still 
controversial and the imaging findings may be explained by several other processes. 
Evidence from micro-array studies does indicate the presence of altered OMR gene 
expression in schizophrenia, but again does not reveal whether these are primary or 
secondary effects. Genetic association studies of OMR genes are required to try and 
resolve whether the observed oligodendrocyte/myelination abnormalities in schizophrenia 
play a primary aetiological role in the disorder or whether they are secondary effects as a 
consequence of the disease. Recently researchers have started to perform association
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analyses targeting OMR genes to determine if they are significantly associated with 
susceptibility for the disease.
One gene which has received strong support for involvement in schizophrenia 
aetiology is neuregulin 1 (NRG1) (Stefansson, Sigurdsson et al. 2002; Stefansson, 
Sarginson et al. 2003; Williams, Preece et al. 2003; Li, Collier et al. 2006). Neuregulin 
has been shown to have numerous functions, including influences on nervous system and 
oligodendrocyte development, synapse formation, neuron-glial signalling, synaptic 
transmission and myelination (Calaora, Rogister et al. 2001; Corfas, Roy et al. 2004; 
Harrison and Law 2006). In vitro experiments studies have shown that NRG1 induces the 
differentiation of oligodendrocyte precursors (Vartanian, Fischbach et al. 1999), as well 
as inducing the proliferation and survival of oligodendrocyte precursors (Canoll, 
Musacchio et al. 1996; Fernandez, Tang et al. 2000). Recently it has been reported that 
one of the associated SNPs in NRG1 is predicted to lead to a gain/loss of a myelin 
transcription factor binding site (Law, Lipska et al. 2006).
The OMR gene which has received the most attention after NRG1 is reticulon 4 
(RTN4, also referred to as NOGO). RTN4 is a myelin associated protein that has been 
shown to inhibit the growth of neurons and nerve terminals. Interest in RTN4 was first 
generated by Novak and colleagues (Novak, Kim et al. 2002) who reported that RTN4 
mRNA was up-regulated in schizophrenic brain, and additionally reported a significant 
association between a genetic variant in the 3’UTR of the gene and schizophrenia 
susceptibility (this gene is discussed more thoroughly in chapter 4).
Another OMR gene where there has been more than a single report of association 
to schizophrenia susceptibility is myelin associated glycoprotein (MAG). MAG has been 
shown to be play important roles in myelination such as maintaining myelin-axonal
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contacts and the structure of myelin sheaths (Gravel, Peterson et al. 1996; Hakak, Walker 
et al. 2001) and has been reported to be down-regulated in schizophrenia (see section 
1.5.1). Association between MAG and schizophrenia has been reported in family and 
case-control based studies at both the individual and haplotype level (Wan, Yang et al. 
2005; Yang, Qin et al. 2005). However, it should be noted that although both studies were 
performed in Han Chinese populations there are inconsistencies in the patterns of the 
association findings, and until the results are confirmed by further replication studies the 
association should be viewed with caution.
A further gene that has recently been reported to be associated with susceptibility 
to schizophrenia is the quaking homolog KH domain RNA-binding gene (QKI) (Aberg, 
Saetre et al. 2006a; Aberg, Saetre et al. 2006b). The authors also demonstrated that two of 
the QKI mRNA splice variants are down-regulated in schizophrenic patients a finding 
which supports the findings of a previous micro-array study which reported that QKI was 
the most robustly down-regulated gene in their schizophrenic brain samples (Katsel,
Davis et al. 2005b).
There has also been association reported between other OMR genes and 
schizophrenia such as: oligodendrocyte lineage transcription factor 2 (OHg2) (Georgieva, 
Moskvina et al. 2006), myelin oligodendrocyte glycoprotein (MOG) (Liu, Qin et al.
2005), proteolipid protein (PLP1) (Qin, Gao et al. 2005), claudin 5 (Sun, Wei et al. 2004) 
and gelsolin (GSN) (Xi, Qin et al. 2004). However the results have yet to be replicated in 
independent samples.
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1.5.8. Possible role of oligodendrocyte and mvelin genes in schizophrenia:
Although the evidence for association between altered OMR function and 
schizophrenia is growing, the molecular basis for the putative altered function and how 
this might contribute to schizophrenia is still unknown. It is not yet clear whether the 
observed oligodendrocyte and myelin abnormalities in schizophrenia are a primary or 
secondary deficit of the disease.
One of the hypotheses of schizophrenia pathology is that the disease is caused by 
a disruption in connectivity between neurons, cortical areas and sub-areas in the central 
nervous system (Friston 1998). However, the basis of this potentially abnormal 
connectivity remains to be discovered. It has been proposed that the altered connectivity 
could be due to disruptions in either the ‘micro-connectivity’ (connections between 
adjacent cells) and/or disruptions in the ‘macro-connectivity’ (connections between 
different distinct brain regions) of schizophrenic brain. The presence of a white matter 
abnormality in schizophrenic brain would complement the hypothesis that schizophrenia 
is a disease caused by disrupted connectivity, as alterations to the myelination process or 
the oligodendrocyte structure of the brain could have profound effects on the connectivity 
of the brain at either the cellular or cortical level.
Thus I decided to focus this series of studies on genes involved with the 
oligodendrocyte and myelination processes and their potential involvement with 
increased susceptibility for schizophrenia.
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1.6. Strategy of the study:
The OMR genes studied were primarily selected based upon their reported altered 
expression in micro-array studies of schizophrenic brain, supported by positional 
evidence from linkage studies and/or the genes putative functional role in the 
neurobiology of schizophrenia.
At the time this project was initiated two micro-array studies had been published 
reporting the altered expression of genes in schizophrenic brain (Hakak, Walker et al. 
2001; Mimmack, Ryan et al. 2002). The first of these studies (Hakak, Walker et al. 2001) 
reported the down-regulation of a group of six genes related to oligodendrocyte and/or 
myelin function in the dorso-lateral prefrontal cortex of schizophrenic brain; myelin and 
lymphocyte protein (MAL), 2', 3'-cyclic nucleotide 3'- phosphodiesterase (CNP), myelin 
associated glycoprotein (MAG), transferrin (TF), gelsolin (GSN) and neuregulin receptor 
tyrosine kinase 3 (ErbB3).
The second study (Mimmack, Ryan et al. 2002) reported up-regulation of several 
members of the apolipoprotein L (APOL) gene family in the prefrontal cortex of 
schizophrenic patients compared to matched controls, a consistent up-regulation of the 
APOL 1, 2 and 4 genes was observed. In a subsequent real-time PCR study the authors 
displayed a 2.6 fold up-regulation of APOL 1, a 2.4 fold up-regulation of APOL 2 and a 
2.7 fold up-regulation of APOL 4 relative to control samples.
I therefore decided to begin this project by focusing my studies upon the genes 
displaying altered expression in these two micro-array studies. Altered gene expression 
can be attributable to either cis- or trans-acting effects. For the purposes of genetic
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association studies it is the former cis-acting sequence variants that are of interest, and I 
therefore, first sought to confirm whether the genes expression was influenced by ex­
acting polymorphisms. Where the presence of cX-acting variants was confirmed, the 
genes were then subsequently screened for evidence of association with schizophrenia 
susceptibility.
All of the OMR genes subsequently studied as part of this project (RTN4, 
RTN4R, OMG, NGFR, GFAP, MOG and SOX 10) were also selected for investigation 
based primarily upon reports of their altered expression in schizophrenic brain, supported 
by evidence from positional, functional or association studies. The experimental 
approaches used to study these genes varied and is described in more detail in each of the 
results chapter.
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Chapter 2. Materials and Methods:
2.1. DNA Samples:
Genomic DNA used in this study was derived from schizophrenia patients and 
blood donor control individuals. The case-control association sample consisted of 709 
Caucasian subjects with schizophrenia from the United Kingdom and Ireland (483 males 
and 226 females) and 710 controls (477 males and 233 females). Control subjects were 
group matched to the cases for age, sex and ethnicity and were recruited from the 
National blood transfusion service (Wales). All patients had a consensus diagnosis of 
schizophrenia according to DSM-IV criteria made by two independent raters following a 
semi-structured interview by trained psychiatrists or psychologists using the Schedules 
for Clinical Assessment in Neuropsychiatry interview (Wing, Babor et al. 1990) and 
review of case records. High levels of reliability (kappa >0.8) were achieved between 
raters for diagnoses. All cases were screened to exclude substance-induced psychotic 
disorder or psychosis due to a general medical condition. The mean age at first 
psychiatric contact was 23.6 (SD 7.7) and the mean age at ascertainment was 41.8 (SD 
13.5). The blood donor controls were not specifically screened for psychiatric illness but 
individuals were not taking regular prescribed medications. In neither country are blood 
donors remunerated even for expenses and as a result, blood donors are not enriched for 
substance abusers or socially disadvantaged people who may have relatively high rates of 
psychosis. Ethics committee approval was obtained in all regions where patients were 
recruited and informed written consent was obtained from all participants. Blood samples
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were taken and DNA extracted by other members of the Cardiff schizophrenia research
group.
2.1.2. Mutation screening sample:
A screening sample consisting of fourteen unrelated Caucasian schizophrenia 
patients (chromosomes =28) was used when screening for polymorphisms. All subjects 
were from the UK, met DSM-IV criteria for schizophrenia and also had at least one 
affected sibling. For the DHPLC mutation screening set, power was calculated using the 
equation: l-(l-f)n, where f  = allele frequency and n = number of chromosomes examined. 
Thus, a screening set of 28 chromosomes provided a power of 80% to detect 
polymorphisms with a minor allele frequency of 0.05, and a power of 95% to detect 
polymorphisms with a minor allele frequency of 0.1.
2.1.3. Pooled DNA samples:
The case control sample was made up of four separate stages the first three each 
containing 184 cases and 184 controls and the fourth containing 157 cases and 158 
controls giving a total number of 709 cases and 710 controls. The four stages of the 
sample were also available in a single pool. Equal volumes of quantified DNA for each of 
the samples within the four case and control stages were mixed together to create case 
and control pools for each stage. The total association sample provides a power of 94% to 
detect a variant with a minor allele frequency of 0.1, conferring an odds ratio (OR) of 1.5, 
at the 0.05 significance level. The pools were constructed by Nadine Norton as described 
(Norton, Williams et al. 2002). Briefly, the concentration of the DNA samples being used
60
to construct the pools was measured using the PicoGreen Quantification Reagent 
(Invitrogen, Paisley) in a Fluoroscan Ascent fluorimeter (Labsystems, Cambridge) and 
then diluted to 4ng/ul (+/- 0.5ng/ul). Pools were then constructed by combining equal 
volumes of each sample. All pools were then validated by genotyping several SNPs both 
in the pools and individually in the corresponding cases and controls that made up the 
pools.
2.1.4. DNA Extraction:
Genomic DNA was extracted from either blood, mouthwash or from sections of 
post-mortem brain tissue using standard laboratory procedures. The DNA concentration 
of each sample was assayed by taking spectrophotometer readings of DNA aliquots. 
Samples were subsequently stored at -20°C until required. I was not directly involved in 
the diagnosis or collection of patients or the extraction of DNA samples.
2.2. Characterisation of gene sequences:
With the emergence of the human genome sequence, there is now a multitude of 
information resources available for any given gene. This information is available on the 
Internet through various sources such as the UCSC Genome browser 
(http://genome.ucsc.edu/), Ensembl (http://www.ensembl.org/) and the National Centre 
for Biotechnology Information (NCBI) databases (http://www.ncbi.nlm.nih.gov/). 
Therefore these sites were the first point of reference for all candidate genes studied in 
this project.
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The cDNA sequence for each gene was initially obtained from either the NCBI 
website (http://www.ncbi.nlm.nih.gov), or the UCSC Genome browser 
(http://genome.ucsc.edu/). Intron/Exon boundaries were determined by alignment 
between cDNA sequence and genomic clones in the Genbank databases using the 
BLAST search program (http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi), or the BLAT 
sequence alignment software (http://genome.ucsc.edu/cgi-bin/hgBlat).
2.3. Polymerase Chain Reaction (PCR):
The polymerase chain reaction (PCR) is a technique used to rapidly amplify large 
quantities of a specific target section of genomic DNA, and is the initial step in all of the 
methods used in this project. The process requires two oligonucleotide primers which are 
specific to the target sequence being amplified. This means they must be complementary 
to the sequence directly flanking the target region and are generally about 15-25 
nucleotides in length.
2.3.1. Primer design:
PCR fragments for this project were designed to span exons, untranslated regions 
(UTR’s), 5’ and 3’ flanking regions and putative promoters. All of the primers used in the 
project were designed using the Internet program Primer 3.0
(www.genome.wi.mit/edu/cgi-bin/primer/primer3_www.cgi). This package checks the 
primers for primer pair compatibility, G-C ratio, primer dimers and hairpin formation. All 
of these things can affect the PCR efficiency and the quality of the end product produced. 
Primer 3.0 also provides a suggested optimum annealing temperature for each of the
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primer pairs. The designed primers were then ordered from Sigma-Genosys 
(http://orders.sigma-genosys.eu.com) (Haverhill, UK).
2.3.2. PCR conditions:
All PCR’s were performed on MJ thermocyclers (MJ Research) under standard 
conditions of lx PCR buffer (Qiagen), 1.5 mM MgC\j, 0.25mM of dNTPs, 0.8pmol of 
each primer, 0.5 units of Hotstart Taq polymerase (Qiagen) and 16ng of genomic DNA. 
The following PCR mixture for a 12pl reaction was used as a starting point for the 
optimisation of all the PCR reactions:
Reagent Volume Final Concentration / Amount
Genomic DNA template (4ng/pl) 4.0pl 16ng
Forward Primer (10pmol/pl) 1.0pl 0.83pmol
R everse Primer (10pmol/pl) 1-OjLil 0.83pmol
2.5mM dNTP mix 1.2pl 0.25mM
10x PCR Buffer (15 mM MgCI2.) 1.2pl 1x Buffer: 1.5 mM MgCI2
Hot Start Taq Polym erase (5u/pl) 0.1 pi 0.5 units
Distilled deionised PCR water Variable
DMSO (Optional) 0 .6-1 .2pl 5-10% of total rxn volume
Final Volume 12pl
Each of the different PCR reactions was optimised to find the most effective 
temperatures and conditions for unique amplification of the various fragments. Initially a 
genomic control sample was amplified at a gradient (range) of different annealing 
temperatures and the conditions generating the best product were selected for use in 
further experiments. Cycling conditions were one cycle at 95°C for 15 mins followed by 
35 cycles of 95°C 30 secs, appropriate annealing temperature 30 secs, 72°C 45 secs, and a 
final extension step at 72°C for 10 mins. A negative control containing water instead of
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genomic template was run with each PCR reaction to ensure reagents were not 
contaminated with genomic template. The PCR products were then separated by 
electrophoresis on agarose gels stained with ethidium bromide to check the product size 
and absence of amplification in negative controls.
2.4. Agarose Gel Electrophoresis:
Following PCR amplification, the products were checked to ensure that 
amplification had been successful. This was done by running the products on a 1.5-3.0% 
Agarose gel. The percentage of the gels varied depending on the fragment size and the 
required resolution of the product bands. (As the fragment size decreases, the gel 
percentage should increase to maintain optimal resolution.) This is true because at a 
higher percentage the small fragments will run more slowly through the gel and hence 
stay in a tighter band and give better resolution. For a 1.5% gel, 1.5g of agarose (standard 
grade, Sigma-Aldrich) was added to 0.5x TBE (50mM Tris pH 7.4, 50mM Boric acid ph
7.4, lOmM EDTA pH 8.0) buffer (ultra pure electrophoretic sequencing grade, National 
diagnostics) to give a final volume of 100ml. The mixture was heated until all the agarose 
was dissolved and then 1.5pl ethidium bromide solution (lOmg/ml) was added. The gel 
was poured into a gel former and the appropriate well formers were placed in the gel. The 
gel was then allowed to set at room temperature and the well combs removed carefully. 
The gel was then placed in 0.5 x TBE buffer. A 5-8pl aliquot of the PCR product, 
together with 3-5pl of a loading buffer (6x loading buffer: 15% Ficoll, 0.25% 
Bromophenol blue, 0.25% Xylene cyanol in water) was then placed in the wells and the 
gel run for about 30 minutes at 100 V in a gel tank. The DNA fragments were always run
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alongside a 1 kb DNA ladder (Invitrogen, Paisley UK) to confirm that the products were 
of the correct size. The gel was then visualised on a UV transilluminator to check product 
quantity, quality and specificity. Photographs were taken using a Kodak Electrophoresis 
Gel documentation and analysis system.
2.5. Post-PCR Purification:
Several of the techniques used in this project require the PCR products used to be 
purified of any unincorporated oligonucleotide primers and dNTP’s. To achieve this, an 
enzyme digestion reaction was used. One unit of shrimp alkaline phosphatase and 
exonuclease I (Amersham Life sciences) was added to 12pl of PCR product, and then 
incubated on a MJ thermocycler at 37°C for 1 hour followed by 20 minutes at 85°C in 
order to inactivate the two enzymes. The shrimp alkaline phosphatase dephosphorylates 
any excess dNTP’s rendering them inert whilst the exonuclease I digests remaining single 
stranded primers.
2.6. Denaturing High Performance Liquid Chromatography:
The identification of DNA sequence variation is one of the key steps in genomic 
analysis. There are numerous techniques available to do this. One of the most widely 
used methods available at the time I started my thesis for comparative DNA analysis was 
called Denaturing High Performance Liquid Chromatography (DHPLC). This is a highly 
sensitive and specific technique for detecting new or unknown sequence variation. The 
method depends upon the detection of heteroduplexes in PCR products by ion-pair 
reverse-phase high-performance liquid chromatography, under partially denaturing
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conditions which can be modified by the temperature at which the HPLC column is 
maintained (O'Donovan, Oefner et al. 1998). The sensitivity of the method is highly 
dependent on the temperature at which the analysis is undertaken. The optimal 
temperature for DHPLC was predicted using DHPLC Melt (Jones, Austin et al. 1999). 
The reaction is temperature sensitive because different DNA sequences will have unique 
compositions of bases and hence a varying amount of hydrogen bonds. These bonds 
require different levels of energy to break them and hence the sequences will have unique 
melting temperatures.
DHPLC offers significant advantages for high throughput screening of single 
nucleotide polymorphisms (SNPs) and short tandem repeats (STRs) in animal, bacterial 
and plant genomes. The procedure is almost totally automated which eliminates time and 
labour in gel preparation, running and analysis. A further advantage is that the PCR 
products are loaded directly without the need for purification. This again saves time and 
labour, but also saves money that would have been spent on purification. The technique is 
fast, cost effective and reliably detects single base changes, as well as small insertions 
and deletions (Jones, Austin et al. 1999). The method has proven to be reliable in several 
studies and the protocols used by me have been shown to have high specificity and 
sensitivity (O'Donovan, Oefner et al. 1998; Jones, Austin et al. 1999).
2.6.1. Chemistry of DHPLC:
DNA molecules are negatively charged. However the coated polystyrene beads 
comprising the stationary phase of the chromatography (DNAsep) column is neutral and 
hydrophobic, so therefore DNA fragments cannot directly bind to the column. A bridging
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molecule is required to help the binding o f the DNA to the stationary phase. This 
molecule is triethylammonium acetate (TEAA). Once the DNA is bound to the column it 
is only removed when the TEAA bridge is broken. This is achieved by the addition o f an 
organic solvent Acetonitrile (ACN). The column is washed in a solution containing an 
increasing ACN gradient until the DNA's bond to the column is broken and the DNA is 
eluted. Therefore the buffers containing the TEAA and ACN are important factors in the 
DHPLC method. See figure 2.1 for an explanation o f how TEAA binds the DNA 
fragments to the column.
Figure 2.1 Binding of DNA with the help of TEAA.
This figure shows how TEAA enables the DNA fragments to bind to the DHPLC column.
DNA
TEAA • The column matrix is electrically neutral
and hydrophobic.
• TEAA has a positively charged head and
a hydrophobic tail. This tail can therefore
*c
C3
bind to the hydrophobic column.
2 • The positive head of the TEAA attracts
C
B the negative DNA fragments and binds toC
J3 them.
oU • The bond between the TEAA and the
column is only broken when ACN is
added to the column.
• The ACN removes the DNA from the
column allowing it to be eluted.
ACN
The other principle behind DHPLC is the formation of heteroduplexes. A sample 
which is heterozygous for a single nucleotide polymorphism (SNP) has a 1:1 ratio o f each
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allele. Heating the PCR product to 95°C and then slowly cooling it hybridises the PCR 
products and forms a mixture of hetero- and homoduplexes. See figure 2.2 for an 
explanation of the production of heteroduplexes.
Figure 2.2 Heteroduplex formation.
This figure shows how the formation of heteroduplexes occurs. If an individual is 
heterozygous for a SNP then the PCR products derived from that individual will contain 
roughly equal numbers of molecules carrying each base at the polymorphic site of each 
allele, (in this case A and G). When the PCR products are denatured and then cooled 
slowly half the DNA forms homoduplexes and half will form heteroduplexes. This is 
where the DNA forms together with a corresponding strand from the other allele, (i.e A to 
C instead of A to T). Heteroduplexes are not as stable to heat denaturation as the 
homoduplexes. The significance of this will be explained later.
wild-type mutant heteroduplexes homoduplexes
AT
I I 
GC
i i  
! I
heat
cool
\
G T AT GC
V V II
Figure adapted from: (An introduction to the Transgenomic WAVE DNA analysis 
system, Transgenomic limited).
DHPLC analysis is performed at a temperature sufficient to partially denature 
(melt) the DNA hetero- and homoduplexes. The hetero- and homoduplexes can now be 
resolved from each other by ion-pair reversed-phase liquid chromatography. 
Heteroduplexes denature more completely at a lower temperature than a corresponding 
homoduplex (see figure 2.3). TEAA preferentially binds to double stranded DNA because
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of the reduced negative charge in a single stranded molecule. Hence more TEAA 
molecules bind under partially denaturing conditions to a homoduplex than a 
heteroduplex (See figure 2.3). As there is a reduced amount o f TEAA bound to the 
heteroduplexes they are bound less strongly to the DNAsep column than homoduplexes. 
This in turn means that they are eluted from the column at an earlier point in the ACN 
gradient because a lower ACN concentration is sufficient to disrupt the weaker TEAA- 
DNA bond. As the DNA is eluted from the column it is detected by a UV (260nm) 
detector and displayed as a chromatogram (see figure 2.5 for an example chromatogram).
Figure 2.3 Denaturation and TEAA binding.
This figure shows how TEAA binds differently to homozygotes and heterozygotes. A 
homozygote has more double stranded DNA than a heterozygote because it does not have 
a set o f mismatched base pairs making it unstable. TEAA preferentially binds to double 
stranded DNA, therefore more TEAA will bind to a homozygote than a heterozygote. The 
increased level o f TEAA means that homozygotes are bound to the column more securely 
and hence are retained by the column longer on the ACN gradient than a heterozygote.
Homozygote Heterozygote
Large area o f single stranded DNA 
due to the instability o f a mismatched 
base pairs in a heteroduplex.
2.6.2. DHPLC Method:
Polymorphism detection was performed by using DHPLC on a Wave™ DNA 
Fragment Analysis System (Transgenomic). The first step in the process was to amplify
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the desired fragment of genomic sequence using a PCR reaction. Before analysis the 
specific melting temperature for the fragment had to be determined. This was done by 
using the DHPLC melt program: (http://insertion.stanford.edu/melt.htmD. The genomic 
sequence for the fragment was pasted into the program which calculated the optimum 
melt temperatures for analysis as well the recommended buffer gradient. Experience in 
the laboratory suggests that a simple correction has to be performed on the suggested 
buffer gradient in order to determine the optimal gradient for use when analysing the 
fragment. The gradient of the buffers is important because it determines when the DNA 
fragments are washed off the DHPLC column. The higher the percentage of buffer B the 
more likely the DNA will be washed off.
DHPLC melt gives the recommended melting temperature for the fragment and 
the corresponding value for B3 at that temperature (see figure 2.4). The value of B3 is 
required in order to calculate the gradient of the ACN buffer to be run. In the example 
below (figure 2.4) the recommended temperature is 62°C. The samples were also run at a 
higher temperature 2°C above the recommended in this case 64°C. This higher 
temperature ensures maximum sensitivity (Jones, Austin et al. 1999). Before the analysis 
was started the gradient of the ACN buffer to be run was calculated. This is done by 
using the value of B3 at the recommended melting temperature. In figure 2.4 the value of 
B3 at 62°C is 63.8. In order to calculate the ACN buffer gradient I subtracted 2-3 off the 
B3 value to determine the percentage of the ACN buffer to use at the start of the gradient 
and then added 8 to this value in order to determine the percentage of the buffer that 
should be run at the end of the gradient. This gives you the increasing range of the ACN 
buffer concentrations required be run on the DNAsep column in order to elute the DNA
fragment (in figure 2.4 the gradient is 60.8%-68.8%). When the reaction was started the 
percentage of ACN buffer being injected into the column is at the lowest value, and then 
as the reaction progresses the concentration increases until the upper value is reached at 
the end of the gradient. Normally the DNA fragment is eluted from the DNAsep column 
at the mid-point of the gradient and washed off to be detected by the UV detector.
See figure 2.4 below for a sample DHPLC melt output and calculation:
Figure 2.4: Example Melt output for a DNA fragment:
This figure shows an example melt output that was calculated for a DNA fragment. The 
fragment was subsequently analysed at the recommended temperature of 62°C and also at 
64°C. The temperature of +2°C was run to maximise sensitivity (Jones, Austin et al. 
1999).
Melting temperature of entire strand: 61.75°C
Temperature = 58° Celsius: 496-497 
Temperature = 59° Celsius: 494-495,
Temperature = 60° Celsius: 490-493,
Temperature = 61° Celsius: 1-24,
Temperature = 62° Celsius: 25-489,
This sequence should be run at all of the following 
temperatures to ensure detection of all polymorphisms.
Recommended temperature: 62°
The following concentrations are rough recommendations 
only. Some adjustment may be necessary. Run from 
B1 to B2 in 0.5 minutes, then B2 to B3 in 3.0 minutes.
Temperature (°C) B1 B2 B3
62 50.0 58.4 63.8
61 50.0 59.8 65.2
60 50.0 61.2 66.6
59 50.0 62.5 67.9
where B=0.1M TEAA, pH 7, 25% acetonitrile
This section provides the corresponding value of B3 
for the fragments various melting temperatures 
enabling the calculation of the ACN buffer gradient 
required to elute the DNA from the DNAsep column
This section shows the different melting 
temperatures for the DNA fragment and 
which section of the fragment (bp) are 
melted at that temperature.
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Before the PCR samples are analysed by DHPLC the denaturation step was 
carried out, by heating the sample to 95°C for 5 minutes and then cooling to 45°C at a 
rate of 1 °C/minute, to promote the formation of heteroduplexes. 5-10pl of the PCR 
product was then injected onto the DNAsep column using a Transgenomic WAVE DNA 
analysis system (Transgenomic Limited). The product was then eluted using the 
calculated acetonitrile gradient in 0.1 M (TEAA) buffer pH7.0, at a constant flow rate of 
0.9ml/min. The gradient was calculated as described above. The gradient is produced by 
mixing buffer A (0.1 M TEAA, 0.1 mM EDTA) and B (25% Acetonitrile, 0.1M TEAA). 
The eluted DNA fragments were detected by a UV detector set at an absorbance of 
260nm, which then produced a chromatogram (see figure 2.5). Analysis took between 5 
and 8 mins/sample including column equilibration and cleaning. Once the analysis is 
complete the chromatograms are interpreted visually in order to determine the presence 
of heteroduplexes.
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Figure 2.5: Example of DHPLC chromatogram outputs.
This figure shows an example of two o f the chromatograms produced when fragments 
were analysed. In the second chromatogram you can see a distinct change in the 
pattern of the peak which indicates heteroduplex formation.
T his contains excess primers and 
dNTPs. Also any PCR product which 
h asn ’t  bound to the column is washed
1 . 5
1.0  -=  
0 . 5  
0.0
Target DNA peak. 
This represents your 
PCR product.
Accelerator/Clean u p  peak.
This peak is where any PCR product 
and genomic template that is still 
bound to the column is washed off. 
The column is also equilibrated 
during this period ready for the next 
sample to be run.
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If a possible heteroduplex was found, the PCR products representing a 
heteroduplex and a homoduplex (normally at least two of each type) were sequenced 
in order to determine the sequence variation present in the fragment.
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2.7. DNA Sequencing:
Automated sequencing was carried out using an ABI 3100 automated 
sequencer, and the Big Dye™ Terminator Cycle Sequencing Ready reaction Kit (PE 
Biosystems.) This is based upon Sanger dideoxynucleotide sequencing, with the four 
ddNTPs being labelled with four different fluorophors. Each fluorophor has a 
different emission wavelength when excited by the laser in the ABI 3100, which 
allows all four termination reactions to be performed in a single tube. The relative size 
of each terminated sequencing product is then determined by electrophoresis in a 
capillary.
2.7.1. Pre-Sequencing Purification:
PCR reactions were cleaned prior to sequencing using one of two techniques. 
Either the QIAquick PCR purification kit (Qiagen), and a microcentrifuge, or a 
multiscreen PCR purification plate (Millipore) and a plate centrifuge. The processes 
remove residual dNTPs, primers and buffer from the PCR products by 
chromatography.
2.7.2. Sequencing Reaction:
Sequencing reactions were performed using the Big Dye Terminator cycle 
sequencing kit (Applied Biosystems) in a total reaction volume of 10pl. Two 
reactions were performed for each PCR fragment, one using the forward PCR primer 
and one the reverse primer. The reaction mix and thermocycling conditions used are 
detailed below:
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Sequencing Reaction Mix:
Big Dye Terminator Mix 2 pi
Big Dye Sequencing Buffer 2pl
Primer (F or R) (5 pmol) 1 pi
Purified PCR product 5 pi
Thermocvcling conditions:
96°C
96°C
50°C
60°C
2 mins
10 secs
5 secs y  25 cycles 
4 mins
2.7.3. Post-Sequencing Purification:
In order to generate high quality DNA sequence data it is important to remove 
unincorporated dye terminators, salt and any other impurities from the sequencing 
product prior to electrophoresis. This was achieved by gel filtration, using Sephadex 
(Sigma) loaded Multiscreen HV filtration plates (Millipore). Dry Sephadex G-50 resin 
was added to the 96 wells of the filtration plate using a column loader (Millipore). 
300pl of ddBhO was then added to each well to hydrate the resin and the plate left to 
stand at room temperature for 3 hours. Before use the filtration plate was then placed 
on top of a 96 well collection plate and spun in a centrifuge at 2500 rpm (900xg) for 5 
min to remove any excess water and compact the columns. The individual sequencing 
products were diluted with 10pi of ddF^O and added to the centre of the individual 
columns. The filtration plate was then placed on top of a fresh 96 well plate, secured 
in position and spun at 2500 rpm (900xg) for 5 min. The eluted sequencing products
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were then dried down using a speed vacuum before being prepared to run on the 
capillary sequencer.
2.7.4. Sequencing Sample Electrophoresis:
Purified sequencing products were prepared for electrophoresis by being 
resuspended in lOpl Hi-Di Formamide (Applied Biosystems). They were then 
subsequently run on an ABI PRISM® 3100 Genetic Analyser using a 36cm capillary 
array and Pop-6™ polymer. The resultant sequencing data was analysed using 
Sequence Analysis software (PE Applied Biosystems) before being imported into 
Sequencher (Gene Codes Corporation) for identification of polymorphisms.
2.8. Pooled Genotyping:
Where possible all the SNPs studied in this project were typed by pooled 
genotyping in order to assay their allele frequencies for association with 
schizophrenia. Pooled genotyping was performed by primer extension using the ABI 
PRISM® SNaPshot™ Multiplex kit (Applied Biosystems).
2.8.1. SNaPshot Genotyping:
The SNaPshot procedure is based on the dideoxy single base extension of an 
unlabeled oligonucleotide primer. The primer binds to a complementary template in 
the presence of fluorescently labelled ddNTPs and AmpliTaq DNA Polymerase. The 
polymerase extends the unlabelled primer by one nucleotide, adding a single ddNTP 
to the 3' end. The ddNTPs are each labelled with a unique fluorescent dye so that they 
can be distinguished after electrophoresis on an ABI 3100 sequencer (see table 2.1). 
Depending upon which base is present at the polymorphic site, a different ddNTP is
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incorporated at the end o f  the primer, therefore allowing the base at the polymorphism 
to be identified (See figure 2.6).
Table 2.1: Fluorescent ddNTPs used in SNaPshot genotvning:
ddNTP Dye Label Colour in Analysed Data
A dR6G Green
C dTAMRA Black
G dRl lO Blue
T (U) dROX Red
Figure 2.6: Diagram of SNaPshot extension reaction:
The 3’ end o f the extension primer should terminate directly adjacent to the 
polymorphic base as shown below. When you carry out the extension reaction the 
primer will anneal to the sequence and the ddNTPs will extend the primer by one 
base. Depending upon which o f  the alleles is represented in the sample you will get 
different coloured peaks when the data are analysed. In the case o f a heterozygote you 
will get two different coloured peaks the same size but they w ill be roughly half the 
height o f the normal homozygote peaks.
Identify SNP in the genomic DNA and
design extension primer. 1______________ G to T
^  Polymorphism
5’-N N N AGCAT GCT CAATCGAAT CCAG N N N N N-3’
Anneal unlabelled extension primer.
5’-TCGTACGAGTTAGCTTAGGT-3’ (20bp Extension Primer)
5’-NNNAGCATGCTCAATCGAATCCAGNNNNN-3’
^ ---------------------Target Nucleotide
Extend primer in the presence of ddNTPs.
^ ------------------ Dye labelled ddNTP
5’-TCGTACGAGTTAGCTTAGGTA-3’
5’-N N NAG CAT GCT CAAT CGAAT CCATN N N N N-3’ (M utation)
5’-N N N AGCAT GCT CAAT CGAATCCAG N N N N N-3’ (Wildtype) 
5’-TCGTACGAGTTAGCTTAGGTC-3’
^ ------------------ Dye labelled ddNTP
Analyse using an ABI 3100 sequencer, to resolve the extension products 
and therefore determ ine genotype.
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2.8.1.1 Extension Primer Design:
Single base primer extension reactions do not allow flexibility with respect to 
the location of the 3’ end of the primer, with the exception of using either the sense or 
anti-sense strand of the sequence. It is therefore important to assess the sequence 
flanking the SNP in order to enable an optimal primer to be designed. All the 
extension primers used in this project were designed by me using software developed 
in house by Dobril Ivanov (http://m034.pc.uwcm.ac.uk/FP_Primer.html). This 
software assess the secondary structure of all the possible extension primers, 
determines the optimal length of the primer and whether to use the sense or anti-sense 
DNA strand.
2.8.1.2 SNaPshot Reaction:
Each DNA pool sample was PCR amplified in triplicate along with a 
heterozygote for the SNP of interest and a negative control. PCR products were 
purified as described in section 2.5. Extension reactions were performed as detailed 
below:
Reaction Mix:
Purified PCR Product 2.0pl
SNaPshot Kit 1.25pl
SnaPshot Buffer 3.75 pi
(200mM Tris-HCl. 5mM MgCl2)
Extension Primer (5 pmol/pl) 0.1 pi
ddFEO____________________________2.9ul
Final reaction volume lOpl
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Thermocvcling conditions:
94°C for 2 min
94°C for 5 sec
43°C for 5 sec I  25 Cycles
60°C for 5 sec J
15°C forever
Following the extension reaction, samples were treated with 1 U of shrimp 
alkaline phosphatase at 37°C for 1 hour followed by 20 min at 85°C. Left untreated, 
the unincorporated fluorescent ddNTPs co-migrate with the labelled primers of 
interest. Removal of the 5’ phosphoryl groups by phosphatase treatment alters the 
migration of the unincorporated fluorescent ddNTPs and thus prevents interference. In 
order to prepare the samples for electrophoresis 1 pi of treated extension product was 
added to 9pl of HiDiformamide (Applied Biosystems).
The samples were run on the ABI PRISM® 3100 Genetic Analyser using a 
36cm capillary and Pop4 polymer (Applied Biosystems). The ABI 3100 separates 
fragments by capillary electrophoresis. The capillaries contain the GeneScan Polymer 
(POP4). Samples are loaded by electrokinetic injection; the capillary and electrode are 
placed into the sample, voltage is applied, and the negatively charged DNA enters the 
capillary and migrates toward the positive electrode at the other end of the capillary. 
As the DNA fragments in the capillaries pass the detection cell they are illuminated 
by a laser. This light excites the attached dye labels causing them to fluoresce. The 
fluorescence that is emitted is separated by wavelength (each dye has a unique 
spectral profile/colour) and recorded by a charge-coupled device (CCD) camera. The 
fluorescence information is then converted into electronic data, which are processed 
by the Genescan Analysis v3.7 (Applied Biosystems) data collection software. The 
output were then analysed using the program Genotyper® v2.5 (Applied Biosystems).
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The only element in the SNaPshot primer extension reaction that is altered for 
different polymorphisms is the amount of extension primer added to the reaction. This 
is of particular importance when genotyping DNA pools where, for accurate 
estimation of allele frequencies, peak heights representing the product corresponding 
to each allele (which are a direct count of the fluorescence emitted) should be above 
1000 and below 6000 relative fluorescence intensity units. Genescan analysis software 
is unable to accurately quantify fluorescent signals outside this range. Analysis of the 
peak heights obtained in optimisation reactions determine the appropriate 
concentration of extension primer to use for further experiments. If the peak heights 
were above 1000 but below 6000, the extension primer concentration would remain at 
5 pmol/pl for genotyping the pools. However if the peak heights were above 6000 or 
below 1000, the concentration was adjusted to correct the heights accordingly. The 
concentration (c) of the extension primer for the required peak height is calculated as 
c =Y’/(Y/X) where, Y’ = required peak height, Y = initial peak height, and X = 
initial primer concentration (Norton, Williams et al. 2002). The estimated allele 
frequency in each pool was determined as the mean of three primer extension assays 
after correction for the degree of unequal allelic representation detected in a 
heterozygote described as ‘Correction for unequal allelic detection’.
2.8.1.3 Correction for Unequal Allelic Detection:
For a bi-allelic marker, the primer extension products for each allele are not 
equally represented. Possible explanations include differential PCR amplification of 
alleles and differential efficiencies of incorporation of the ddNTPs for each allele 
specific reaction (Norton, Williams et al. 2002). A further explanation is the unequal 
emission energies of the different fluorescent dyes. In order to allow for unequal
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representation of alleles the estimated allele frequencies from pools were corrected 
using the mean of the ratios obtained from the analyses of four heterozygotes using 
the equation:
Frequency of allele A /(a) = A/(A+kB) where A and B are the peak 
heights of the primer extension products representing alleles A and B in 
pools, and k = is the mean of the four replicates of A/B ratios observed in 
a heterozygote (Hoogendoorn, Norton et al. 2000).
Based upon the number of subjects in each pool, the estimated allele 
frequencies can be used to estimate the number of each allele in the pool. The allele 
numbers in the cases and controls are then used to test for allelic association using a 
Chi-squared test under 1 degree of freedom. Any SNP showing an allelic association 
in the pools at the p=0.05 level was typed individually in the case control sample.
2.9. Allelic Expression Assay:
Genetic influences on gene expression may be either cis-acting or trans-acting. 
Cis-acting factors usually operate through effects on RNA transcription, RNA 
stability or translational efficiency and are usually located within the affected gene 
locus itself, although they can also be located some distance from the coding 
sequence. Trans-acting factors usually operate remotely on both copies of a gene, 
such as effects on transcription factors or hormones, and are not physically located at 
the influenced gene locus. Recently, it has been proposed that the expression of an 
identified disease gene can be used as an endophenotype for quantitative linkage 
analysis (expression quantitative trait loci; eQTL), and may therefore provide a
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method for mapping both cis- and trans-acting polymorphic loci which affect gene 
expression and modulate disease susceptibility. However, in order to assay the genes 
studied in this project for potential cis-acting influences on gene expression I used a 
highly quantitative allele specific expression assay developed in the host department 
(Bray, Buckland et al. 2003a; Bray, Buckland et al. 2003b).
The principle of the assay is that in heterozygous carriers of a cis-acting 
polymorphism that affects the transcription or stability of a species of mRNA, the 
quantity of mRNA originating from each gene copy will be unequal. The simplest 
method for distinguishing between mRNA molecules originating from each copy of a 
pair of autosomal genes is to use an exonic polymorphism as a copy specific tag 
(Bray, Buckland et al. 2003a). It is then possible to apply quantitative methods of 
allele discrimination to mRNA samples originating from individuals who are known 
to be heterozygous for the marker polymorphism in order to measure relative copy 
expression (Bray, Buckland et al. 2003a). Factors that can influence the measured 
amount of total expression of a specific gene (e.g. tissue preparation, mRNA quality, 
drug exposure, pre-agonal state, hormones, trans-effects secondary to regulatory 
polymorphisms in other genes) will, in the absence of a cis-acting allele-specific 
interaction, influence the amount of mRNA originating from each chromosome 
equally, and are therefore controlled for by this assay. While not allowing the 
measurement of total RNA abundance, the allelic expression assay does have the 
major advantage of allowing the detection of small polymorphic cis-acting influences 
even in the face of large trans-acting influences.
Post-mortem brain tissue was obtained from frontal, parietal or temporal 
cortex of 60 white European unrelated anonymized human adults of whom 50 were
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from the UK (the MRC London Neurodegenerative Diseases Brain Bank) and 10 
were from Sweden (Department of Clinical Neuroscience, Karolinska Institute, 
Stockholm). All were free from a diagnosis of psychiatric or neurological disorder at 
the time of death. Genomic DNA and RNA were extracted from each individual tissue 
sample, with subsequent DNAse treatment of RNA. All of the DNA/RNA extraction 
and subsequent reverse transcription was kindly performed by Nick Bray (Bray, 
Buckland et al. 2003a).
Heterozygotes for the transcribed marker SNP were identified by genotyping 
genomic DNA from all subjects. Allelic expression was estimated as described by 
(Bray, Buckland et al. 2003a; Bray, Buckland et al. 2003b). Briefly, DNAse-treated 
RNA samples were subject to RT-PCR, primer extension with allele-specific dye 
terminator incorporation using the proprietary SNaPshot kit (PE Applied Biosystems), 
and the relative levels of the products representing each transcribed allele measured 
on a capillary sequencer. Samples were assayed using primers based on single exonic 
sequence, capable of amplifying either genomic DNA or cDNA. The cDNA samples 
were assayed alongside the corresponding heterozygote genomic DNA, which 
represents the assay output in the presence of a perfect 1:1 ratio of the two alleles. The 
ratio obtained from genomic DNA thus provided a correction factor for any 
inequalities in the efficiency of allelic representation specific to each assay 
(Hoogendoom, Norton et al. 2000). Absence of genomic DNA in the RNA extracts 
was confirmed by including RNA samples that had not been reverse transcribed. 
Analysis of heterozygous samples was performed as two separate experiments. In 
each experiment, two cDNA samples were assayed in duplicate for each heterozygous 
individual (as two separate RT reactions), alongside the corresponding genomic DNA 
sample.
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When assessing the results of the expression assays an arbitrary threshold of a 
20% relative expression difference was used to indicate the presence of a cis-acting 
variant affecting gene expression as described by (Yan, Yuan et al. 2002; Bray, 
Buckland et al. 2003a). On the result graphs this threshold is represented by a ratio 
greater than 1:1.2 or lower than 1:0.83.
Calculation of power for allelic expression assays is based upon the binomial 
distribution, Hardy-Weinberg equilibrium at the regulatory SNP, and no LD with the 
marker SNP. The probability of an individual being homozygous at a putative 
regulatory locus with alleles in Hardy-Weinberg equilibrium is p 2 + q2, where p  and q 
are the two allele frequencies. The probability of n individuals all being homozygous 
(and therefore not detected in the allelic expression assay) for a regulatory 
polymorphism is then (p2 + q2)n. This also applies for n individuals selected for 
heterozygosity at the marker locus if there is no relationship (ie LD) between the
9 9 mgenotypes at each locus. The power to detect one heterozygote is then 1 -(p + q ) . If 
the marker and the regulatory variant are in LD, the power will be increased as a 
higher proportion of people selected for heterozygosity at the marker locus will also 
be heterozygous for the regulatory variant.
2.10 Individual Genotyping:
A variety of techniques were used to perform this including SNaPshot, 
Acycloprime™ Fluorescence Polarisation (FP), Amplifluor (Fluorescence Intensity) 
and Sequenom MALDI-TOF genotyping. These are described in greater detail below.
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2.10.1 SNaPshot Genotyping:
In order to genotype individual DNA samples using the SNaPshot kit (Applied 
Biosystems), samples were individually amplified in a standard 12pl PCR reaction, 
and then processed in the same way as explained for pooled DNA samples (see 
section 2.8.1 above). When the data are imported into Genotyper for analysis the 
peaks are manually labelled in order to distinguish between the homozygotes of both 
alleles and heterozygotes. The results are then converted into a table and exported into 
an Excel workbook containing all of the sample information. The cases and controls 
are then separated according to their sample IDs, and the genotypes counted and 
formed into contingency tables for statistical analysis.
2.10.1.1 Multiplex SNaPshot genotyping:
Due to the high cost of genotyping samples individually using SNaPshot the 
genotyping assays are usually run as multiplexes. To type multiple SNPs 
simultaneously the assays need to be designed to ensure that none of the reaction 
products conflict with each other on the SNaPshot electrophorogram. To achieve this, 
the extension primers are designed to be different lengths ranging from 15-35bp long 
with a minimum gap between each SNP of around lObp. It is also possible to assay 
two SNPs using extension primers that are the same length if the SNPs do not have 
any incorporated ddNTPs in common. It is also possible to use a mixture of forward 
and reverse extension primers in the assay allowing a further degree of flexibility. By 
using a combination of forward and reverse primers it is usually possible to design 
multiplexes containing 6-8 SNPs depending on the specific composition of the alleles 
present.
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Sequences containing SNPs of interest are either amplified by PCR as separate 
reactions and then pooled together or are amplified as part of a multiplex PCR 
reaction. The PCR product is then cleaned as described in section 2.5. The SNaPshot 
reaction is performed as described in section 2.8.1, except that multiple extension 
primers are added to the reaction. The assay is then run and analysed on the ABI 3100 
genetic analyser along with the internal size standard (LIZ 120) (Applied biosystems). 
The data are then exported into Genotyper 2.5 (Applied biosystems) and the 
genotypes determined. It is important to optimise the SNaPshot reaction to ensure that 
the allele peak heights are within the acceptable range and that all of the alleles are 
distinguishable from each other on the electrophorogram as the output is not 
determined by size alone but also in part by conformation.
2.10.2 Acycloprime™ Fluorescence Polarisation (FP):
The Acycloprime-FP process is also based upon single base primer extension 
using one of two fluorescently labelled ddNTP terminators. The identity of this base is 
determined by the increased fluorescence polarization of its attached dye (Hsu, Chen 
et al. 2001; Kwok 2002). The principle is that variation in fluorescence polarization 
occurs between fluorescently labelled molecules of different molecular weight. A 
small molecule containing a fluorophore rotates and tumbles rapidly, whereas a large 
molecule rotates and spins more slowly. If a polarising light is used to excite the 
fluorphore, small molecules will emit light in all directions and the degree of 
polarisation will be lost. However, large molecules rotating slowly tend to emit more 
light in the plane of polarisation therefore maintaining high levels of fluorescence 
polarisation (see figure 2.7) (Kwok 2002).
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Figure 2.7: Fluorescence polarisation.
Adapted from the Perkin Elmer website: (www.perkinelmer.com/lifesciences).
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observed
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A fluorophore linked to a large 
molecule has slow motion and the 
emitted light remains polarised
A fluorophore linked to a small 
molecule has fast motion and 
the emitted light is depolarised
To perform the assay 4pl o f each DNA sample was aliquoted into 96 well 
PCR plates (ABgene) and a standard 8pi PCR cocktail aliquoted into the PCR plates 
containing the DNA samples. The samples were then amplified using standard PCR 
cycling conditions (as described in section 2.3) and then cleaned to remove any 
unincorporated dNTPs and unused PCR primers using the standard SAP and EXO I 
PCR purification method (as described in section 2.5). Following clean up o f  the 
PCR, 5 pi o f the product was aliquoted into 96 well black PCR plates (ABgene). Each 
AcycloPrime FP reaction only uses a mix o f  two ddNTPs (Acyclo Terminator mix), it 
is therefore important that the correct ddNTP mix, corresponding to the two alleles o f 
the SNP being genotyped is used. The ddNTP combinations used are G/A, G/C, G/T, 
C/A, C/T and A/T and are all labelled with R110/Tamra fluorescent dyes. The 
extension primer is diluted to 1 Opmol/pl and the number o f  reaction cycles is variable,
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with the majority of assays working at 10-25 cycles. For each individual reaction the 
following reaction mix is added to the PCR:
Reaction Mix:
Purified PCR product 5.0pl
ddH20  2.975pl
Extension Primer (10pmol/pl) 0.5pl
Terminator Mix 0 .5jli1
Reaction Buffer 1 .Opl
Acvclonrime Enzyme_____________ 0.025ul
Total reaction volume lOpl
The samples extension reactions are run as follows:
Thermocvcling conditions:
95°C 2 min
95°C 15 sec-i
55°C 30 sec J 5 - 3 0  cycles
Once the primer extension reaction has been completed the samples were 
chilled for about 10 minutes before being analysed. This increases viscosity and 
exaggerates the effect of molecular size on fluorescence polarization. The samples are 
then analysed using an Analyst HTS Assay Detection platform (LJL Biosystems) 
which is a fluorescence polarization (FP) capable fluorometer. After analysis the data 
is imported into an Excel macro (available from Perkin Elmer) and the genotypes 
scored by cluster analysis. See example of output graph below:
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Figure 2.9: Example of an FP genotyping output graph.
The graph shows one o f the FP genotyping output graphs generated during the 
individual genotyping o f the CNP rs 12952915 polymorphism. The clusters represent 
the different types o f genotype, with the small cluster near zero representing the 
reaction dropouts and negative controls.
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2.10.3. Amplifluor:
This technique is based on PCR amplification o f genomic DNA using two, 
allele-specific tailed primers that introduce priming sites for universal energy-transfer 
labelled primers. The reaction requires a single step and no post-PCR handling 
(Myakishev, Khripin et al. 2001). The assays are designed with the use o f the 
Amplifluor™  Assay Architect™  software available at the amplifluor website 
(www.serologicals.com).
Genomic DNA is PCR amplified in the presence o f five primers: Two forward 
allele-specific tailed primers, a single reverse primer, and two ‘universal’ energy- 
transfer labelled primers each containing a sequence identical to one o f  the allele 
specific tailed primers and labelled with either a green dye (fluorescein, FAM) or a
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red dye (sulforhodamine, SR). The aim of the assay is to have one homozygote yield 
green fluorescence only, the other homozygote red only, and the heterozygote a mix 
of red and green fluorescence. The two different allele specific primers contain a 
single allele specific nucleotide at the 3’ end preceded by 15-20bp complementary to 
the sequence flanking the SNP. They then each have a different ~20bp tail at the 5’ 
end of the primer which is identical to the 3’ tail of one of the energy-transfer labelled 
primers. The sequence for the common reverse primer is chosen to avoid any inverted 
repeats and overlap with any of the allele specific or energy transfer primers. The 
structure of the energy transfer labelled primers is universal for all reactions. The 3’ 
end is identical to the tail of one of the allele specific primers. The 5’ hairpin structure 
then contains both a fluorophore (SR or FAM) and a quencher (Dabsyl). In this 
hairpin state the primers emit very low levels of fluorescence because the energy from 
the fluorophore is transferred to the nearby quencher. However after incorporation 
into a PCR product the hairpin is linearized, leading to the separation of the 
fluorophore and quencher and an enhancement in the level of fluorescence. The step 
by step reaction is shown below in figure 2.10.
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Figure 2.10: Amplifluor™ genotyping of a G/T polymorphism.
Adapted from the Chemicon website: (www.chemicon.com).
SNP G/T - Allele G SNP G/T - Allele T
(a) Forward allele-specific reaction
T >
(b) Reverse reaction, building the complement to the tails
J J , (c) Forward reaction with universal ET primers
Q  (d) Reverse reaction, opening the hairpin structure
Red. SR
DaOsyl
i. FL
Dabsyl
a) Allele specific primers containing a 5 ’ tail unique to one o f  the energy 
transfer primers anneal to the target DNA and are extended by Taq polymerase. This 
leads to the production o f a fragment with either tail 1 or tail 2 at the 5 ’ end, (or both 
in the case o f a heterozygote).
b) The common reverse primer then binds to this amplified product and is 
elongated by Taq polymerase resulting in synthesis o f the complement to the tail 
sequence.
c) Energy-transfer labelled primers anneal specifically to the tail sequence o f 
the reverse reaction and are elongated by Taq polymerase.
d) The complementary strands are then synthesized using the product o f the 
previous reaction as template. This leads to the opening o f the hairpin structure at the 
tail o f the energy-transfer labelled primers as they are incorporated into the double 
stranded product, separating the fluorophore and quencher which in turn gives the 
desired increase in green or red fluorescence.
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The PCR primer mix used in the amplifluor reaction is as follows: (All primer stocks 
are kept at a concentration of lOOpmol/pl).
Forward primer (Allele 1) 2.5pi
Forward primer (Allele 2) 2.5pl
Reverse primer 25 pi
ddH20  470pl
For each individual reaction the following reaction mix is added: The assay uses 
Titanium Taq DNA polymerase and Titanium reaction buffer (BD Biosciences).
Reaction Mix:
Titanium Buffer (10 x) 0.5pl
dNTPs (2.5mM) 0.4pl
Primer Mix 0.07pl
SR Labelled primer 0.07pl
FAM Labelled primer 0.07pl
Titanium Taq polymerase 0.05pi
ddH20  3.84pl
Genomic DNA (Dried down)______ 4.0ul
Total reaction volume 5.0pl
The samples are exposed to thermal cycling as follows:
Thermocvcling conditions:
96°C 4 min
96°C 10 sec
58/60°C 5 sec ^  20 cycles
72°C 10 sec
96°C 10 sec
55°C 20 sec ^ 22 cycles
72°C 40 sec
72°C 3 min
}
}
The reaction cycling conditions are in two stages. The first stage at 58-60°C 
involves the annealing and extension of the allele specific primers on the DNA 
template. These extended primers are then used with the reverse primer to create the
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complimentary tails to the labelled universal primers. The second stage involves the 
annealing o f  the universal labelled primers to their com plim entary sequence and then 
a subsequent extension o f  these labelled prim ers to unfold their hairpin structures and 
allow a fluorescent signal to be generated (see figure 2.10 above).
The samples are analysed using an Analyst HTS Assay Detection Platform 
(LJL Biosystems). The results in the form o f  fluorescent signal intensity readings for 
the two dyes (FAM and SR) are then imported into an Excel worksheet (available 
from www.serologicals.com) and plotted on a graph. The clusters o f  points on the 
graph represent the three genotype classes and the worksheet then creates a file 
containing the genotypes in the form o f  11, 12, 22, where 1 corresponds to the allele 
specific to the SR dye and 2 corresponds to the allele specific to the FAM  dye (see 
figure 2.11 below).
Figure 2.11: Example o f an Am plifluor genotyping graph:
This figure shows an example o f  an amplifluor genotyping graph. The fluorescence 
intensity values cluster into four groups. The upper left cluster on the plot is 
homozygotes with high fluorescence intensity for SR, the upper right cluster is 
heterozygotes with high fluorescence intensity for both the SR and FAM dyes, and the 
lower right cluster is hom ozygotes with high fluorescence intensity for the FAM dye. 
The bottom left cluster on the graph represents the failed PCR reactions and negative 
controls with low fluorescence intensity for both dyes.
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2.10.4. Sequenom MALDI-TOF:
The Sequenom MassArray™ Homogenous MassExtend™ (hME) uses matrix 
assisted laser desorption ionisation time-of-flight (MALDI-TOF) mass spectrometry 
to analyse primer extension products. The method like several of the other assays is 
based on PCR followed by an allele specific primer extension step. However, unlike 
other assays Sequenom extension primers can be designed to anneal either directly or 
closely adjacent to the polymorphic site, meaning that primer extension is not always 
by just a single base. This variable extension is made possible by using a specific 
mixture of terminator nucleotides during the extension reaction including both 
appropriate deoxynucleotides and dideoxynucleotides to terminate the reaction. The 
mass of the primer extension product generated is then analysed and used to 
determine the nucleotides present at the polymorphism.
2.10.4.1. Multiplex assay design:
In order to make the method as high throughput and cost effective as possible 
the PCR and hME primer extension reactions are carried out in multiplex. In order to 
achieve this, multiplexes were designed using the Assay design 2.0 software provided 
by Sequenom. The software analyses the flanking sequences, primer parameters and 
secondary structures for each polymorphism and then creates an optimum set of 
multiplex reactions, with a maximum of eight SNPs per assay.
2.10.4.2. Optimisation of extension primers:
The concentrations of the hME extension primers in the primer mix need to be 
adjusted to give approximately equal amounts of product representing each SNP. This 
is achieved by running an aliquot of your extension primer mix on the mass array to
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determine the initial peak heights, followed by an adjustment of the primer 
concentrations in the mix if required to ensure equal peak heights for all of the 
extension primers.
2.10.4.3. Multiplex PCR optimisation:
This is achieved by amplifying 16 control DNA samples and also 8 negative 
controls (water). 2pl of each sample is aliquoted into a 384 well PCR plate and then 
dried down by incubating at 65°C for 15mins. The forward and reverse PCR primers 
for all of the SNPs are combined into a primer mix with a final concentration of 
lpmol/pl for each of the separate primers. The following mastermix is then made and 
5 pi added to each of the samples:
Multiplex PCR Reaction Mix:
Genomic DNA (dried) 2pl
ddH20  3.39pl
PCR Buffer 1 Ox (Qiagen) 0.625pi
MgCl2 (25mM) 0.325 pi
dNTPs (25mM) 0.1 pi
Hotstart Taq (Qiagen) 0.06pl
F and R PCR primers (1 nmol/ul) 0.5ul 
Total reaction volume 5 pi
The reaction is performed on a thermocycler using the following PCR program: 
Sequenom PCR program:
95°C 15mins
95 °C 20 secs
56°C 30 secs
72°C 1 mins
72°C 3 mins
4°C hold
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The PCR products are examined by electrophoresis on an agarose gel to check 
that the correct sized products have been generated and there is no contamination 
present. Due to the large amount of primers being added to the reaction it is important 
to recognise any primer dimers that are present in either the DNA samples or the 
negative controls and not mistake them for either PCR product or contamination.
Once the multiplex PCR has been optimised successfully the association sample can 
be aliquoted into 384 well PCR plates and then amplified as described above using the 
same multiplex PCR mix and PCR program.
2.10.4.4. PCR purification:
Before the hME primer extension reaction, the PCR product must be cleaned 
in order to remove any unincorporated dNTPs from the reaction. A 2pi mix 
containing 0.3pi of shrimp alkaline phosphatase (SAP), 0.17pl of SAP buffer and 
1.53pi of ddtEO is added to each PCR reaction and then incubated at 37°C for 30 mins 
followed by an enzyme denaturation step of 85°C for 15 mins.
2.10.4.5. hME primer extension reaction:
Once the multiplex PCR has been SAP treated the hME extension reaction can 
then be performed. It is important to use the right mixture of terminator nucleotides 
(hME extension mix) to perform the reaction. This is important to ensure that the 
appropriate dideoxynucleotides and specific deoxynucleotide are present to extend the 
primer through the polymorphic site and then to terminate the extension reaction at 
the appropriate point in the sequence. This ensures that the allele-specific extension 
products generated each have a unique mass, which can then be used to identify the
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genotypes present. The following reaction mix is prepared and then 2pl of the mix 
added to each cleaned PCR product:
hME Extension Reaction Mix:
ddH20  0.76pl
Appropriate hME Extend Mix 0.2pl
Adjusted Extension Primer Mix 1 .Opl
Thermosequenase 0.04pl
The reaction proceeds on a thermo cycler using the following program:
hME Extension reaction program:
94°C 2 mins 
94°C 5 secs "I
52°C 5 secs >- cycle 100 times.
72°C 5 secs J 
4°C forever
2.10.4.6. Desalting of extension product:
Prior to mass spectroscopy any residual salts remaining in the reaction 
products must be removed as these interfere with the MALDI-TOF analysis. This is 
achieved by the addition of Sequenom clean resin, which forms complexes with the 
salt ions in the reaction. 6mg of resin is added to each reaction followed by a 30 
minute mixing step on a plate rotator. Following mixing, the reactions are centrifuged 
at 3000rpm for 10 mins to prepare the samples to be spotted onto the mass array chip.
2.10.4.7. Running and analysing spectra:
The desalted samples are spotted onto a mass array Spectrochip (Sequenom) 
using a Sequenom nanodispenser robot. The Spectrochip is then loaded into the 
MALDI-TOF mass spectrometer ready for each of the samples to be analysed. The
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MALDI-TOF reaction is performed by firing a laser at the spotted multiplex extension 
product on the spectrochip resulting in the ionisation of the product. The length of 
time for the resultant ions to be extracted into the mass analyser (time of flight) is 
recorded and the masses and corresponding genotypes of the extension product is 
determined in real time by the mass array software (Sequenom). The software 
automatically calls the genotypes for each of the SNPs in the multiplex assay 
according to the masses present, and then produces a results output file which is saved 
to an attached computer.
2.10.5 Genescan Fluorescent PCR:
This method is particularly useful for genotyping insertion/deletions and 
repeat elements. A FAM fluorophore fluorescently labelled PCR primer (either the F 
or R primer), is used in a standard PCR reaction and then the PCR products analysed 
on an ABI 3100 genetic analyser (Applied biosystems) to determine the size of the 
PCR products and therefore the corresponding alleles present.
The PCR is performed effectively as described in section 2.3. The PCR 
product is then diluted (usually 1:50 ) in order to produce suitable electrophorogram 
peak heights, and then subjected to electrophoresis on the ABI 3100 genetic analyser 
(Applied biosystems) along with a suitable size standard (usually ROX 400/500) 
(Applied biosystems). During electrophoresis the products are excited by a laser light 
resulting in fluorescence which is then detected by a photo multiplier tube (PMT).
The samples are subsequently analysed with the Genescan software (Applied 
biosystems), to determine the product sizes and therefore the corresponding alleles 
present.
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2.11. Tag SNP identification by Entropy:
During some of the projects in this thesis, a low redundancy set of SNPs for 
haplotype analysis was selected using an Entropy method developed in house by V 
Moskvina, and described in (Peirce, Bray et al. 2006). Entropy as a measure of 
haplotypic diversity was calculated as:
£  = - £ / i o g 2/
/=1
where f x is the frequency of the i-th haplotype, and k is the number of distinct 
haplotypes in the sample. The haplotype frequencies^ were obtained using the EM- 
algorithm realized in the “Eh-plus” software (Xie 1993; Zhao, Curtis et al. 2000).
The basic principle of defining tag-markers is that the larger the value of 
entropy, the more informative is the set of markers forming the haplotype. It should 
be noted that the informativity of a set of tag markers is relative to the quantity of 
genetic information input into the analysis. For m biallelic markers (e.g. SNPs), the 
number of possible haplotypes is 2m. The full amount of information for these m 
markers is:
2m
EfuU =-S/, l0g2/ ,
7=1
where f  are the m-markers haplotype frequencies. Calculating entropies for each 
subset of these m markers and dividing them by Ejuii, we obtain the relative amount of 
information (values between 0 and 1) provided by a particular subset of markers, 
compared with the full set of markers. By this method, haplotype-tagging SNPs can 
be selected even in the absence of a clear haplotypic block structure. A similar 
approach is described in (Ackerman, Usen et al. 2003).
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2.12. Statistical Analysis:
During this thesis contingency tables were used to test genotypes and alleles 
for association with schizophrenia, and to calculate odds ratios. All analyses are 2- 
tailed. For the DHPLC mutation screening set, power was calculated using the 
equation: l-(l-f)n, where f  = allele frequency and n = number of chromosomes 
examined. Thus a screening set of 28 chromosomes (14 individuals) has a 95% power 
to detect an allele with a frequency of 10%. Power estimations and sample size 
requirements for case-control samples were calculated using the web based program 
provided by the UCLA department of statistics (http://calculators.stat.ucla.edu/). The 
D’ and r2 estimates of linkage disequilibrium (LD) were calculated using various 
versions of Haploview
(http://www.broad.mit.edu/personal/jcbarret/haploview/index.php). Haplotype 
frequency analysis was performed using EH plus (Xie 1993) with a permutation test 
(Zhao, Curtis et al. 2000). All polymorphisms typed individually were tested for 
deviation from Hardy-Weinberg equilibrium using a goodness of fit test implemented 
by the HW program (in house software) written by Peter McGuffin and Peter 
Holmans. Group comparisons of allelic expression assay data were analyzed using t- 
tests (two tailed), and correlation analyses were performed using the Pearsons 
correlation coefficient.
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Chapter 3.1. Analysis of oligodendrocyte related candidate
genes differentially expressed in schizophrenic brain.
3.1.1 Introduction:
In this section, I describe my analysis of the oligodendrocyte and/or 
myelination related (OMR) genes that were identified as being differentially 
expressed in the brains of schizophrenics in the study which provided much of the 
impetus for this thesis (Hakak, Walker et al. 2001) (described in chapter 1, section 
1.51). The OMR genes reported to be down-regulated in that study are myelin and 
lymphocyte protein (MAL), 2', 3'-cyclic nucleotide 3'- phosphodiesterase (CNP), 
myelin associated glycoprotein (MAG), transferrin (TF), gelsolin (GSN) and avian 
erythroblastic leukemia viral oncogene homolog 3 (ErbB3).
MAL is a proteolipid expressed by oligodendrocytes and Schwann cells. 
Expression occurs during myelin formation and the protein is then predominantly 
found in compact myelin (Frank 2000). MAL has been proposed to have several 
functions including vesicular transport of myelin proteins and lipids to the myelin 
membrane during myelination and as a structural component in compact myelin 
(Frank 2000).
CNP is an oligodendroglial transmembrane protein synthesized by 
oligodendrocytes early in myelination, is associated with non-compacted myelin and 
is widely used as a marker protein of myelin-forming glial cells (Braun 2004). 
Although the proteins precise functions are unknown, it has been shown to interact 
with mitochondria and cytoskeletal proteins and has been proposed to promote 
microtubule assembly or act as a membrane anchor for tubulin (Bifulco, Laezza et al.
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2002; Lee, Gravel et al. 2005). These and other putative functions for CNP are 
discussed more extensively in section 3.2.
MAG is a minor but important component of myelin. It is expressed only by 
myelin forming cells when they come into contact with axons and is thought to be 
involved in the initiation of myelination in the CNS (Stewart and Davis 2004). MAG 
has also been shown to be important in maintaining myelin-axonal contacts and the 
structure of myelin sheaths (Gravel, Peterson et al. 1996; Hakak, Walker et al. 2001)
TF is an iron transport glycoprotein usually synthesized in hepatocytes, but 
which is also synthesized in other cell types including oligodendrocytes. There is 
evidence that the function of TF in the brain is not restricted to iron transport but my 
also involve a role in myelin production and the maintenance of myelin stability 
(Sow, Lamant et al. 2006). It has been shown that in the brains of mice expressing 
reduced transferrin levels, the myelin sheath is 30% thinner than normal (Saleh, 
Espinosa de los Monteros et al. 2003).
GSN is a cytosolic protein which is expressed in high concentrations in 
developing oligodendrocytes and is also enriched in neuronal growth cones (Stewart 
and Davis 2004). GSN has been shown to have anti-apoptotic properties; a process 
which is essential for nervous system development (Xi, Qin et al. 2004).
ErbB3 is a receptor-protein tyrosine kinase that binds neuregulin proteins and 
is believed to be involved in cell survival, migration and differentiation (Stewart and 
Davis 2004). One of the ErbB3 ligands is Neuregulin 1 (NRG1), which is in turn 
involved in numerous cellular functions including the establishment of the 
oligodendroglial lineage, the maintenance and growth of neuronal cells, and the 
survival of oligodendroglial cells (Corfas, Roy et al. 2004). Additionally NRG1 has 
now been found to be associated with schizophrenia in several populations and
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samples (Stefansson, Sigurdsson et al. 2002; Stefansson, Sarginson et al. 2003; 
Williams, Preece et al. 2003; Owen, Craddock et al. 2005; Li, Collier et al. 2006).
Altered gene expression can result from either cis or trans-acting factors. If a 
genes altered expression plays a primary aetiological role in disease rather than being 
either involved in the pathophysiological pathway or a secondary effect of the disease, 
then it is the former c/s-acting genetic effects that are of relevance. Therefore for the 
purposes of genetic association studies the presence of cis-acting variants is of 
interest, with the hypothesis being that if altered expression is of aetiological 
relevance, then the mechanisms causing this phenomenon can be expected to be 
associated with disease. Therefore the initial focus of this study was to screen the 
genes reported to be down-regulated in schizophrenia (Hakak, Walker et al. 2001) for 
the presence of cis-acting sequence variants.
3.1.2 Results;
The first experiments were allelic expression assays to ascertain whether the 
reported expression differences (Hakak, Walker et al. 2001) could potentially be 
attributable to cis-acting genetic factors. At the time of this study only four of the 
genes of interest had a marker SNP in public databases suitable for use in the allelic 
expression assay. In order to be suitable for use in the assay the marker has to be 
located within the exonic sequence of the gene, and have a common enough minor 
allele frequency to provide the assay with the power to detect common variation 
affecting the expression of the gene (see table 3.1). The four genes with suitable 
markers were CNP, MAG, TF and ErbB3. The results of the allelic expression assays 
are summarised below in table 3.1. The allelic expression analysis depicting all 
individual data points are shown below in figures 3.1, 3.2, 3.3 and 3.4.
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Table 3.1: Summary of the allelic expression assay results:
Summary of the allelic expression assay results showing the gene name, marker SNP 
used in the assay, the number of informative heterozygotes, the power of the assay to 
detect a regulatory variant at a frequency of 0.1 and 0.05, the number of individuals 
displaying an expression difference greater than 20% and the maximum expression 
difference observed between alleles.
GENE
Marker
SNP
assayed
Number of 
assayed  
heterozygotes
Power to detect a 
regulatory variant at a 
frequency of (0.1/0.05)
No of individuals 
displaying 
variation > 20%
Maximum
expression
difference
CNP rs2070106 25 99% (0.1) 92% (0.05) 21 (21-67%) 67%
MAG rs1126770 22 99% (0.1) 89% (0.05) 0 11%
TF rs8649 18 97% (0.1) 83% (0.05) 0 13%
ERBB3 rs2271189 24 99% (0.1) 91% (0.05) 0 20%
Only one of the four genes (CNP) displayed evidence for the presence of a cis- 
acting sequence variant influencing the expression of the gene (see figures 3.1-3.4).
Of the 60 subjects for whom brain was available, 25 individuals were heterozygous 
for CNP SNP rs2070106 and therefore informative for analysis. Allelic expression 
analysis of these individuals revealed that in each case, the A allele was expressed at a 
lower level relative to the G allele (figure 3.1). The data points from each individual 
cDNA sample showed good reproducibility, with a mean co-efficient of variation of 
0.07. When data from all the individuals were combined and then analysed using a 
Mann-Whitney test, the A allele was significantly under-expressed (p < 0.0001). The 
analysis was repeated and gave similar results (p < 0.0001). Across the two 
experiments, the mean relative reduction of the A allele was 24%. Since the same 
allele is under expressed in every sample, the data suggest that the altered expression 
is caused by either a direct effect of the marker SNP itself or the effect of an untested 
variant which is in strong LD with the marker SNP.
No evidence for the presence of any common ds-acting sequence variants 
affecting the expression of MAG, TF or ErbB3 was detected. The failure to detect any
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common ds-acting polymorphisms cannot be attributed to a lack o f power, as all three 
genes had a good power to detect regulatory variants at a frequency o f 0.1 and 0.05 
(see table 1.1). It should also be noted that the power calculations are conservative, in 
that they assume that there is no LD present between the marker variant and the 
functional variant. I f  there is LD present between the marker and regulatory variant, 
the power will be increased as a higher proportion o f people selected for 
heterozygosity at the marker locus will also be heterozygous for the regulatory 
variant.
Figure 3.1; CNP (rs2070106) allelic expression assay:
The graph shows the corrected genomic and cDNA ratios for CNP SNP rs2070106 in 
25 heterozygotes. Data are expressed as the mean o f the ratio o f A:G for two 
measurements for each genomic DNA sample and o f four measurements o f each 
cDNA sample.
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Figure 3.2: MAG (rsl 126770) allelic expression assay:
The graph shows the corrected genomic and cDNA ratios for MAG SNP rsl 126770 in 
22 heterozygotes. Data are expressed as the mean o f the ratio o f C:T for two 
measurements for each genomic DNA sample and o f four measurements o f each 
cDNA sample.
Genomic cDNA
Figure 3.3: TF (rs8649) allelic expression assay:
The graph shows the corrected genomic and cDNA ratios for TF SNP rs8649 in 18 
heterozygotes. Data are expressed as the mean o f the ratio o f G:C for two 
measurements for each genomic DNA sample and o f four measurements o f each 
cDNA sample.
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Figure 3.4: ErbB3 (rs2271189) allelic expression assay:
The graph shows the corrected genomic and cDNA ratios for ErbB3 SNP rs2271189 
in 24 heterozygotes. Data are expressed as the mean o f the ratio o f G:A for two 
measurements for each genomic DNA sample and of four measurements o f each 
cDNA sample.
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Chapter 3.2. 2'. 3'-Cvclic Nucleotide 3'- Phosphodiesterase
(CNP) a candidate gene for Schizophrenia:
3.2.1. Introduction
Following the findings of my initial allelic expression studies I decided to 
examined the specific hypothesis that sequence variants within the CNP gene that are 
responsible for influencing its expression are associated with increased susceptibility 
to schizophrenia.
In addition to the original identification of CNP as a differentially expressed 
gene in schizophrenia (Hakak, Walker et al. 2001) and the results of my allelic 
expression assay, CNP was of particular interest for several other reasons. Firstly,
CNP has been consistently shown to be down-regulated in several other studies of 
schizophrenia (Aston, Jiang et al. 2004; Katsel, Davis et al. 2005b; Dracheva, Davis et 
al. 2006) (see chapter 1, table 1.1). The mRNA findings are also supported by reports 
of a significant reduction at the protein level in both the anterior frontal cortex (Flynn, 
Lang et al. 2003) and the hippocampus (Dracheva, Davis et al. 2006) of schizophrenic 
brains compared to controls.
Secondly, CNP maps to chromosome 17q21.2, spans 11 kb of genomic 
sequence and contains four exons. This is a region of the genome in which my host 
department had at the time I started, recently observed genome wide significant 
evidence for linkage (LOD 8.32, genome-wide empirical p value < 0.02) to 
schizophrenia in a single multiply affected pedigree (Williams, Norton et al. 2003). 
The involvement of this region in schizophrenia has been supported by a recent meta­
analysis (Lewis, Levinson et al. 2003) and additional linkage studies (Rees, Fenton et
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al. 1999; Klei, Bacanu et al. 2005) (see figure 3.5). Additionally there is also 
significant (Dick, Foroud et al. 2003; Tomas, Canellas et al. 2006) and suggestive 
(Bennett, Segurado et al. 2002; Ewald, Wikman et al. 2005) evidence o f linkage to 
this region in bipolar disorder (see figure 3.5). Given the reports o f  linkage to the 
region o f  chromosome 17 where CNP is located and the evidence for altered 
expression o f CNP in schizophrenia, the gene is a plausible candidate gene for study 
as to its involvement in susceptibility to schizophrenia.
Figure 3.5. Chromosome 17 linkage region.
Summary o f the linkage findings reported on chromosome 17 for schizophrenia and 
bipolar disorder. The figure shows the linkage studies and the corresponding region o f 
chromosome 17 they reported to be linked to disease, along with the location o f  the 
four genes located on chromosome 17 which were studied as part o f  this project.
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CNP transcripts encode for two prenylated myelin protein isoforms, CNP1 (46 
kDa, 400 amino acids) and CNP2 (48 kDa, 420 amino acids) that differ by the 
presence o f  alternative translation start sites in the first two exons o f  the gene 
(O'Neill, Minuk et al. 1997). Both isoforms are identical except that the CNP2 
isoform has a 20 amino acid extension at the N-terminus (Lee, O'Neill et al. 2006).
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There are also two promoter regions of the gene encoding for the two mRNA 
transcripts, one of which (CNP2) can generate both CNP protein isoforms.
CNP accounts for about 4% of the protein in central nervous system myelin, 
but only accounts for about 0.4% of the protein in peripheral nervous system myelin 
(Rasband, Tayler et al. 2005). Numerous studies have shown an association between 
CNP protein expression and myelinating cells (Braun 2004). However, immuno- 
electron microscopy of myelin has shown that CNP is associated only with non­
compacted myelin regions, such as the inner mesaxon and paranodal loops, and that it 
is absent from compacted myelin (Lappe-Siefke, Goebbels et al. 2003). Analysis of 
the amino acid sequence of CNP shows a high homology between the different 
mammalian species. For instance the homology between the mouse and human CNP 
sequence is 85% (Braun 2004).
Gravel and colleagues (Gravel, Di Polo et al. 1998) reported evidence that ex­
acting regulatory elements required to direct the spatial and temporal expression of 
CNP in oligodendrocytes are located within 4kb of the 5’end of the mouse CNP gene. 
In an earlier study (Gravel, Peterson et al. 1996) a similar region of mouse 5’ DNA 
sequence was used as a CNP putative promoter to drive the expression of the human 
CNP gene in the oligodendrocytes of transgenic mice, and the authors suggested that 
the human and mouse CNP promoter sequences are therefore similar.
CNP is found in cytoplasm, and its expression appears at an early stage of 
development in oligodendrocyte precursors, preceding the onset of myelination. Its 
expression is then maintained at a high level as myelination proceeds (Lee, Gravel et 
al. 2005). Although high levels of CNP are seen in differentiating oligodendrocytes in 
parallel with the major structural proteins such as myelin basic protein (MBP) or 
proteolipid protein (PLP), the expression of CNP has been shown to occur before
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either of these proteins are expressed, indicating a possible role for CNP before or 
during the initiation of myelination (Braun 2004). CNP protein continues to be 
expressed throughout adulthood, when it shows a high turnover compared with the 
other major myelin related proteins, suggesting a possible ongoing role for CNP in the 
CNS after neuronal development and myelination (Flynn, Lang et al. 2003).
The precise function of the CNP gene in oligodendrocytes is not known, 
although the expression pattern of the protein would suggest an important role in 
oligodendrocyte development, myelination and possibly maintenance of the myelin 
sheath (Lee, Gravel et al. 2005). These hypotheses are supported by various animal 
studies. Several studies have demonstrated that premyelinating oligodendrocytes from 
transgenic CNP over-expressing mice produce aberrant and redundant membranous 
extensions from their oligodendrocyte processes and myelin intemodes (Gravel, 
Peterson et al. 1996; Yin, Peterson et al. 1997). However, in contrast to the over­
expressing CNP mice, a study by (Lappe-Siefke, Goebbels et al. 2003) reported that 
CNP-null transgenic mice appeared to have normal myelination although they did 
display progressive neurodegeneration, axonal loss and swelling, which led to 
premature death. The mice also displayed ataxia and hindlimb impairments at about 
four months of age, as well as progressive reduction in overall brain size and 
progressive enlargement of ventricles and corpus callosum atrophy (Lappe-Siefke, 
Goebbels et al. 2003). Enlarged ventricles and corpus callosum atropy are consistent 
with some pathological features observed in schizophrenia (Harrison 1999; Cahn, 
Hulshoff Pol et al. 2002; Ho, Andreasen et al. 2003). More recent analysis of the 
CNP-null mice has revealed that the deficiency of CNP leads to disrupted axoglial 
interactions in the CNS and major abnormalities in the structure of the paranodal 
loops as early as three months of age, and before the onset of any axonal or neuronal
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/degeneration (Rasband, Tayler et al. 2005). The authors suggest that CNP deficiencies 
result in disrupted axoglial signalling and underlie the mechanism responsible for the 
progressive axonal death observed later in the CNP-null mice.
Interestingly CNP gene expression has been shown to be increased by lithium 
treatment (Wang and Young 1996). Lithium is often used as a highly effective 
treatment for psychiatric diseases, although its role in schizophrenia is not well 
established. If CNP is in fact involved with the control of the myelination process then 
the therapeutic effects of lithium treatment might be due to its regulating one or more 
of these myelination processes.
A final piece of circumstantial evidence concerning a possible relationship 
between CNP and schizophrenia comes from its potential interaction with the protein 
quaking homolog, KH domain RNA binding (mouse) (QKI). QKI is an RNA binding 
protein in myelin producing cells and is required for the cell-cycle arrest of 
oligodendrocyte progenitor cells and the subsequent differentiation of 
oligodendrocytes (Larocque, Galameau et al. 2005). Zhang and colleagues (Zhang 
and Feng 2001) showed that CNP binds to QKI transcripts weakly and that the 
expression of CNP mRNA is nearly normal in the brain of QKI null transgenic mice. 
However, the authors also report that CNP protein levels were significantly reduced in 
the brains of the same QKI null mice. The authors propose that this reduction in CNP 
is unlikely to result from a failure in CNP translation but instead is probably the result 
of accelerated protein degradation possibly as a consequence of a lack of QKI. This 
finding is of interest as QKI has recently been shown to be the most significantly 
down-regulated gene in a micro-array study of schizophrenic brain (Katsel, Davis et 
al. 2005b). The gene has also been reported to be associated with schizophrenia 
(Aberg, Saetre et al. 2006a; Aberg, Saetre et al. 2006b) and my host department has
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recently observed a significant association (p=0.002) between several genetic variants 
in the gene and susceptibility to schizophrenia (Georgieva, O’Donovan, unpublished 
data). If the theory Zhang and colleagues (Zhang and Feng 2001) proposed, that a lack 
of QKI protein leads to the increased degradation of CNP protein is correct, then the 
reports of reduced QKI expression in schizophrenic brain (Katsel, Davis et al. 2005b), 
would tie in with the results demonstrating a reduction of CNP at the protein level in 
schizophrenic brain (Flynn, Lang et al. 2003; Dracheva, Davis et al. 2006) and may 
indicate the presence of an interaction between the roles these two genes play in 
schizophrenia aetiology.
So in summary based on the reports of linkage to the broad region of 
chromosome 17 where CNP is located, evidence for altered expression of CNP in 
schizophrenic brain at both the mRNA and protein level, the genes proposed function 
in oligodendrocyte function and the myelination process, and the results of the CNP 
knockout mouse studies reporting central nervous system pathological characteristics 
reminiscent of some of the pathological features observed in schizophrenic patients, 
CNP is a highly plausible candidate gene for schizophrenia, albeit one of many highly 
plausible genes.
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3.2.2 Materials and Methods:
In this section I describe methodological issues specific to this section of the 
thesis. A more detailed analysis of the methods and techniques used can be found in 
chapter 2.
3.2.2.1 Patient Samples;
The case/control sample used in this chapter is described in chapter 2. The 
pedigree showing evidence for linkage to 17q consists of a single generation of 6 
siblings with DSM IV schizophrenia (diagnosed as described in chapter 2) from 
which DNA was available. DNA was also available from one parent of unknown 
diagnostic status.
3.2.2.2 Polymerase Chain Reaction PCR:
Primers to amplify the exons, promoters, flanking sequences and introns of the 
CNP genomic sequence based upon alignment of mRNA sequence (NM 033133) and 
the corresponding genomic sequence (NT 010755.14). The primers used to generate 
the various amplimers are listed in tables 3.3 and 3.4 respectively. PCR amplification 
was performed under standard conditions.
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Table 3.3: Primer information for the amplimers used during the initial CNP screening experiments:
This table shows the details of the primers used during the initial mutation screening of the CNP gene in 14 cases, including the forward and 
reverse PCR primer sequences, the size of the fragments and the optimised reaction conditions and annealing temperatures. HS indicates the use 
of hot start taq polymerase and GC indicates the use of a GC rich PCR protocol.
Fragment
Name
Genomic region 
covered
Forward Primer 
(5’ to 3’)
Reverse Primer 
(5’ to 3’)
Size
(bp)
Annealing 
Temperature (°C)
CNP_1 Exon 1 CTTGGACAGGAAACTCAAAAAT CT GCGT GTT G AGGGGT AACT 441 bp HS54
CNP_2 Exon 1 GACCCT GCCT C ACT CACTT C GTTTGCAAGACGCTTCCTC 472bp GC60
CNP_3 Exon 1 CCCCCGGGCTATGTAAAG GTAAAGGGTCCCCTCCTCTG 566bp GC60
CNP_4 Intron 1 C AGT CT CAT C ACGCGGAAC GGCT GAGT GCACAGAGAAGG 458bp HS54
CNP_5 Intron 1 AGGAATGTGTGGCT ITI I CG AGGAAT GT GT GGCTTTTTCG 450bp HS54
CNP_6 Exon 2 C ATTT C AAAG AGCT GCTCC A CATTT C AAAG AGCT GCTCC A 446bp HS54
CNP_7 Exon 2 AGGACCT GGCTGCCT ACT G ATT GT CGCAGCT CCTT CTT G 363bp HS54
CNP_8 Exon 3 TGAGCTGTAGTGGGTTGCTG T GGC ACCGGTACCTAT CTT C 360bp HS60
CNP_9 Exon 4 T GTTAAAG AAAT CTTACT CC AAGG C ACT CATAT GAT GGT GCAGGA 452bp HS54
CNP_10 Exon 4 ACTACGGGAAAGGCAAACCT GGGGCTCT G AGGT GTCTCC 460bp HS54
CNP_11 Exon 4 GCCCAGAGCTGGGTGAGT GCGGCT GCTT AACT GTTCT G 445bp HS54
CNP 12 Exon 4 CCT CCCCTT C ACACCATAAC AGGATTAAC AT G ATTTATTT CATTAT C 519bp HS50
115
Table 3.4: Primer information for the amplimers used during the additional CNP screening experiments:
This table shows the details of the primers used during the additional screening of the complete genomic sequence of the CNP gene, including 
the forward and reverse PCR primer sequences, the size of the fragments and the optimised reaction conditions and annealing temperatures.
Fragment
Name Genomic region covered
Forward Primer 
(5’ to 3’)
Reverse Primer 
(5’ to 3’)
Size
(bp)
Annealing 
Temperature (°C)
CNP_b_1 5’ Flanking/Put prom seq CAGGTCCCTTGACTGCAAAC GAGAAAAGCGGGAAGAAAGA 597bp HS 60
CNP_b_2 5’ Flanking/Put prom seq CGGCCT G ACAT GAACAAACT TCTGGTTCCTGTCTGCTGAA 425bp HS 60
CNP_b_3 5’ Flanking/Put prom seq GGCCTTCGGGAGAATTAGAG TT CTT CC ACG AT GCT CTT CC 409bp HS 60
CNP_b_4 5’ Flanking/Put prom seq T C ACT CTT GC AAACCCT GAG CCT GT CC AAGT GCT GTGCT A 504bp HS 60
CNP_b_5 5’ Flanking/Put prom seq TCTGGGTGGCATAATCAGGT CTGCGT GTT G AGGGGTAACT 549bp HS 60
CNP_b_6 Intronic Sequence GG ACTT CCTGCCGCTCTACT CCAAGAC AAGGGACAGT GGT 427bp HS 60
CNP_b_7 Intronic Sequence CTTT CCT CCCACCACACCTA GTAAACCCC AC AT CCCT CCT 423bp HS 60
CNP_b_8 Intronic Sequence ACT CAT GGGTTT GT GGCAT C TGGT GCACACCT GTAGTCCT 444bp HS 60
CNP_b_9 Intronic Sequence CAACCTCTGCCTCCCAGA T C AC AGGTAC AGGGCTT GCT 423bp HS 60
CNP_b_10 Intronic Sequence GGGAATTTGTGCCTGTATGG CTT GATT CGT CCC AT CTT GG 438bp HS 60
CNP_b_11 Intronic Sequence GCTGGT CGGT AGC AC AAAA CTT GCT GGCCC ATTACATTT 436bp HS 60
CNP_b_12 Intronic Sequence T CT GCCCAGGATTAGAGCAG CT CAGCT CT GCC AT GTACCA 470bp HS 60
CNP_b_13 Intronic Sequence GGG AAC ACT GGGGT AT AT GG CC AGG AGGC AG AGG AT AC AG 414bp HS 60
CNP_b_14 Intronic Sequence CAAT GTAAAGCC AGAGAATTTTAACT C AGCAACCCACTAC AGCT CA 406bp HS 60
CNP_b_15 Intronic Sequence GCACCTGGCCTGAGAATTT GGCACCGGTACCTAT CTT C A 430bp HS 60
CNP_bJ6 Intronic Sequence AGTCTTCCCCAGGGACACAT T GT GG ATAT GGGT GACAT GC 547bp HS 60
CNP_b_17 Intronic Sequence CTTACACCCACAGCCACTGA CGC AC AC AAC AGCT GCTACT 544bp HS 60
CNP_b_18 Intronic Sequence AGT CT GACCTCACCCTGTCC CGT GAAGGCCTT GG AGTAAG 527bp HS 60
CNP_b_19 Intronic Sequence GGGT C AGCT GTT CCT C AAG A AGGTTT GCCTTT CCCGTAGT 457bp HS 60
CNP_b_20 3’ Flanking sequence T CGGGTT GT C ACT C AAC AAA T CTT CCCT GGT GCTT GAAGT 518bp HS 60
CNP b 21 3’ Flanking sequence TGGTAT GGGTTT CT CCC AGT GGGTT CG AGGGAG AT GGTAG 534bp HS 60
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3.2.2.3 Pooled Genotyping:
All of the polymorphisms studied in the CNP gene were genotyped in the 
pooled association sample by primer extension using the ABI SNaPshot reaction 
method. The SNPs, their flanking sequences and the extension primers used for the 
pooled genotyping assays are shown in table 3.5. For each SNP the pools were 
amplified in triplicate along with an individual heterozygous for each SNP.
3.2.2.4 Individual Genotyping techniques:
During the completion of the experiments presented in this chapter several 
individual genotyping techniques were utilised. These included Acycloprime FP, 
Amplifluor, Sequenom MALDI-TOF, and multiplex SNaPshot genotyping. All of 
these techniques are described in section 2.10. All genotypes were scored blind to 
affection status, and each plate of samples contained a mixture of equal numbers of 
cases and controls.
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Table 3.5: Polymorphism and primer extension reaction information for the CNP gene.
This table shows the nineteen polymorphisms detected within the CNP gene, their rs numbers if available, the sequence flanking each of the 
polymorphisms, the extension primer used to assay the polymorphism by primer extension and the expected alleles in the primer extension 
reaction.
SNP number. rs Number SNP Flanking sequence Extension primer Expected Alleles
CNP-4359 G/A 
CNP-2086 C/T 
CNP-2084 C/G 
CNP -1148 AG Ins/Del 
CNP-351 G/A 
CNP -96 T/C 
CNP 1868 T/G 
CNP 1944 AFT 
CNP 2371 A/G 
CNP 3235 A/G 
CNP 3582 C/T 
CNP 3625 T/C 
CNP 4926 A/G 
CNP 6961 G/A 
CNP 7230 G/A 
CNP 7284 G/A 
CNP 8157 T/C 
CNP 8634 C/T 
CNP 8962 C/T
rs4796750 
rs8080978 
rs8080979 
rs10540926 
rs12952915 
rs4432296 
rs8078650
rs4258677
rs12952456 
tV\2S5Q675 
rs12602950 
rs2070106 
rs11079028
rs 11296 
rs4796751
GCCGACCCCCATTC[A/G]TGCTTCCCGCAGGC 
GGCGCCAACCACCA[C/T]GCCTGGCTAA I I I I 
CGCCAACCACCACG[C/G]CTGGCTAA I I I I I G  
GGTGCCAAGAAGAA[AG]GGTTTCAGGAGGGT 
TCCTGCT AAT CC AC[G/A]GG ACCGGGG AGGGT 
GGCCGGGCT CGGGT[T/C]GT GCCACCGCT GGA 
AT GT AGGT GGC AGG[T/G]T GGGGCCTT AT AAG 
TACTCAAAGGAT GG[A/T]GCACGAAGCAGCAG 
T CAGGCCT CGG ACT[A/G]CT C AATTT ACT CAT 
TTTATTTATG AG AC[G/AJG AGT CTT GCT CT GT 
GCAGTGGGGCAATTfC/TJGGCTTACTGCAACC 
T G AAGG AATT GT GG\T IGY3GGT G AGGG AGGG A 
TCCGAGTGI M I GC[G/A1CTGGGCCTCGGTGG 
GCCATCTTCACGGG[G/A]TACTACGGGAAAGG 
CCT CT AAT GCT CAC[G/A]CT CCCAACACAAGG 
CCT GG ACCAAAGCT[G/A] ACGAGGCT GGGCCA 
GCCCTCCACTGCCC[C/T]CTGTTCAGTAACAG 
GG AAGCT CCTGGTA[T/CJGGGTTT CT CCC AGT 
C ACCTT G AAC ACC A[C/T]GCTT G AC AGG AC AG
TAAGCGCAGTAGCCGACCCCCATTC 
GGGACT ACAGGCGCCAACCACC A 
CT GTACT AAAAATACAAAAATTAGCCAG 
G AAAT G AG AAAGGT GCC AAG AAG AA 
GCCT C ACT CACTT CCT GCT AAT CC AC 
CGGGAGTCCAGCGGTGGCAC 
GCG AC AAT GT AGGT GGCAGG 
CTCTCTGCCTCCTGCTGCTTCGTGC 
GCCACAAACCCATGAGTAAATTGAG 
T C AAAGTT GCTTTT AAT ATTT ATTT ATGAG AC 
CGGGAGATGGAGGTTGCAGTAAGCC 
AT CT GCGGGGTT G AAGG AATT CT CC 
GAT GCTT AGT GT CCG AGT GI MTGC 
GT C AGGGCCAT CTT CACGGG 
CGCCCT CTT CCCCT CTAAT GCT CAC 
CCATT C AGG AACCT GG ACC AAAGCT 
GTT CCT GGGGT GCCCT CCACT GCCC 
CCCT AG AG AACT GGGAGAAACCC 
GGCTACT CACCTT GAACACCA
G (Blue) & A (Green) 
C (Black) &T (Red) 
G (Blue) & C (Black) 
A (Green) & G (Blue) 
G (Blue) & A (Green) 
A (Green) & G (Blue) 
T (Red) & G (Blue) 
T (Red) & A (Green) 
T (Red) & C (Black) 
G (Blue) & A (Green) 
G (Blue) & A (Green) 
T (Red) 8. C (Black) 
G (Blue) & A (Green) 
G (Blue) & A (Green) 
G (Blue) & A (Green) 
G (Blue) & A (Green) 
C (Black) & T (Red) 
A (Green) & G (Blue) 
C (Black) & T (Red)
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3.2.3 Results.
Given the results of the allelic expression assays I decided to undertake 
additional genetic studies of CNP. Initially this involved testing the specific 
hypothesis that the lower expression A allele of rs2070106 would be associated with 
schizophrenia. Individual genotyping of marker rs2070106 in the case control sample 
was consistent with this hypothesis at a level that meets conventional levels of 
significance (p = 0.04, OR = 1.2, 95% Cl (1.0-1.40)). Genotypic analysis of the data 
revealed no stronger evidence of association (see table 3.6).
Table 3.6: Individual genotyping of rs2070106 in the schizophrenia sample:
Individual genotyping results for marker rs2070106 in the schizophrenia association 
sample. Genotypic and allelic counts as well as allele frequencies in the cases and 
controls, with the corresponding chi-square and p-values are given.
SNP Genotypes Alleles
rs2070106 G>A G/G G/A A/A G A
Cases 288 319 74 895 (0.66) 467 (0.34)
Controls 325 303 59 953 (0.7) 421 (0.3)
= 4.31 (2df) P = 0.11 yf = 4.15 (ldf) P = 0.04
Given the positive association detected for rs2070106, which supports the 
hypothesis that lower expression would be associated with disease, I decided to 
expand my study of the CNP gene further in order to look for non-synonymous SNPs 
and other variants that might be responsible for the genes altered expression and also 
any markers in LD with rs2070106. This was performed initially by de novo mutation 
discovery of the CNP exons and flanking intronic sequence using 14 unrelated 
schizophrenic individuals. This revealed two novel sequence variants (rsl 2952915, 
7284 G>A) and two variants already lodged in the Chip bioinformatics database 
(rs4432296 and rs2070106). SNP labelling is based on genomic sequence (NT
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010755.14) and follows the labelling protocol as suggested (den Dunnen and 
Antonarakis 2001). Of these polymorphisms, two were located in the coding sequence 
(rs2070106 and 7284 G>A), neither encoded for an amino acid change, although the 
rs2070106 polymorphism is a synonymous mutation in the final exon coding for 
glycine (G376G). The polymorphisms were then genotyped through the pooled case 
control sample, which revealed a trend for association between the lower expression 
A allele of rs2070106 and schizophrenia (p = 0.06) consistent with the individual 
genotyping data, but no trend for the other three polymorphisms (see table 3.9).
To continue the search for a functional locus in LD with rs2070106, located 
within either intronic, 5’ or 3’ sequence, I performed a more detailed analysis of the 
CNP locus. This was performed by genotyping in pools markers from the public 
databases at a minimum density of one SNP per 5kb across the gene (see table 3.9, 
markers highlighted in grey). No further evidence for association to schizophrenia 
was detected.
However, the optimal approach to LD mapping remains a subject of 
controversy and I have therefore used two approaches. The first was as described 
above to genotype all the above markers in pools on the premise that reduced degrees 
of freedom means that single locus LD analysis based upon a fairly dense set of 
markers maybe more powerful than multi-locus analysis if genotypes at one of the 
tested markers correlate strongly with those at the undetected locus (Kruglyak 2005). 
This type of technique has been used successfully in my laboratory to detect a 
putative susceptibility locus for dyslexia (Cope, Harold et al. 2005) and Alzheimer’s 
disease (Grupe, Li et al. 2006). The second approach I used was based upon haplotype 
analysis, where the aim was to type a subset of the SNPs that could retrieve >95% of
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the haplotype diversity across the gene that would have been captured by individually 
genotyping all of the detected SNPs. This was achieved by using an entropy method 
to determine the redundant markers (see materials and methods section). In order to 
perform this analysis, all of the SNPs I had detected along with the markers contained 
within the 5kb grid were initially genotyped in 96 unrelated DNA control samples to 
allow the LD structure to be elucidated and to allow estimation of the haplotype 
frequencies. The subsequent entropy analysis revealed that by typing three further 
markers individually (rsl2952915, rsl 1296 and rs4796751) in addition to rs2070106,
I could extract 98% of the haplotypic diversity that would have been provided by 
genotyping all the markers individually.
These three additional markers were genotyped individually in the association 
sample but displayed no further evidence for association at the individual level (see 
table 3.7). Haplotype analysis was performed on all of the possible haplotype 
combinations, but none of the 2, 3 or 4 marker global haplotypes were significant (see 
table 3.8) and there was no more significant evidence for association for any of the 
single haplotypes. All of the genotypes were in Hardy-Weinberg equilibrium.
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Table 3.7: Individual genotyping for CNP markers rs!2952915. rsl 1296 and 
rs4796751 in the schizophrenia sample.:
Individual genotyping results for CNP markers r s l2952915, rsl 1296 and rs4796751. 
Genotypic and Allelic counts, the allele frequencies and the corresponding chi-square 
and p-values for the markers are given.
sn p
Genotypes Alleles
nl2952915 G>A G/G G/A A/A G A
Cases 445 212 19 1102 (0.82) 250 (0.18)
Controls 445 205 28 1095 (0.81) 261 (0.19)
^  = 1.84 (2df) P = 0.39 y? = 0.25 (ldf) P = 0.62
nll296 T>C T/T T/C C/C T C
Cases 582 73 1 1237 (0.94) 75 (0.06)
Controls 597 83 4 1277 (0.93) 91 (0.07)
= 2.05 (2df) P = 0.36 yf = l.o i (ldf) P = 0.32
rs4796751 G>A G/G G/A A/A G A
Cases 435 165 19 1035 (0.84) 203 (0.16)
Controls 483 176 19 1142 (0.84) 214(0.16)
^  = 0.18(2df) P = 0.91 yf — 0.18 (ldf) P = 0.67
Table 3.8 Initial CNP haplotype analysis.
Results of the initial CNP haplotype analysis. All 2, 3 and 4 marker haplotypes are 
shown, with their corresponding global p-values and also the most significant single 
haplotype p-values. The markers 1-4 refer to SNP’s rsl2952915, rs2070106, rsl 1296, 
and rs4796751 respectively.
Haplotype Most significant 
single haplotype
Global p-value
1-2 0.07 0.09
1-3 0.62 0.86
1-4 0.65 0.86
2-3 0.06 0.16
2-4 0.12 0.43
3-4 0.67 0.84
1-2-3 0.1 0.17
1-2-4 0.09 0.54
1-3-4 0.44 0.89
2-3-4 0.12 0.52
1-2-3-4 0.09 0.58
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32.3.1 Family 702 pedigree analysis:
As mentioned before, my host department previously reported genome wide 
significant evidence for linkage (LOD 8.32, genome-wide empirical p value < 0.02) to 
schizophrenia in a single pedigree (family 702) (Williams, Norton et al. 2003). In 
order to determine if this linkage finding might be the result of variation in CNP I 
sequenced the exons of CNP in all 7 of the available family members o f the family 
702 pedigree. Two additional sequence variants present in the family were discovered 
(4926 A>G, 7230 G>A) and genotyped through the pooled association sample. The 
results are presented in table 3.9. Neither was associated with schizophrenia or 
changed the predicted amino-acid sequence of the encoded CNP.
Based upon the linkage data (Williams, Norton et al. 2003) it was expected 
that all of the affected siblings would show identity by descent for both maternal and 
paternal chromosomes, and therefore with respect to any one CNP marker, the 
affected individuals would all have the same genotype. However, for some of the 
markers (rs4432296, r s l2602950, rsl 1079028 and 7284 G>A) homozygous and 
heterozygous genotypes were observed indicating that among the siblings, a minimum 
of three parental chromosomes were represented with respect to the CNP locus (see 
figure 3.6). The availability of parental DNA allowed me to determine that each 
affected subject received the same paternal copy of CNP and therefore that for the 
CNP locus, both maternal chromosomes were represented in the affected individuals. 
Interestingly, despite this, all the affected individuals in the family are homozygous 
for the minor lower expression A allele at marker rs2070106 (see figure 3.6). Under 
the null hypothesis the prior probability that the single transmitted paternal 
chromosome transmitted would carry this allele is equal to the control minor allele 
frequency (0.3) while that of the mother being homozygous for this allele is the square
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of the allele frequency (0.09). Therefore given the known pattern o f  chromosom al 
transmissions in this family, the prior probability that by chance, both parents would 
have genotypes that would allow  all affected individuals to be hom ozygous for the 
lower expression allele = 0.027 (0.3*0.09). I f  the presence o f  linkage is not allowed 
for, given the known parental genotypes (father heterozygous, m other uninform ative 
homozygous), the corresponding probability o f  all the siblings being homozygous for 
the A allele is 0.56= 0.015 (the probability o f  the heterozygous father transm itting the 
A allele to all six o f  the siblings).
Figure 3.6 Family 702 pedigree.
Family 702 pedigree showing the six affected male siblings diagnosed w ith DSM-IV 
schizophrenia. The genotypes present at six CNP markers are given for the father and 
the six siblings, indicating the presence o f  a m inim um  o f  three parental chromosomes 
represented within the siblings.
702-01
r s l2952915 9 9
rs4432296 t t
rsl 2602950 a a
rs2070106 9 a
rsl 1079028 9 9
7284 G/A a a
O
702-04 702-06 702-07 702-08 702-09 702-10
rs12952915 9 9 9 9 9 9 9 9 9 9 9 9
rs44322 96 t t t c t t t t t t t c
rs12602950 a a a 9 a a a a a a a 9
rs2070106 a a a a a a a a a a a a
rs11079028 9 a 9 9 9 a 9 a 9 a 9 9
7284 G/A a 9 a a a 9 a 9 a 9 a a
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3.2.3.2 Analysis of the complete CNP genomic sequence.
After performing the analysis on the exonic sequence o f  the family 702 
pedigree I decided that in order to study the gene more com prehensively the entire 11 
Kb of CNP genomic sequence should be screened for sequence variation in the 14 
unrelated schizophrenic patients and also the family 702 pedigree. The screening o f 
this additional sequence resulted in an additional 9 polym orphism s being detected 
(rs8080978, rs8080979, rsl0540926 , rs8078650, 1944 A>T, 3235 A>G, rsl2952456, 
rsl2950675 and 8962 C>T). All o f  these m arkers were then genotyped through the 
pooled association sample, but none showed any evidence o f  association w ith 
schizophrenia (see table 3.9). All o f  the additional SNPs were also genotyped in 96 
unrelated control subjects in order to calculate the D ’ and r2 values (see figure 3.8 and 
table 3.10). This genotyping was achieved by using two m ultiplex SNaPshot reactions 
as described in the m ethods section. A n exam ple o f  each o f  the resultant SNaPshot 
electrophorograms is shown in appendix 3.6 and 3.7 at the end o f  this chapter.
Figure 3.7 Schematic diagram of CNP.
Diagram o f CNP (adapted from the UCSC Genom e Browser), indicating the positions 
of all the genotyped polym orphism s. For num bering o f  polym orphism s, +1 indicates 
the ‘A’ o f  the most 5 ’ ATG translation initiation codon. The gene is displayed (5’-3’).
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T able 3.9: Summary' o f  the pooled gen otyp ing  data for  all o f  the C N P polym orphism s studied  in this project:
Pooled genotyping results for the CNP SNPs. Markers highlighted in grey were detected during the initial gene screening experiment or were 
studied in the original 5 Kb marker grid. Markers labelled with (*) were detected during the sequencing o f the exonic sequence in the family 702 
pedigree. Markers labelled with (0) were detected during the sequencing o f the remaining genomic sequence o f CNP. The markers minor allele 
frequencies are shown along with the corresponding chi-square and p-values.
SNP Data Pooled Genotyping data
SNP number. rs Number UCSC position (HG 16, July 2003)
Minor Allele 
Cases (freq)
Minor Allele 
Controls (freq) Difference Chi-square P-value
CN P-4359 G/A rs4796750 40,487,709 A= (0.3) A= (0.31) 0.01 0.3 0.58
CN P-2086 C/TO rs 8080978 40,489,982 T= (0.2) T= (0.22) 0.02 1.7 0.20
CN P-2084 C/GO rs 8080979 40,489,984 G= (0.05) G= (0.05) 0 0.2 0.63
CN P-1148 AG Ins/Del 0 rsl 0540926 40,490,919 AG Del= (0.2) AG Del= (0.22) 0.02 0.6 0.45
CN P-351 G/A rsl 2952915 40,491,717 A= (0.22) A= (0.22) 0 0.005 0.94
CNP -96 T/C rs4432296 40,491,972 C= (0.33) C= (0.32) 0.01 0.02 0.89
CNP 1868 T/GO rs 8078650 40,493,936 G= (0.2) G= (0.21) 0.01 0.53 0.47
CNP 1944 ATT 0 40,494,011 T= (0.03) T= (0.03) 0 0.006 0.94
CNP 2371 A/G rs4258677 40,494,439 G= (0.12) G= (0.11) 0.01 0.04 0.84
CNP 3235 A/G 0 40,495,303 G= (0.28) G= (0.3) 0.02 0.9 0.34
CNP 3582 C/T 0 rsl 2952456 40,495,650 T= (0.19) T= (0.2) 0.01 0.18 0.67
CNP 3625 T/C 0 rsl 2950675 40,495,693 C= (0.15) C= (0.17) 0.02 2.1 0.15
CNP 4926 A/G * rsl 2602950 40,496,994 G= (0.29) G= (0.31) 0.02 1.1 0.30
CNP 6961 G/A rs2070106 40,499,029 A= (0.28) A= (0.22) 0.06 3.5 0.06
CNP 7230 G/A * rsl 1079028 40,499,298 A= (0.22) A= (0.2) 0.02 1.2 0.27
CNP 7284 G/A 40,499,352 A= (0.13) A= (0.13) 0 0.2 0.67
CNP 8157 T/C rs11296 40,500,225 c= (0.1) C= (0.11) 0.01 0.3 0.58
CNP 8634 C/T rs4796751 40,500,702 T= (0.18) T= (0.19) 0.01 0.3 0.58
CNP 8962 C/T0 40,501,030 T= (0.05) T= (0.04) 0.01 1.5 0.22
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Figure 3.8: LD structure of the CNP genomic region.
Haploview LD plot o f the CNP genomic region displaying the D’ values between the CNP markers and the LD block present as defined by 
Gabriel and colleagues (2002).
/  82 9 34 4
29 14 ^  26
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Table 3.10: Summary of the LD between CNP markers:
Summary of the LD analysis results for the CNP polymorphisms in 96 controls. The table shows the marker names and the D’ and r2 values. The 
results shown above the diagonal line of grey squares are D’ values and the results shown below the diagonal line are r2 values.
SNP ID
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rs4796750
rs8080978
rs8080979
rsl 0540926
rsl 2952915
rs4432296
rs8078650
CNP 1944 A>T
rs4258677 0.03 0.0
CNP 3235 A>G
rsl 2952456
rsl 2950675 0.4 0.75
rs12602950
rs2070106 0.11 0.23
rsl 1079028
CNP 7284 G>A 0.01 0.0
rs11296
rs4796751 0.01 0.01
CNP 8962 C>T
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3.2.3.3 Additional entropy analysis.
Following the comprehensive mutation detection that was carried out on the 
CNP locus in both the family 702 pedigree and the mutation screening set I performed 
an additional entropy analysis on the 19 CNP polymorphisms. By calculating the 
haplotype frequencies of all the markers, it was possible to utilise the entropy analysis 
technique, to determine the subset of markers that would extract >95% of the genetic 
information contained within the gene that would have been captured by individually 
genotyping all of the nineteen discovered SNPs. This entropy analysis revealed that 
by individually typing a further six additional markers (rs4796750, rs l0540926, 3235 
A>G, rs l2602950, rsl 1079028 and 7284 G>A) in addition to the four markers that 
had already been genotyped individually, it would be possible to extract >98% of the 
haplotypic diversity that would have been provided by genotyping all of the markers 
(see table 3.11).
Table 3.11. Results of Entropy analysis.
Entropy analysis results for the 19 CNP polymorphisms. The number of 
polymorphisms required to be genotyped and the maximum percentage of haplotypic 
diversity that could be extracted by genotyping those polymorphisms is shown.
Number of markers 
to be genotyped
Maximum percentage 
of haplotypic diversity 
extracted
1 0.24
2 0.44
3 0.62
4 0.76
5 0.88
6 0.96
1 0.98
8 0.99
9 1.0
10 1.0
129
Genotyping of the additional six markers was performed using a Sequenom MALDI- 
TOF multiplex assay, as described in the materials and methods chapter. No evidence 
for association with schizophrenia at either the genotypic or allelic level was found 
(see Table 3.12).
Table 3.12: Additional individual genotyping results for CNP markers in the 
schizophrenia case control sample:
Individual genotyping data produced when the CNP markers (rs4796750, rs l0540926, 
3235 A>G, rs l2602950, rsl 1079028, and 7284 G>A) were typed in the schizophrenia 
case control sample. Genotypic and allelic counts, the allele frequencies and the 
corresponding chi-square and p-values for the markers are given.
SNP
Information Summary of Genotypic data Summary of Allelic data
*4796750 G> A G/G G/A A/A G A
! Cases 
I Controls
330
347
240
254
46
55
900 (0.73) 
948 (0.72)
332 (0.27) 
364 (0.28)
■i = 0.37 (2df) P = 0.83 Ilf = 0.20 (ldf) P = 0.65
*10540926 AG 
Ins/Del Ins/Ins Ins/Del Del/Del AG Ins AG Del
Cases
Controls
414
435
194
203
23
28
1022 (0.81) 
1073 (0.81)
240 (0.19) 
259 (0.19)
X2 = 0.27 (2df) P = 0.87 = 0.08 (ldf) P = 0.78
3235 A>G A/A A/G G/G A G
Cases
Controls
331
344
238
265
56
55
900 (0.72) 
953 (0.72)
350 (0.28) 
375 (0.28)
X2 = 0.53 (2df) P = 0.77 X2 = 0.02 (ldf) P = 0.89
*12602950 A>G A/A A/G G/G A G
Cases
Controls
347
365
259
283
61
62
953 (0.71) 
1013 (0.71)
381 (0.29) 
407 (0.29)
X2 = 0.18 (2df) P = 0.91 X2 = 0.004 (ldf) P = 0.95
*11079028 G>A G/G G/A A/A G A
Cases
Controls
334
381
173
177
25
28
841 (0.79) 
939 (0.80)
223 (0.21) 
233 (0.2)
X2 = 0.69 (2df) P = 0.71 X2 = 0.39 (ldf) P = 0.53
_7284G>A G/G G/A A/A G A
Cases 
_ Controls
475
506
144
148
9
10
1094 (0.87) 
1160 (0.87)
162 (0.13) 
168 (0.13)
X2 = 0.08 (2df) P = 0.96 X2 = 0.04 (ldf) P = 0.85
130
’12.3.4 Haplotype analysis.
All possible haplotype com binations w ere analysed, up to and including the 
ten marker haplotype (data not shown). The perform ance o f  exhaustive haplotype 
analysis was necessary as the percentage o f  haplotypic diversity predicted to be 
captured by the entropy m ethod is based upon the subsequent analysis o f  all possible 
haplotypes. None o f  the global p-values w ere more significant than the result detected 
individually for marker rs2070106 (see table 3.13), (table 3.13 only shows 2 and 3 
marker sliding windows for ease o f  presentation).
Table 3.13. CNP Haplotype analysis.
CNP haplotype analyses results. The tw o and three m arker haplotype sliding windows 
are shown, with their corresponding global p-values.
Marker Two marker haplotype sliding window Three marker haplotype sliding window
4796750
9540926
2952915
35A>G
1 2 9 5 0
2570106
1079028
34G>A
7296
<796751
0.88
0.9
0.99
0.97
0.07
0.22
0.9
0.73
0.84
0.94
0.99
0.99 ■ _____
0.19 ■ _____
0.6 ■ _____
0 5 2  ■
0.79
0.77
3.2.3.5 Familial schizophrenia analysis:
Given the previous evidence reporting linkage o f  the region o f  chromosom e 
17 containing CNP to schizophrenia in a m ultiply affected fam ily (W illiam s, N orton 
et al. 2003), I decided to analyse the rs2070106 data in the subset o f  our association 
sample which had a positive fam ily history o f  schizophrenia. In the association 
sample a patient is classified as having a positive family history i f  they have at least 
one affected first degree relative. W hen this subset o f  the cases was tested against the
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control sample there was no evidence for association between marker rs2070106 and 
susceptibility to familial schizophrenia at either the genotypic (p=0.29) or allelic 
(p=0.12) level (see table 3.14).
Table 3.14: Individual genotyping of rs2070106 in the familial schizophrenia 
sample:
Individual genotyping results for marker rs2070106 in the familial subset of the 
schizophrenia association sample. Genotypic and allelic counts as well as allele 
frequencies are given, with the corresponding chi-square and p-values.
SNP Genotypes Alleles
rs2070106 G>A G/G G/A A/A G A
Cases 58 69 16 185 (0.65) 101 (0.35)
Controls 325 303 59 953 (0.7) 421 (0.3)
5^  = 2.51 (2df) P = 0.29 5^  = 2.40 (ldf) P = 0.12
3.2.3.6 Gender analysis.
Analysis by gender was of interest given that the six affected family 702 
siblings were all male. No significant differences were found in the allele frequencies 
between the cases and controls in females (table 3.16), whereas in males there was a 
significant difference (table 3.15).
Table 3.15: Individual genotyping data for marker rs2070106 in the male 
sample:
Summary of the rs2070106 genotyping data in males. Genotypic and allelic counts, 
the allele frequencies and the corresponding chi-square and p-values for the data are 
given.
L SNP Genotypes Alleles
$>70106 G>A G/G G/A A/A G A
Cases 190 216 58 596 (0.64) 332 (0.36)
_ Controls 214 202 41 630 (0.69) 284 (0.31)
= 4.76 (2df) P = 0.09 = 4.58 (ldf) P = 0.03
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Table 3.16: Individual genotyping data for marker rs2070106 in the female 
sample:
Summary of the rs2070106 genotyping data in females. Genotypic and allelic counts, 
the allele frequencies and the corresponding chi-square and p-values for the data are 
given.
SNP Genotypes Alleles
n2070106 G>A G/G G/A A/A G A
Cases 98 103 13 299(0.69) 135 (0.31)
Controls 108 98 18 314(0.70) 134(0.30)
yf = 1.19 (2df) P = 0.55 = 0.15 (ldf) P = 0.70
If the observed male gender effect is a genuine finding and not the result of chance or 
small female sample size, then a significant difference between the male and female 
cases might be expected to exist. When the analysis was performed a significant 
difference between the genotypes and also a trend towards significance between the 
allele frequencies present in the male and female cases was revealed (table 3.17). The 
analysis was also repeated in the control sample to determine whether the observed 
gender difference was present in the general healthy population. This analysis 
revealed no significant difference between either the genotypic or allelic frequencies 
in the male and female controls (table 3.18).
Table 3.17: Genotyping data for rs2070106 in male and female cases:
Genotyping data for rs2070106 in the male and female schizophrenic patients. 
Genotypic and allelic counts, the allele frequencies and the corresponding chi-square 
and p-values for the data are given.
SNP Genotypes Alleles
R2070106 G>A G/G G/A A/A G A
Male Cases 
Jemale Cases
190 (0.41) 
98 (0.46)
216(0.46) 
103 (0.48)
58 (0.13) 
13 (0.06)
596 (0.64) 332 (0.36) 
299(0.69) 135(0.31)
X2 = 6.66 (2df) P = 0.03 Z2 = 2.86 (ldf) P = 0.09
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Jable 3.18: genotyping data for rs2070106 in male and female controls:
Genotyping data for rs2070106 in the male and female controls. Genotypic and allelic 
counts, the allele frequencies and the corresponding chi-square and p-values for the 
data are given.
SNP Genotypes Alleles
rs2070106 G>A G/G G/A A/A G A
Male Controls 
Female Controls
214(0.47) 
108 (0.48)
202 (0.44) 
98 (0.44)
41 (0.09) 
18(0.08)
630(0.69) 284(0.31) 
314(0.70) 134(0.30)£ = 0.22 (2df) P = 0.89 ^  = 0.19 (ldf) P = 0.66
3.3 Discussion;
I screened four genes (CNP, MAG, TF and ErbB3) reported, in the study 
(Hakak, Walker et al. 2001) which formed the inspiration for this thesis, to be down- 
regulated in schizophrenia for the presence of cis-acting sequence variants affecting 
the genes expression in human brain. Altered gene expression can be a consequence 
of either cis- or trans-acting effects. If altered expression plays a primary aetiological 
role in disease, rather than being either involved in the pathophysiological pathway or 
being a secondary effect of the disease, it is the former cis-acting genetic effects that 
are of relevance. I therefore first sought to confirm whether expression of any of the 
genes was in fact influenced by cis-acting polymorphisms. The results of the allelic 
expression analyses clearly confirmed the presence of such cis-acting variants only in 
the case of CNP. The observation that in every sample, the A allele of CNP marker 
rs2070106 is under expressed compared to the G allele suggests that either the marker 
SNP itself is responsible for the altered expression, or that the actual functional 
variant is in strong linkage disequilibrium (LD) with the marker SNP.
If it is postulated that the under expression of CNP in schizophrenia is of 
aetiological relevance then the mechanisms responsible for this phenomenon can be 
expected to be associated with the disorder. This leads to the following specific
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hypothesis. If CNP under expression is aetiologically significant then the lower 
expression A allele of marker rs2070106 will be associated with disease. When the 
marker was genotyped individually in the case-control sample the results were 
consistent with this hypothesis, although they only just meet the conventional criteria 
for significance (p = 0.04, OR = 1.2, 95% Cl (1.0-1.40)). Additional analysis of the 
data revealed a slightly stronger association in males (p=0.03), along with a 
significant difference between the male and female cases (see table 3.17).
Following these initial results I performed further direct and indirect genetic 
analysis of CNP, in order to look for non-synonymous SNPs, functional variants in 
LD with rs2070106 and any further association signals. This analysis involved the use 
of a dense set of markers as well as ultimately sequencing the complete genomic 
sequence of CNP and its flanking sequence. A total of nineteen sequence variants 
were detected and subsequently analysed for association (see figure 3.7 and table 3.9). 
Analysis of these polymorphisms revealed no further evidence for association to 
schizophrenia, either at the single marker or haplotype level. This would suggest that 
if the original finding reflects a true association, marker rs2070106 is likely to be the 
schizophrenia susceptibility variant per se, or is in LD with a marker beyond the 
region that I sequenced.
I have also tried to determine whether variation at the CNP locus might be 
responsible for the previous report of linkage to 17q in a single multiply affected 
family. In order to do this I sequenced the exons of CNP in all the family members of 
the 702 pedigree. This analysis did not reveal any common polymorphisms or 
mutations in the exonic sequence that might account for the linkage. Interestingly, the 
results of this analysis did reveal that the 17q region of the genome where CNP 
resides had a lower level of IBD sharing than had been previously predicted by the
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linkage study. However, all of the affected siblings within the pedigree were 
homozygous for the lower expression A allele of marker rs2070106. This observation 
of transmissions in the siblings would be expected to occur by chance around 3 times 
in 100 (0.03), and provides independent support for CNP playing a role in 
susceptibility to schizophrenia. It should be noted, that as the putative susceptibility 
allele has a homozygosity rate of 10% in the general population, the allele is unlikely 
to be a highly penetrant recessive genotype, and therefore unless there are loci that 
interact with rs2070106 fixed in the family cannot account for the reported linkage 
finding in the multiply affected family on its own.
Whilst it has been possible during this project to confirm the presence of ex ­
acting sequence variants that affect the expression of the CNP gene, the expression 
assay does not allow the exact location or function of these variants to be determined. 
The location of cX-acting variants may be in transcribed sequence itself, promoters, 
intronic sequence or in distant regulatory elements (Levine and Tjian 2003), making it 
a very difficult proposition to locate the variants, Although mutation analysis of CNP 
did not reveal polymorphisms predicted to change the amino acid sequence of the 
gene, rs2070106 showing modest association to schizophrenia and associated with 
lower expression is located in the genes coding sequence close to the 3’UTR, where 
the occurrence of SNPs may affect the genes expression. At present, bioinformatics 
analysis (http://pupasnp.bioinfo.cnio.es/) does not predict any functional role for 
rs2070106. However, there have been examples reported where synonymous SNPs 
have been shown to affect gene expression (Duan, Wainwright et al. 2003; Capon, 
Allen et al. 2004; Pagani, Raponi et al. 2005), so it is possible this marker itself is 
responsible for the altered expression. However, it should be noted that an alternative 
explanation would be that the association and altered expression observed at this
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marker are as a result of strong linkage disequilibrium with the true functional variant. 
If this is true, then it is unlikely that the functional variant is located within the genes 
exonic sequence or introns as these have been comprehensively screened as part of 
this project. As mentioned earlier these could be located either distal or proximal to 
the gene in regulatory elements. Analysis of the available HapMap data revealed the 
presence of strong LD extending up to 300kb from the CNP locus.
It is also of note that rare sequence variants with small minor allele 
frequencies may not have been detected during this project. The screening set used in 
the project to perform mutation detection provided a power of 80% to detect 
polymorphisms with a minor allele frequency of 0.05, and a 95% power to detect 
polymorphisms with a minor allele frequency of 0.1. This means it is likely that 
polymorphisms with minor allele frequencies of around 0.05 or lower will not have 
been detected and tested for association to schizophrenia. Recent advances in 
mutation screening technology and the advent of high throughput genotyping 
techniques mean that if the project was being repeated today it would now be feasible 
to perform mutation screening on large numbers (hundreds) of cases and controls and 
thus allow rare polymorphisms with low minor allele frequencies to be detected and 
tested for association. For example a screening set of one hundred cases and one 
hundred controls would provide a power of 98% to detect polymorphisms with a 
minor allele frequency of 0.01 and a power of 87% to detect polymorphisms with a 
minor allele frequency of 0.005.
A further point is the design of the project itself. At the time the project was 
conceived, the genetic databases and genome information available on the internet 
were limited compared to what is available now. If the project was being designed at 
the present time I would perform it differently. The rapid expansion in the genetic
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information available combined with the release of the latest version of the HapMap 
project allows for the selection of specific ‘tag’ markers in order to screen genes using 
an LD mapping approach, as well as allowing for the use of haplotype analysis. The 
method allows the selection of the minimal set of markers that are required to be 
genotyped in order to obtain the genetic information that would be extracted by typing 
all of the genetic markers contained within a gene either individually or through the 
use of haplotype analysis. Even at the present time there are only five CNP markers 
with genotype information for the European-American population contained within 
the HapMap database, including rs2070106. Analysis of the data revealed these 
markers to all be singleton tag markers. Using my earlier entropy analysis it was 
possible to calculate that if the five markers were genotyped they would extract about 
80% of the haplotypic diversity that would have been obtained by typing all of the 19 
detected SNPs in CNP. Although the HapMap database currently does not contain all 
of the genetic diversity within CNP, it does provide reasonable coverage of the 
genetic information contained within the gene and would still be a good starting point 
for the genes investigation.
Recently it has been shown that CNP interacts with mitochondria and 
cytoskeletal proteins and may act to promote microtubule assembly or act as a 
membrane anchor for tubulin and as such CNP has been proposed as a potential 
candidate responsible for coordinating the reorganisation of the cytoskeleton during 
the process outgrowth of oligodendrocytes. This theory is supported by the results of 
several studies. Firstly, Bifulco and colleagues (Bifulco, Laezza et al. 2002) 
demonstrated that CNP was a membrane bound microtubule associated protein that 
was able to link tubulin to membranes. The authors proposed that CNP may regulate
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cytoplasmic microtubule distribution, by acting as a membrane anchor for 
microtubules. Secondly, Lee and colleagues (Lee, Gravel et al. 2005) demonstrated 
that CNP interacts with tubulin heterodimers and promotes microtubule assembly.
The authors additionally demonstrated that CNP was able to induce microtubule and 
F-actin reorganisation, which are both necessary procedures for process outgrowth 
and arborisation in oligodendrocytes. During myelinogenesis oligodendrocytes create 
highly branched processes that target and wrap around axons to form the myelin 
sheath. The presence of the myelin sheath is essential for the successful and rapid 
delivery of action potentials along the axons. This important role of oligodendrocytes 
is itself critically dependant upon the establishment of an adequate oligodendrocyte 
support structure. This is provided by the cytoskeleton, which is constructed from 
microtubules and microfilaments (Lee, Gravel et al. 2005). Disruption to the structure 
of this cytoskeleton or its component parts might have a critical impact on the 
functionality of oligodendrocytes and subsequently upon the formation of the myelin 
sheath and the function of axons themselves.
Also, recent analysis of CNP-null mice has revealed that deficiency of CNP 
leads to disrupted axoglial interactions in the CNS and also major abnormalities in the 
paranodes and paranodal loops (Rasband, Tayler et al. 2005). The paranodal loops are 
the principal site of axoglial contacts and have been shown to influence the regulation 
of several important axonal functions including the clustering of ion channels and cell 
adhesion molecules, and also the control of axonal survival (Rasband, Tayler et al. 
2005). It has therefore been suggested that CNP is required for maintaining the 
integrity of paranodes and that disrupted axoglial signalling caused by a deficiency in 
CNP underlies the progressive axonal death observed in the CNS of CNP-null mice 
(Rasband, Tayler et al. 2005). Given the reduced expression of CNP observed in
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schizophrenic brain and the proposed role of CNP in maintaining both the structure 
and function of the cytoskeleton and also the integrity of paranodes and axoglial 
signalling. The gene may play an important role in causing the oligodendrocyte and 
myelination abnormalities observed in schizophrenic brain.
In conclusion I have shown that CNP expression is under the influence of cis- 
acting polymorphism, and that consistent with previous micro-array findings of 
reduced CNP expression in schizophrenic brain, the allele associated with lower CNP 
expression is also associated with schizophrenia. The findings, while supported by a 
strong directional prior hypothesis and by further observations in a family showing 
linkage to the region, are weak and certainly require independent replication in large 
suitably powered association samples. This might be problematic given the power 
required to detect markers with small effect size. For example, in the case of 
rs2070106 with a minor allele frequency (controls) of 0.3, an odds ratio of 1.2 and a 
disease prevalence of 0.01, a sample of 1100 cases and 1100 controls is required to 
provide an 80% power to detect association at p=0.05, and a sample of 1500 cases and 
1500 controls is required to provide a 90% power to detect association at p=0.05. 
Nevertheless, the results provide support for the specific hypothesis that reduced CNP 
expression in schizophrenic brain may be aetiologically relevant to schizophrenia. 
Moreover, the data also provides support for the more general hypothesis that altered 
myelination and/or oligodendrocyte function may play a role in schizophrenia 
aetiology. These findings therefore provide further inspiration to study other OMR 
genes in schizophrenia.
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3.4 A ppendix: Sam ples o f E x p erim en ta l d a ta
Appendix 3.1: DHPLC chrom atograph.
Example o f DHPLC traces produced for CNP am plim er b l analysed at 64°C, for 
screening set samples 6, 12, 13 and 14. The graph shows the peaks representing these 
samples PCR products, and changes in the peak shape indicates the presence o f  a 
heteroduplex.
Shoulder on this peak indicates 
the presence of a heteroduplex 
in this PCR product
4 . 0 4 . 5 5 . 0 5 . 5 6 . 00 . 5 1 . 5 2 . 0 2 . 5 3 . 0 3 . 51.0
R e t e n t io n  Time (n in )
Appendix 3.2: DHPLC chrom atograph.
Example o f DHPLC traces produced for CNP am plim er b20 analysed at 63°C, for 
screening set sample 12 and three m em bers o f  the family 702 pedigree. The graph 
shows the peaks representing these samples PCR products, and changes in the peak 
shape indicates the presence o f  a heteroduplex.
The change in peak shape indicates 
the presence of a heteroduplex in 
these PCR products
6 . 05 . 0 5 . 54 . 53 . 5 4 . 02 . 5 3 . 02 . 00.0 0 . 5 1.0 1 . 5
Appendix 3.3: Sequencing electrophorograms for CNP.
This appendix shows exam ples o f  the different sequencing electrophorogram s that 
were produced during the classification o f  each o f  the polym orphisms detected as a 
result o f screening the entire CNP genom ic sequence. The polym orphism  is indicated 
with an arrow.
Sequence electrophorograms for the CNP 
rs8080978 C>T polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
Frag 1 6F
Sequence electrophorograms for the CNP 
rs8080979 C>G polymorphism, showing a C- 
G heterozygote in the top panel and a C-C 
homozygote in the lower panel.
con1 fr2f
4 f2i
Sequence electrophorograms for the CNP 
rs4432296 T>C polymorphism, showing a T-C 
heterozygote in the top panel and a T-T 
homozygote in the lower panel.
Frag 6 5F
Frag 6 2F
Sequence electrophorograms for the CNP 
rs8078650 T>G polymorphism, showing a T-G 
heterozygote in the top panel and a T-T 
homozygote in the lower panel.
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Frag 11 12R
Frag 11 14R
Sequence electrophorograms for the CNP 1944 
A>T polymorphism, showing a A-T 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
Sequence electrophorograms for the CNP 3625 
T>C polymorphism, showing a A-A 
homozygote in the top panel and a A-G 
heterozygote in the lower panel. The 
sequencing trace is taken from the anti-sense 
strand.
Frag 10 5F
Sequence electrophorograms for the CNP 3235 
A>G polymorphism, showing a A-G 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
Frag 11 5R
Frag 15 1F
Sequence electrophorograms for the CNP 4926 
A>G polymorphism, showing a A-A 
homozygote in the top panel, a A-G 
heterozygote in the middle panel and a G-G 
homozygote in the lower panel.
Sequence electrophorograms for the CNP 3582 
C>T polymorphism, showing a G-A 
heterozygote in the top panel and a G-G 
homozygote in the lower panel. The 
sequencing trace is taken from the anti-sense 
strand.
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Sequence electrophorograms for the CNP 
rs2070106 G>A polymorphism, showing a A- 
A homozygote in the top panel, a G-A 
heterozygote in the middle panel and a G-G 
homozygote in the lower panel.
Sequence electrophorograms for the CNP 7230 
G>A polymorphism, showing a T-T 
homozygote in the top panel, a C-T 
heterozygote in the middle panel and a C-C 
homozygote in the lower panel. The 
sequencing trace is taken from the anti-sense 
strand.
26_B04~1 .AB1
25_A04~1 AB1
Sequence electrophorograms for the CNP 7284 
G>A polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel. The 
sequencing trace is taken from the anti-sense 
strand.
Frag 20 6R - ■ - - - 
fi f l C C C  N T R C C R Q
f^i f l C C C
s .  J  \
N T  R C  C fi G
\M!)0r
Frag 20 10R
R R C C C  G T R C C R G
R R C C C
-w. / .  'i_
T G  T A C C f i G
Sequence electrophorograms for the CNP 
rs4796751 C>T polymorphism, showing a G- 
A heterozygote in the top panel and a G-G 
homozygote in the lower panel. The 
sequencing trace is taken from the anti-sense 
strand.
Frag 21 5F
Frag 21 13F
Sequence electrophorograms for the CNP 8962 
C>T polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
15JG02~1 AB1
26_B04~1.AB1
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F0D02.D3 CNP_b4 F
151/4 CNP>4
131/3 CNP_b4 F
Sequence electrophorograms for the CNP -1148 AG Ins/Del polymorphism, showing a AG-Del 
homozygote in the top panel, a AG-Ins heterozygote in the middle panel and an AG-Ins homozygote in 
the lower panel.
Appendix 3.4: FP genotyping graph for rs2070106.
This figure shows an example o f  an FP genotyping graph produced during individual 
genotyping o f CNP rs2070106. The FP values cluster into four groups. The upper left 
comer o f  the plot represents the homozygote samples for allele A with a high FP for 
TAMRA, the right upper com er o f  the plot shows the heterozygote samples with a 
high FP for TAMRA and ROX, the lower right com er o f  the plot shows the 
homozygote samples for allele G with a high FP for ROX, and the bottom left comer 
o f the graph shows the failed PCR reactions and negative controls with low FP values 
for both TAMRA and ROX.
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Appendix 3.5: Multiplex SNaPshot electrophorogram for CNP;
This figure shows an example o f  the SNaPshot electrophorograms produced by the 
individual multiplex SNaPshot genotyping reaction performed on the CNP markers 
rs4796750, CNP -351 G>A, and rs8080978. The electrophorogram shows an 
individual who is heterozygous at each locus. Alleles are labelled and the size o f each 
SNaPshot extension product in base pairs is given.
36B_D05_.FSA 7 Blue 36b 36b
-4 0 0 0
-3 0 0 0
-2 0 0 0
-1 0 0 0
CNP -351 
/  37bp Allele G
rs4796750 
27bp Allele
36B-D05 FSA 7 Green 36b 36b
-3000
-2000
-1000
CNP -351 
f  38bp Allele A
rs4796750 
28bp Allele A
36B_D05_.FSA 7 Yellow 36b 36b
-2 0 0 0
-1 5 0 0
-1000
-500
rs8080978 
> Allele C-f 26bp
36B_D05_.FSA 7 Red 36b 36b
-3 0 0 0
-2000
-1 0 0 0
rs8080978 
) Allele Tf  28bp
Appendix 3.6: M ultiplex SNaPshot electrophorogram for CNP:
This figure shows an example o f  the SNaPshot electrophorograms produced by the 
individual multiplex SNaPshot genotyping reaction performed on the CNP markers 
rs8078650, CNP 7284 G>A, and CNP 3625 C>T. The electrophorogram shows an 
individual who is heterozygous at each locus. Alleles are labelled and the size o f each 
SNaPshot extension product in base pairs is given.
4 9 A_A07 FSA 1 Blue 49a 49a
p3000
-2000
-1000
CNP 7284 
Allele G
rs8078650 
28bp Allele G y  35bp
49A_A07_.FSA 1 Green 49a 49a
CNP 7284 
36bp Allele A -1000
-5 0 0
4 9 A_A07 FSA 1 Yellow 49a 49a
-1 5 0 0
-1 0 0 0
-5 0 0
CNP 3625 
Allele Cy  33bp
49A_A07_.FSA 1 Red 49a 49a
CNP 3625 
y  35bp Allele
-2000
-1 5 0 0
-1000
-5 0 0
rs8078650 
30bp Allele T
Appendix 3.7: Sequenom MALDI-TOF genotyping output graph:
This figure shows an example o f  a Sequenom genotyping output graph for the CNP 
marker rs4796750. The graph displays a plot o f  the genotype intensities. The green 
cluster in the top left represents the G-G homozygotes with a high intensity for the 
higher mass extension product representing the G allele, the yellow cluster in the mid 
right represents the G-A heterozygotes with a high intensity for both the high and low 
mass extension products, the blue cluster in the bottom right com er represents the A- 
A homozygotes with a high intensity for the lower mass product representing the A 
allele, and the red cluster in the bottom left represents the PCR failures and negative 
controls which do not have a high intensity for either o f the alleles extension products.
■  Call C luster Graph
t i m _ r s 4 7 9 6 7 5 0
H W  C hi Square 1 0872 P-value: 0.2971 
+  No Call(13) A A(23) ■  AG(154) ▼ G(194)
Low M ass Intensity.
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Chapter 4. The NOGO receptor complex and schizophrenia:
4.1.1. Introduction:
In this chapter I report analysis of four genes involved in the NOGO receptor 
complex: Neurite outgrowth inhibitor (NOGO), NOGO receptor (NGR), 
Oligodendrocyte myelin glycoprotein (OMG) and Nerve growth factor receptor 
(NGFR). A direct genetic approach was applied. The genes were screened for 
polymorphisms and the identified SNPs tested for association with schizophrenia in 
DNA pools. The genes were also assayed for the presence of c/s-acting sequence 
variants affecting their expression in brain.
The NOGO complex genes were selected for study primarily on the basis of 
reported over-expression of NOGO mRNA in post mortem schizophrenic brain 
(Novak, Kim et al. 2002), supported by positional and/or functional evidence for their 
involvement in schizophrenia.
4.1.2. The NOGO Receptor Complex;
In the adult central nervous system (CNS), axons which are lesioned or 
damaged do not regenerate. This is in contrast to that in the adult peripheral nervous 
system (PNS) (He and Koprivica 2004). The failure of damaged axons to regenerate 
in the adult CNS is thought to be the result of inhibitory factors (Woolf and 
Bloechlinger 2002). Much of this inhibition has been attributed to myelin (Filbin 
2003). Myelination appears to coincide with the loss of neuronal regenerative ability 
(Novak, Kim et al. 2002). Oligodendrocytes, as well as making myelin, produce 
growth inhibitory proteins that become embedded within the myelin sheath (Woolf 
and Bloechlinger 2002). An important breakthrough in the understanding of axon
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regeneration was the identification of several of these inhibitory molecules and their 
receptors. At least three proteins contribute to the inhibitory action of CNS myelin on 
axonal growth and development: NOGO (Chen, Huber et al. 2000; GrandPre, 
Nakamura et al. 2000; Prinjha, Moore et al. 2000), OMG (Wang, Koprivica et al.
2002) and MAG (McKerracher, David et al. 1994). Fournier and colleagues (Fournier, 
GrandPre et al. 2001) identified a binding partner for NOGO that they called the 
NOGO receptor (NgR). NgR was shown to be expressed on the surface of certain 
neurons and in combination with NOGO lead to axonal growth cone collapse. More 
recently it has been shown that all three of the major myelin neuronal inhibitors 
interact and bind to the same receptor (NgR) with high affinity (Liu, Fournier et al. 
2002; Wang, Koprivica et al. 2002). It has been suggested that there is functional 
redundancy within the myelin inhibitors, as the presence of any one is sufficient to 
activate an inhibitory signal via the receptor complex (Filbin 2003). Although NgR is 
essential for NOGO, MAG and OMG to exert their inhibitory effect, it is unable to 
transduce the inhibition signal across membranes as it contains no transmembrane 
domains. The inhibitory signal is instead transmitted via a transmembrane co­
receptor, the nerve growth factor receptor (NGFR)/p75 neurotrophin receptor (Wang, 
Kim et al. 2002; Wong, Henley et al. 2002). It has also been shown that RhoA a 
member of the Rho GTPase family is activated by this inhibitory complex and is also 
involved in inhibiting neurite outgrowth (Hasegawa, Fujitani et al. 2004). RhoA in its 
GTP-bound form induces rigidity in the actin cytoskeleton and it is thought this 
prevents axon elongation and results in growth cone collapse (Hasegawa, Fujitani et 
al. 2004).
The myelin associated neurite inhibitors have been proposed to have other 
functions including involvement in myelination, maintaining functional and structural
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relationships between glial cells and axons and in maintaining and regulating the 
structural plasticity of the nervous system (He and Koprivica 2004).
Three independent mouse knockout models have been made for NOGO. The 
first (Kim, Li et al. 2003) showed improved axon regeneration in young Nogo 
knockout mice after spinal cord injury. However a second study (Zheng, Ho et al.
2003) displayed no evidence of increased axon regeneration. The third (Simonen, 
Pedersen et al. 2003) reported an improvement in axonal growth but only a small 
number of axons regenerated. These results demonstrate the redundancy of the 
inhibitory molecules in the regulation of axon regeneration.
The myelin inhibitory proteins and their receptors are expressed in both the 
CNS and the PNS during development suggesting they may in part control the growth 
of axons during this period (Huber, Kolodkin et al. 2003). As neuronal networks 
develop, the growth of axons is progressively halted. It has been postulated that the 
lack of axonal regeneration in the adult CNS may result from reactivation of the 
mechanisms responsible for controlling growth of the complex neuronal system 
during development (Woolf 2003). During development the course of an individual 
axon is controlled by many extracellular guidance prompts as well as axonal 
signalling (He and Koprivica 2004). The extension of axons from their cell body 
begins with the formation of small growths whose tips form a specialised structure 
called the axonal growth cone. The growth cone interacts with its surrounding 
environment to determine the direction and extent of axon elongation. When the 
growth cone comes into contact with CNS myelin, its cytoskeletal structure is altered 
causing it to collapse preventing further axonal growth (Woolf and Bloechlinger
2002). The myelin inhibitory proteins are thought to play a role in this process. 
Recently, it has also been suggested that the myelin inhibitory proteins might function
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as a repulsive contact-guidance mechanism guiding axons along myelinated tracts as 
well as being responsible for terminating growth by collapsing the axonal growth 
cone (Raisman 2004). If the NOGO complex does have a function in the growth and 
guidance of axons it is possible that any alteration in the expression or functional 
ability of the genes could allow misregulation of development, which could disrupt 
connectivity of the CNS. In fact it has been suggested that the main role of the NOGO 
complex may be more related to the long term preservation of the existing wiring and 
connectivity present in the adult CNS, and that the suppression of any neuronal 
regeneration or growth is a necessary consequence of this function (Woolf and 
Bloechlinger 2002).
4.1.3 The NOGO receptor genes:
4.1.3.1 Neurite outgrowth inhibitor (NOGO):
The neurite outgrowth inhibitor (NOGO), also known as Reticulon 4 (RTN4), 
gene is located on chromosome 2pl3-pl4, spans 78kb of genomic sequence and 
contains nine exons. Several genome scan studies (Coon, Myles-Worsley et al. 1998; 
DeLisi, Shaw et al. 2002; Straub, MacLean et al. 2002) and a meta-analysis (Lewis, 
Levinson et al. 2003) have reported evidence that this region is linked to 
schizophrenia.
NOGO is a member of the reticulon family of proteins, which are usually 
associated with the endoplasmic reticulum. The NOGO gene encodes for three 
transcripts (NOGO-A, -B and -C) by alternative splicing and promoter use. The 
longest transcript is NOGO-A and contains a unique amino-terminal region (He and 
Koprivica 2004). NOGO-A is highly expressed in oligodendrocytes but not in 
Schwann cells, a finding consistent with the notion that NOGO-A acts as a CNS
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myelin associated inhibitor. NOGO-A is also expressed in certain central and 
peripheral neurons (He and Koprivica 2004). The NOGO-A isoform that is observed 
in oligodendrocytes mostly associates with the endoplasmic reticulum, however, it has 
also been observed on the oligodendrocyte surface and on the innermost loop of the 
myelin membrane (Filbin 2003). NOGO-A has at least two inhibitory domains. One 
of these is termed NOGO-66 as it is coded for by a 66-amino acid sequence and is 
common to all isoforms of NOGO. The second domain termed amino-NOGO is 
unique to NOGO-A and is located in the extended N-terminus of the protein. The 
most common structure of NOGO-A observed in the myelin membrane places the 
NOGO-66 domain outside the cell and the N- and C-terminals including the amino- 
NOGO domain within the cytoplasmic space (Filbin 2003).
The NOGO gene is expressed during neural development. Halabiah and 
colleagues (Al Halabiah, Delezoide et al. 2005) showed that NOGO and its receptor 
are expressed during human fetal development, with the strongest expression being 
observed in the cortical and ventricular zones of the brain. The authors suggested that 
the early expression might indicate a more diverse function for the gene than just its 
known neuronal growth inhibition activity and that it may be involved with shaping 
the neuronal circuitry during development (Gregorio, Mury et al. 2005). Mingorance 
and colleagues (Mingorance, Fontana et al. 2004) have suggested that the NOGO 
receptor complex may play an important role during the development of the 
hippocampal connections in the brain and that they might subsequently be involved in 
maintaining neuronal plasticity in the adult brain. The hippocampus is a brain region 
that has been implicated in the aetiology of schizophrenia (Harrison 1999).
Novak and colleagues (Novak, Kim et al. 2002) reported that NOGO mRNA 
is over expressed in schizophrenic post mortem cerebral cortex. Quantitative RT-
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PCR, showed an average 60% over expression of NOGO in the schizophrenic 
samples. In principle this might result in increased NOGO receptor stimulation and 
consequently prematurely limit neural development, cause disturbed or abnormal 
neural connectivity, as well as interfering with any neural regeneration or remodelling 
in the mature nervous system. All of the above would fit in with the hypothesis that 
schizophrenia is a disorder of altered connectivity (Friston 1998; Benes 2000).
The NOGO gene has also been implicated in multiple sclerosis (MS). Kamezis 
and colleagues (Kamezis, Mandemakers et al. 2004) looked at NOGO deficient mice 
affected with experimental autoimmune encephalomyelitis (EAE), an animal model of 
MS. They reported that the EAE mice lacking NOGO displayed less sighs of 
inflammatory demyelination and axonal damage than NOGO expressing control mice 
with EAE, and subsequently developed less severe phenotypes. They concluded that 
NOGO is likely to play a role in the development of EAE and as a result may be 
involved in the aetiology of MS. Satoh and colleagues (Satoh, Onoue et al. 2005) 
reported that NOGO expression was up-regulated in surviving oligodendrocytes at the 
edge of active demyelinating lesions in MS brains compared to controls, whilst the 
expression of the NOGO receptor was also increased in astrocytes and 
microglia/macrophages within these MS lesions compared to their expression levels 
in the brains of controls. The authors suggested that this increased expression of 
NOGO and its receptor may play a role in the active demyelinating lesions observed 
in MS.
Several molecular genetic studies of schizophrenia have targeted NOGO. The 
results have been varied but there has been some evidence for an association to 
schizophrenia reported (see table 4.1). Initially Novak and colleagues (Novak, Kim et 
al. 2002) detected a CAA insertion polymorphism within the 3’UTR of the gene that
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they reported to be associated with schizophrenia. The frequency of individuals 
homozygous for the insertion was significantly higher in schizophrenics compared to 
controls (p=0.002). The authors also detected a second polymorphism in the 3’UTR, a 
TATC deletion upstream of the CAA insertion which they did not test for association 
with schizophrenia but was reported to be almost always co-inherited with the 
associated insertion (Novak, Kim et al. 2002). More recently (Tan, Chong et al. 2005) 
examined NOGO in a Chinese case control study. They did not observe a significant 
association for either polymorphism in their overall sample, but when they analysed 
females alone they detected significant association to schizophrenia for both the CAA 
insertion (p=0.03) and the TATC deletion (p=0.01). They also examined haplotypes in 
females and again detected a significant association to schizophrenia with the 
haplotype containing the CAA insertion and TATC deletion polymorphisms. 
Interestingly, a second Chinese case control study (Chen, Gu et al. 2004a) reported no 
evidence of association with the polymorphisms individually, but examination of the 
supplementary data from that paper reveals a significant association to the same 
haplotype (p=0.03) in females. It should be noted that there are some haplotype 
frequency differences between the two Chinese studies raising the concern of an error 
in allele labelling.
Some studies have failed to provide evidence of association with 
schizophrenia. Two studies (Covault, Lee et al. 2004; Gregorio, Mury et al. 2005) 
typed the CAA insertion polymorphism in case control samples. Xiong and colleagues 
(Xiong, Rouleau et al. 2005) typed the polymorphisms in case control and trio 
samples, but all failed to find any association with schizophrenia for either 
polymorphism individually or at the haplotypic level. It should be noted that the 
sample sizes of the negative replication studies are small and therefore the power to
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detect an association might be low. It is also of note that the sample studied by Xiong 
and colleagues (2005) was ascertained from a mixture of ethnic backgrounds. One 
interesting observation from the replication studies is that the allele frequencies of the 
two polymorphisms differ quite significantly between the different samples and ethnic 
groups tested, making it hard to compare the results of the studies together.
Table 4.1 Summary of previous RTN4 association studies in schizophrenia.
This table shows the sample sizes, polymorphisms tested, the corresponding allele 
frequencies and a summary of the results for all of the previous RTN4 association 
studies.
Author Cases/Controls(Gthinicity) Polymorphism
Allele Freq 
(Cases)
Allele Freq 
(Controls) Results
Novak et 
al, 2002
81 / 61 
(North American 
Caucasians)
CAA insertion 
in the 3’UTR CAA Ins (0.41) CAA Ins (0.22)
CAA insertion significantly 
associated with 
schizophrenia (p=0.002).
Covault et 
al, 2004
57 / 243 
(European 
Americans)
CAA insertion 
in the 3’UTR CAA Ins (0.43) CAA Ins (0.43)
No significant difference 
between cases and controls.
Gregorio 
et al, 2005
181/427 
(Brazilian)
CAA insertion 
in the 3’UTR CAA Ins (0.36) CAA Ins (0.38)
No significant difference 
between cases and controls.
Xiong et 
al, 2005
462 / 153 
(96 French-Canadian, 
83 Tunisian,
283 Other Europeans)
CAA insertion 
and TATC 
deletion in the 
3’UTR
CAA Ins (0.43) 
TATC Del 
(0.50)
CAA Ins (0.42) 
TATC Del 
(0.49)
No significant difference 
between cases and controls.
Tan et al, 
2005
363 /253 
(Females 93/129) 
(Ethnic Chinese)
CAA insertion 
and TATC 
deletion in the 
3’UTR
CAA Ins (0.35) 
(Female 0.36) 
TATC Del 
(0.39) 
(Female 0.41)
CAA Ins (0.30) 
(Female 0.27) 
TATC Del 
(0.34) 
(Female 0.30)
Significant allelic and 
haplotypic association with 
CAA insertion (p=0.03) and 
TATC deletion (p=0.01) in 
female schizophrenics.
Chen et al, 
2004
403 / 347 
(Han Chinese)
CAA insertion 
and TATC 
deletion in the 
3’UTR
CAA Ins (0.69) 
TATC Del 
(0.65)
CAA Ins (0.66) 
TATC Del 
(0.61)
Significant haplotypic 
association in female 
schizophrenics (p=0.03).
4.1.3.2 NOGO receptor (NgR):
The NOGO receptor (NgR)/Reticulon 4 receptor (RTN4R) gene is located on 
chromosome 22ql 1, spans 26kb of genomic sequence and contains two exons. The 
gene maps on the edge of the VCFS critical region. This region is deleted in most
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cases of VCFS, a syndrome associated with a marked increased risk of developing 
schizophrenia (Murphy, Jones et al. 1999; Murphy 2002). A wider region of 
chromosome 22q has also been implicated in several linkage studies (Gill, Vallada et 
al. 1996; DeLisi, Shaw et al. 2002; Williams, Norton et al. 2003), and a recent meta­
analysis of the linkage data has provided further support for the involvement of this 
region (Lewis, Levinson et al. 2003).
Sinibaldi and colleagues (Sinibaldi, De Luca et al. 2004) recently looked at the 
NgR gene as a potential candidate gene for schizophrenia. They used DHPLC to 
screen 120 schizophrenic patients and detected three rare coding mutations, two non- 
synonymous (R119W and R196H) and one synonymous (L18L). The two non- 
synonymous SNPs were each detected in a single schizophrenic patient but none of 
300 controls when they were subsequently genotyped for these polymorphisms. 
However since the design was based only on screening cases, we cannot conclude that 
the rare non-synonymous SNPs are associated with schizophrenia, because by design 
any unique (or very rare variants) will only to be detected in cases. Thus at present 
there is no reliable evidence implicating NgR in schizophrenia.
4.1.3.3 Oligodendrocyte myelin glycoprotein (OMG):
Oligodendrocyte myelin glycoprotein (OMG) is located on chromosome 
17ql 1.2 approximately 10 Mb centromeric of the CNP locus, where it is embedded 
within intron 1 of the neurofibromatosis type 1 (NF1) gene. It spans 2.5kb of genomic 
sequence and contains two exons, with the first exon being untranslated. The OMG 
and NF1 genes are transcribed in different directions. The 17ql 1 region has 
previously been implicated with schizophrenia in a single pedigree (Williams, Norton 
et al. 2003). The involvement o f this region in schizophrenia has been supported by a
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recent meta-analysis (Lewis, Levinson et al. 2003), and an additional linkage study 
(Klei, Bacanu et al. 2005). Additionally there is also significant (Dick, Foroud et al.
2003) and suggestive (Bennett, Segurado et al. 2002; Ewald, Wikman et al. 2005) 
evidence of linkage to this region in Bipolar disorder.
OMG is a glycosylphosphatidylinositol (GPI)-linked protein expressed in both 
oligodendrocytes and neurons. OMG is a relatively minor component of CNS and 
PNS myelin accounting for less than 1% of the structure (Filbin 2003). The timing of 
OMG expression in oligodendrocytes correlates with the onset o f myelination; the 
protein can be detected on the surface of oligodendrocytes and on myelin layers 
adjacent to axons (He and Koprivica 2004). Vourc’h and colleagues (Vourc'h, Dessay 
et al. 2003) have shown an increase in OMG expression during the post-natal period 
of CNS development, with the peak expression level occurring during the later stages 
of myelination. This would indicate that OMG may be involved in CNS 
myelogenesis, possibly playing a role in processes such as the arrest of 
oligodendrocyte proliferation, the arrest o f myelination or the compaction of myelin 
(Vourc'h, Dessay et al. 2003). Finally, in a recent study Vourc’h and colleagues 
(Vourc'h, Martin et al. 2003) reported an association between a G21D G>A non- 
synonymous SNP in the OMG gene and autism. Although there is no strong case for a 
link between the two diseases, both autism and schizophrenia are neurodevelopmental 
disorders, making it feasible that genes involved in one disease may also be involved 
with the other.
4.1.3.4 Nerve growth factor receptor (NGFR/p75):
The Nerve growth factor receptor (NGFR)/p75 Neurotrophin receptor is 
located on chromosome 17q21-q22, spans 19kb of genomic sequence and contains six
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exons. As I mentioned earlier in chapter 3 this region of chromosome 17 has been 
putatively linked to schizophrenia in a single pedigree (see section 3.2.1, figure 3.5).
NGFR/p75 is highly expressed in both glial cells and neurons during 
development. Expression then declines to a low level in adulthood (He and Koprivica
2004). As well as binding to nerve growth factor, NGFR has also been shown to bind 
to all known neurotrophins. Neurotrophins are key mediators of peripheral nervous 
system myelination and play an important role in the survival and development of 
neurons and the establishment and maintenance of synapses during development and 
adulthood (Rajakumar, Leung et al. 2004). Cosgaya and colleagues (Cosgaya, Chan et 
al. 2002) have shown that myelin formation is dependant on the presence of 
functional p75 receptors. In a further study Chan and colleagues (Chan, Cosgaya et al. 
2001) demonstrated that the brain derived neurotrophic factor (BDNF) acts through 
the p75 receptor to enhance the formation of myelin, and that removal of endogenous 
BDNF inhibited myelination. Several independent studies have previously reported 
associations between polymorphisms in the BDNF gene and psychiatric disorders 
such as schizophrenia (Neves-Pereira, Cheung et al. 2005; Chen, Chen et al. 2006), 
bipolar disorder (Sklar, Gabriel et al. 2002; Lohoff, Sander et al. 2005; Green, 
Raybould et al. 2006) and major depression (Schumacher, Jamra et al. 2005). A more 
recent study (Rajakumar, Leung et al. 2004), demonstrated that rats with 
compromised p75 receptor function during cortex development were associated with 
dopamine hyper-responsivity and impaired prepulse inhibition, both features 
associated with schizophrenia (Marenco and Weinberger 2000; Parwani, Duncan et al. 
2000).
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4.2 Materials and Methods:
Briefly described here are the specific methods used to study the NOGO 
receptor complex genes. More detailed explanations of the methods and samples used 
are described in Chapter 2.
4.2.1 Polymerase Chain reaction (PCR1:
PCR fragments to span exons, UTRs, putative promoter and limited amounts 
of 5’ and 3’ flanking regions were designed using the web based program Primer 3.0 
(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). The primers used 
to generate amplimers for the purpose of DHPLC for each gene studied are listed 
below in tables 4.2, 4.3, 4.4 and 4.5 respectively.
It was necessary to attempt a long range PCR due to regions of chromosome 
22 having high homology with the NgR exon 1 and flanking intronic sequence. It was 
hoped that by using primers that anneal specifically to perform the long range PCR, 
the product could then be used to perform a subsequent nested PCR reaction 
amplifying only the region of interest in NgR. The long range PCR was performed 
using the Expand long template PCR system (Roche Diagnostic, Germany). The 
reaction mix was performed as per manufacturer’s instructions and is shown below:
Expand Long Template PCR System. Reaction mix:
R eagen t V olum e Final Concentration / Amount
Genomic DNA tem plate (40ng/pl) 6.0pl 240n g
Forward Primer (10pm ol/ul) 3.0nl 300nM
R everse Primer (10pm ol/pl) 3.0pl 300nM
10 mM dNTP mix 2.5pl 500uM
Buffer (22.5 mM MgCb.) 5.0pl 1x Buffer: 2 .2 5  mM MgCI2
Expand long tem plate en zy m e (5u/pl) 0.75pl 3 .7 5  units
Distilled deion ised  w ater 29.75pl
Total reaction volum e 50.0pl
I
159
Expand Lone Template PCR System. Cycling Conditions:
Temperature Time Cycles
94°C 2 mins 1
94°C 10 secs
55-65°C 30 secs 10
68°C 15 min
94°C 15 secs
55-65°C 30 secs 25
68°C 15 mins + 20 secs per cycle
68°C 15 mins 1
4°C hold
A variety of different conditions, including a selection of amplification 
primers and reaction mixes and protocols were attempted but unfortunately 
amplification of the specific genomic region of interest was unable to be achieved.
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Table 4.2. PCR primers and conditions used for RTN4/NOGO assays.
This table shows details of the RTN4 PCR assays for the purpose of mutation detection, including PCR primers, size of fragment, the reaction 
conditions and annealing temperature. (HS indicates that hot start taq polymerase was used).
Fragment Name Spanning Forward Primer (5’ to 3’)
Reverse Primer 
(5’ to 3’) Size (bp)
Annealing Temp 
(°C)
RTN 4_1 Putative Prom CCC AT GGCAAT C AAACTTT C TCACTGCATGCCTACTCTGG 412bp HS 60
RTN 4_2 Putative Prom TT GAGCAACTT G AAAGC AGGT CG AAATT GGG AGGAAAACAG 486bp HS 60
RTN 4_3 Putative Prom AAGGCCCCAAACTCTCTTTG CC ACTTT GGGT AACCGT GAG 471 bp HS 64
RTN 4_4 Exon 1 ACTCTCAGTTCCCCCAGGAT ACT G AGCCGAGGG ACCT ACT 522bp HS 64
RTN 4_5 Exon 1 TGGCCT C ACT CCT AGCT CAT CG AAGT CATTT CCG AAGT CC 498bp HS 64
RTN 4_6 Exon 1 AGG ACG AAG ACCT GGAGG AG ACC AGCCC AAAGCAT CT G 505bp HS 58
RTN 4_7 Exon 1/lntron 1 CCCCTCCCTCI I I IGTGTG CACCTTTT CC AAAGG AGC AA 412bp HS 60
RTN 4_8 Exon 2 TAGGC ACCC ACCCGTAGTAG CT GGGCC AAGT CC ACACTAA 548bp HS 64
RTN 4_9 Exon 3 CT GAGT GAAAGCTT GGGAT G GAC AAAAC ATT CT CGGAACCA 510bp HS 64
RTN 4_10 Exon 3/lntron 3 GAGCCT GT GAT ACGCT CCT C GGC AATT AC AT GCT GT GC AA 493bp HS 64
RTN4J1 Intron 3/ Exon 4 ATTT ACCC AGT GCCCCTT CT G AAAG AAGCGGCT GAG AG AG 485bp HS 64
RTN 4_12 Exon 4 TGTCCT GCTT GAAACTGCTG CCC ATACT CGCT CAAAT GGT 506bp HS 64
RTN 4_13 Exon 4 GAGTT GCAGT GGAAGCTCCT TCTCAGAATCCTGTGCTGCT 462bp HS 64
RTN 4_14 Exon 4 TAACCCAGCAGCAACTGAGA GGT GAT G AGCT GGGCTGTAT 513bp HS 64
RTN 4_15 Exon 4 T GC AGTT CCT AGT GCT GGT G AGGT GGC AAAGC ACT GAGTT 514bp HS 64
RTN 4_16 Exon 4 CCT G ACGTT CCAC AAAAACA AAAGGT CAT GGGGCAATT CT 499bp HS 60
RTN 4_17 Exon 4/lntron 4 CT AAT GCCCCGG AT GGAG GGT G AAT GCT GAGT GCAAG A 498bp HS 64
RTN 4_18 Exon 5 T GC AGCT CC ATTT GGT AT G A AAACCG AAT GCC AGT G AAAC 544bp HS 60
RTN 4_19 Exon 6 GAT GG AGC AAAT CC AAATT G A CT CCT CC AT CAT GAGCCTTT 468bp HS 60
RTN 4_20 Exon 7 GT GGC AG AGC AT C AG ATT C A AAC AC AAGTTTAC AGCCAT GT G A 524bp HS 64
RTN 4_21 Exon 8 GGGTAAG AT GC ACCCTT GGT AAGCT CCT GGC AC AC AAT CT 407bp HS 64
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RTN 4_22 Exon 9/ Exon 10 GT GGCT CCT C AAC AGC AG AT TT CT CAC AAT CCAGC AC ACC 526bp HS 64
RTN 4_23 Exon 10/ Exon 11 ACCTCTCTTTCAGGCACAGA TT CAAT CC AGGG ATTTTT GC 463bp HS 60
RTN 4_24 Exon 11 AGCAGC AGCAAACAAAACT G CGGC AAG ACT AT CT GC AACA 402bp HS 64
RTN 4_25 Exon 11 CCTGTCTTGACTGCCATGTG GGT GGCT GG AAGGTAAAGGT 434bp HS 60
RTN 4_26 Exon 11 GC AGG AAT G AC AAAGCTT GC TT C ACAAT GCATT CCACAG A 473bp HS 60
RTN 4_27 Exon 11 TCCAAAAATGTTGTTTGTTTGC AGC AAT AGT GT CCGT GT GT C A 527bp HS 60
RTN 4_28 Exon 11 T GCACC AAT GTTTTAACT C AC A CT GGCTACTT GCATTT GT C A 488bp HS 60
Table 4.3: PCR primers and conditions used for RTN4-R/NOGO-R assays.
This table shows details of the RTN4-R PCR assays for the purpose of mutation detection, including PCR primers, size of fragment, the reaction 
conditions and annealing temperature. (HS indicates that hot start taq polymerase was used).
Fragment Name Spanning Forward Primer (5' to 3') Reverse Primer (5' to 3') Size (bp) Annealing Temp CO
NOGO-R Long PCR Dup Exon Var A CAAT GCATACGT CCCATT GAC CAT G AACTAACGT GTCTCT C AGGAT 11,436bp
Long Range PCR 
60-68 (Gel Extract)
NOGO-R Prom 1a A Putative Prom GGTCCT CACTT CCT CT GCAC GCAGGT GT CCCTT CT CAAT C 426bp HS 60
NOGO-R Prom 1a B Putative Prom CT G ACT CCC AGC ACTT CTCC CT C ACG AAACCC AT G AAT CC 487bp HS 60
NOGO-R Ex 1a A Exon 1 CAGCAAGGGGCTTCTGTG CGGGG ACT GAAAGT CGTTT 535bp Couldn’t Opt
NOGO-R Ex 1a B Exon 1 AAT GCGCCGCCTTT GT CT G AAGCGGC AACTTTT CCT G 577bp Couldn’t Opt
NOGO-R Prom 1 b A Putative Prom AG AAAG AGAGC AGAGAGGGT GT C AGCT GGCTAAG AGC AGG AT 459bp HS 66
NOGO-R Prom 1b B Putative Prom CT GT GGT CC ACT CCTT CCTC AT AGCCT CCCAGT GGGTT CT 430bp HS 66
NOGO-R Ex 1b Exon 1 CAT GTAGGGCCTT GGT GAAG CAGACTCCCCATACCACACC 599bp HS 66
NOGO-R Ex 2A Exon 2 AGGTCCT CCT GAGACCCAAT G AGCT GT GCATTATCGCT GA 439bp HS 66
NOGO-R Ex 2B Exon 2 GCAACCTCACCATCCTGTG GGCAGCGCTGATAGATTGTT 484bp HS 66
NOGO-R Ex 2C Exon 2 AGCCT CG ACCGT CT CCTACT GCT CCAGTACT G AGGCCTT G 439bp HS 66
NOGO-R Ex 2D Exon 2 CCTT ACC AT CCC AT CT GGAC T GT AC AC AC ACCT GGCT GCT 526bp HS 61
NOGO-R Ex 2E Exon 2 AG AAGGCT C AGGTGCCCTA GCACCT GACATT GG AGCT G 545bp HS 66
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Table 4.4; PCR primers and conditions used for OMG assays.
This table shows details of the OMG PCR assays for the purpose of mutation detection, including PCR primers, size of fragment, the reaction 
conditions and annealing temperature. (HS indicates that hot start taq polymerase was used).
Fragment Name Spanning Forward Primer (5’ to 3’)
Reverse Primer 
(5’ to 3’)
Size
(bp)
Annealing 
Temperature (°C)
OMG_1 Putative Prom ACAGCCTAAACCCAAATTCA ACT CT AGG AGCC ACCTTTT GT AT 467bp HS 60
OMG_2 Putative Prom GT GGC AATAAAGC ACCC AAT TT GCAC ATTT CAT CTTT CT GG 512bp HS 60
OMG_3 Putative Prom CCACT G AAGAGT GG AGC AAA T CCCCC AAC AT GGT GATTAT 531 bp HS 60
OMG_4 Exon 1 CCT AAAAGGGAAG ACGGAACA AAGCT CT GCAACCACCT GAT 534bp HS 60
OMG_5 Exon 1 TGTGCACCTCTTGCCATAAA GC ACTT G AAAAAT CC AG ACC A 501 bp HS 60
OMG_6 Exon 1 TGCT GC AGT GT C AGTT GAGG CCTT C AATT GGGCT AT GT GG 521 bp HS 60
OMG_7 Exon 1 GGGGGAGGGAGAGAGAAAAT CCAGGGT CCT C AG ATTGGTA 517bp HS 60
OMG_8 Exon 1 T AT GC AC AG AG AGGC AC AGG GGT C AAAAG ATT GGT CT GGAA 546bp HS 60
OMG_9 Exon 1 T GCCCT CC AAACTAC ATATCG GCACC AAACGTT GTTT CCTT 454bp HS 60
OMG_10 Exon 1 T GCAGACAGT GGACACCATT T C AGGGAGGAGT GCTTTCAT 518bp HS 60
OMG_11 Exon 1 GCTCAATGTTGTGGTCATGC T GGAAAGCCAAAT GACACAG 413bp HS 60
OMG_12 Exon 1 AAAAATGAAATGI I I IAAGGCTTC GC I I'TTT GAAGAGCTTTTGTCC 409bp HS 60
OMG_13 Exon 1 CAT CCC AT G AAT GGTT ATGCT CT GT CCC AT GCCT AGCCTT A 535bp HS 60
163
Table 4.5: PCR primers and conditions used for NGFR assays.
This table shows details of the NGFR PCR assays for the purpose of mutation detection, including PCR primers, size of fragment, the reaction 
conditions and annealing temperature. (HS indicates that hot start taq polymerase was used).
Fragment Name Spanning Forward Primer (5’ to 3’)
Reverse Primer 
(5’ to 3’)
Size
(bp)
Annealing 
Temperature (°C)
NGFRJ Putative Prom GGC ICI I GA'I C l CCCTTTTG T GCACACACACACTGACACC 506bp HS 60
NGFR__2 Putative Prom AAGCCC AT GGAGACACT CAC GGAGT CCATT CCGACAT CAT 406bp HS 64
NGFRJ Putative Prom GAGT GC AT GAG AACGGT GT G TTAG AGCCT CT C ACCCAT CC 529bp HS 60
NGFR_4 Redesign Exon 1 GAACAGGAACCGCAGTGG GCTAAC ACT C ACCCCCAGAA 494bp HS 62
NGFRJ Exon 1 CGGACCGAGCTGGAAGTC TTCTCTCGCCTTGGTTCTGT 518bp HS 64
NGFR_6 Exon 2 CCCCT GT C AGCTTT GAT GTT CTCCT CCCT CT GCACACTTC 523bp HS 64
NGFRJ Exon 3 CCAACTTTCACAGGCTAGGG C AC ACGGT GTT CT GCTT GT C 402bp HS 64
NGFR_8 Redesign Exon 3 GC AATAGGGG AGGG AG AG AC C AGAG AGGGGTT CTTT GCT G 664bp HS 62
NGFR_9 Exon 4 CAGAGTCACCCAGCAAGT CA AG AC AGGG AT GAGGTT GTCG 428bp HS 64
NGFRJ 0 Exon 4 GCCl I I ICTCCCAGAGATCC GGGAT GAGGACACAAGCAGT 561 bp HS 64
NGFRJ 1 Exon 5 CGGCAGAGCACAGATACTCA AAAGCCT CC ATTT CCC AAGT 441 bp HS 64
NGFRJ 2 Exon 5/lntron 5 AGGCT GAGGAAACAGAAGCA T GAACTCCTTT CCCCAAC AG 582bp HS 60
NGFRJ 3 Exon 6 GCT GGAGT GACAGGAGGAAG CT GCACAGACT CT CCACGAG 475bp HS 64
NGFRJ 4 Exon 6 CCCGAGCACATAGACTCCTT GTT CCT CGATT CCTCCCTCT 588bp HS 64
NGFRJ 5 Exon 6 CCTT CT CCCACACT GCTAGG CTTCAAGCCATTTCCCAGAA 466bp HS 60
NGFRJ 6 Exon 6 GCACCGCCTT CT CT AAAT G A ATT CCCT CCG AT GCTT CT CT 496bp HS 60
NGFRJ 7 Exon 6 CCT CACCTTGCAACACACAG TAGAGGGGAGCCACACTCAC 514bp HS 64
NGFRJ 8 Exon 6 G ACT GT G ACCT GT GGGG ATT AAGG AGGGG AGGT GAT AGG A 542bp HS 60
NGFRJ 9 Exon 6 CCCTT G AGCT G AGAT GGAAC CT CT GACTT GCCT GTGGT C A 483bp HS 60
NGFR_20 Exon 6 AGGAAGCTAGCCAGCTGTGA AGCCTCCCTTTGTCTTCCTC 451 bp HS 60
NGFR_21 Exon 6 GGTT GTTT GGCC AAGT CCT TTT CAC AGG AC AGC AT CTGG 506bp HS 60
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4.2.2 Genotvping:
Every SNP identified was typed in pools using the ABI SNaPshot™ kit. PCR 
primers used are listed in tables 4.2 to 4.5 and extension primers are listed in tables 
4.6,4.20, 4.22 and 4.24.
Any SNP showing an association in the pools at the p=0.05 level was typed 
individually. Where a polymorphism could not be assayed with a primer extension 
assay, like the VNTR in fragment RTN4 24, it was typed individually in the UK case 
control sample. This was performed by assaying the polymorphism by size using a 
fluorescently labelled PCR primer. The forward PCR primer was labelled with the 
fluorophore FAM. The PCR products were analysed on the ABI 3100 Genetic 
Analyser. An example o f an electrophorogram is shown in the appendix at the end of 
this chapter (section 4.5, appendix 4.4).
4.3 Results:
4.3.1 NOGO / RTN4:
Determination of NOGO genomic structure was based on alignment of the 
cDNA sequence NM 020532 and the genomic sequence available from the UCSC 
Genome Bioinformatics website (http://genome.ucsc.edu).
I identified nineteen SNPs in NOGO along with two insertion/deletions a 
VNTR and a variable length poly A sequence (See appendix 4.3 for sequencing 
results). There were no coding SNPs, synonymous or non-synonymous. The variants 
were located in 5’-UTR (rs6545468), 3’-UTR (77258 G>A, 77394 VNTR, 
rsl 1464312, 77878 AAC-Ins and 77996 AAT-Ins), 5’ flanking region (rsl2465266, 
rsl2477141, rs2968789, rsl3387836, -739 A>G, rsl348528, rsl822618 and 
rs6545469), 3’ flanking region (rs2588510, rs887 and 78775 C>G) and introns
(rsl3002841, rsl3401937, rsl7046589 , rs2580769, rs2255026 and rs2255112) (see 
figure 4.1).
Figure 4.1. Schematic diagram of NOGO.
Diagram o f NOGO (adapted from the UCSC Genom e Browser), indicating the 
positions o f the identified polym orphism s. For num bering o f  polym orphism s, +1 
indicates the ‘A ’ o f  the ATG translation initiation codon. The gene is displayed (3’-
5’).
chr2 (p!6.1> ■ ■ I  ■  I ■  I  I  II D O I■  ■ I I  I II ■ H I  I nr
ctTr2 : I 55060000! 55070000I 55080000! 55090000I 55100000I 55110000I 55120000! 55130000I
GENOTYPEO SNPS
7677S_C>G | r *25©07691 r* 17646569 | r* 13461937| r*6545468|
r*867 | r s 13002641 | r*65454691
rS2588516 | r s l 622616 |
77996JW_Ins | r*1348528|
77878_86C_Ins | 739_G>fl |
77504_Poly_6 | r s 13387836 |
77394_VNTR j rs29687891
77256_G>6 | PS12477141 |
rs2255112 | r s l 2465266 j
rS2255026 |
RePSeq Genes
The 77878 AAC-Ins and the 77394 V NTR are the same polym orphism s 
reported to be associated with schizophrenia in previous studies (Novak, K im et al. 
2002; Chen, Gu et al. 2004a; Tan, Chong et al. 2005). Seventeen o f  the detected 
polymorphisms were successfully genotyped in the pooled association sample. The 
extension primers used for pooled genotyping are listed in table 4.6. The m inor allele 
frequency o f  SNPs -739 A>G, 77258 G>A, 78775 O G  and the 77996 AAT-Ins were 
undetectable using pooled genotyping. The 77394 V N TR and 77504 poly A 
polymorphisms were incom patible w ith prim er extension genotyping assays. The 
calculated allele counts and frequencies for all o f  the genotyped polym orphism s are 
shown in table 4.7. There were no significant differences observed betw een the allele 
frequencies o f the cases and controls for any o f  the assayed polym orphism s.
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Table 4.6; Polym orphism  and prim er extension reaction Information.
This table shows the sequence flanking each of the NOGO/RTN4 polymorphisms, the extension primer used to assay the polymorphism and the 
expected alleles in the primer extension reaction.
SNP number. rs Number SNP Flanking sequence Extension primer Expected Alleles
-1447 G>A rs12465266 CTAATT CTT GAA[G/A]T CCAGT GCGCAT CATTT CGG AGGTACTAATT CTT GAA G (Blue) & A (Green)
-1409 O T rsl 2477141 CAC AT CTAATTT[C/T] AGCCTAGCTACA C ATTTTACACTTAC AGC ACAT CTAATTT C (Black) &T (Red)
-1196 T>C rs2968789 T CT GC AACTACT[T/C]T CTTTAAACT CT TTT AT GAGGCT GG AG AGTTTAAAG A A (Green) & G (Blue)
-1123 A>G rsl 3387836 AAACC AAT G ACT[ A/G]T GGGGCTT CCT G ATT CCT GC AT AT C AAACC AAT G ACT A (Green) & G (Blue)
-739 A>G N/A CTTT GAGT G AAC[A/G] AAT AATYI I I IA AT GT AGTTT GG AACTTT GAGT GAAC A (Green) & G (Blue)
-732 O T rsl 348528 T G AAC R AAT AAT[C/T]TTTT ATTT C AAA TAAGGAI I I I IAAAGAI I I I IGAAATAAAA G (Blue) & A (Green)
-646 C>G rs1822618 TT CTT CCTTT CC[C/G]GGGAGGAAAGTT CCAGT CGGGTTT CTT CCTTT CC C (Black) & G (Green)
-472 O T rs6545469 TGAACGCAATCC[C/T]AGCCGGTAAGAG GGC ACTT CCT CT CT CTTACCGGCT G (Blue) & A (Green)
-205 G>C rs6545468 CGGCGGCGGCAA[G/C]T GGGGACAGGGC CGCCACCCGCCCTGTCCCCA C (Black) & G (Blue)
22715A>G rsl 3002841 ATTTTAGTAAAC[A/G]GT AAGT CTTT AC TTATTAATTGCTATTAACATTTCATTTTAGTAAAC A (Green) & G (Blue)
25222 O A rsl 3401937 TT C AGGT AAT CC[C/A] AT CT AT AT GC AG T GGC AT G AAAGCACAAAACT GC ATATAG AT G (Blue) & T (Red)
40387 A>C rsl 7046589 GTT GT AT ACC AG[A/C] AAAT GT CAT GCT AGT GAAAC AGAACAGC AT GACATTT T (Red) & G (Blue)
62818 T>G 
76398 G>A
rs2580769
rs2255026
T C AGGT GAG AT G[T /G]CT GG AAAAC AAG 
CCAAATCATTCC[G/A]TTC I I I I IGAAA
CAAT GCAT GCCTT GTTTTCCAG 
GT GTTTATT CCT CCCAAAT C ATTCC
A (Green) & C (Black) 
G (Blue) & A (Green)
76636 A>C rs2255112 GT GGTTAATAAG[A/C]TTCTTTAGCAAC GGAATTATTACCGTTGCTAAAGAA T (Red) & G (Blue)
77258 G>A N/A GTTT CAC AG AT C[G/A]TT GTTAG AT CTT CAT GGCTAAAAATAAAGAT CTAACAA C (Black) & T (Red)
77394 VNTR N/A TTT CCTAT CT[AT CT/AAT CTAT CT]G AGGC ACT GG Unable to assay with an extension primer.
77504 Poly A rsl 1464312 T AG AAAAAAAAAAAAAAA[A/-]GCCCTTTT C A Unable to assay with an extension primer.
77878 AAC-lns N/A TAG AACT CC AAC[AAC/-] AT C AATTT C ATT AAT GCCACACACATAGAACT CCAACA T (Red) & A (Green)
77996 AAT-lns N/A T AT GC AAG AAAT[AAT/-]TATTAATT AC AA AAAT AT C AAAC ATT GTTAT GCAAGAAAT T (Red) & A (Green)
78188G>A rs2588510 GCTT C AACC AGC[G/A] AAT GGT AGCTT G AGT GGGTAAACT GCTT C AACC AGC G (Blue) & A (Green)
78368 T>C rs887 CAAT GTTTTAAC[T/CJCACATATAT CAT TAAATTCATGCACCAATGI I I I AAC T (Red) & C (Black)
78775 C>G N/A GTAAAT GTTAGT[C/G]TATT CTAC AATT ATGAGGCAI I I ICAATTGTAGAATA G (Blue) & C (Black)
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Table 4.7: Pooled genotyping data for NOGO/RTN4.
This table shows the estimated minor allele frequencies and allele counts in pooled samples of 535 cases and 552 controls for all of the 
polymorphisms in the NOGO/RTN4 gene, along with their corresponding p-values.
SNP Data Pooled Genotyping data
SNP number. rs Number Minor Allele Cases (freq) Minor Allele Controls (freq) Difference Chi-square P-value
-1447 G>A rsl 2465266 G= 136 (0.13) G= 151 (0.14) 0.01 0.44 0.51
-1409 O T rsl 2477141 T= 116(0.11) T= 133 (0.12) 0.01 0.78 0.38
-1196 T>C rs2968789 C= 98 (0.09) C= 117 (0.11) 0.02 1.26 0.26
-1123 A>G rsl 3387836 G= 352 (0.33) G= 358 (0.32) 0.01 0.05 0.82
-739 A>G Minor allele frequency too rare to assay.
-732 C>T rsl 348528 T= 128 (0.12) T= 136 (0.12) 0 0.07 0.79
-646 O G rs1822618 G= 121 (0.11) G= 144 (0.13) 0.02 1.53 0.22
-472 O T rs6545469 T= 94 (0.09) T= 75 (0.07) 0.02 3.00 0.08
-205 G>C rs6545468 C= 460 (0.43) C= 479 (0.43) 0 0.03 0.85
22715A>G rsl 3002841 G= 102 (0.1) G= 123 (0.11) 0.01 1.52 0.22
25222 O A rsl 3401937 C= 131 (0.12) C= 111 (0.1) 0.02 2.63 0.11
40387 A>C rsl 7046589 C= 160 (0.15) C= 196 (0.18) 0.03 3.11 0.07
62818 T>G rs2580769 T= 233 (0.22) T= 245 (0.22) 0 0.05 0.82
76398 G>A rs2255026 G= 166 (0.16) G= 192 (0.17) 0.01 1.39 0.24
76636 A>C rs2255112 C= 456 (0.43) C= 490 (0.44) 0.01 0.69 0.41
77258 G>A Minor allele frequency too rare to assay.
77394 VNTR Incompatible with a primer extension assay.
77504 Poly A rsl 1464312 Incompatible with a primer extension assay.
77878 AAC-lns AAC lns= 475 (0.44) | AAC lns= 491 (0.45) 0.01 0.001 0.97
77996 AAT-lns Too rare to assay.
78188G>A rs2588510 A= 445 (0.42) A= 460 (0.42) o 0.001 0.97
78368 T>C rs887 C= 344 (0.32) C= 377 (0.34) | 0 0.98 0.32
78775 C>G Minor allele frequency too rare to assay.
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As the 77394 VNTR was incompatible with primer extension genotyping in 
the pools, and was of high a priori interest because it is reported to be in strong LD 
with the 77878 AAC-Ins polymorphism previously associated with schizophrenia, I 
genotyped the polymorphism individually in the case-control sample. This was 
achieved by using a Genescan fluorescent PCR assay (as described in section 2.10.5). 
The results of the individual genotyping are shown in tables 4.8 and 4.9 below. The 
VNTR was found to be significantly associated with schizophrenia at both the 
genotypic (p=0.02) and allelic level (p=0.02). Homozygote genotypes containing the 
smaller repeat length (allele 1) are over represented in cases compared to the controls, 
and this is reflected in the allelic association.
Table 4.8: Genotype counts for the NOGO 77394 VNTR.
Genotype counts for the 77394 VNTR polymorphism in the case-control sample, and 
corresponding p-value after analysis using CLUMP. Allele 2 is the ATCT Insertion 
and allele 3 is the AATCTATCT Insertion.
77394 VNTR Cases (n = 658) Controls (n = 712)
Genotype Count Frequency Count Frequency
1-1 165 0.25 145 0.20
1-2 303 0.46 355 0.50
1-3 32 0.05 20 0.03
2-2 135 0.21 171 0.24
2-3 22 0.03 17 0.02
3-3 1 0.001 4 0.005
Xl= 12,73 P= 0.02
Table 4.9: Allele counts for the NOGO 77394 VNTR.
Allele counts for the 77394 VNTR polymorphism in the association sample and 
corresponding chi-square and p-values. Allele 2 is the ATCT Insertion and allele 3 is 
the AATCTATCT Insertion.
SNP Alleles
77394 VNTR 1 2 3
Cases 665 (0.51) 595 (0.45) 56 (0.04)
Controls 665 (0.47) 714(0.50) 45 (0.03)
L1 = 7.77 p = 0.02
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Given previous reports of the 77878 AAC-Ins polymorphisms association with 
schizophrenia, I also genotyped this polymorphism individually even though it did not 
show an association with schizophrenia when genotyped in the pooled sample, see 
table 4.7. The results are shown in table 4.10. No evidence for association with 
schizophrenia was found at either the genotypic or allelic level. The allele frequencies 
are similar to the results of the pooled genotyping, except for a small difference (0.03) 
in the frequencies of the controls. This is possibly the result of the enlarged control 
sample that was individually genotyped or may be attributable to experimental 
variation in the pooled genotyping experiment.
Table 4.10: Individual genotyping results for 77878 AAC in/del polymorphism.
Genotype and allele counts and frequencies for the 77878 AAC in/del polymorphism 
in the schizophrenia association sample. Both genotypic and allelic chi-square and p- 
values are shown.
SNP Genotypes Alleles
77878 AAC Ins
Cases (n=666) 
Controls (n=714)
Del/Del Del/Ins Ins/Ins
200 (0.30) 343 (0.52) 123 (0.18) 
228 (0.32) 374 (0.52) 112 (0.16)
Del Ins
743 (0.56) 589 (0.44) 
830 (0.58) 598 (0.42)
■x? = 2.02 P = 0.36 3C* = 1.54 P = 0.21
4.3.1.1 Gender analysis.
Following the results of Tan and colleagues (Tan, Chong et al. 2005), which 
reported an association between the two NOGO 3’UTR polymorphisms and 
schizophrenia in females, I analysed my data according to gender.
The results of the 77394 VNTR analyses are shown in tables 4.11, 4.12, 4.13 
and 4.14 below. The VNTR was associated with schizophrenia at the genotypic level 
(p=0.02) in females (table 4.11). At the allelic level the association with schizophrenia 
was also stronger in females (p=0.004), with the smaller allele again being over 
represented in the cases compared to the controls (table 4.12). In males the
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polymorphism displayed a trend towards significance at the genotypic (p=0.08) level 
(table 4.13) but did not show any evidence for association with schizophrenia at the 
allelic (p=0.422) level (table 4.14).
Table 4.11: Genotyping of the NOGO 77394 VNTR in females.
Genotype counts for the 77394 VNTR polymorphism in the female association 
sample and corresponding p-value after analysis using CLUMP. Allele 2 is the ATCT 
Insertion and allele 3 is the AATCTATCT Insertion.
77394 VNTR Cases (n = 211) Controls (n = 232)
Genotype Count Frequency Count Frequency
1-1 48 0.23 41 0.18
1-2 107 0.51 120 0.52
1-3 9 0.04 5 0.02
2-2 37 0.18 63 0.27
2-3 9 0.04 3 0.01
3-3 1 0.004 0 0
x2 = 12.23 P= 0.022
Table 4.12: Allele counts for the NOGO 77394 VNTR in females.
Allele counts for the 77394 VNTR polymorphism in the female association sample 
and the corresponding chi-square and p-values. Allele 2 is the ATCT Ins and allele 3 
is the AATCTATCT Ins.
SNP Alleles
77394 VNTR 1 2 3
Cases (n=211) 212 (0.50) 190 (0.45) 20 (0.05)
Controls (n=232) 207 (0.45) 249 (0.54) 8 (0.01)
X2 = U-17 p = 0.004
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¥Table 4.13: Genotyping of the NOGO 77394 VNTR in males.
Genotype counts for the 77394 VNTR polymorphism in the male association sample 
and the corresponding p-value after analysis using CLUMP. Allele 2 is the ATCT 
Insertion and allele 3 is the AATCTATCT Insertion.
77394 VNTR Cases (n = 431) Controls (n = 479)
Genotype Count Frequency Count Frequency
1-1 113 0.26 104 0.22
1-2 187 0.44 234 0.49
1-3 23 0.05 15 0.03
2-2 96 0.22 108 0.23
2-3 12 0.03 14 0.03
3-3 0 0.0 4 0.008
X2 = 9.66 P= 0.08
Table 4.14: Allele counts for the NOGO 77394 VNTR in males.
Allele counts for the 77394 VNTR polymorphism in the male association sample and 
the corresponding chi-square and p-values. Allele 2 is the ATCT Ins and allele 3 is the 
AATCTATCT Ins.
SNP Alleles
77394 VNTR 1 2 3
Cases (n=431) 436(0.51) 391 (0.45) 35 (0.04)
Controls (n=479) 457 (0.48) 464 (0.48) 37 (0.04)
x2 = 1.72 P f0 .4 2
Given the gender effect observed with the 77394 VNTR I also performed an analysis 
comparing the female cases against the male cases. No evidence of a significant 
difference was observed between the genders of the cases at either the genotypic 
(p=0.19) or allelic (p=0.88) level, suggesting that the increased association observed 
in females is likely to be attributable to differences in the control sample. The female 
controls were subsequently analysed against the males, revealing no evidence of a 
significant difference at the genotypic level (p=0.19), but a weakly significant 
difference was observed between the genders at the allelic level (p=0.04).
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Although the 77878 AAC-Ins was not associated with schizophrenia in the whole 
case-control sample given the increased association observed in females for the 77394 
VNTR, I re-analysed the AAC insertion polymorphism to look for a gender effect.
The results are shown in table 4.15 and 4.16 below. No association with schizophrenia 
was observed, although there was a trend similar to that reported (Tan, Chong et al. 
2005) with the homozygote insertion frequency being more frequent in the female 
cases than controls and the insertion allele also being more frequent in the cases (table 
4.15). In males, there was no evidence of association observed at either the genotypic 
(p=0.82) or allelic (p=0.61) level (table 4.16).
Table 4.15: Individual genotyping results for 77878 AAC Ins in females.
Genotype and allele counts and frequencies for the 77878 AAC Insertion 
polymorphism, in the female association sample. Both genotypic and allelic chi- 
square and p-values are shown.
SNP Genotypes Alleles
77878 AAC Ins Del/Del Del/Ins Ins/Ins Del Ins
Cases (n=211) 61 (0.29) 113 (0.54) 37(0.17) 235 (0.56) 187 (0.44)
Controls (n=234) 77 (0.33) 128 (0.55) 29 (0.12) 282 (0.60) 186 (0.40)
_ ^  = 2.58 . P = 0.28 1? -  1.90 P = 0.17
Table 4.16: Individual genotyping results for 77878 AAC Ins in males.
Genotype and allele counts and frequencies for the 77878 AAC Insertion 
polymorphism in the male association sample. Both genotypic and allelic chi-square 
and p-values are shown.
SNP Genotypes Alleles
77878 AAC Ins
Cases (n=439) 
Controls (n=479)
Del/Del Del/Ins Ins/Ins
135 (0.31) 221 (0.50) 83 (0.19) 
151 (0.32) 245 (0.51) 83 (0.17)
Del Ins
491 (0.56) 387 (0.44) 
547(0.57) 411 (0.43)
^  = 0.39 P = 0.82 y* = 0.26 P = 0.61
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4.3.1.2 Haplotype analysis.
As the previous studies (Novak, Kim et al. 2002; Tan, Chong et al. 2005) 
reported that the two polymorphisms were in high linkage disequilibrium with each 
other I analysed my data to determine the extent of LD in my sample. This revealed 
that the two polymorphisms are in strong LD with each other (D’= 0.96). As the 
VNTR is not a bi-allelic marker I was unable to directly calculate an r2 value between 
the two markers. However, by collapsing the 77394 VNTR genotyping data (grouping 
the two larger alleles 2 and 3 together) I was able to calculate both a D’ and r2 value. 
This revealed that the two polymorphisms are in strong LD with each other (D’=0.96, 
r2 =0.74).
Haplotype analysis for the two markers revealed no stronger evidence for 
association (global p-value = 0.07, 5df) and none of the individual haplotypes were 
more significantly associated than the individual association finding (table 4.17).
Table 4.17. Haplotype analysis of NOGO.
Haplotype counts and frequencies for the NOGO data, the corresponding global p- 
value and the individual haplotype chi-square and p-values.
Haplotype Cases (freq) Controls (freq) Chi-square P-value
AAC Del - ATCT Del 93 (0.07) 81 (0.06) 2.32 0.13
AAC Del - ATCT Ins 583 (0.45) 701 (0.49) 5.91 0.02
AAC Del - AATCTATCT Ins 54 (0.04) 45 (0.03) 2.13 0.14
AAC Ins - ATCT Del 565 (0.43) 581 (0.41) 1.64 0.2
AAC Ins - ATCT Ins 7 (0.005) 13 (0.009) 1.10 0.29
AAC Ins - AATCTATCT Ins 2(0.001) 1 (0.0002) 0.85 0.36
Global p-value 0.07 (5 df)
I also performed haplotype analysis on the data according to gender as a result
of the gender effect observed for the VNTR polymorphism. The haplotype analysis of 
the female data showed evidence of association (global p-value = 0.01, 5df) (table
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4.18) but was less significant than the association result for the individual VNTR 
genotyping data in females. Although none of the individual female haplotype 
combinations were more significant than the original VNTR association, the 
frequency of the putative risk haplotype (AAC Ins - ATCT Del) (Tan, Chong et al. 
2005) is over represented (increase of 5%) in the cases compared to the controls, 
whilst the putative protective haplotype (AAC Del - ATCT Ins) is over represented 
(increase of 9%) in the controls (table 4.18) a finding consistent with the observations 
made in previous studies (Chen, Gu et al. 2004a; Tan, Chong et al. 2005). The 
haplotype analysis of the male data revealed no evidence of association (global p- 
value = 0.24, 5df) with no individual haplotype combinations displaying any 
association (table 4.19).
Table 4.18. Haplotype analysis of NOGO in females.
Haplotype counts and frequencies for the female NOGO data, the corresponding 
global p-value and the individual haplotype chi-square and p-values.
Haplotype Cases (freq) Controls (freq) Chi-square P-value
AAC Del - ATCT Del 27 (0.06) 27 (0.06) 0.14 0.71
AAC Del - ATCT Ins 187 (0.44) 245 (0.53) 5.95 0.01
AAC Del - AATCTATCT Ins 20 (0.05) 7 (0.02) 7.75 0.005
AAC Ins - ATCT Del 184 (0.44) 180 (0.39) 2.29 0.13
AAC Ins - ATCT Ins 2 (0.005) 4(0.01) 0.75 0.39
AAC Ins - AATCTATCT Ins 1 (0.002) 1 (0.002) 0.89 0.34
Global p-value 0.01 (5 df)
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wTable 4.19. Haplotype analysis of NOGO in males.
Haplotype counts and frequencies for the male NOGO data, the corresponding global 
p-value and the individual haplotype chi-square and p-values.
Haplotype Cases (freq) Controls (freq) Chi-square P-value
" AAC Del - ATCT Del 62 (0.07) 53 (0.06) 2.23 0.14
^  AAC Del - ATCT Ins 384 (0.45) 456 (0.48) 1.39 0.24
"AAC Del - AATCTATCT Ins 33 (0.04) 37 (0.04) 0.001 0.97
AAC Ins - ATCT Del 368 (0.43) 401 (0.42) 0.25 0.62
AAC Ins - ATCT Ins 3 (0.004) 7 (0.008) 1.02 0.31
AAC Ins - AATCTATCT Ins 2 (0.002) 1 (0.001) 2.71 0.1
Global p-value 0.24 (5 df)
4.3.1.3 Allelic expression assay of NOGO.
Given that the main rational for studying NOGO was based upon the observed 
over expression of NOGO in schizophrenia (Novak, Kim et al. 2002), I assayed the 
NOGO/RTN4 gene for evidence of cis-acting sequence variation affecting the gene 
expression using the allele specific expression assay (Bray, Buckland et al. 2003a), 
described in section 2.8.
The G>C SNP rs6545468, located in the 5’UTR was chosen as a tag SNP for 
the assay as it has a high minor allele frequency (0.4). Of the 60 brain samples that 
were genotyped for SNP rs6545468, 35 were heterozygous and informative for the 
assay. Of the 35 heterozygotes assayed 17 displayed an expression difference greater 
than the arbitrary 20% threshold when compared to the corresponding average 
genomic ratio (see Graph 4.1). On the graph this threshold is represented by a ratio 
greater than 1:1.2 or lower than 1:0.83. The data points from each individual cDNA 
sample showed reasonable reproducibility, with an average SD of the mean of 0.11. 
The individuals who demonstrated a relative expression difference which exceeded 
the 20% threshold showed expression differences ranging from a 27% increase of the
i
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G allele relative to the C allele (1:0.79), to a 40% decrease o f the G allele relative to 
the C allele (1:1.40).
Graph 4.1: RTN4 Allelic Expression assay: rs6545468.
Corrected genomic and cDNA ratios for rs6545468. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for 
NOGO/RTN4 (n=35). Data are expressed as the mean o f the ratio o f G:C for two 
measurements o f each genomic DNA sample and two measurements o f each cDNA 
sample.
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I also analysed the allelic expression data to determine whether the 77394 
VNTR genotype correlated with the relative expression difference observed in the 
allelic expression assay by comparing the mean relative expression difference o f the 
samples heterozygous (1-2) for the VNTR against the mean relative expression 
difference for the homozygous samples (1-1,2-2). The heterozygotes were compared 
against both homozygotes as allelic expression differences are assumed to reflect 
heterozygosity at functional loci. The analysis revealed no evidence o f a correlation 
between a samples VNTR genotype and the relative allelic expression difference
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observed in the rs6545468 assay (mean 1-2 difference 1.17, mean 1-1,2-2 difference 
1.09) (p = 0.14). Analysis of the markers revealed low levels of LD (D’=0.27, 
r2=0.07), and all four haplotypes were observed. Given the low LD, the phase is 
difficult to establish and as such the allelic expression differences would not be 
expected in one direction. Therefore the analysis was also repeated after converting all 
of the relative expression differences to be positive and again revealed no evidence of 
a correlation between VNTR genotype and the observed relative expression difference 
(mean 1-2 difference 1.19, mean 1-1,2-2 difference 1.15) (p = 0.28).
4.3.2 NgR / RTN4-R:
The NgR intron/exon boundaries were defined by alignment of the cDNA 
sequence NM 023004 and the genomic sequence available from the UCSC Genome 
Bioinformatics website (http://genome.ucsc.edu). This revealed a region of 
chromosome 22 with high homology for the first exon and flanking intronic sequence 
(see figure 4.2). Given the high homology of the exon to two regions of the 
chromosome the use of standard sized PCR amplicons was not possible as it would 
have amplified two genomic stretches simultaneously. To circumvent this problem a 
long range PCR followed by a subsequent nested PCR reaction was attempted. 
However, after several attempts at performing a long range PCR reaction to amplify 
the specific region of the genome containing the exon of interest, it was only possible 
to obtain a PCR product which contained multiple products of varying molecular 
sizes. Further efforts were made to screen the exon by gel extracting the PCR product 
band of the correct size and then attempting to perform nested PCR using this product 
as a template. However, no specific NgR products were obtained.
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Figure 4.2: Schematic diagram of NgR on chromosome 22.
Diagram o f the NgR gene (not to scale), representing the genomic structure on 
chromosome 22. The genes two exons are displayed with the start o f  translation 
indicated by an arrow. The region o f  high hom ology for exon one and its flanking 
intronic sequence is displayed.
Region of high homology for exon 
1 and flanking intronic sequence
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Mutation detection revealed only one SNP in N gR which was located in the 5 ’ 
flanking region (-1807 C>T). The polym orphism  identified was genotyped in the 
pooled association sample. No evidence o f  association w ith schizophrenia was found 
(table 4.21). The extension prim er used for pooled genotyping is listed in table 4.20. It 
should be noted that the m inor allele frequency o f  the polym orphism is vary rare 
(0.01-0.02), which increases the likelihood o f  technical variation occurring whilst 
performing pooled genotyping.
4.3.2.1 Allelic expression assay o f NgR.
I was unable to assay the N gR gene for ds-ac ting  variants affecting the 
expression o f  the gene, due to the lack o f  an exonic polym orphism  w ithin m y study or 
the public databases.
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Table 4.20: Polymorphism and primer extension reaction information.
This table shows the sequence flanking each of the NgR/RTN4-R polymorphisms, the extension primer used to assay the polymorphism and the 
expected alleles in the primer extension reaction.
SNP number. rs Number SNP Flanking sequence Extension primer Expected Alleles
-1807 C>T N/A CTTCCTCCTGCC[C/T]GGCTCCAACCCC TGGT CC ACT CCTT CCT CCT GCC C (Black) & T (Red)
Table 4.21: Pooled genotyping data for NgR/RTN4-R.
This table shows the estimated allele frequencies and allele counts for all of the polymorphisms in the NOGO-R/RTN4-R gene, along with their 
corresponding p-values.
SNP Data Pooled Genotyping data
SNP number. rs Numbers Alleles Cases (freq)
Alleles Controls 
(freq) Difference Chi-square P-value
-1807 O T N/A C= 1082 (0.98) T= 22 (0.02)
C= 1090 (0.99) 
T= 14 (0.01) 0.01 1.81 0.18
180
4.3.3 O M G :
Determination o f  OM G intron/exon boundaries was based on the alignm ent o f 
the cDNA sequence NM  002544 and the genom ic sequence available from the UCSC 
Genome Bioinformatics website (http://genom e.ucsc.edu).
Mutation detection assays using DHPLC and subsequent sequencing analysis 
identified three SNPs in the OM G gene (See appendix 4.3 for sequencing traces), one 
non-synonymous SNP G21D (rsl 1080149) and two 5’ flanking region SNPs 
(rs9902893 and rs9902427) (see figure 4.3).
Figure 4.3 Schematic diagram of OMG.
Diagram o f the OMG gene (adapted from  the UCSC G enom e Browser), indicating the 
positions o f  the identified polym orphism s. Gene is shown (3 ’-5’).
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AU three polym orphism s were genotyped in the pooled association sample. 
The extension primers used for pooled genotyping are listed in table 4.22. The 
calculated allele counts and frequencies for all o f  the genotyped polym orphism s are 
shown in table 4.23. No significant differences were observed between the allele 
frequencies in the cases and controls for any o f  the polym orphism s. The non- 
synonymous G 21D polym orphism  has been previously reported to be associated with 
autism (Vourc'h, M artin et al. 2003).
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%Table 4.22: Polymorphism and primer extension reaction information for OMG.
This table shows the sequence flanking each of the OMG polymorphisms, the extension primer used to assay the polymorphism and the expected 
alleles in the primer extension reaction.
SNP number. rs Number SNP Flanking sequence Extension primer Expected Alleles
-2289 C>T 
-2081 O T  
61 G>A
rs9902893 
rs9902427 
rsl 1080149
AT CMC AAT AAA[C/T]TT CT AT GTT GCG 
AAAGAGACI I I C[C/T]TTAC AC AT AACA 
TTCTCACACCTG[G/A]TA I I I IATGCAT
AAT AAAGCACCC AAT CAACAAT AAA 
AACG AGT AATATTT AGC AT GTT AT GT GT AA 
TT GG AG AGG AC AAAT GCAT AAAAT A
C (Black) &T (Red) 
G (Blue) & A (Green) 
C (Black) &T (Red)
Table 4.23: Pooled genotyping data for OMG.
This table shows the estimated allele frequencies and allele counts for all of the polymorphisms in the OMG gene, along with their 
corresponding p-values.
SNP Data Pooled Genotyping data
SNP number. rs Numbers Alleles Cases (freq)
Alleles Controls 
(freq) Difference Chi-square P-value
-2289 O T rs9902893 C= 718 (0.67) T= 352 (0.33)
C= 718(0.65) 
T= 386 (0.35) 0.02 1.04 0.31
-2081 O T rs9902427 C= 715 (0.67) T= 355 (0.33)
C= 706 (0.64) 
T= 396 (0.36) 0.03 1.98 0.16
61 G>A rsl 1080149 G= 912 (0.85) A= 158 (0.15)
G= 917(0.83) 
A= 187 (0.17) 0.02 1.92 0.17
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4.3.3.1 Allelic expression of OMG.
Given the two pronged screening strategy employed in this project (described 
in chapter 1), I assayed the OMG gene for cis-acting sequence variation affecting the 
gene expression using the allele specific expression assay (Bray, Buckland et al. 
2003a) described in section 2.8.
Marker rsl 1080149 was selected for analysis given its fairly informative 
minor allele frequency (0.17). O f 60 subjects for whom brain was available, 12 
individuals were heterozygous for SNP rsl 1080149. O f the 12 OMG heterozygous 
individuals, none showed a relative expression difference beyond the 20% limit of 
measurement error (cDNA ratios varied from 1:1.05 to 1:0.95) (Graph 4.2). The data 
points from each individual cDNA sample showed good reproducibility, with an 
average SD of the mean o f 0.04. The assay provides no evidence for the presence o f a 
ds-acting variant affecting the allelic expression o f OMG.
Graph 4.2: OMG Allelic Expression assay: rsl 1080149.
Corrected genomic and cDNA ratios for rsl 1080149. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for OMG 
(n=12). Data are expressed as the mean o f the ratio o f G:A for two measurements of 
each genomic DNA sample and two measurements of each cDNA sample.
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4.3.4 N G FR :
Determination o f  the N G FR  intron/exon boundaries was based on the 
alignment o f the cDNA sequence N M _002507 and the genomic sequence available 
from the UCSC Genome Bioinform atics website (http://genom e.ucsc.edu). M utation 
detection assays identified fifteen SNPs along w ith an insertion/deletion (See 
appendix 4.3 for sequencing traces). There was one non-synonym ous SNP S205L 
(rs2072446), one coding synonymous SNP G265G (rsl 1466155), eight 3 ’-UTR SNPs 
(rsl 1466164, rsl 804011, rs7224806, rs734194, rs741071, rs741072, rs741073 and 
rsl 1466173), one 5 ’ flanking region SNP (rsl 1466123) and five intronic 
polymorphisms (331 G>A, rs l 1466133, rs4794056, 10801 A>G and rs2072445) (see 
figure 4.4).
Figure 4.4: Schematic diagram of NGFR.
Diagram o f NGFR (adapted from the UCSC Genome Browser), indicating the 
positions o f the identified polymorphisms. For numbering o f  polym orphisms, +1 
indicates the ‘A ’ o f  the ATG translation initiation codon. Gene is shown (5’-3’).
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All sixteen o f  the polymorphisms were genotyped in the pooled association 
sample, table 4.25. The extension primers used for pooled genotyping are listed in 
table 4.24. No significant differences were observed between the allele frequencies o f  
the cases and controls for any o f  the polymorphisms.
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Table 4.24: Polymorphism and primer extension reaction information.
This table shows the sequence flanking each of the NGFR polymorphisms, the extension primer used to assay the polymorphism and the 
expected alleles in the primer extension reaction.
SNP number. rs Number SNP Flanking sequence Extension primer Expected Alleles
-486 A>C 
331 G>A 
6583 C-lns 
6637 O T  
10801 A>G 
14932 G>T 
15039 O T  
15220 O T  
18255 A>G 
18490 O A  
18684 T>C 
18829 T>G 
18910 T>C 
18923 T>C 
19106G>A 
19421 G>C
rs11466123 
N/A 
rs11466133 
rs4794056 
N/A 
rs2072445 
rs2072446 
rs11466155 
rs11466164 
rs1804011 
rs7224806 
rs734194 
rs741071 
rs741072 
rs741073 
rs11466173
AAGGCTCCAGGG[A/C]GAAGGTGAAGCC 
GT GGGGG AGCTG[G/A]G AGGGGT CTTT C 
AGAACCCCCCCC[C/-]AACCCACCCCAG 
T CCG AT CT CCCT[C/T]CAT CCAGGT GT C 
CT GGCAGGCAAT[A/G]GGGGAGGGAGAG 
ACACGGCAGTGG[G/T]TTAGAGCTAAAA 
CCCCAGAGGGCT[C/T]GGACAGCACAGC 
T GT GGTT GT GGG[C/T]CTT GTGGCCTAC 
AACGGGGAGGCC[ A/G] AGT GCAGGCT GG 
CCTCTGCCT GT C[C/A]CT CT C AGGC AT G 
T CT CC AT GAGTT[T/CJTTT CT CTT GGGC 
CTGGCGTCTGTC[T/G]T CAAGGGCTTAC 
CCC AG AAGGTT G[T/C]G AT GAAG AAAAG 
GAT GAAGAAAAG[T/C]GGGCCAGTGTGG 
CCT G AAGTT GG A[G/A]T GAGT GT GGCT C 
T ACT CCCCTT GA[G/C]CT GAGAT GGAAC
CCAT CTT CCT CCGCCT CT GGCTT CACCTT C 
CAT GCCCCCT CTT G AAAG ACCCCT C 
GGT GTTT GATT CCCCGGAAG AACCCCCCCC 
GCCAGTCTGACCCTCCGATCTCCCT 
T CAGCGTCCT GGCAGGC AAT 
CCCCACTCCTCCCI I I IAGCTCTAA 
ATTACACGGTCCACACCCCCAGAGGGCT 
CAT CCTGGCT GCT GT GGTT GT GGG 
CCCAAAGCCAGACAGCAACGGGGAGGCC 
GGT GCT GCTT CCCT CT GCCT GT C 
AGAAATCTCACI I I ICTCCATGAGTT 
C ATT CCT CC ACGT GTAAGCCCTT G A 
GGGTT GGCT GGGCCCAGAAGGTT G 
CCGCATTCCCACACTGGCCC 
CTGTTCTGI I I IGCCTGAAGTTGGA 
GGCCCCI I I I IACTCCCCTTGA
T (Red) & G (Blue)
C (Black) &T (Red) 
C (Black) & A (Green) 
C (Black) &T (Red) 
A (Green) & G (Blue) 
C (Black) & A (Green) 
C (Black) & T (Red) 
C (Black) &T (Red) 
A (Green) & G (Blue) 
C (Black) & A (Green) 
T (Red) & C (Black) 
A (Green) & C (Black) 
T (Red) & C (Black) 
A (Green) & G (Blue) 
G (Blue) & A (Green) 
G (Blue) & C (Black)
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Table 4.25: Pooled genotyping data for NGFR.
Estimated minor allele frequencies and minor allele counts for all of the polymorphisms detected in NGFR, along with their corresponding chi- 
square and p-values.
SNP Data Pooled Genot fping data
SNP number. rs Numbers Minor Allele Cases (freq)
Minor Allele 
Controls (freq) Difference Chi-square P-value
-486 A>C rs11466123 C= 24 (0.02) C= 27 (0.02) 0 0.1 0.76
331 G>A A= 53 (0.05) A= 48 (0.04) 0.01 0.45 0.50
6583 C-lns rs11466133 C lns= 125 (0.12) Clns= 136 (0.12) 0 0.21 0.65
6637 C>T rs4794056 T= 180 (0.17) T= 168 (0.15) 0.02 1.04 0.31
10801 A>G G= 173 (0.16) G= 176 (0.16) 0 0.02 0.89
14932 G>T rs2072445 T= 96 (0.09) T= 102 (0.09) 0 0.05 0.83
15039 O T rs2072446 T= 54 (0.05) T= 63 (0.06) 0.01 0.47 0.49
15220 O T rs11466155 T= 371 (0.35) T= 382 (0.35) 0 0.001 0.97
18255 A>G rs11466164 G= 157 (0.15) G= 162 (0.15) 0 0.0001 0.99
18490 O A rs1804011 A= 307 (0.29) A= 328 (0.3) 0 0.27 0.60
18684 T>C rs7224806 C= 138 (0.11) C= 152 (0.11) 0.01 0.36 0.55
18829 T>G rs734194 G= 137 (0.13) G= 156 (0.14) 0.01 0.82 0.37
18910 T>C rs741071 C= 467 (0.44) C= 483 (0.44) 0 0.002 0.96
18923 T>C rs741072 C= 496 (0.46) C= 508 (0.46) 0 0.03 0.87
19106G>A rs741073 A= 319 (0.3) A= 332 (0.3) 0 0.02 0.89
19421 G>C rs11466173 C= 80 (0.08) C= 71 (0.06) 0.02 0.92 0.34
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4.3.4.1 Allelic expression assay of NGFR.
Marker rsl 804011 was selected for allelic expression analysis given its high 
informativity (minor allele frequency 0.3). Of the 60 subjects for whom brain was 
available, 26 were heterozygous for SNP rsl 804011. O f the 26 NGFR heterozygous 
individuals, seven showed a relative expression difference o f > 20% compared to the 
corresponding average genomic ratios (see Graph 4.3). The data points from each 
individual cDNA sample showed good reproducibility, with an average SD of the 
mean o f 0.09. The C:A ratio in cDNA departed from the genomic 1:1 ratio in both 
directions with the expression difference ranging from a 215% increase in the A allele 
relative to the C allele (1:3.15) to a 82% decrease o f the A allele relative to the C 
allele (1:0.55). That the expression difference goes in both directions on the graph 
might reflect the effect o f a m -acting variant that is in low LD with the tag SNP that 
was used or the presence of more than one variant affecting the genes expression.
Graph 4.3: NGFR Allelic Expression assay: rsl804011.
Corrected genomic and cDNA ratios for r s l804011. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for NGFR 
(n=26). Data are expressed as the mean o f the ratio o f C:A for two measurements of 
each genomic DNA sample and two measurements o f each cDNA sample.
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4.4 Discussion:
In this chapter I have sought to test the hypothesis that genetic variants within 
the NOGO gene and also within its associated receptor complex might be associated 
with susceptibility to schizophrenia. There have been previous studies (Novak, Kim et 
al. 2002; Chen, Gu et al. 2004a; Tan, Chong et al. 2005) reporting association 
between various polymorphisms in the NOGO gene and schizophrenia susceptibility, 
although it should be noted that there have also been several negative association 
studies published (Covault, Lee et al. 2004; Gregorio, Mury et al. 2005; Xiong, 
Rouleau et al. 2005).
There are three main reasons for the failure of an association study to 
replicate: a) the original association finding is a false positive caused by statistical 
chance or other problems with the study design (e.g genotyping error) and the lack of 
replication is correct, b) the original association finding is true and the lack of 
replication is a false negative result caused by a lack of power in the second study, c) 
the original association finding is true in that particular population but there is no 
association present in a second population because of differences that exist in the 
phenotypes between the samples or genetic and environmental backgrounds of the 
two populations. There are several factors which can influence power.
Given the at best modest effect sizes thought to exist for the common genetic 
variants contributing to complex diseases the sample size of a replication study is a 
critical factor in determining whether replication will be successful. The samples of 
cases and controls studied must be large enough to prevent the study from being under 
powered and hence failing to detect an association. However the success of a 
replication study is not solely determined by the size of the sample but is also 
influenced by other factors, such as differences in; the effect size, local patterns of
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LD, the allele frequency of the disease allele, and differences in the gene-gene and 
gene-environment interactions between the populations studied.
The ability to replicate an association finding is influenced by the effect size 
of the associated variant. Researchers reporting a negative replication often state that 
the power of their study was sufficient to detect an associated variant with a certain 
magnitude of genetic effect. However, it is important to recognise that the true effect 
size of the genetic variant may have been over estimated in the initial association 
study. In a meta-analysis study of 370 genetic studies addressing 36 reported 
associations (Ioannidis, Ntzani et al. 2001), the authors demonstrated that the initial 
effect size of the associated variant was over estimated in 26 of the 36 reported 
associations studied. Hence a replication study might report a negative result due to 
unknowingly being under powered to detect the associated variant with its lower 
genetic effect size.
The local LD structure around the associated variant can also influence the 
results of a replication study. This is of particular importance if the variant reported to 
be associated with disease is not the true causal variant, but is instead associated with 
disease by virtue of linkage disequilibrium with the causal variant. If the extent of 
historical recombination is different between the associated and causal variants in 
different populations, then the strength of the association will also differ between the 
populations and may account for the lack of positive replication. This problem could 
be avoided by testing the causal variant itself, or a marker which is in high LD with 
the causal variant in both populations, however this requires the identification of the 
true causal variant, something which is often not possible in molecular genetic studies 
of complex diseases.
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The allele frequency of the associated disease allele is a significant factor in 
determining the success of a replication study. The frequency of an allele can differ 
depending on the ethnicity of the population being studied. Two distinct populations 
from different ethnic backgrounds are likely to have different genetic histories, rates 
of disease and also different allele frequencies at some loci. Thus if a replication study 
is performed in a population that is not identical to the original association population 
allele frequency differences for the reported disease allele may account for the lack of 
a positive association finding. Indeed, the original association may be true in the 
specific population tested, whilst not being associated in the second genetically 
distinct population. This factor is likely to be of particular importance if an 
association is reported with a rare genetic variant. Rare variants are thought to have a 
higher likelihood of being population specific, due to originating fairly recently in 
history and hence still being specific to a founder population or slightly less recently 
and being found in one major ethnic group (Risch 2000). This would tend to make 
any association reported with rare variants less replicable in distinct populations. 
Common variants are thought to be more likely to be found globally in most 
populations, making an association more reproducible in many ethnically diverse 
populations (Risch 2000).
The allele frequency of a disease allele can also be influenced by 
ascertainment bias relating to the phenotype. The phenotype of a person normally 
determines their selection for study (e.g schizophrenic or healthy control). However 
the method of selection can also influence the phenotype being selected. For instance, 
a sample of schizophrenic patients ascertained from a hospital inpatient clinic, may be 
enriched for specific phenotype components, for example gender, disease severity, or 
violence, compared to a sample of outpatient schizophrenics living in the community.
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If phenotypic variation results from genetic variation, certain allele frequencies in the 
inpatient sample may differ from those of an independent sample of schizophrenics 
collected using a different ascertainment method. Thus association reported in the 
inpatient association sample may not replicate due to the associated variant being a 
specific risk factor for the particular phenotype selected in your sample.
A further factor relating to the replication of association studies and the 
disease allele frequency is the reliability of disease diagnosis. In schizophrenia and 
other psychiatric disorders there is no definitive diagnostic test for the presence of 
disease and hence a diagnosis is made by clinicians using symptom rating scales. This 
provides the potential for diagnoses to be made slightly differently depending on a 
patients clinician, the symptom rating scale being used and their interpretation of the 
patients symptoms. This could lead to different patients being diagnosed with slightly 
different phenotypes (schizophrenia/schizoaffective /bipolar disorder etc) even though 
both display identical symptoms. These differences in diagnosis could again lead to 
allele frequency differences between association study samples and therefore 
influence the outcome of replication studies.
Finally it is likely that common complex diseases are the result of both genetic 
and environmental factors and their interactions with each other. If an associated 
variants influence on disease susceptibility is only present on a certain genetic and/or 
environmental background, then the different gene-gene and gene-environment 
interactions that are present in distinct populations might influence the replication of 
an association study by changing the effect size at any given locus.
When undertaking molecular genetic studies researchers often ignore the 
possibility that there may be genotype-environment interactions present. However it is 
likely that distinct populations will have been exposed to different environment
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factors and hence in a similar way to gene-gene interactions; it is possible that 
different combinations of gene-environment interactions may be responsible for 
disease susceptibility in different populations. For instance it has been shown that a 
variant within the promoter of the hepatic ligase gene has a different influence on high 
density lipoprotein metabolism depending on the presence of a high-fat or low-fat diet 
(Ordovas, Corella et al. 2002). Thus an association study of this genetic variant in 
populations with different dietary fat intakes might give inconsistent results. The 
influence of gene-environment interactions on replication studies may be impossible 
to avoid as collecting two independent samples exposed to exactly the same 
environment is virtually impossible.
The only way to confirm/exclude the report of an association is by gaining 
confidence through the findings of many large sufficiently powered independent 
replication studies reporting association with the same allele, in the same phenotype, 
with the same direction of effect and with a p-value low enough to survive stringent 
correction for multiple testing.
Four genes involved with the NOGO receptor complex (NOGO, NgR, OMG 
and NGFR) have been examined in this study. A total of forty three polymorphisms 
were detected by DHPLC in the four genes. Of these forty three variants, thirty seven 
were genotyped in the pooled association sample. Of the seven variants that were not 
genotyped, the minor allele frequency of four was too rare to allow reliable allele 
frequency estimates by pooled genotyping and two of the polymorphisms were not 
compatible with genotyping by using a primer extension assay. Of the thirty seven 
polymorphisms successfully typed in the pooled samples none showed significant 
differences between the schizophrenia case and control pools.
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However, when individual genotyping was performed on the NOGO 77394 
VNTR polymorphism, a significant (uncorrected) association with schizophrenia was 
observed at both the genotypic (p=0.02) and allelic level (p=0.02), with the shorter 
repeat VNTR being over represented in the schizophrenics compared to control 
subjects. As one of the previous studies (Tan, Chong et al. 2005) reported the 
presence of a gender effect in females, my data was also analysed according to 
gender, revealing that the association was stronger in females, with the smaller repeat 
of the VNTR being strongly associated with schizophrenia (p=0.004). In light of the 
previous reports of association between the 77394 AAC insertion and schizophrenia, 
and the fact the VNTR and insertion had been reported to be in strong LD with each 
other, I decided to also genotype the AAC insertion individually. No evidence of 
association between the 77394 AAC insertion and schizophrenia in either my whole 
sample or the female subgroup was observed, although the AAC insertion frequency 
was increased in schizophrenics in both of the tested samples. Haplotypic analysis 
based on the two NOGO variants was significant but less so than the VNTR 
polymorphism alone. Although the two polymorphisms did not both display evidence 
of association with schizophrenia in my sample they do however both appear to be 
highly related to each other (D’=0.96, r2 =0.74).
In addition to the genetic analysis of the four NOGO receptor complex genes 
three were analysed for c/s-acting variants affecting the genes expression in the brain. 
The NgR gene was unable to be assayed for altered expression due to the lack of a 
suitable marker SNP to perform the assay. Both the NOGO and NGFR genes 
displayed evidence for the presence of genetic variants affecting their expression in 
the brain. The relative cDNA allelic expression differences observed for both NOGO 
and NGFR deviated from the genomic 1:1 ratio in both directions, which might
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indicate either the effect of a cis-acting variant that is only in weak LD with the tag 
SNP used (NOGO rs6545468, NGFR rsl 804011) or possibly the presence of more 
than one genetic variant affecting the genes expression. The evidence of a c/s-acting 
variant causing an expression difference in the NOGO gene is consistent with the 
exhibition of a cis-acting allele. If the findings of Novak and colleagues (Novak, Kim 
et al. 2002) who reported a 60% over expression of NOGO cDNA in schizophrenic 
brain compared to controls are confirmed in other samples, this would suggest it is at 
least possible that it may reflect a primary change resulting from a regulatory variant 
rather than a secondary effect. However, as yet the causal variant is unknown.
As NOGO has been proposed to have an important role in the control of 
synaptic plasticity and neuronal migration, altered expression of this gene in 
schizophrenia may contribute to the abnormal neuronal connectivity which is 
postulated as a mechanism underlying schizophrenia (Friston 1998; Benes 2000). 
Unfortunately during this project it was not possible to determine the exact location of 
the genetic variants causing the altered expression in either the NOGO or NGFR 
genes. However, the 3’UTR of genes are known to play an important role in the 
regulation of mRNA stability, translation initiation and mRNA localisation (Kuersten 
and Goodwin 2003) and contain various elements responsible for regulating gene 
expression, including the poly A tail which enhances translation (Munroe and 
Jacobson 1990), AU rich sequences responsible for inhibiting translation (Kruys, 
Marinx et al. 1989), exonic splicing enhancer (ESE) sequences (Schaal and Maniatis 
1999) and various other sequences such as seleno-cysteine insertions which may have 
a profound effect on mRNA stability or translational efficiency (Low and Berry 
1996). It is possible therefore that polymorphisms contained within the 3’UTR of a 
gene may have a profound effect on the genes expression and as a result it is possible
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that the polymorphisms contained within the NOGO genes 3’UTR contribute to the 
altered expression of the gene seen in schizophrenia (Novak, Kim et al. 2002). 
However, it should be noted that when I analysed my data for the 77394 VNTR 
against the allelic expression data for NOGO, I detected no evidence of a significant 
correlation between the VNTR genotype present and the extent of the relative allelic 
expression difference observed in my sample, suggesting this variant is not functional 
or at least not the predominant functional variant.
The results of my study are not entirely consistent with the findings from other 
association studies (see table 4.1). Although the evidence for association in my 
sample is modest, the associated allele of the 77394 VNTR is the same as that 
reported by Tan and colleagues (Tan, Chong et al. 2005), and the association is also 
stronger in the female subgroup of my sample (p=0.004). However, Novak and 
colleagues (Novak, Kim et al. 2002) reported association between the 77878 AAC 
insertion and schizophrenia, but there was no evidence for association of this 
polymorphism detected in my sample. LD analysis of the two polymorphisms 
revealed that they are related (D’=0.96, r2=0.74). However, as the polymorphisms are 
not in perfect LD it is feasible that association with schizophrenia may not be detected 
for both polymorphisms.
There is no obvious explanation for the differences observed in the results of 
the various association studies, but it might be feasible that different LD structures or 
alleles are responsible for association to schizophrenia in different populations. This 
would be supported by the marked observed differences in the two polymorphisms 
allele frequencies across the various previous association studies (table 4.1). The 
studies were performed in several ethnically distinct populations including samples 
consisting of North American and European Caucasians, ethnic and Han Chinese and
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Brazilians. Similar allele frequencies to those detected in my study for the 77878 
AAC-insertion were reported in two studies (Covault, Lee et al. 2004; Xiong, Rouleau 
et al. 2005) which were both composed of European Caucasians. However, the allele 
frequency of the polymorphism reported in the other studies was inconsistent. 
Surprisingly even the two large studies performed in samples of Chinese descent 
(Chen, Gu et al. 2004a; Tan, Chong et al. 2005) reported markedly different allele 
frequencies for both of the polymorphisms studied, indicating the possible existence 
of allele frequency differences within the Chinese population or alternatively allele 
labelling error.
It is also possible that the sample sizes used in the various studies were not 
sufficiently large enough to enable the detection of genetic associations with small 
effect sizes. Two of the negative replication studies (Covault, Lee et al. 2004; 
Gregorio, Mury et al. 2005) were performed in small samples of cases (table 4.1) 
whilst the other negative study (Xiong, Rouleau et al. 2005) was performed in a 
moderately large case sample (462) but the small control sample (153) may have 
compromised the power of the study to detect an association.
In order to try and clarify a possible role for NOGO in susceptibility to 
schizophrenia further the use of independent replication studies performed in 
sufficiently large and powerful association samples is required. These studies should 
ideally test all of the non-redundant genetic variation contained within the gene for 
association to schizophrenia. Additionally given the increasing evidence that some 
genetic susceptibility loci may be common to diseases crossing the whole spectrum of 
psychiatric disorders it has been suggested that in order to comprehensively study 
genes for association to psychiatric diseases a more detailed approach to the analysis 
of sub-phenotypes should be employed (Craddock, O'Donovan et al. 2006; Craddock,
196
Owen et al. 2006). Such studies would be facilitated by extending the work presented 
here by identifying the variant driving the allele specific differences in expression.
The results of my studies on NgR, OMG and NGFR provided no evidence that 
sequence variations within these genes are associated with susceptibility to 
schizophrenia. The allelic expression assay of NGFR provided evidence of at least 
one ds-acting sequence variant affecting the genes expression in the brain, whilst no 
evidence of altered expression was detected for the other two genes. Again as for 
NOGO, further studies to identify the variant responsible would help power future 
studies.
However, on the basis of my results alone I cannot exclude these genes from 
playing a role in the aetiology of schizophrenia. In order to do this with any 
confidence would at least require the genotyping of all the non-redundant genetic 
variation contained within the gene in a large, sufficiently powered association 
sample, which was representative of both the general disease and healthy populations. 
As most of the genotyping performed in this project was performed in pooled samples 
the extent of the linkage disequilibrium structure (LD) between the polymorphisms 
was not determined for any of the genes and hence the level of redundancy was not 
ascertained. Retrospective analysis of the data contained within the HapMap (version 
2.0) database revealed only three genetic variants within OMG, of which one was 
detected in my study (rsl 1080149) and very low levels of LD across the gene. 
Analysis of NgR again revealed a low level of genetic variation within the gene (6 
markers) and moderately high levels of LD across the gene. NGFR did contain a high 
level of genetic variation, including seven markers detected in my study, but very 
little evidence of LD was detected spanning the gene. On the basis of the HapMap 
data it appears that not all of the non-redundant genetic variation contained within
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these genes was genotyped in this project. It is however not surprising that all of the 
non-redundant variation was not screened as a) the genes intronic sequence was not 
screened for genetic variation, b) SNPs incompatible with pooled genotyping or that 
had a minor allele frequency which was too rare were not genotyped in the pooled 
samples, c) the screening set used for mutation detection might not have been 
powerful enough to detect some rare variants (power of 80% to detect a variant with a 
MAF of 0.05). It is also a possibility that the association sample employed in this 
project was not sufficiently large enough to provide the power required to detect 
association present with rare genetic variants or variants with small genetic effect 
sizes. As an example, the association sample used in this project provides a power of 
94% to detect a variant with a MAF of 0.1, conferring an odds ratio of 1.5, at the 0.05 
significance level, but only a power of 32% to detect a variant with a MAF of 0.1, 
conferring an odds ratio of 1.2, at the 0.05 significance level.
In summary the results of my study provide at least weak support for the 
hypothesis that the NOGO receptor complex may play a role in the aetiology of 
schizophrenia. Additionally my results provide support for sequence variation within 
the gene playing a role in altering the expression of the gene in the human brain and 
possibly schizophrenia. However, the results of this study need independent 
replication in other large sufficiently powered association samples, before any more 
definitive conclusions can be drawn from the results.
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4.5  A p p en d ix:
S a m p les  o f  E x p e r im en ta l d a ta .
Appendix 4.1.
Example o f DHPLC chrom atographs produced for RTN4 am plim er 22 analysed at 
56°C, for screening set samples 1, 2, 3 and 4. The graph shows the peaks representing 
these samples PCR products, and changes in the peak shape indicates the presence o f 
a heteroduplex.
Shoulder on this peak indicates 
the presence of a heteroduplex 
in this PCR product
5 . 0 5 . 5 6 . 02 . 0 2 . 5 3 . 0 3 . 5 4 . 0 4 . 50 . 5 1.0 1 . 5
Appendix 4.2.
Example o f  DHPLC chrom atographs produced for N G FR am plim er 6 analysed at 
62°C, for screening set sam ples 2, 3, 4 and 8. The graph shows the peaks representing 
these samples PCR products, and changes in the peak shape indicates the presence o f 
a heteroduplex.
Shoulder on this peak indicates 
the presence of a heteroduplex in 
this PCR product
6 . 05 . 0 5 . 54 . 54 . 03 . 0 3 . 52 . 52 . 00 . 5 1.0 1 . 50 . 0
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Appendix 4.3:
Examples o f the different sequencing electrophorogram s produced for each o f the 
polymorphisms that were detected as a result o f  screening the four NOGO receptor 
complex genes in this project. The SNP is indicated with an arrow.
12R
14R
Sequence electrophorograms for the RTN4 - 
1447 G>A polymorphism, showing a T-T 
homozygote in the top panel and a T-C 
heterozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
12R
14R
Sequence electrophorograms for the RTN4 - 
1409 O T  polymorphism, showing a G-G 
homozygote in the top panel and a G-A 
heterozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
3F
Sequence electrophorograms for the RTN4 - 
1196 T>C polymorphism, showing a T-C 
heterozygote in the top panel and a T-T 
homozygote in the lower panel.
14F
Sequence electrophorograms for the RTN4 - 
1123 A>G polymorphism, showing a A-G 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
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13F
Sequence electrophorograms for the RTN4 - 
739 A>G polymorphism, showing a A-A 
homozygote in the top panel and a A-G 
heterozygote in the lower panel.
3F
14F
Sequence electrophorograms for the RTN4 
732 O T  polymorphism, showing a C-C 
homozygote in the top panel and a C-T 
heterozygote in the lower panel.
13F
14F
Sequence electrophorograms for the RTN4 - 
646 O G  polymorphism, showing a C-C 
homozygote in the top panel and a C-G 
heterozygote in the lower panel.
12F
13F
Sequence electrophorograms for the RTN4 - 
422 C>T polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
4R
Sequence electrophorograms for the RTN4 - 
205 G>C polymorphism, showing a G-G 
homozygote in the top panel, a G-C 
heterozygote in the middle panel and a C-C 
homozygote in the lower panel.
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13F
Sequence electrophorograms for the RTN4 
22705 A>G polymorphism, showing a A-G 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
Sequence electrophorograms for the RTN4 
25222 O A  polymorphism, showing a C-A 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
73F
Sequence electrophorograms for the RTN4 
40387 A>C polymorphism, showing a A-C 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
8F
10F
Sequence electrophorograms for the RTN4 
62818 T>G polymorphism, showing a T-G 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
Sequence electrophorograms for the RTN4 
76398 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
14F
Sequence electrophorograms for the RTN4 
76636 A>C polymorphism, showing a A-A 
homozygote in the top panel, a A-C 
heterozygote in the middle panel and a C-C 
homozygote in the lower panel.
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Sequence electrophorograms for the RTN4 
77258 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
12R
Sequence electrophorograms for the RTN4 
78188 G>A polymorphism, showing a C-C 
homozygote in the top panel, a C-T 
heterozygote in the middle panel and a T-T 
homozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
13R
12R
Sequence electrophorograms for the RTN4 
78368 T>C polymorphism, showing a A-G 
heterozygote in the top panel and a A-A 
homozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
Sequence electrophorograms for the RTN4 
78775 C>G polymorphism, showing a C-G 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
TTT
Sequence electrophorograms for the OMG • 
2289 C>T polymorphism, showing a C-C 
homozygote in the top panel, a C-T 
heterozygote in the middle panel and a T-T 
homozygote in the lower panel.
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12 F
—
Sequence electrophorograms for the OMG - 
2081 C>T polymorphism, showing a C-C 
homozygote in the top panel, a C-T 
heterozygote in the middle panel and a T-T 
homozygote in the lower panel.
T E ir
Sequence electrophorograms for the OMG 61 
G>A polymorphism, showing a G-G 
homozygote in the top panel and a G-A 
heterozygote in the lower panel.
12 F
12 F
Sequence electrophorograms for the NGFR 
331 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
Sequence electrophorograms for the NGFR 
6583 C-Ins polymorphism, showing a C-Del 
homozygote in the top panel and a C-Ins 
heterozygote in the lower panel.
12 F
Sequence electrophorograms for the NGFR 
6637 C>T polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
Sequence electrophorograms for the NGFR - 
486 A>C polymorphism, showing a A-A 
homozygote in the top panel and a A-C 
heterozygote in the lower panel.
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Sequence electrophorograms for the NGFR 
10801 A>G polymorphism, showing a A-G 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
1st
Sequence electrophorograms for the NGFR 
14932 G>T polymorphism, showing a G-T 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
13 F
Sequence electrophorograms for the NGFR 
15220 C>T polymorphism, showing a C-C 
homozygote in the top panel, a C-T 
heterozygote in the middle panel and a T-T 
homozygote in the lower panel.
4 R
Sequence electrophorograms for the NGFR 
18255 A>G polymorphism, showing a A-G 
heterozygote in the top panel and a T-T 
homozygote in the lower panel.
Sequence electrophorograms for the NGFR 
15039 C>T polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
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Sequence electrophorograms for the NGFR 
18490 O A  polymorphism, showing a C-C 
homozygote in the top panel, a C-A 
heterozygote in the middle panel and a A-A 
homozygote in the lower panel.
Sequence electrophorograms for the NGFR 
18684 T>C polymorphism, showing a T-C 
heterozygote in the top panel and a T-T 
homozygote in the lower panel.
Sequence electrophorograms for the NGFR 
18829 T>G polymorphism, showing a A-C 
heterozygote in the top panel and a A-A 
homozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
Sequence electrophorograms for the NGFR 
18910 T>C polymorphism, showing a A-A 
homozygote in the top panel, a A-G 
heterozygote in the middle panel and a G-G 
homozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
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-f  I L H £  f l |T f  flA flA g
/VYWxA/yW^
n j-  ,T f  riA g ,T Cc ftA RA 8
Sequence electrophorograms for the NGFR 
19421 G>C polymorphism, showing a G-C 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
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Sequence electrophorograms for the NGFR 
18923 T>C polymorphism, showing a A-A 
homozygote in the top panel, a A-G 
heterozygote in the middle panel and a G-G 
homozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
Sequence electrophorograms for the NGFR 
19106 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
1U  U  /  f  / I  $ £ § £ 1 t  T  IT g g £ flA / £ ftA;ftA flA
f  t i H -t ia a tg a a a  a a f  a g g & g g g a a
£ f  iT ft /  f  iT a  ft a  a  g  f t g : g  g  g  ft g  g  g  g g  ,T g  a  ft
f  g  tt  ft r  cc /  g  ft g  g  g  f t g  tT g  g  iT g  s  f t ft ,T f t ft ft ft
Sequence electrophorograms for the RTN4 77394 VNTR polymorphism, showing a normal 
homozygote sequence trace in the top and lower panels, an ATCT-INS heterozygote in the upper 
middle panel and an AATCTATCT-INS heterozygote in the lower middle panel.
12F
T A G  A A C  T C C A : :A C A T C  A A T T T C A T  T G
T fl G A A C  T E C A A E A T C A R T  T T C A T F E
T A G  A A C  T C C  A A C  A T C  A T C  T N N T  I N G_
T A G  A R C  T C C A R C  A T C A T C T N N T T N G
T A G  A A C  T C  C A A C  A A C  A T  C A A I----- 1— J _ £ — A
T A G  A A C  T C  C A A C  A A C  A T C  R A T  T T C  A
Sequence electrophorograms for the RTN4 77878 AAC-Ins polymorphism, showing a normal 
homozygote sequence trace in the top panel an AAC-INS heterozygote trace in the middle panel and an 
AAC-INS homozygote trace in the lower panel.
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12F
14F
Sequence electrophorograms for the RTN4 77878 AAT-Ins polymorphism, showing an AAT-INS 
heterozygote trace in the top panel and a normal homozygote trace in the lower panel.
Appendix 4.4:
Example o f the ABI G enescan electrophorogram  produced w hilst genotyping the 
NOGO 77394 VNTR polym orphism . You are able to see the three different alleles 
that are present, the 144bp variant containing no repeats, the 148bp variant with the 
ATCT insertion and the 153bp variant w ith the A ATCTA TCT insertion present.
6 Blue B o x -5 -1 1 F0102 .041 1_E03_N.FSA
-3 0 0 0
-2000
-1 0 0 0
144bp
15 Blue B o x -6 -2 4  C079212 0 J0 0 6 —.FSA
-3 0 0 0
-2000
-1 0 0 0
148bp144bp
2 Blue B o x -6 -2 5  C0807121 _A08 FS A
-3 0 0 0
-2000
-1 0 0 0
144bp 148bp
4 Blue B o x -6 -2 6  C0808122JD 08—.FSA
-6 0 0 0
-4 0 0 0
-2 0 0 0
148bp
6 Blue B o x -6 -2 7  C 08131 23_E08 FSA
-2 0 0 0
-1 5 0 0
-1 0 0 0
-5 0 0
153bp144bp
8 Blue B o x -6 -2 8  C 08321 24JG 08 FSA
-4 0 0 0
-2 0 0 0148bp
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Chapter 5. Myelin Candidate genes and Schizophrenia:
5.1 Introduction:
As I described in chapter 1 there is now increasing evidence that an 
oligodendrocyte function / myelination defect or deficit plays a role in the aetiology 
of schizophrenia. There are many genes involved in the processes of myelin 
formation, function and maintenance. In this chapter I examine three OMR genes; 
glial fibrillary acidic protein (GFAP), myelin oligodendrocyte glycoprotein (MOG) 
and sex-determining region Y-box 10 (SOX 10), selected for study on the basis of 
reported altered expression in schizophrenia and previous linkage evidence.
5.1.1 GFAP:
Glial fibrillary acidic protein (GFAP) is located on chromosome 17q21, a 
region of the genome which has previously been implicated in schizophrenia, as 
described in chapter 3, section 3.2.1.
Glial fibrillary acidic protein (GFAP) is the major intermediate filament in 
astrocytes. Intermediate filaments (IFs) form a group of cytoskeletal proteins believed 
to play a role in the mechanical strength and shape of cells and their processes 
(Liedtke, Edelmann et al. 1996). Astrocytes expressing GFAP provide structural as 
well as trophic support to neurons. Their roles include modulation of synaptic 
function, production of neurite growth factors, clearance of ions and 
neurotransmitters, neuronal metabolism, guidance during neuronal migration, and 
production of extracellular matrix proteins and adhesion molecules (Fatemi, Laurence 
et al. 2004). Recently, it has been demonstrated that GFAP-positive astrocytes also
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serve as primary progenitors of new oligodendrocytes as well as neurons in the adult 
brain (Menn, Garcia-Verdugo et al. 2006). Astrocytes are also important for the 
development and maintenance of myelin sheaths and the central nervous system 
(CNS) (Liedtke, Edelmann et al. 1996; Webster, O'Grady et al. 2005). Astrocytes 
ensheath the areas of neurons that are not covered by oligodendrocytes, such as the 
nodes of Ranvier, neuronal cell bodies and synapses (Cotter, Pariante et al. 2001). 
Also oligodendrocytes share intercellular junctions solely with astrocytes, such that 
each oligodendrocyte is isolated from other oligodendrocytes except via an astrocyte 
intermediary (Webster, O'Grady et al. 2005). These astrocyte intermediaries are 
important as they link oligodendrocytes together allowing the cells to communicate 
and also exchange ions and small molecules between oligodendrocytes (Webster, 
O'Grady et al. 2005). Therefore abnormal astrocytic numbers, density and/or function 
could have profound effects on the viability and activity of oligodendrocytes and 
ultimately impact the integrity of the neuronal systems (Webster, O'Grady et al. 
2005).
Animal models have also suggested that GFAP is necessary for the long-term 
maintenance of CNS myelination. Liedtke and colleagues (Liedtke, Edelmann et al. 
1996) showed that GFAP null mice displayed abnormal myelination. Abnormalities 
included the presence of actively myelinating oligodendrocytes in adults, 
nonmyelinated axons in optic nerve, reduced myelin thickness in spinal cord, as well 
as alterations in the blood-brain barrier, disorganisation of white matter architecture 
and vascularisation, and hydrocephalus in older mice associated with loss of white 
matter. The authors therefore concluded that GFAP expression is essential for normal 
white matter architecture and that its absence led to CNS demyelination (Liedtke, 
Edelmann et al. 1996).
211
Several studies have shown a decrease in glial number and GFAP levels in 
various areas of the brain from individuals with schizophrenia and mood disorder, 
supporting the previous micro-array results (Tkachev, Mimmack et al. 2003) who 
showed GFAP expression differences in both schizophrenics and bipolar patients 
versus controls. Johnston-Wilson and colleagues (Johnston-Wilson, Sims et al. 2000) 
examining GFAP in astroglia, described a reduction of GFAP protein levels in the 
frontal cortex of post mortem brain from schizophrenic and mood disorder patients 
compared to controls. Whilst, Rajkowska and colleagues (Rajkowska, Miguel- 
Hidalgo et al. 2002) have shown a reduction in the number of GFAP labelled 
astrocytes in the dorsolateral preffontal cortex of schizophrenic patients compared to 
control subjects. In a further study, Fatemi and colleagues (Fatemi, Laurence et al.
2004) showed that GFAP levels were reduced by 14.5% in schizophrenic cerebellum 
versus controls and more recently Webster and colleagues (Webster, O'Grady et al.
2005) found decreased levels of GFAP in the white matter of post mortem anterior 
cingulate cortex (ACC) from schizophrenia and bipolar disorder patients compared to 
controls. This difference was also present in the grey matter but did not reach levels of 
statistical significance. The anterior cingulate cortex is an area which has been 
previously implicated in the pathophysiology of schizophrenia, and is involved in the 
regulation of emotion, attention, cognition, arousal and motor control (Webster, 
O'Grady et al. 2005).
Mutation in the exonic sequence of GFAP causes Alexander disease, a rare 
disorder of the CNS (Aoki, Haginoya et al. 2001; Li, Johnson et al. 2005). Forms of 
the disease exist which differ by age of onset and also in their clinical and 
pathological presentation. However they are all united by the defining feature of the 
disease which is the widespread presence of protein aggregates called Rosenthal
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fibres containing GFAP in astrocytes (Aoki, Haginoya et al. 2001; Li, Johnson et al.
2005). The most common form of the disorder affects infants and young children and 
is characterised by progressive failure of myelination and an absence of myelin in the 
frontal lobes, usually leading to death before adulthood. However, the juvenile and 
adult forms of the disease progress more slowly with myelin and mental ability 
remaining relatively intact (Aoki, Haginoya et al. 2001; Li, Johnson et al. 2005). 
Symptoms of psychosis have not been reported in Alexander disease, although the 
disease is usually fatal before patients reach adolescence (Aoki, Haginoya et al.
2001), the period usually associated with the development of psychosis.
Considering the various lines of evidence discussed above, including the 
location of GFAP in a region of linkage to schizophrenia, the evidence for altered 
expression of GFAP in schizophrenia, and the genes involvement in the myelination 
process, I decided to investigate GFAP.
5.1.2 MOG:
Myelin oligodendrocyte glycoprotein, (MOG) is located on chromosome 
6p21.3 close to the human leukocyte antigen (HLA) region. It is a member of the 
immunoglobulin super family and is expressed on the surface of oligodendrocytes and 
the lamellae of myelin sheaths in the CNS. The human leukocyte antigen (HLA) 
system has been examined in several molecular genetic studies of schizophrenia. The 
results have been variable, with a number of associations reported between different 
antigens and schizophrenia (Sasaki, Matsushita et al. 1999; Akaho, Matsushita et al. 
2000; Nunes, Borelli et al. 2005) although there have also been many studies 
reporting negative results within the region reviewed by (Wright, Nimgaonkar et al. 
2001). There have also been several genetic studies looking for linkage to
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schizophrenia in this region. Some reported non-significant results, whilst others 
(Schwab, Albus et al. 1995; Straub, MacLean et al. 1995) showed linkage to 
schizophrenia both telomeric and centromeric to the HLA region. More recently 
(Schwab, Hallmayer et al. 2000; Straub, MacLean et al. 2002) have both reported 
significant linkage to schizophrenia in the HLA region (6p22.3) and have also 
presented evidence supporting the case for dysbindin (DTNBP1) as a schizophrenia 
gene in this same region (Straub, Jiang et al. 2002; Schwab, Knapp et al. 2003). These 
findings are supported by the results of a meta-analysis (Lewis, Levinson et al. 2003) 
reporting evidence of linkage between 6p21-6p22 and schizophrenia. Put together 
these results provide evidence for the presence of a susceptibility locus in the region 
of 6p21-22.
MOG has been proposed to play several roles in the CNS. These roles include; 
controlling and maintaining myelination, modulating cell to cell interactions, acting as 
a cellular adhesion molecule between bundles of nerve fibres, regulating 
oligodendrocyte microtubule stability, and/or mediating interactions between myelin 
and the immune system (Johns and Bernard 1999). However the precise function of 
MOG in the CNS still remains to be determined (Johns and Bernard 1999). MOG 
itself is only a minor component of CNS myelin representing around 0.05-0.1% of the 
total myelin protein (Johns and Bernard 1999). MOG is specifically expressed on the 
outermost lamellae of the myelin sheath as well as the cell body and processes of 
oligodendrocytes. Expression of MOG is developmentally late and correlates with the 
later stages of myelinogenesis (Clements, Reid et al. 2003). It has been suggested that 
MOG has a role in the completion, compaction, and/or maintenance of myelin, 
evidence that further suggests a role for MOG as an adhesion molecule in the CNS 
(Clements, Reid et al. 2003).
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Sites near the HLA locus have been implicated in other neuropsychiatric 
disorders, such as narcolepsy and obsessive compulsive disorder (OCD) and the 
demyelinating disease MS (Wright, Nimgaonkar et al. 2001). One study (Zai, 
Bezchlibnyk et al. 2004) reported an association between OCD and MOG. The 
authors reported both association to an individual SNP and a slightly more significant 
haplotypic association. Multiple sclerosis (MS) is an inflammatory disease of the CNS 
characterised by localised myelin destruction and axonal degeneration (Clements,
Reid et al. 2003). Antibody induced demyelination is an important component of 
pathology in multiple sclerosis. Antibodies are directed against surface antigens of 
myelin and oligodendrocytes in the CNS, in particular antibodies to MOG, which is a 
highly encephalitogenic glycoprotein concentrated in the outer lamella of the myelin 
sheath and hence exposed to the environment. Antibodies to MOG have been shown 
to be elevated in MS patients, and they have therefore been implicated as mediators of 
MS demyelination (Marta, Montano et al. 2005).
Gene expression studies have reported a decrease in MOG mRNA expression 
in post mortem brain from schizophrenic and bipolar patients compared to controls. 
Tkachev and colleagues (Tkachev, Mimmack et al. 2003) reported a 2.58 fold 
decrease of MOG expression in schizophrenics, a finding supported by the results of 
an independent study (Katsel, Davis et al. 2005b) reporting a 2.05 fold down- 
regulation of MOG in schizophrenics. In a further study (Aston, Jiang et al. 2005) 
reported a 3.2 fold decrease of expression in bipolar patients compared to controls.
Previous genetic studies of MOG and schizophrenia have yielded mixed 
results. Liu and colleagues (Liu, Qin et al. 2005) screened MOG using microsatellites 
in 532 trios and found weak association (p=0.02) between microsatellite D6S299 and 
schizophrenia, although the result would not withstand correction for multiple testing.
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A three marker haplotype gave a slightly more significant result (p=0.01). However, 
(Zai, King et al. 2005) studied four polymorphisms in MOG for association with 
schizophrenia, using 111 schizophrenia probands and their families. They did not 
observe significant evidence for biased transmission of alleles at any of the 
polymorphisms. Haplotype analysis was also not significant. They also used a second 
sample of 182 cases and matched controls which again did not show significant 
association for any of the polymorphisms or haplotypes tested.
The MOG gene can be considered as a possible candidate for schizophrenia 
for several reasons a) its location in an established linkage region for schizophrenia, 
b) its association with white matter abnormalities, c) its altered expression in 
schizophrenic patients, d) its involvement in diseases with phenotypic overlaps with 
schizophrenia such as multiple sclerosis and e) the modest evidence from previous 
studies which show putative evidence of association to schizophrenia.
5.1.3 SOX 10;
Sex-determining region Y-box 10 (SOX 10) is located on chromosome 
22ql3.1, which is a putative region of linkage to schizophrenia (Owen, Craddock et 
al. 2005). There have been several studies suggesting that the 22ql 1-13 region on 
chromosome 22 is linked to schizophrenia (Gill, Vallada et al. 1996; DeLisi, Shaw et 
al. 2002; Williams, Norton et al. 2003), and two meta-analyses of the linkage data 
have provided further support for the involvement of this region (Badner and Gershon 
2002; Lewis, Levinson et al. 2003). Sox 10 is located 18 Megabases downstream from 
the VCFS region, VCFS being a syndrome in which there is an increased risk of 
developing schizophrenia. It has been shown that about a third of VCFS cases suffer 
schizophrenia like psychosis (Murphy, Jones et al. 1999; Murphy 2002), a figure
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which is much higher than the 1% prevalence rate of schizophrenia in the general 
population.
Sox 10 belongs to the SRY box family of transcription factors, it contains a 
high mobility group (HMG) DNA binding domain and a trans-activation domain at its 
C-terminus. The HMG domain binds to and bends the minor groove of DNA, causing 
a conformational change, which in turn facilitates cooperative binding of 
transcriptional factors (Wei, Miskimins et al. 2004). Sox 10 is involved in 
development of neural crest derivatives and fate determination of glial cells in the 
neural crest lineage (Inoue, Khajavi et al. 2004). It also controls the proliferation and 
differentiation of Schwann cells and oligodendrocytes (Inoue, Khajavi et al. 2004). 
Glial cells of the peripheral nervous system (PNS) are generated by neural crest cells. 
These glia include satellite cells located in ganglia as well as Schwann cells which 
ensheath peripheral axons (Britsch, Goerich et al. 2001). Without Sox 10, no glia 
develop in the peripheral nervous system (Stolt, Rehberg et al. 2002). Sox 10 is also 
strongly expressed in the CNS in regions such as the corpus callosum and cerebral 
and cerebellar cortex (Stolt, Rehberg et al. 2002). The onset of SOX 10 expression in 
the CNS coincides with the onset of oligodendrocyte development (Stolt, Schmitt et 
al. 2005). Unlike other Sox proteins, Sox 10 continues to be expressed and is involved 
in activating myelin gene expression as part of the terminal differentiation program in 
oligodendrocytes (Stolt, Schmitt et al. 2005). Sox 10 is thought to stimulate the 
transcription of myelin related genes in both the peripheral and central nervous 
system. These genes include protein zero in Schwann cells of the PNS and myelin 
basic protein (MBP) in the CNS (Wei, Miskimins et al. 2004). Protein zero makes up 
more than 50% of the total myelin protein in mature Schwann cells, where it is 
involved in myelin compaction (Peirano, Goerich et al. 2000).
217
Several studies using DNA micro-arrays to study gene expression in 
psychiatric diseases have reported down regulation of Sox 10 in post-mortem 
schizophrenic brain. Tkachev and colleagues (Tkachev, Mimmack et al. 2003) 
reported a 1.88-1.99 fold down regulation of SOX 10 in schizophrenia, a result 
supported by an independent micro-array study (Katsel, Davis et al. 2005b). Aston 
and colleagues (Aston, Jiang et al. 2005) reported a 1.5 fold decrease in expression in 
bipolar patients compared to controls. Recently, following up on these results, 
(Iwamoto, Bundo et al. 2005b) showed that patients with schizophrenia had a higher 
percentage of methylated Sox 10 and lower expression levels of Sox 10 compared 
with control subjects. There was an inverse correlation between the percentage of 
methylated Sox 10 and the expression level, suggesting that downregulation of Sox 10 
was possibly caused by Sox 10 methylation. The authors also showed that 
methylation status of Sox 10 was correlated with down regulation of other 
oligodendrocyte genes that were differentially expressed in schizophrenia, including 
MAG, OLIG 2, MOBP and CNP. They subsequently concluded that the expression in 
the genes is under the direct or indirect control of Sox 10.
Studies on patients with heterozygous Sox 10 mutations have identified an 
association between SOX 10 mutations and deficiencies in peripheral and/or central 
nervous system myelin (Britsch, Goerich et al. 2001). Mutations in SOX 10 have been 
shown to cause neurological diseases including peripheral demyelinating neuropathy, 
central demyelinating leukodystrophy, Waardenburg syndrome, and Hirschsprung 
disease (Iwamoto, Bundo et al. 2005b). Leukodystrophies are a heterogeneous group 
of genetic diseases that affect primarily the central nervous system myelin. They 
typically involve the motor systems with prominent CNS symptoms and slow mental 
deterioration (Pingault, Bondurand et al. 2001). Some are degenerative
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(demyelinating diseases), whereas others are due to a developmental defect in CNS 
myelin formation (dysmyelinating diseases) (Pingault, Bondurand et al. 2001).
This interpretation of the data from Sox 10 deficient humans is consistent with 
the findings of animal studies that have shown Sox 10 null mice have profound 
defects in both peripheral and central myelin (Britsch, Goerich et al. 2001).
In the peripheral nervous system, expression of erbB3 is thought to be 
influenced by Sox 10 (Britsch, Goerich et al. 2001), although the presence of Sox 10 
binding sites within the erbB3 gene has not been reported and it is therefore not clear 
whether Sox 10 regulation of this gene is direct (Mollaaghababa and Pavan 2003). 
ErbB3 is a receptor kinase that binds neuregulins. ErbB3 like Sox 10 has a critical 
function in the development of neural crest derivatives including Schwann cells and 
oligodendrocytes (Mollaaghababa and Pavan 2003). The involvement of Sox 10 in the 
regulation of erbB3 is made more interesting by reports implicating one of the erbB3 
ligands, Neuregulin 1 (NRG1) as a susceptibility gene for schizophrenia in several 
studies (Stefansson, Sigurdsson et al. 2002; Stefansson, Sarginson et al. 2003; Owen, 
Craddock et al. 2005; Li, Collier et al. 2006), and reports of altered erbB3 expression 
in schizophrenia (Hakak, Walker et al. 2001; Tkachev, Mimmack et al. 2003; Aston, 
Jiang et al. 2004; Katsel, Davis et al. 2005b).
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5.2 Methods:
Analysis of the three genes was based upon a direct association approach as 
described in Chapter 1.
PCR fragments to span exonic sequence, putative promoter and limited 
amounts of 5’ and 3’ flanking regions were designed and the primers used to generate 
amplimers for the purpose of DHPLC for each gene studied are listed below in tables 
5.1, 5.2, and 5.3 respectively.
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Table 5.1: PCR primers and conditions for GFAP assays.
The table shows the fragment name, region o f genomic sequence amplified, the Forward and Reverse primer sequences, the size o f the fragment
and the reaction conditions used to amplify all o f the GFAP fragments utilised during the assaying o f the gene.
Fragment Name Spanning Forward Primer (5’ to 3’)
Reverse Primer 
(5’ to 3’)
Size
...(bp)
Annealing 
Temp (°C)
GFAPJ 5’ Flank / Put Prom GGC AT CTT GGG ATAAAAGC A AGGT CACCCCTT CCTT GT CT 548bp HS 64
GFAP_2 5’ Flank / Put Prom CAT GT GTAACGGCTTT GTGG AAAGGG AAGG AAGGGCT GTA 483bp HS 64
GFAP_3 5’ Flank / Put Prom GCCCTT G AGGGT ACAGAACA AGGCAGGT GGT ACCT GGAG 461 bp HS 64
GFAP_4 Exon 1 ACCCTTT CTT GACCCACCTT GCGAACCTT CT CGAT GTAGC 569bp HS 64
GFAP_5 Exon 1 AATGCTGGCTTCAAGGAGAC CCAGCCAT GAAT GAAAC ACA 584bp HS 64
GFAP_6 Exon 2 / Exon 3 TTAAGGCAAAAGCCCACATC CCAGCG ACT CAAT CTT CCTC 518bp HS 64
GFAPJ Exon 3 TAAGGCAAGGCT GAGGAAT G GTACC AGGGCT CAGGGTACA 451 bp HS 64
GFAPJ Exon 4 TTGGCAGGTAGAGACAGGAA GGCAAGCCATCTCACTTCTC 485bp HS 60
GFAP_9 Exon 5 T C ATT CATT CGCTT GCT GAC CT CT CCAGGGACT CGTT CT G 571 bp HS 60
GFAP_10 Redesign Exon 6 CTCGAAACCTCCCCAAGT C TGACTGCCTGCTATGTGTGA 439bp HS 60
GFAPJ 1 Exon 7 I I I I ICAGCCTTGTGTGCAG T CT GCAGGTT GG AGAAGGT C 533bp HS 60
GFAPJ 2 Exon 7 AAGG AAAAGGGCGTT CAAGT ACACTCAGAAGGGCAGTGCT 463bp HS 60
GFAPJ 3 Exon 8 GCAGCAGCACTATTGGGATT AGGGACTGAGGAAACGGAAT 448bp HS 64
GFAPJ 4 Exon 8 GT GGT GAAGACCGTGGAGAT C AG AGGGGGT GGT G AGATAA 557bp HS 64
GFAPJ 5 Exon 9 AACC AC AGT GGG AGCT CAT C TTGGGGGTGAGTTTCTTGTT 525bp HS 60
GFAPJ6 Redesign Exon 9 ACCTGAGCTCCCCACCAC CCCC ACCCAT CTT AG ACT G A 594bp HS 60
GFAPJ 7 Exon 9 CTGGGCTCAAGCAGTCTACC C ACCC AC AACCCCTACTT GT 466bp HS 64
GFAPJ 8 Exon 9 TGTGTACGT GG AG AGGG AT G ACTTT GCT CGT GCCT C AGTT 545bp HS 60
GFAPJ 9 Exon 9 T GCT GCTT CTTAACCCCAGT GC AGT GCCCT G AAG ATTAGC 548bp HS 60
GFAP_20 Exon 9 CTTT CCCT CC ACT CCTT CCT GGTCTGGGACCTGATCTGAG 522bp HS 64
GFAP_21 Exon 9 GT GCCCTACTT CC AT CCT G A CCT GAAGGGT GT C AAC AGGT 536bp HS 60
GFAP_22 Exon 9 GT GCCC AT G AGAT GT C AC AC CCT CCAT GT CTT CACCACCT 598bp HS 62 DMSO
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Table 5.2: PCR primers and conditions for the MOG assays.
The table shows the fragment name, region o f genomic sequence amplified, the Forward and Reverse primer sequences, the size o f the fragment
and the reaction conditions used to amplify all o f the MOG fragments utilised during the assaying o f the gene.
Fragment Name Spanning Forward Primer (5’ to 3')
Reverse Primer 
(5’ to 3’)
Size
(bp)
Annealing
Temperature
(°C)
MOG_1 5’ Flank / Put Prom C AGCT CT GCC ACT CCCTAGT TTGGGGGTGGTAAG AT GT GT 364bp HS 62
MOG_2 5’ Flank / Put Prom I I I IGACAGCTTGCTTGGTG GCAGCAAGGGGTAGAAACAC 402bp HS 62
MOG_3 5’ Flank / Put Prom T CTAGCTCCTTACGCCC AT C G ACC AGC ATT GGTAGCAGGT 377bp HS 62
MOG_4 5’ Flank / Put Prom ATTT GGT G AGGC AT ACTTGC T CTACCGCG AAT CCAAACT C 404bp HS 62
MOG_5 Exon 1 TT GCCT CT CT GAGCACACC TCCT GGAGAT CC AACCTTT G 393bp HS 62
MOG_6 Exon 1 CCC ACT GATT AGCCCCTAG A CCCCAGG AAACT AGCCTTT C 505bp HS 62
MOG_7 Exon 2 TTTGAAGCAGCCCTTCTCAT TTGGCCACCCAACAGTTAAT 477bp HS 62
MOG_8 Exon 3 GT GT GT CAT GCACCTT CCAC CAAT GT GAG ACCCT GCCTCT 255bp HS 62
MOG_9 Exon 4 AT GCT G AGT GTT GGGG ATT C T CC AAG AAGCC AGCT CATTT 231 bp HS 62
MOG_10 Exon 5 / Exon 6 TTTCCAGGCTGCAGAGAAAT GAGAGGAAGGGACTCAACCA 505bp HS 62
MOG_11 Exon 7 GGAGGCAGTACI I I ICTCATCC T CTTTT GGCTT CCC ATT C AG 353bp HS 62
MOG_12 Exon 7 / Exon 8 GGTTGCCTT GAT CAT CT GCT TCCT CCTTT CCT CT GGG AAT 486bp HS 62
MOG_13 Exon 8 AAAAGCCAGGAAAGGGAGAC CCC ATAGC AAAG AT GCC AGT 538bp HS 62
MOG_14 Exon 8 CTT GGGGACAT CT CAT CCAT GTAGGCT GCCAAG AC AAGG A 542bp HS 62
MOG_15 Exon 8 AAACCT GGAGAT GGGGAGAA GCCCACCACTAT GCT CAGTT 444bp HS 62
MOG_16 redesign Exon 8 CTT GATGGT CAGACACAAACA AAT GG AAGC AT GG AGGT GAT 684bp HS 62
MOG_17 Exon 8 CTCCCT CTACT CC AGCCT C A CCATT GCAGCAAGT CTTT CA 451 bp HS 62
MOG_18 Exon 8 GGTCACAGATAGGGCAAAGG ACGCCACCAGAAGATACACC 515bp HS 62
MOG_19 Exon 8 GTGCCT GG AAT CCT C AAAGT GGCAAGAAGAAAGAGCTT CG 545bp HS 62
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Table 5.3; PCR primers and conditions for the SOX 10 assays.
The table shows the fragment name, region o f genomic sequence amplified, the Forward and Reverse primer sequences, the size o f the fragment
and the reaction conditions used to amplify all o f the SOX 10 fragments utilised during the assaying o f the gene.
Fragment Name Spanning Forward Primer (5' to 3') Reverse Primer (5' to 3') Size(bp)
Annealing
Temperature
(°C)
SOX 10 Prom 1 
SOX 10 Prom 2 
SOX 10 Ex 1 
SOX 10 Ex 2A 
SOX 10 Ex 2B 
SOX 10 Ex 3 
SOX 10 Ex 4A 
SOX 10 Ex 4B 
SOX 10 Ex 4C 
SOX 10 Ex 4D 
SOX 10 Ex 4E
Putative Promoter 
Putative Promoter 
Exon 1 
Exon 2 
Exon 2 
Exon 3 
Exon 4 
Exon 4 
Exon 4 
Exon 4 
Exon 4
AGGAGAGGCCAAGGAAAGAG 
GTCTGCAGAGAAGGGACCAG 
CCCAAGATAAGCCTCAGCAA 
GAT GGGTTTAGCT GGAGCAG 
AAGGT C AAG AAGG AGC AGC A 
T CCAAGAT GGACACT CAGAGG 
C ACCT GCCTCTAACCT GCTT 
G AC ACT CCGCCT GG AT CT C 
CT AC ACGGCC AT CT CT GACC 
GG AGGCCTTACC ACT CCTATG 
CCAGCTCCCTCTTCCCTTAC
CCCTCT G AGAAGT GCAG AGC 
CTT CAT CCCCAACACTCAGG 
AACGGGGTTTAG AGGAG AGC 
ACGGGG AACTT GT CAT CGT 
ACCT GGT CTT CCAGCCCTAT 
CAT CCAGCC AT CT CCT GT CT 
T CT GT CTT C ACCT GGGCTTT 
CAAGGAACAGGGCACACAG 
CTAGCCCTTAGGCACTGTGG 
GCT GT C ACT CT CT GGG AAGC 
G AAG AG AC AGGCC AGGT C AG
402bp 
499bp 
532bp 
409bp 
408bp 
430bp 
438bp 
481 bp 
551 bp 
515bp 
425bp
HS 60 
HS 64 
HS 60 
HS 60 DMSO 
HS 60 
HS 60 
HS 60 
HS 67 
HS 60 
HS 60 
HS 60
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5.3 Results:
5.3.1 G F A P :
The GFAP intron/exon boundaries were defined by alignm ent o f  the cDNA 
sequence NM _002055 and the genom ic sequence (http://genom e.ucsc.edu). M utation 
detection assays revealed twenty three SNPs, an insertion/deletion, and a poly T 
simple sequence repeat (See appendix 5.3 for sequencing results). There were two 
coding synonymous SNPs Y14Y (41 O T )  and P140P (rs2229011), ten 3 ’-UTR SNPs 
(8155 G>A, rs l 1558961, rs8067254, 8769 G>A, rs3744470, rs l042329 , 9661 T>C, 
9759 C>T, 9768 C>T and 9834 T>C), three 5 ’-flanking region polym orphism s 
(rs3760379, rs2070934 and -508 poly T) two 3 ,-flanking region SNPs (rsl2222  and 
rs3744473) and eight intronic polym orphism s (602 C>T, 657 Del C, 1960 G>T, 
rs3744468, rs2289671, 4677 C>T, rs2289679 and rs l 1651396) (figure 5.1).
Figure 5.1. Schematic diagram of GFAP.
Diagram o f the GFAP gene (adapted from  the UCSC Genome Browser), indicating 
the positions o f  the identified polym orphism s. For num bering o f  polym orphisms, +1 
indicates the ‘A ’ o f  the A TG  translation codon. The gene is displayed (3’-5’).
17 ci2  2 ic hr 1 7
chr 17 r  4B34eeeeT 403459001 40350000I
GCNOTYPEO SNPS
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r s 12222 | 8155_G>ft| 4677_C>T | 1960_G>T | 41_C>T |
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Twenty one of the SNPs and the insertion/deletion were successfully 
genotyped in the pooled association sample. For two of the SNPs the minor allele 
frequencies were too rare to be assayed, whilst the poly-T sequence was incompatible 
with a primer extension genotyping assay. The extension primers used for pooled 
genotyping are listed in table 5.4. The calculated allele counts and frequencies for all 
of the genotyped polymorphisms are shown in table 5.5. Markers 140 G>A, 1960 
G>T and 9834 T>C showed evidence for association in pools. However, all have a 
low minor allele frequency making the pooled genotyping assay more prone to 
inaccuracy and error. Given the possible inaccuracy in the pooled genotyping results I 
decided to type these three SNPs in 96 unrelated control subjects and 30 CEPH trios 
to a) confirm that the estimated pooled allele frequencies were approximately correct 
before continuing with individual genotyping of the whole association sample, b) 
determine the LD relationships for marker redundancy.
I
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Table 5.4: Polymorphism and primer extension reaction details for GFAP.
Table of the polymorphisms identified in the GFAP gene, including the sequence flanking each of the polymorphisms, the extension primer used 
to assay the polymorphism by SNaPshot and the expected alleles in the primer extension reaction.
SNP number. rs Number SNP Flanking sequence Extension primer Expected Alleles
-1001 T>C rs3760379 AGCC AGCT CAT G[T/C]GTAACGGCTTT G CCTT G ACAGCT CCAC AAAGCCGTTAC A (Green) & G (Blue)
-518 T>A rs2070934 TTCCCTTTTTT l'[T/A]TTTTTTTTTT GT GT AC AGCCCTT CCTTCCCI I n  TIT T (Red) & A (Green)
-508 Poly T 
41 O T
N/A
N/A
CCCTTTTTTTTTT I I I I 'l IT [T/-JGTGAGACAAG 
TCGCCGCTCCT A[C/T]GT CT CCT C AGGG
Unable to assay by primer extension.
T CACCT CCGCTGCTCGCCGCTCCTA C (Black) & T (Red)
140 G>A rs2229011 CCCT CCACT CCC[G/A]ACCCGGGT GGAT GCTCGAATGCCCCCTCCACTCCC G (Blue) & A (Green)
602 C>T N/A CACTATCCTTGC[C/T]CCCCAACATGAT CCCTACCT CTT G ATGGGGC ACTAT CCTT GC C (Black) & T (Red)
657 Del-C N/A GGGG AT CT GAT G[C/-]CCGC AT GCCTT C GACCCT GGACT CCT GGCAG AAGGC AT GCGG G (Blue) & C (Black)
1960 G>T N/A ATT CG AACT CCT[G/T]GCCG AGGGGC AG GG AAAG AG AC AAG AG AGCATT CG AACT CCT G ( Blue) & C (Black)
2044 O T rs3744468 T ACCGCTT CT CT[C/T] ACCCT GGT CAGG AGCCCTGGTACCGCTT CT CT C (Black) &T (Red)
3895 A>G rs2289671 GAAGGGCCAGGG[A/G]CGAGGACCTGGG GCCCCGCCCTCGACCCAGGTCCTCG T (Red) & C (Black)
4677 O T N/A CT CC AG ATAGC A[C/T]GTT GGCTGCTGG CCTT GCAGACGTTT GGAACT CCAGATAGCA C (Black) & T (Red)
4762 OG rs2289679 AT GAT GGCCCCG[C/G]ACCAAGACCC AG CGTT CAAGTT GT CAT GAT GGCCCCG C (Black) & G (Blue)
8012 O T rsl 1651396 T CGGGG ACTT CC[C/T] AAGGTT AC ACAG C ACC ACC ACG AGGCT GT GTAACCTT G (Blue) & A (Green)
8155 G>A N/A AGGACCCACCT G[G/AJT GGCCT CT GCCC AAGG AT GT GAT GT G AGGCAGG ACCCACCT G G (Blue) & A (Green)
8167 OG rsl 1558961 GT GGCCT CT GCC[C/G]CGT CT CAT GAGG CCT GCTT CTGCTCGGGCCCCT CAT GAGACG G (Blue) & C (Black)
8477 O T rs8067254 CAT CGCCCTCC A[C/TJAT CCCT GATT CC GCACCT ACT ACAT CGCCCT CCA C (Black) & T (Red)
8769 G>A N/A T GG AGCC ACC AT[G/AlCCC AGCT C AG AG GT AGCT GGG ATT AT AG ATT GG AGCCACC AT G (Blue) & A (Green)
8953 T>A rs3744470 GCT GT GGGC AGG[T /A]GGG AGCTT GATT GAT CCCCC AAGT GCT GAG AAT C AAGCT CCC A (Green) & T (Red)
9140 G>A rsl 042329 AATT GGGAT GGC[G/A]CTAGGCATACAA C ACCC AC AACCCCTACTT GTATGCCTAG C (Black) & T (Red)
9661 T>C N/A T GT GCCCAGAGA[T/C]GGG ACT GGGAGG G AGC AG ACT GGT GGGAT CTGT GCCCAG AG A T (Red) & C (Black)
9759 O T N/A TTTCCCTCCACT[C/T]CTTCCTGCCACC CC AAG ACTTGGT GTCCTTT CCCT CCACT C (Black) &T (Red)
9768 O T N/A ACT CCTT CCT GC[C/T] ACCT GCT GCT GC CCT G AAG ATT AGCAGC AGCAGC AGC AGCAGGT G (Blue) & A (Green)
9834 T>C N/A GCT G AGG AAAAA[T/C] AAAG AC AAAT GC CCTTTAGT CGCT G AGGAAAAA T (Red) & C (Black)
10125 O T rs12222 C AGT GTTT ACC A[C/T]T GGAT AAAT CT G G AAAGT GT GAACT CAGATTTAT CCA G (Blue) & A (Green)
10566 T>C rs3744473 AGGCTGGGTAG[T/C]GCCCATGAGATG AGG AT CT GAG AACG AGGCT GGGTAG T (Red) & C (Black)
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pp*"-" Table 5.5: Fooled genotyping data for GFAP.
Estimated minor allele frequencies and minor allele counts for the GFAP polymorphisms, with the corresponding chi-square and p-values. 
Significant p-values are displayed in bold.
SNP Data Pooled Genotyping data
SNP number. rs Number Minor Allele Cases (freq) Minor Allele Controls (freq) Difference Chi-square P-value
-1001 T>C rs3760379 T= 465 (0.43) T= 440 (0.4) 0.03 2.90 0.09
-518 T>A rs2070934 A= 382 (0.36) A= 391 (0.35) 0.01 0.02 0.89
-508 Poly T Incompatible with a primer extension assay.
41 C>T T= 18 (0.02) T= 17 (0.02) 0 0.07 0.79
140 G>A rs2229011 A= 70 (0.07) A= 49 (0.04) 0.03 4.65 0.03
602 O T T= 174 (0.16) T= 176 (0.16) 0 0.04 0.84
657 Del-C C-lns= 178 (0.17) C-lns= 171 (0.16) 0.01 0.53 0.47
1960 G>T T= 90 (0.08) T= 53 (0.05) 0.03 11.53 0.001
2044 O T rs3744468 T= 119 (0.11) T= 109 (0.1) 0.01 0.90 0.34
3895 A>G rs2289671 G= 472 (0.44) G= 493 (0.45) 0.01 0.07 0.79
4677 O T T= 145 (0.14) T= 137 (0.12) 0.02 0.63 0.43
4762 OG rs2289679 G= 319(0.3) G= 350 (0.32) 0.02 0.91 0.34
8012 O T rsl 1651396 T= 301 (0.28) T= 318 (0.29) 0.01 0.12 0.73
8155 G>A A= 41 (0.04) A= 52 (0.05) 0.01 1.02 0.31
8167 O G rsl 1558961 G= 306 (0.29) G= 326 (0.3) 0.01 0.23 0.63
8477 O T rs8067254 T= 149 (0.14) T= 147 (0.13) 0.01 0.17 0.68
8769 G>A Minor allele frequency too rare to assay.
8953 T>A rs3744470 A= 130 (0.12) A= 156 (0.14) 0.02 1.87 0.17
9140 G>A rsl 042329 A= 125 (0.12) A= 115(0.1) 0.02 0.89 0.35
9661 T>C C= 307 (0.29) C= 347 (0.31) 0.02 1.94 0.16
9759 C>T T= 116 (0.11) T= 103 (0.09) 0.02 1.37 0.24
9768 C>T Minor allele frequency too rare to assay.
9834 T>C C= 30 (0.03) C= 75 (0.07) 0.04 18.82 0.001
10125 O T rs12222 T= 324 (0.3) T= 350 (0.32) 0.02 0.51 0.47
10566 T>C rs3744473 C= 307 (0.29) C= 336 (0.3) 0.01 0.79 0.37
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Individual genotyping revealed the minor allele frequency for SNPs 140 G>A and 
1960 G>T were consistent with the estimated allele frequency of the controls in the 
pooled genotyping assay (table 5.6). However, for 9834 T>C the minor allele 
frequency in the 96 controls and 30 trios was lower than in the pooling assay, 
suggesting that the polymorphism was not assayed accurately by pooled genotyping. 
LD analysis of the markers revealed the three polymorphisms were in D’=l with each 
other but only had a value of r2=<0.01.
Table 5.6 Control genotyping of 140 G>A. 1960 G>T and 9834 T>C.
Genotype and allele counts and frequencies for the GFAP SNPs 140 G>A, 1960 G>T 
and 9834 T>C after genotyping in 96 controls and 30 trios.
SNP Genotypes Alleles (freq)
140 G>A G/G G/A A/A G A
164 15 0 343 (0.96) 15 (0.04)
1960 G>T G/G G/T T/T G T
153 9 0 315(0.97) 9 (0.03)
9834 T>C T/T T/C C/C T C
172 1 0 345 (0.995) 1 (0.005)
I therefore decided to genotype the two 140 G>A and 1960 G>T polymorphisms 
individually. This was achieved by performing two Amplifluor genotyping assays 
using the protocol as described in section 2.10.3. (See appendix 5.4 for amplifluor 
assay design).
The genotyping results are shown (tables 5.7 and 5.8). No significant differences were 
found in the cases and controls. The failure to replicate the pooling results is not 
totally unexpected as with small minor allele frequencies a very small change in the 
allele frequency can make a large difference to the statistical significance of the result. 
In this case the minor allele frequency of 140 G>A was reduced by only 0.02 in the
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cases, whilst there was a reduction of 0.04 and 0.02 in the cases and controls 
respectively for 1960 G>T, but these small differences were enough to make the two 
results non-significant.
Table 5.7: Individual genotyping results for SNP 140 G>A.
Individual genotype and allele counts and frequencies for GFAP 140 G>A after 
genotyping in the schizophrenia association sample. Both genotypic and allelic p- 
values are shown as calculated using CLUMP.
SNP Genotypes Alleles
140 G>A G/G G/A A/A G A
Cases 557 63 0 1177 (0.95) 63 (0.05)
Controls 635 59 1 1329 (0.96) 61 (0.04)
1.96 2df P = 0.34 7? = 0.69 P = 0.40
Table 5.8: Individual genotyping results for SNP 1960 G>T.
Individual genotype and allele counts and frequencies for GFAP 1960 G>T after 
genotyping in the schizophrenia association sample. Both genotypic and allelic p- 
values are shown as calculated using CLUMP.
SNP Genotypes Alleles
1960 G>T G/G G/T T/T G T
Cases 548 48 2 1218(0.96) 52 (0.04)
Controls 656 47 0 1359 (0.97) 47 (0.03)
•£ = 2.62 2df P = 0.29 ^ = 1 .0 6 P = 0.30
Haplotype analysis was performed on the two individually genotyped markers. The 
analysis revealed no evidence of association (global p value =0.38) with no individual 
haplotypes displaying a significant difference between the cases and controls.
5.3.1.1 Allelic expression assay of GFAP.
The G>C polymorphism rsl 1558961 was selected as a tag for analysis 
because of its suitable minor allele frequency of 0.3. Of the 60 subjects for whom 
brain was available, 27 were heterozygous. This subset of 27 individuals provided a 
power of approximately 93% to detect the effect of a regulatory variant present at a
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frequency o f 0.05, and a power o f 99% to detect a variant at a frequency o f 0.1. O f the 
27 GFAP heterozygous individuals, one showed a relative expression difference o f > 
20% compared to the corresponding average genomic ratios (see Graph 5.1), the 
cDNA presenting with a corrected ratio o f 1:0.78. The data points from each 
individual cDNA sample showed excellent reproducibility, with an average SD o f the 
mean of 0.03. The assay therefore provides evidence for the presence o f a rare e x ­
acting variant affecting the allelic expression o f the GFAP gene. Whether this ex­
acting variant is responsible for the results o f previous expression studies (Tkachev, 
Mimmack et al. 2003; Fatemi, Laurence et al. 2004; Webster, O'Grady et al. 2005) is 
unclear though given its frequency, it is unlikely unless it is dramatically more 
common in cases. It seems more likely that the observation o f altered GFAP 
expression results from trans-acting factors.
Graph 5.1: GFAP Allelic Expression: rsl 1558961.
Corrected genomic and cDNA ratios for rsl 1558961. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for GFAP 
(n=27). Data are expressed as the mean o f the ratio o f G:C for two measurements of 
each genomic DNA sample and two measurements o f each cDNA sample.
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5.3.2 M O G :
Determination o f  the M OG intron/exon boundaries was based on alignment o f 
the cDNA sequence NM  002433 and the genom ic sequence available from the UCSC 
Genome Bioinformatics w ebsite (http://genom e.ucsc.edu).
M utation detection identified tw elve SNPs, along w ith a V N TR and a poly T 
simple sequence repeat (See appendix 5.3 for sequencing results). There was one non- 
synonymous SNP V171L (rs2857766), one synonym ous SNP S5S (rs3130250), five 
3’-UTR polym orphisms (rs9257936, rs2535243, rs3135049, rsl984840  and 
rs9256961), three 5 ’ flanking SNPs (rs29228, rs29235 and rs29234) and four intronic 
polymorphisms (rs9278232, rsl7184514 , rsl318631 and rs l 122947) (figure 5.2).
Figure 5.2. Schematic diagram of MOG.
Diagram o f the M OG gene (adapted from the UCSC Genom e Brow ser), indicating the 
positions o f  the identified polym orphism s. For num bering o f  polym orphism s, +1 
indicates the ‘A ’ o f  the A TG  translation codon. The gene is displayed (5 ’-3’).
Chr61 2973500OI 297400001 297450001
GENOTYPED SNPS
PS29228 | rS9278232 1 r s 17184514 | rsl122947|
PS29235 | rs28577661 rs92579361
PS29234 | r s l318631 | PS2535243
rs3130250| rs3135049|
r s l984840 I 
rs9256961|
I RefSeci GenesRefSeq Genes________________^  g ------------------------------------------ ........... ++
All twelve o f  the detected SNPs w ere genotyped in the pooled association 
sample, although the V N TR  and poly-T  sequence were unable to be typed in the pools 
as they were incom patible w ith prim er extension genotyping. The extension primers 
used for pooled genotyping are listed in table 5.9. The calculated allele counts and 
frequencies from all o f  the pooled genotyping o f  the polym orphism s are shown in 
table 5.10. No significant differences were observed between the allele frequencies o f 
the cases and controls for any o f  the polym orphism s.
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Table 5.9: Polymorphism and primer extension reaction details for MOG.
Table of the polymorphisms identified in the MOG gene, including the sequence flanking each of the polymorphisms, the extension primer used 
to assay the polymorphism by SNaPshot and the expected alleles in the primer extension reaction.
SNP number. rs Number SNP Flanking sequence Extension primer Expected Alleles
-1909 G>A 
-909 T>C 
-875 A>C 
14 G>A 
7412 Poly T 
9016 G>C 
10423 T>G 
10521 G>A 
13447 G>A 
14789 C>T 
14875 A>G 
15034 C>T 
15052 G>A 
15126 VNTR
rs29228 
rs29235 
rs29234 
rs3130250 
rs9278232 
rs2857766 
rsl 7184514 
rsl 318631 
rsl 122947 
rs9257936 
rs2535243 
rs3135049 
rsl 984840 
rs9256961
T CT CGGAC AAAA[G/A]C AGAAAT GT AT G 
ACCT GCT ACCAA[T/CJGCT GGT CT CACA 
CT C AGCT G AGCC[A/C] AG AGGT GAG AG A 
GGCAAGCTT AT C[G/A]AG ACCCT CT CT G 
G AATTTTTTTTTTTTTTT[T/-]G AG AC AGT GT CT 
CT GCAGAT CACT[G/C]TT GGCCT CGT CT 
AT GTT GCCTTTT[T/G]CT ATTTT AGG AA 
GGAAAT GGT CCC[G/A]TT CTTGGAT CGT 
GGG AAAGGT GCT[G/A]TT CAT CTT CC AC 
TTAATAAAGATA[C/T]GAGTTTTGGCCG 
GGT C AGG AGTT C[A/G] AG ACC AGCCT GG 
GAGCT GAGAT CG[C/T]GCCACT GCACT C 
T GC ACT CT AGCC[G/A]G AGT G AC AG AGT 
TAAATAAAT AAA[-/TAAA] AAATAAT AATTAC
CT CCTT ACGCCC AT CT CGGAC AAAA 
T GAGAATT GCAAGT GT GAGACCAGC 
AAAATGACCI I I CTCTCACCTCT 
G AAC AGTAGAG AT GGCAAGCTTAT C 
Unable to assay by primer extension.
GCAGAGGAAGACGAGGCCAA 
TCTGCTCGAAGI I I ICCTAAAATAG 
I I I I IGGCATAACGGAAATGGTCCC 
ATAGGGAGGATGTGGGAAAGGTGCT 
AAAC AAGCTAGGT GCT AATTAAT AAAG ATA 
GGGCGAAT CACGAGGT CAGGAGTT C 
C AG AGGTT GC AGT GAGCT GAGAT CG 
CCACT GCACT CTAGCC 
Unable to assay by primer extension.
G (Blue) & A (Green) 
A (Green) & G (Blue) 
T (Red) & G (Blue) 
G (Blue) & A (Green)
C (Black) & G (Blue) 
A (Green) & C (Black) 
G (Blue) & A (Green) 
G (Blue) & A (Green) 
C (Black) &T (Red) 
A (Green) & G (Blue) 
C (Black) &T (Red) 
G (Blue) & A (Green)
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Table 5.10: Pooled genotyping data for MOG.
Estimated minor allele frequencies and minor allele counts for all of the pooled genotyping of the MOG polymorphisms, along with the 
corresponding chi-square and p-values.
SNP Data Pooled Genotyping data
SNP number. rs Numbers Minor Allele Cases (freq)
Minor Allele 
Controls (freq) Difference Chi-square P-value
-1909 G>A rs29228 A= 329 (0.24) A= 326 (0.23) 0.01 0.45 0.50
-909 T>C rs29235 C= 65 (0.05) C= 64 (0.04) 0.01 0.09 0.76
-875 A>C rs29234 C= 76 (0.05) C= 72 (0.05) 0 0.32 0.57
14 G>A rs3130250 A= 228 (0.17) A= 240 (0.17) 0 0.03 0.87
7412 Poly T rs9278232 Incompatible with a primer extension assay.
9016 G>C rs2857766 C= 381 (0.28) C= 372 (0.26) 0.02 0.95 0.33
10423 T>G rsl 7184514 G= 93 (0.07) G= 105 (0.07) 0 0.38 0.54
10521 G>A rs1318631 A= 349 (0.25) A= 334 (0.23) 0.02 1.47 0.23
13447 G>A rsl 122947 G= 236 (0.17) G= 254 (0.18) 0.01 0.19 0.66
14789 C>T rs9257936 T= 156 (0.11) T= 158 (0.11) 0 0.05 0.82
14875 A>G rs2535243 G= 247 (0.18) G= 270 (0.19) 0.01 0.43 0.51
15034 C>T rs3135049 T= 169 (0.16) T= 160 (0.15) 0.01 0.71 0.39
15052 G>A rsl 984840 A= 218 (0.2) A= 223 (0.2) 0 0.01 0.92
15126 VNTR rs9256961 Incompatible with a primer extension assay.
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As the 15126 VNTR (rs9256961) could not be assayed using the pooled genotyping 
primer extension method I decided to genotype the polymorphism individually using a 
Genescan fluorescent PCR assay (as described in section 2.10.5). The VNTR was 
made up of variable number of 4bp TAAA repeats. The calculated allele counts and 
frequencies for the VNTR genotyping are shown in table 5.11 below. No significant 
difference was observed between the allele counts in the cases and the controls.
Table 5.11: Allelic genotyping results for the MOG 15126 VNTR polymorphism.
Allele counts and frequencies observed when the MOG 15126 VNTR was genotyped 
using a fluorescent PCR. There were a total of ten alleles observed each 4bp apart. 
Chi-square and p-values calculated using CLUMP.
15126 VNTR Cases Controls
Allele No
(Size bp):
Allele Count Allele Freq Allele Count Allele Freq
1 (232bp) 0 0 2 0.001
2 (236bp) 2 0.002 1 0.0007
3 (240bp) 7 0.005 11 0.008
4 (244bp) 83 0.064 90 0.063
5 (248bp) 68 0.052 77 0.054
6 (252bp) 288 0.22 272 0.19
7 (256bp) 368 0.28 408 0.29
8 (260bp) 251 0.19 278 0.20
9 (264bp) 230 0.18 278 0.20
10 (268bp) 7 0.005 7 0.005
X2 = 7.232 P= 0.642
5.3.2.1 Allelic expression assay of MOG.
The MOG 14 G>A polymorphism (rs3130250) was selected as a tag marker 
for the assay due to its suitable minor allele frequency (0.17). Of the 60 subjects, 12 
were heterozygous for rs3130250. This subset of 12 individuals provided a power of 
approximately 70% to detect the effect of a regulatory variant present at a frequency 
of 0.05, and a power of 90% to detect a variant at a frequency of 0.1. Of the 12
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heterozygous individuals, only one showed a relative expression difference o f > 20% 
compared to the corresponding average genomic ratios (see Graph 5.2), with the 
cDNA presenting with a corrected ratio o f 1:0.74. This corresponds to a 35% increase 
in expression o f the A allele relative to the G allele. The data points from each 
individual cDNA sample showed excellent reproducibility, with an average SD of the 
mean o f 0.03. Although only one individual showed an expression difference greater 
than the arbitrary 20% threshold described by (Bray, Buckland et al. 2003a), there 
was an interesting trend in the rest o f the data. When cDNA data from all o f the 
individuals was combined, the A allele was significantly over-expressed (p = 0.03, 
99%CI), with an average 8% increase o f the A allele relative to the G allele.
Graph 5.2: MOG Allelic Expression A: rs3130250.
Corrected genomic and cDNA ratios for rs3130250. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for MOG 
(n=12). Data are expressed as the mean o f  the ratio o f A:G for two measurements o f 
each genomic DNA sample and two measurements o f each cDNA sample.
Genomic cDNA
235
Given the significant overall expression difference observed I performed a second 
assay using a different tag SNP to try and replicate the expression findings from the 
first experiment. The MOG 9016 G>C polymorphism (rs2857766) was selected as a 
marker for the assay. O f the 60 subjects for whom brain was available, 18 were 
heterozygous for rs2857766 and informative for analysis. O f the 18 heterozygous 
individuals, none showed a relative expression difference o f > 20% compared to the 
corresponding average genomic ratios (see Graph 5.3). The data points from each 
individual cDNA sample showed good reproducibility, with an average SD o f the 
mean of 0.03. When the cDNA data from all o f the individuals were combined, the C 
allele was significantly over-expressed (p = 0.006, 99%CI), displaying an average 5% 
increase o f the C allele relative to the G allele.
Graph 5.3: MOG Allelic Expression B: rs2857766.
Corrected genomic and cDNA ratios for rs2857766. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for MOG 
(n=18). Data are expressed as the mean o f the ratio o f C:G for two measurements of 
each genomic DNA sample and two measurements o f each cDNA sample.
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Alternative transcripts of MOG exist. However, the rs3130250 tag SNP is a 
synonymous mutation in all of the known transcripts, whilst the rs2857766 tag SNP is 
a non-synonymous mutation in the majority of transcripts and is located in the 3’UTR 
of the remaining transcripts. The two marker SNPs are both therefore conserved in the 
exonic sequence of all known transcripts of MOG and hence the allelic expression 
assays should detect the presence of altered total expression within the different gene 
transcripts. LD analysis of the two allelic expression markers revealed the markers to 
be related (D’ = 1.0, r2 = 0.04). Further analysis revealed the presence of three 
haplotypes; the common G-G and the two rarer A-G and G-C haplotypes. The two 
rare alleles (A-C) are not observed together as they appear to be on different 
haplotype backgrounds. Therefore the expression of both the rare alleles haplotypes is 
independently increased compared to the common haplotype. Or conversely the 
common haplotype is always under expressed compared to the two rare haplotype 
backgrounds. The results of the assays would suggest the existence of one or more 
c/s-acting variants which have a modest effect on the expression of the MOG gene.
The 9016 G>C marker (rs2857766) is a non-synonymous SNP which results 
in a codon change from valine (non-polar) to leucine (non-polar), whilst rs3130250 is 
synonymous. Given the exonic location, possible function of the 9016 G>C SNP and 
because of the interesting expression results I decided to genotype the SNPs 
individually in the schizophrenia association sample. This was achieved by using a 
Sequenom MALDI-TOF genotyping assay for both of the SNPs (as described in 
section 2.10.4). The results of the individual genotyping for rs3130250 and rs2857766 
are shown below in tables 5.12 and 5.13 respectively. There was a significant 
difference between the allelic case and control counts for the non-synonymous
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rs2857766 (table 5.13), caused by an increased frequency of the minor C allele in the 
cases (0.27) compared to the controls (0.24). No significant difference between the 
genotype or allele counts in the cases and controls was detected for rs3130250. In the 
expression assays the minor alleles of both markers displayed a relative increase in 
expression. Therefore the results of the individual genotyping, with an increased 
frequency of the minor alleles in schizophrenic cases are consistent with increased 
MOG expression in schizophrenia. However, the results of previous micro-array 
studies (Tkachev, Mimmack et al. 2003; Katsel, Davis et al. 2005b) have actually 
reported a reduced expression of MOG in schizophrenia, a finding which is 
contradictory to these results. This reported down-regulation must therefore result 
from trans-acting factors and is not likely to be aetiological. Though, the non- 
synonymous SNP might be of aetiological importance if it affects a trans-acting factor 
to influence expression and may still account for the reduced expression.
Table 5.12: Individual genotyping results for rs3130250.
Genotype and allele counts and frequencies for MOG SNP rs3130250 in the 
schizophrenia association sample. Both genotypic and allelic p-values are shown.
SNP Genotypes Alleles
14 G>A GIG G/A A/A G A
Cases 430 153 20 1013 (0.84) 193 (0.16)
Controls 492 171 15 1155 (0.85) 201 (0.15)
X2 = 1.498 P = 0.473 X2 = 0.683 P = 0.408
Table 5,13: Individual genotyping results for rs2857766.
Genotype and allele counts and frequencies for MOG SNP rs2857766 in the 
schizophrenia association sample. Both genotypic and allelic p-values are shown.
SNP Genotypes Alleles
9016 G>C G/G G/C C/C G C
Cases 302 225 43 829 (0.73) 311 (0.27)
Controls 368 230 34 966 (0.76) 298 (0.24)
X2 = 4.422 P = 0.110 X2 = 4.349 P = 0.037
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Haplotype analysis was performed on all o f  the individually genotyped markers 
including the VNTR polymorphism. None o f  the global haplotype p-values for the 
two or three marker haplotypes revealed any evidence o f  association and there were 
no individual haplotypes that displayed a significant difference between the cases and 
controls (data not shown).
5.3.3 SOX 10:
Determination o f the SOX 10 intron/exon boundaries was based on the 
alignment o f the cDNA sequence NM  006941 with genomic sequence available from 
the UCSC Genome Bioinformatics website (http://genom e.ucsc.edu).
Mutation detection assays revealed three SNPs; two coding synonymous SNPs 
D6D (17 O T )  and H309H (rsl39884), and one 3 ’-UTR SNP (rsl39883) (figure 5.3) 
(See appendix 5.3 for sequencing results).
Figure 5.3. Schematic diagram of SOX 10.
Diagram of the SOX 10 gene (adapted from the UCSC Genome Browser), indicating 
the positions o f the identified polymorphisms. For numbering o f  polymorphisms, +1 
indicates the ‘A ’ o f  the ATG translation codon. The gene is displayed (3’-5’).
chr22 <ql3.1) W 4 k 1 ^ M ^ ^ - ^ ^ T T T 2 i  ■  w  b m m  j s .  i iw w q i 3 . 3 l i  I
”7 CMT22: 36760000! 367050661
GENOTYPED SNPS
r s 139383 |
r s 139884 |
  RefSeq Genes
_______SOXl 6 — — p i  ------------— ..............a    
All three o f the SNPs were genotyped in the pooled association sample (table 
5.15). The extension primers used for pooled genotyping are listed in table 5.14. No 
significant differences were observed between the allele frequencies o f  the cases and 
controls.
367100601
17_C>T|
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Table 5.14: Polymorphism and primer extension reaction details for SOX 10.
Table of the polymorphisms identified in the SOX 10 gene, including the sequence flanking each of the polymorphisms, the extension primer 
used to assay the polymorphism by SNaPshot and the expected alleles in the primer extension reaction.
SNP number. rs Number SNP Flanking sequence Extension primer Expected Alleles
17 O T  
9815 O T  
10764 G>A
N/A 
rs139884 
rs139883
GGAGGAGCAGGA[C/T]CTATCGGAGGTG 
GC ACCC AGGCC A[C/T]GT G AGC AGCT AC 
GAG ACT GT GCCC[G/A]G AGCT GGCCGTG
CT CAGCT CCACCT CCGATAG 
GCCCAAT GGGCACCCAGGCCA 
GCCACCCAGAGACTGTGCCC
G (Blue) & A (Green) 
C (Black) & T (Red) 
G (Blue) & A (Green)
Table 5.15: Pooled genotyping data for Sox 10.
Estimated allele frequencies and counts for the SOX 10 polymorphisms, along with the corresponding p-values.
SNP Data Pooled Genotyping data
SNP number. rs Numbers Alleles Cases (freq)
Alleles Controls 
(freq) Difference Chi-square P-value
17 C>T N/A C= 680 (0.92) T= 56 (0.08)
C= 686 (0.93) 
T= 50 (0.07) 0.01 0.37 0.55
9815 C>T rs139884 C= 462 (0.63) T= 274 (0.37)
C= 462 (0.63) 
T= 274 (0.37) 0 0 1
10764 G>A rs139883 A= 458 (0.62) G= 278 (0.38)
A= 467 (0.63) 
G= 269 (0.37) 0.1 0.24 0.63
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5.3.3.1 Allelic expression assay of SOX 10.
The G>A marker rs l39884 was selected for analysis given its informative 
minor allele frequency of 0.37. Of the 60 subjects for whom brain was available, 24 
individuals were heterozygous for SNP rs l39884. This subset of 24 individuals 
provided a power of approximately 91% to detect the effect of a regulatory variant 
present at a frequency of 0.05, and a power of 99% to detect a variant at a frequency 
of 0.1. Of the 24 SOX 10 heterozygous individuals, none showed a relative expression 
difference of > 20% compared to the corresponding average genomic ratios (see 
Graph 5.4), the cDNA ratios varied from 1:1.1 to 1:0.87. The data points from each 
individual cDNA sample showed good reproducibility, with an average SD of the 
mean of 0.025. The assay therefore provides no evidence for the presence of a ex­
acting variant affecting the allelic expression of the Sox 10 gene, and suggests that the 
down-regulation observed in micro-array studies are caused by the effects of 
environmental or other trans-acting factors acting upon the gene. This is inconsistent 
with the reports of increased methylation reducing the genes expression (Iwamoto et 
al, 2005b). However, it is also possible that the results of the micro-array studies were 
influenced by confounding factors such as methodological artefacts, experimental 
variation and sample differences (Katsel, Davis et al. 2005c). Although it is of note 
that the down regulation of SOX 10 has been reported in independent studies 
(Tkachev, Mimmack et al. 2003; Iwamoto, Bundo et al. 2005b; Katsel, Davis et al. 
2005b) providing support for the observed expression differences as a genuine 
finding.
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Graph 5.4: SOX 10 Allelic Expression: rs!39884.
Corrected genomic and cDNA ratios for rsl 39884. Comparison between the observed 
corrected genomic ratios and the corrected cDNA ratios assayed for SOX 10 (n=24). 
Data are expressed as the mean of the ratio o f G:A for two measurements o f each 
genomic DNA sample and two measurements o f each cDNA sample.
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5.4 Discussion:
In this chapter I report analysis o f three genes (GFAP, MOG and SOX 10) 
relevant to myelin function for which there is altered expression data, and are all 
located within reported linkage regions. By testing candidate genes located within 
regions of linkage the prior probability o f detecting a risk variant is enhanced, 
especially if the candidates are also selected to have a functional relevance to 
schizophrenia. In this chapter a direct genetic analysis approach was taken to screen 
the genes exonic and flanking intronic sequence, whilst an indirect approach was used 
to screen the genes for any ds-acting variants within regulatory elements.
A total of forty two polymorphisms were detected. Of these, thirty seven were 
successfully genotyped in the pools, the minor allele frequency of two polymorphisms 
were too rare to allow reliable allele frequency estimates by pooled genotyping and 
three were not compatible with genotyping by using a primer extension assay. Of the 
thirty seven polymorphisms successfully typed in the pools only two GFAP markers 
showed significant differences between the case and control pools, p=<0.05 in each 
case: GFAP 140 G>A and GFAP 1960 G>T. However, when these two SNPs were 
individually genotyped in the association sample, no significant difference was 
observed in the allele frequencies of either SNP between cases and controls (see 
tables 5.7 and 5.8). The detection of a false positive result is not be unexpected as 
with a level of significance of 0.05 you would expect a positive finding to occur by 
statistical chance once in every twenty polymorphisms genotyped. Though if the 
findings were attributable to chance then the results would also be expected to 
replicate when the identical samples were genotyped individually. However, in this 
case the pooled and individual genotyping were performed in slightly different sized 
samples, as at the time of study only 535 cases and 552 controls of the association
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samples were available in a pooled format, thus the observed differences in allele 
frequency might be attributable to the slightly different sizes of the genotyped 
samples. It is also possible that the positive findings were caused by technical error in 
the SNaPshot pooled genotyping. This technical error is likely to have been inflated in 
this case as both polymorphisms had low minor allele frequencies making accurate 
allele frequency estimation by pooled genotyping more difficult.
As well as screening the three genes for genetic association to schizophrenia I 
have also assayed the genes to look for the presence of cis-acting sequence variants 
which affect the expression of the genes. In the case of the SOX 10 gene there was no 
evidence for a genetic variant affecting expression significantly, whilst there was 
evidence for modest altered allelic expression of the GFAP gene caused by a rare ex­
acting variant. The results of my SOX 10 allelic expression assay does not support the 
findings of previous studies (Tkachev, Mimmack et al. 2003; Iwamoto, Bundo et al. 
2005b; Katsel, Davis et al. 2005b) which reported a marked two-fold down regulation 
of the gene in schizophrenia. The failure to detect any common cX-acting variants 
affecting SOX 10 expression can not be explained by a relative lack of power, as the 
subset of 24 individuals used to perform the assay provided a power of approximately 
91% to detect the effect of a regulatory variant present at a frequency of 0.05, and a 
power of 99% to detect a variant at a frequency of 0.1. The observed expression 
differences in the micro-array studies may reflect the effects of trans-acting factors. 
However the findings of Iwamoto and colleagues (Iwamoto, Bundo et al. 2005b) who 
reported a higher frequency of methylated SOX 10 alleles correlated with the genes 
reduced expression might provide support for the existence of cX-acting effects. It is 
also of note that none of the brain samples used in my allelic expression assay were 
from schizophrenic patients. Thus if the altered expression of SOX 10 is caused by an
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epigenetic process highly specific to schizophrenic brain, the failure to detect any 
significant allelic expression differences in my assay would not be unexpected.
The results of the MOG allelic expression assay were potentially more 
interesting. Whilst there was no large expression differences observed between 
haplotypes there was a relative increase in expression of the minor alleles observed 
for two independent assays, although the two markers were related (D’=1.0, r2=0.04). 
This on its own is not particularly interesting, but when the two marker SNPs were 
subsequently genotyped individually in the case-control sample the minor allele 
frequency of the non-synonymous marker rs2857766 was increased in schizophrenics 
compared to controls, with the C allele being significantly associated (uncorrected) 
with schizophrenia (p=0.03) (table 5.13). Haplotype analysis of individually typed 
markers revealed no stronger association with schizophrenia at global haplotype or 
specific haplotype level. That the expression assays displayed a relative increase of 
the minor alleles expression, when taken with the results of the individual genotyping 
which displayed an increased frequency of the minor alleles in schizophrenia, would 
support a theory of MOG expression being increased in schizophrenia.
However, it should be noted that my results indicating a possible increase in 
expression of the MOG gene in schizophrenia contradict with the results of the 
previous micro-array studies (Tkachev, Mimmack et al. 2003; Katsel, Davis et al. 
2005b), which report down-regulation of the gene in schizophrenic brain. My data 
suggests that common c/s-acting factors are not individually responsible for the large 
2-3 fold expression differences observed in these studies and that the micro-array 
findings are likely to be attributable to trans-acting factors or environmental effects 
such as medication usage.
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The results of my association and allelic expression analysis of the MOG gene 
along with the results of the previous studies by (Liu, Qin et al. 2005; Zai, King et al. 
2005) are not compelling and provide little evidence for the involvement of MOG in 
the aetiology of schizophrenia. However, further examination of the non-synonymous 
SNP is probably warranted to independently replicate the results.
With regard to the successfully typed polymorphisms in GFAP and Sox 10,1 
conclude that there is no evidence of association with schizophrenia. However, as I 
discussed earlier (chapter 4, section 4.4) I cannot completely exclude these genes 
from being involved in susceptibility to schizophrenia.
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5.5  A p p en d ix:
E x am p les o f  ex p er im en ta l d ata  fo r  ch a p ter  5,
Appendix 5.1.
Example o f DHPLC chromatographs produced when GFAP am plim er 4 was analysed 
at 65°C, for screening set samples 1, 2, 3 and 5. The chrom atograph shows the peaks 
representing these samples PCR products, with changes in the peak shape indicating 
the presence o f a heteroduplex.
Shoulder on this peak indicates 
the presence of a heteroduplex 
in this PCR product
3 . 5 4 . 5 5 . 0 5 . 5 6 . 0 6 . 51 . 5 2 . 0 2 . 5 3 . 0 4 . 00 . 0 0 . 5 1.0
Appendix 5.2.
Example o f the DHPLC chromatographs produced when MOG amplimer 6 was 
analysed at 62°C, for screening set samples 11, 12, 13 and 14. The chromatograph 
shows the peaks representing these samples PCR products, w ith changes in the peak 
shape indicating the presence o f  a heteroduplex.
The double peaks for these samples 
indicate the presence of a 
heteroduplex in these PCR products
s.s4.S 5.0S.S2 . 00.0 O.S 1.0
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Appendix 5.3:
Examples o f the different sequencing electrophorograms produced for each o f  the 
polymorphisms that were detected as a result o f  screening the three m yelination genes 
in this project. (Polymorphisms are indicated with an arrow).
Sequence electrophorograms for the GFAP 
1001 T>C polymorphism, showing a T-T 
homozygote in the top panel, a T-C 
heterozygote in the middle panel and a C-C 
homozygote in the lower panel.
10 F
T T T T T T T T T T T
T T T T T T T T T
AAAAAAAAAM
11 F
T T T T T N T T T T T
T T T T T N
/V W V \j
i T T
w vAAA
12  F
T T T T T A  T T T T T
T T T T T f l T  T
M A A / ^ M
Sequence electrophorograms for the GFAP 
518 T>A polymorphism, showing a T-T 
homozygote in the top panel, a T-A 
heterozygote in the middle panel and a A-A 
homozygote in the lower panel.
Sequence electrophorograms for the GFAP 41 
O T  polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
12 R
Sequence electrophorograms for the GFAP 
140 G>A polymorphism, showing a C-C 
homozygote in the top panel and a C-T 
heterozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
Sequence electrophorograms for the GFAP 
602 C>T polymorphism, showing a C-C 
homozygote in the top panel and a C-T 
heterozygote in the lower panel.
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Sequence electrophorograms for the GFAP 
657 Del-C polymorphism, showing a G-G 
homozygote in the top panel and a Del-G 
heterozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
Sequence electrophorograms for the GFAP 
1960 G>T polymorphism, showing a G-G 
homozygote in the top panel and a G-T 
heterozygote in the lower panel.
13 F
Sequence electrophorograms for the GFAP 
2044 O T  polymorphism, showing a C-C 
homozygote in the top panel and a C-T 
heterozygote in the lower panel.
Sequence electrophorograms for the GFAP 
3895 A>G polymorphism, showing a T-T 
homozygote in the top panel and a T-C 
heterozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
Sequence electrophorograms for the GFAP 
4677 C>T polymorphism, showing a C-C 
homozygote in the top panel and a C-T 
heterozygote in the lower panel.
Sequence electrophorograms for the GFAP 
4762 C>G polymorphism, showing a G-G 
homozygote in the top panel and a G-C 
heterozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
249
ITT
Sequence electrophorograms for the GFAP 
8012 O T  polymorphism, showing a C-C 
homozygote in the top panel and a C-T 
heterozygote in the lower panel.
12 F
Sequence electrophorograms for the GFAP 
8155 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
13 F
Sequence electrophorograms for the GFAP 
8167 C>G polymorphism, showing a C-C 
homozygote in the top panel and a C-G 
heterozygote in the lower panel.
3 F
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Sequence electrophorograms for the GFAP 
8477 C>T polymorphism, showing a C-C 
homozygote in the top panel and a C-T 
heterozygote in the lower panel.
Sequence electrophorograms for the GFAP 
8769 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
12 F
Sequence electrophorograms for the GFAP 
8953 T>A polymorphism, showing a T-A 
heterozygote in the top panel and a T-T 
homozygote in the lower panel.
250
17?
Sequence electrophorograms for the GFAP 
9140 G>A polymorphism, showing a G-G 
homozygote in the top panel and a G-A 
heterozygote in the lower panel.
13 F
Sequence electrophorograms for the GFAP 
9661 T>C polymorphism, showing a T-T 
homozygote in the top panel and a T-C 
heterozygote in the lower panel.
13 F
14 F
Sequence electrophorograms for the GFAP 
9759 C>T polymorphism, showing a C-C 
homozygote in the top panel and a C-T 
heterozygote in the lower panel.
12 F
Sequence electrophorograms for the GFAP 
9768 C>T polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
Sequence electrophorograms for the GFAP 
9834 T>C polymorphism, showing a A-G 
heterozygote in the top panel and a A-A 
homozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
13 R
14 R
Sequence electrophorograms for the GFAP 
10125 C>T polymorphism, showing a G-G 
homozygote in the top panel, a G-A 
heterozygote in the middle panel and a A-A 
homozygote in the lower panel. The sequence 
is taken from the anti-sense strand.
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MOG 2 7F
)G 2 13F
Sequence electrophorograms for the MOG - 
1909 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
MOG 4 14F
Sequence electrophorograms for the MOG - 
909 T>C polymorphism, showing a T-C 
heterozygote in the top panel and a T-T 
homozygote in the lower panel.
TTWTWi
MOG 4 3F
Sequence electrophorograms for the MOG - 
875 A>C polymorphism, showing a A-C 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
6 12F
Sequence electrophorograms for the MOG 14 
G>A polymorphism, showing a G-G 
homozygote in the top panel and a G-A 
heterozygote in the lower panel.
MOG 9 4F
Sequence electrophorograms for the MOG 
9016 G>C polymorphism, showing a G-C 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
10 14F
Sequence electrophorograms for the MOG 
10423 T>G polymorphism, showing a T-G 
heterozygote in the top panel and a T-T 
homozygote in the lower panel.
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MOG 10 6F
Sequence electrophorograms for the MOG 
10521 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a G-G 
homozygote in the lower panel.
MOG 12 1F
MOG 12 10F
Sequence electrophorograms for the MOG 
13447 G>A polymorphism, showing a A-A 
homozygote in the top panel, a G-A 
heterozygote in the middle panel and a G-G 
homozygote in the lower panel.
MOG15 9F
MOG15 6F
Sequence electrophorograms for the MOG 
14789 C>T polymorphism, showing a C-C 
homozygote in the top panel, a C-T 
heterozygote in the middle panel and a T-T 
homozygote in the lower panel.
12 F
10 F
Sequence electrophorograms for the MOG 
14875 A>G polymorphism, showing a A-A 
homozygote in the top panel, a A-G 
heterozygote in the middle panel and a G-G 
homozygote in the lower panel.
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10F
Sequence electrophorograms for the MOG 
15034 O T  polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
10 F
1 _A01 —TI.AB1
Sequence electrophorograms for the SOX 10 
9815 C>T polymorphism, showing a C-T 
heterozygote in the top panel and a C-C 
homozygote in the lower panel.
19j C03_T.AB1
; _ t  A B 1
Sequence electrophorograms for the SOX 10 
10764 G>A polymorphism, showing a G-A 
heterozygote in the top panel and a A-A 
homozygote in the lower panel.
Sequence electrophorograms for the MOG 
15052 G>A polymorphism, showing a G-G 
homozygote in the top panel, a G-A 
heterozygote in the middle panel and a A-A 
homozygote in the lower panel.
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Sequence electrophorograms for the MOG 15126 VNTR polymorphism, showing four different length 
sequencing traces for the TAAA varible number tandem repeat.
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Appendix 5.4:
Amplifluor assay design for GFAP 140 G>A and 1960 G>T. 
140 G>A Ampliflour assay:
Allele 1 primer red:
G AAGGT CGGAGT CAACGG ATT|AAT GCCCCCT CCACT CCCG 
Allele 2 primer green:
G AAGGT G ACC AAGTT CAT GCT AAT GCCCCCT CCACT CCCA 
Common Reverse primer:
AT CAT CTCTGCCCGCT CACT
1960 G>T Ampliflour assay:
Allele 1 primer red:
GAAGGT CGGAGT C AACGGATTTT CT GCCTGCCCCT CGGCC 
Allele 2 primer green:
GAAGGT GACCAAGTT CAT GCTT CTT CT GCCT GCCCCT CGGCA 
Common Reverse primer:
AGGGAGACGGAAAGAGACAAGA
Appendix 5.5:
Example o f an Amplifluor assay graph produced whilst genotyping the GFAP 1960 
G>T SNP in the schizophrenia association sample.
■o
0)
Homozygote G-G 
samples
Heterozygote G-T 
samples
PCR failures and 
negative controls
$0004 100000 150000 200000 250000 300000 350000 400000 454000
green
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Appendix 5.6:
Example o f the Genescan electrophorogram s produced when genotyping the MOG 
VNTR polymorphism. The numbers below the electrophorogram s correspond to the 
fragment sizes in base pairs. W hen a electrophorogram  has two peaks it represents a 
heterozygote o f  the two peaks corresponding repeat lengths.
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Chapter 6. The APO L gene family and schizophrenia.
6.1 The APO L gene family;
Members of the apolipoprotein L (APO L) gene family are both positional and 
functional candidate genes for schizophrenia. All six members of the APO L gene 
family are located in close proximity on chromosome 22ql2.3, a region that has been 
suggested by linkage studies to contain one or more schizophrenia susceptibility genes 
(see section 4.1.3.2, chapter 4).
Other support for the possible involvement of the APOL gene family comes 
from the gene expression study performed by (Mimmack, Ryan et al. 2002). This 
study used a custom cDNA micro array to examine expression of the APO L gene 
family followed by a replication study using real-time PCR in an independent sample 
of brains. A consistent up-regulation of the APO L 1, 2 and 4 genes was seen in 
schizophrenics compared to controls. The authors demonstrated a 2.6 fold up- 
regulation of APO L 1, a 2.4 fold up-regulation of APO L 2, and a 2.7 fold up- 
regulation of APO L 4 relative to the control samples. Alterations in the expression of 
other apolipoproteins have also been observed in schizophrenia. Thomas and 
colleagues (Thomas, Dean et al. 2001) reported a 1.9-3.9 fold increase in APO D 
expression levels in the dorso lateral prefrontal cortex (DLPFC) of schizophrenic 
patients compared to controls, and also in the prefrontal cortex of bipolar patients. The 
function of APO D is not clear but it has been proposed to play a neuroprotective role, 
to be involved with lipid transport in the CNS during maintenance and tissue repair, 
and also to play a role in the transport of cholesterol in the CNS (Thomas, Dean et al. 
2001). A further study (Dean, Laws et al. 2003) reported a significant increase in the 
levels of APO E protein in the prefrontal cortex of schizophrenic patients compared to
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controls. When taken together these three studies on APO D, E and L which all report 
increased levels of their respective apolipoproteins in the prefrontal cortex of 
schizophrenic patients, would support the hypothesis that apolipoproteins play a role 
in the aetiology of schizophrenia.
APO L proteins belong to the high density lipoproteins. Monajemi and 
colleagues (Monajemi, Fontijn et al. 2002) have shown that the APO L gene family 
has arisen relatively recently in evolution, with APO Ls 1-4 probably arising as a 
result of tandem duplication events. The APO L gene family are thought to be 
involved in the transport of high-density lipoproteins (HDLs) in cell membranes and 
to have an important role in the development and maintenance of cell membrane 
structure and function (Sutcliffe and Thomas 2002; McGhee, Morris et al. 2005). 
Lipoproteins provide cells with lipids vital to normal cell functioning. Lipids are used 
to generate energy, as building blocks for biomembranes and play an important role in 
cell signalling (Danik, Champagne et al. 1999). Most lipoproteins are widely 
expressed in tissues, including the brain (Danik, Champagne et al. 1999).
APO L proteins are functionally associated with apolipoprotein Al (APO Al), 
the main protein component of high density lipoprotein (Sutcliffe and Thomas 2002). 
APO Al plays an important role in cholesterol transport (Dietschy and Turley 2001; 
Sutcliffe and Thomas 2002). Given their association with APO Al, APO L proteins 
are also thought to be of importance in cholesterol transport. The cholesterol content 
of membranes is important in cellular processes such as modifying gene transcription 
and signal transduction both in the adult brain and during neurodevelopment 
(Mimmack, Ryan et al. 2002). The nervous system is thought to contain almost a 
quarter of the total body content of unesterified cholesterol. These cholesterols are
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largely located in two pools, the membranes of glial cells and neurons and secondly in 
myelin sheaths (Dietschy and Turley 2001). Brain cholesterol is thought to be almost 
exclusively synthesized in situ in the brain (Dietschy and Turley 2001). It has been 
proposed that any changes in the cholesterol content of the CNS may affect the 
integrity of neurons and myelin (Dietschy and Turley 2001).
It is thought that myelin is assembled by vesicular trafficking of membranes 
that contain myelin specific proteins, glycolipids and cholesterol. It has been 
suggested that myelin membranes result from the accumulation of ‘myelin-specific 
rafts’ in which cholesterol is closely related with myelin specific membrane proteins 
(Saher, Brugger et al. 2005). A myelin sheath is essentially a spiral extension of the 
oligodendrocytes plasma membrane and appears in cross-section as a compact, 
multilayered stack of membranes. In addition to the myelin specific membrane 
proteins, myelin contains a very high content of lipids (about 70% of its dry weight). 
Of this lipid content, around 25% is cholesterol, a figure which is higher than the 20% 
content level that is seen in normal plasma membranes (Saher, Brugger et al. 2005). In 
a recent study, Saher and colleagues (Saher, Brugger et al. 2005) reported that 
cholesterol plays an essential function in central nervous system (CNS) myelination. 
They reported that mutant mice lacking the ability to synthesize cholesterol in 
oligodendrocytes had severely defective myelin synthesis. However the mutant mice 
survived as mutant oligodendrocytes were able to use cholesterol from neighbouring 
wild-type cells of other types. The authors showed that myelin cannot be synthesized 
without cholesterol, not even at the slightly reduced levels of cholesterol content 
found in normal plasma membranes. They therefore concluded that cholesterol
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availability is a critical prerequisite and an essential rate limiting factor o f myelin 
membrane growth during brain maturation.
Given the location o f the APOL gene family on chromosome 22ql2.3, the 
evidence pointing to the altered expression o f the genes in schizophrenia and the 
possible involvement o f the gene family in cholesterol transport, a vital component o f 
successful myelination and brain development, I decided to study the gene family.
Figure 6.1: Genomic organisation of the APO L gene family.
Schematic diagram showing the genomic organisation o f  the APOL gene family on 
chromosome 22ql2.3 the genes position relative to the VCFS region and the direction 
o f transcription (indicated by the arrows).
55kb 411kb 23kb 21 kb 13kb
~15Mb
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6.1.2 Strategy for this study;
A different approach has been applied in the study o f the APOL genes than 
has been employed in the rest o f this project. Like the other genes studied the APO Ls 
have been proposed as candidates essentially on the basis o f their altered expression in 
tissues originating from schizophrenic patients compared to controls and their location 
in a region o f the genome previously implicated in schizophrenia. Thus the first step 
was to look for evidence o f polymorphic c/s-acting influences on the genes 
expression. This was to determine whether the expression differences previously seen 
in micro-array studies were potentially attributable to common genetic variation or 
were caused by other environmental or trans-acting factors. Where these initial
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studies demonstrated that expression of the genes was influenced by c/s-acting 
sequence variation, genetic studies were performed to test the genes for association 
with schizophrenia. Unlike the other genes studied as part of this thesis the APO Ls 
were tested for association by genotyping the case control pools through a 5kb grid of 
marker SNP’s spanning the gene. This indirect marker grid approach was used rather 
than the direct method employed for other genes in this thesis as the genetic variation 
causing expression differences is likely to be located outside exonic sequence. By 
using a grid approach the aim was to detect association to the true susceptibility 
variants by virtue of linkage disequilibrium (LD) between these and the marker SNPs.
6.2 M ethods;
A detailed description of the methodologies and samples used can be found in 
Chapter 2. The PCR primers used to generate amplimers, along with the extension 
primers used to perform primer extension reactions for the allelic expression and 
association analysis of each gene, are listed below in tables 6.1, 6.2, 6.3, 6.4 and 6.5 
respectively.
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Table 6.1: PCR and primer details for the APOL 1 assays:
This table shows the rs numbers o f the SNPs used in the APOL 1 assays, the forward and reverse PCR primers used to amplify the sequence
around these polymorphisms, the size of the PCR fragment and the PCR conditions used. It also shows the sequence flanking each of the SNPs,
the extension primers used in the SNaPshot reaction and the expected alleles in the reaction.
Fragment
Name rs number
Forward PCR Primer 
(5* to 3')
Reverse PCR Primer 
(5' to 3')
Size
bp
Annealing
Temp
SNP Flanking 
sequence Extension primer (5’ to 3’)
Expected
Alleles
Apol 1_A rs2227089 tgtgttccaaaattgtacgaga tccgatggcacaatctgtag 230bp HS 60 ctttac[A/T]tctcaa tttgttatctgcaaaaagtgtttactttac A (Green) & T (Red)
Apol 1_B rs136150 ccccatgttgtcttgaggat gaggcagtcatccctggtaa 215bp HS 60 ggctggt[A/T]cccatc acaggggaccagtagaggggatggg T (Red) & A (Green)
Apol 1_C rs136154 aagggagaatgcagagacca ccggccacctcattcttaat 194bp HS 60 ttcttc[A/T]tctgtg ctctcgctgtctggattttactttcttc A (Green) & T (Red)
Apol 1_D rs713753 aaggccttagaggcaactcc tcccactcacatgtcctctg 243bp HS 60 aaccaa[C/T]accaag cctttgggcaggatcttggt G (Blue) & A (Green)
Apol 1_Exp rs2239785 aggcagatgagctccgtaaa tgagagagccagacaccaca 231 bp HS 60 gaaaagt[A/G]agcttg agccttcttatgttatcctcaagct T (Red) & C (Black)
Apol 1 _E rs2012928 cagctctccccatcttgtgt aggtctcagggaaatgacca 220bp HS 60 caatca[A/G]cactga gtcctggagacttgggtccaatca A (Green) & G (Blue)
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Table 6.2: PCR and primer details for the APOL 2 assays:
This table shows the rs numbers of the SNPs used in the APOL 2 assays, the forward and reverse PCR primers used to amplify the sequence
around these polymorphisms, the size o f the PCR fragment and the PCR conditions used. It also shows the sequence flanking each of the SNPs,
the extension primers used in the SNaPshot reaction and the expected alleles in the reaction.
Fragment
Name rs number
Forward PCR Primer 
(5' to 3')
Reverse PCR Primer 
(5‘ to 3')
Size
bp
Annealing
Temp
SNP Flanking 
sequence Extension primer (5’ to 3’)
Expected
Alleles
Apol 2_A rs1974458 ctgccactgctttcctgtct cggaggacgtgtctggttat 245bp HS 60 attgca[A/G]gaataa gtgatctacccccatgtccttattc T (Red) & C (Black)
Apol 2_B rs1557533 ggggaaacagaccaagatga tggaggatttccgtgacttt 249bp HS 60 ttttct[A/G]gaaact gtttatttgatcatcaccttttagtttc T (Red) & C (Black)
Apol 2_C rs2157249 agaactcacgcactgcctct tgaactcctcccctctctga 225bp HS 60 tcagaga[C/T]gccaag aatgagggcaacaggagatcagaga C (Black) & T (Red)
Apol 2_D rs2003813 ctgcaggtcaacctcctctc ctgcatcctgacctctcctc 187bp HS 60 ctgggc[C/T]gtgtca tcctgacctctcctcggggtgacac G (Blue) & A (Green)
Apol 2_E rs5995263 gctccatgcgatctctatcc gtgttgacctgcccttgagt 234bp HS 60 atggaa[A/T]taatta caatcaaatagaaacaaattttacaaatggaa A (Green) & T (Red)
Apol 2_Exp rs2017689 actggagagtgtggggaatg tacacccccagaaggacaag 295bp HS 60 ggggtc[A/G]gtagtg gagaagaaacagcagctccactac T (Red) & C (Black)
Apol 2_F rs2016988 agttcctgggtggatcactg tcagccctcatggtcttttc 238bp HS 60 agtttg[C/G]aaaaac aaagcagacatctacctctagtttg C (Black) & G (Blue)
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Table 6.3: PCR and primer details for the APOL 3 assays:
This table shows the rs numbers o f the SNPs used in the APOL 3 assays, the forward and reverse PCR primers used to amplify the sequence
around these polymorphisms, the size o f the PCR fragment and the PCR conditions used. It also shows the sequence flanking each of the SNPs,
the extension primers used in the SNaPshot reaction and the expected alleles in the reaction.
Fragment
Name rs number
Forward Primer 
(5' to 3')
Reverse Primer 
(5' to 3')
Size
bp
Annealing
Temp
SNP Flanking 
sequence Extension primer (5’ to 3’)
Expected
Alleles
Apol 3_A rs132673 tggatgaagctgatccctta tgctcctgctcatactggaa 141bp HS 60 tttact[A/G]ggaggc tagttggtgtgagtgggaagcctcc T (Red) & C (Black)
Apol 3_B rs132661 gcagaaatcattccgctctc ctgcactgggatggattctt 183bp HS 60 gagagt[A/G]tattac gcaaagtgtattgaagcacagtaata T (Red) & C (Black)
Apol 3_C rs132656 ctggaaaagtcacgctcctc ccctgaccccttcttcctaa 230bp HS 60 gggggg[c/T]ggatgt gtctttgtcttttactcccacatcc G (Blue) & A (Green)
Apol 3_D rs2097465 gtcctccttaggcgttgttg ggagctgctttgctgagagt 255bp HS 60 gtcctc[C/T]ctgggc ttgaccaaactgcaggcttgcccag G (Blue) & A (Green)
Apol 3__E rs2017329 caggaggtggagtttgtggt tcccttcccaattaaaagca 138bp HS 50 DMSO agaaaa[A/T]aaaaaa gctaattttgatgttcagattttccttttttt
A (Green) 
& T (Red)
Apol 3_F rs132644 ggctcccattttgaaacaga cacttgggcatagagtgcaa 216bp HS 52 DMSO tgctta[C/T]tgtaaa aaaatattgactcatgcatacatgctta
C (Black) & 
T (Red)
Apol 3_G rs132635 cagcctgtggcgttttacta ccactgatgggtcgaaactc 238bp HS 60 accatg[C/T]tttctc tggaatatttcccgtacatggggagaaa G (Blue) & A (Green)
Apol 3_H rs80578 tctctttggttggggacttg gtgagaagagggaggcactg 321 bp HS 60 tcagaa[C/T]gcccca gtcccaaatggcagttcagaa C (Black) & T (Red)
Apol 3_Exp rs132618 ttacgaagccacacaaacca cacatccagtgcaaggaaga 211bp HS 60 ttgacc[A/T]ccactt cgaatctcagctggaagtgg T (Red) & A (Green)
Apol 3_J rs13261-7 gccctcctcctgtgacataa ccaaacagccacctgaattt 219bp HS 60 agcaag[C/T]gattga agaagaagagtgtgtgtgcagtagcaag C (Black) & T (Red)
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Table 6.4: PCR and primer details for the APOL 4 assays:
This table shows the rs numbers of the SNPs used in the APOL 4 assays, the forward and reverse PCR primers used to amplify the sequence
around these polymorphisms, the size o f the PCR fragment and the PCR conditions used. It also shows the sequence flanking each of the SNPs,
the extension primers used in the SNaPshot reaction and the expected alleles in the reaction.
Fragment
Name rs number
Forward PCR Primer 
(5* to 3’)
Reverse PCR Primer 
(5’ to 3’)
Size
bp
Annealing
Temp
SNP Flanking 
sequence Extension primer (5’ to 3’)
Expected
Alleles
Apol 4_A rs132743 ggttcaaatggggtgaaatg ggacttgggcaacacattct 237bp HS 62 gaaaat[C/Gltaattt agggagaaagtgaggaagaaaatta G (Blue) & C (Black)
Apol 4_B rs2005590 caggcctgctcttgttgaag tctagtccctccaccctgtg 224bp HS 62 gctcat[C/Tlgttcag caccacctggaaaaatcatgctcat C (Black) & T (Red)
Apol 4_C rs1812023 ggagggagcaatcagactca accagctggatcttgctcag 226bp HS 62 gcctgg[A/G]tgcaaa agtggtagagccgggatttgca T (Red) & C (Black
Apol 4_D rs132734 ccatcctccttggtcattgt ggagccatgtgggtttttct 182bp HS 62 gacaca[A/G]tgcgtc gactgttagcctcaactaggacaca A (Green) & G (Blue)
Apol 4_E rs6000179 acaaggctaaggtccggtct ccaaactggaggaggttttg 215bp HS 62 tttatc[A/C]ctggaa aattaggacattatttgattagttccag T (Red) & G (Blue)
Apol 4_F rs2007468 gaggttacctgggcaattca ggaggattaacaccgaacca 226bp HS 62 acgcac[A/G]aatctc gcgatgaagcctggaagagatt T (Red) & C (Black
Apol 4_Exp rs132700 gaaaggcttcgtgtcattgc caattggtcagtgctggttg 279bp HS 60 ccaaca[C/T]aacgcc gcatcctgtctgtcattggcgtt G (Blue) & A (Green)
Apol 4_G rs2227167 ggttccgggctacttttctc actgaccaattggaggcatt 243bp HS 62 tgcaaa[A/G]gaaagc tggcttcgtcaaaatcaagtgcaaa A (Green) & G (Blue)
Apol 4_H rs916336 ttggaagcttttgcaggagt caggattgacatgggtcaca 185bp HS 62 ctgtct[C/G]tctctg tccatgagacatagagggacagaga G (Blue) & C (Black)
Apol 4_J rs1966267 acagaccatgagggctgaat aggtgtgctccactgctctt 165bp HS 62 ctcaac[A/G]tctctc ggaaagcacagcagaatttgagaga T (Red) & C (Black
Apol 4_K rs132691 ggagcacctgctgtcatctt ggcgaggacgaaatttatca 203bp HS 62 cgctgg[C/G]acctga gtggaaaggggcaaggaacgctgg C (Black) & G (Blue)
Apol 4_L rs132683 ttatcaggcccatacccaaa ttggccttttatggggatta 188bp HS 62 tatgct[A/G]gtttat tgattagtacaggaagggtataaac T (Red) & C (Black
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Table 6.5: PCR primer details for APOL 5 assays:
This table shows the rs numbers of the SNPs used in the APOL 5 assays, the forward and reverse PCR primers used to amplify the sequence
around these polymorphisms, the size o f the PCR fragment and the PCR conditions used. It also shows the sequence flanking each of the SNPs,
the extension primers used in the SNaPshot reaction and the expected alleles in the reaction.
Fragment
Name rs number
Forward PCR Primer 
(5* to 3')
Reverse PCR Primer 
(5* to 3') Size bp
Annealing
Temp
SNP Flanking 
sequence Extension primer (5’ to 3’)
Expected
Alleles
Apol 5_A rs1540297 atgggtccagttttgtggtc caagccagaagggtaaaacg 197bp HS 62 tgtggt[C/T]gagaat cactgttatctggttgtgtggt C (Black) & T (Red)
Apol 5_B rs5999971 tgcaggagaactaggggtga agtccctgctgaatgacacc 238bp HS 62 aagaag[C/T]tgcaat ttcagacactctctctcacattgca G (Blue) & A (Green)
Apol 5_C rs2009168 ttgctggttttctcccaatc ggcagcagagtttgttgtga 196bp HS 62 gctgca[A/G]caatag ctctcccacagagctcagctgca A (Green) & G (Blue)
Apol 5_D rs2076671 atccaactctggcttcatgg tgctctcagttcctctgctg 246bp HS 62 tctgga[C/T]ggctag ctctctgcacccctctagcc G (Blue) & A (Green)
Apol 5_Exp rs2076672 tggggctggcttcttactta cacacgggatcctcgaac 226bp HS 60 caagga[C/T]ggagac cctggaggatggggcaagga C (Black) & T (Red)
Apol 5_E rs2016586 catgccagacctagcagtga gttcagtggtgacagggtga 197bp HS 62 gaaaag[G/T]actagg tcattcttcactttgcacacctagt C (Black) & A (Green)
Apol 5_F rs5995165 gttggaaacaaccctctgga ctttccctcacaccacaggt 150bp HS 62 gagggg[A/G]tggtga ccacactggttcaggtcacca T (Red) & C (Black)
Apol 5_G rs879680 gaaaggcctgtgcaacctaa aaggaggcaagtgtgcaaag 226bp HS 62 aattgc[C/T]gtctgt aaattggtttcccggctcacagac G (Blue) & A (Green)
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6.3 Results:
6.3.1 Allelic Expression assays:
Of the six genes in the APOL gene family, only APOL 1-5 contained a 
suitable database polymorphism at the time of this study for use as a tag SNP in the 
allelic expression assay. The known polymorphisms in APOL 6 were either not in the 
exonic sequence or did not have an informative minor allele frequency. Therefore the 
gene was not screened for altered allelic expression.
APOL 1:
The G>A polymorphism rs2239785 was selected for analysis. Of the 60 
subjects for whom brain was available, 11 were heterozygous. The 11 heterozygotes 
yield a power of approximately 67% to detect the effect of a regulatory variant present 
at a frequency of 0.05, and a power of 89% to detect a variant at a frequency of 0.1.
Of the 11 heterozygous individuals, six showed a relative expression difference of > 
20% (see Graph 6.1). The data points from each individual cDNA sample showed 
moderate reproducibility, with an average SD of the mean of 0.13. The cDNA allelic 
expression ratio has departed from the genomic 1:1 ratio in both directions with the 
expression difference ranging from a 68% increase of the A allele relative to the G 
allele to an 88% decrease of the A allele relative to the G allele. That the expression 
differences go in both directions on the graph might reflect the effect of a cw-acting 
variant that is only in low LD with the tag SNP that was used or that there is more 
than one variant affecting the genes expression.
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Graph 6.1: Apol 1 Allelic Expression, rs2239785.
Corrected genomic and cDNA ratios for rs2239785. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for APOL 1 
(n=l 1). Data are expressed as the mean of the ratio of G:A for two measurements for 
each genomic DNA sample and four measurements of each cDNA sample.
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APOL 2:
The A>G polymorphism rs2017689 was selected for analysis. The 16 
heterozygotes for this marker yields a power of approximately 80% to detect the 
effect of a regulatory variant present at a frequency of 0.05, and a power of 96% to 
detect a variant at a frequency of 0.1. Of the 16 heterozygous individuals, nine 
showed a relative expression difference of > 20% compared to the corresponding 
average genomic ratios (see Graph 6.2). The data points from each individual cDNA 
sample showed good reproducibility, with an average SD of the mean of 0.08. The 
allelic expression ratio has departed from the genomic 1:1 ratio in both directions with 
the expression difference ranging from a 62% increase of the A allele relative to the G 
allele to a 56% decrease of the A allele relative to the G allele.
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Graph 6.2: Apol 2 Allelic Expression, rs2017689.
Corrected genomic and cDNA ratios for rs2017689. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for APOL 2 
(n=16). Data are expressed as the mean o f the ratio o f G:A for two measurements for 
each genomic DNA sample and four measurements of each cDNA sample.
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APOL 3:
The T>A polymorphism rsl32618 was selected for analysis. O f the 60 
subjects for whom brain was available, 20 were heterozygous. The 20 heterozygotes 
yields a power o f approximately 86% to detect the effect o f a regulatory variant 
present at a frequency of 0.05, and a power o f 98% to detect a variant at a frequency 
of 0.1. O f the 20 heterozygous individuals, two showed a relative expression 
difference o f > 20% compared to the corresponding average genomic ratios (see 
Graph 6.3). The data points from each individual cDNA sample showed reasonable 
reproducibility, with an average SD o f the mean o f 0.11. The cDNA ratio departed 
from the genomic 1:1 ratio in both directions with the expression difference ranging 
from a 21% increase o f the T allele relative to the A allele to a 49% decrease o f the T 
allele relative to the A allele.
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Graph 6.3: Apol 3 Allelic Expression, rs!32618.
Corrected genomic and cDNA ratios for rsl32618. Comparison between the observed 
corrected genomic ratios and the corrected cDNA ratios assayed for APOL 3 (n=20). 
Data are expressed as the mean of the ratio o f A:T for two measurements for each 
genomic DNA sample and four measurements o f each cDNA sample.
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APOL 4:
The C>T polymorphism rs 132700 was selected for analysis. The 24 
heterozygotes for this marker yields a power o f approximately 91% to detect the 
effect o f a regulatory variant present at a frequency of 0.05, and a power o f 99% to 
detect a variant at a frequency o f 0.1. O f the 24 heterozygous individuals, seventeen 
showed a relative expression difference o f > 20% compared to the corresponding 
average genomic ratio (see Graph 6.4 and 6.5). The data points from each individual 
cDNA sample showed poor reproducibility, with an average SD o f the mean o f 0.48. 
Given the observation o f almost mono-allelic expression for some individuals it was 
necessary to remove these samples when plotting the standard allelic expression assay 
graph (graph 6.4) to enable the observation o f the smaller relative expression
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differences present. The samples displaying large expression differences were then 
visualised by plotting all o f the assayed individuals on an allelic expression log scale 
graph (graph 6.5). The cDNA ratio has departed from the genomic 1:1 ratio in both 
directions with evidence o f nearly complete mono-allelic expression observed for 
three individuals, two displaying a corrected cDNA ratio o f 1:14.65 (1368% increase 
o f the C allele relative to the T allele) and another with a ratio o f 1:0.17 (488% 
decrease o f the C allele relative to the T allele) (see Graph 6.5).
Graph 6.4: Apol 4 Allelic Expression, rs!32700.
Corrected genomic and cDNA ratios for rs 132700. Comparison between the observed 
corrected genomic ratios and the corrected cDNA ratios assayed for APOL 4 (n=24). 
Data are expressed as the mean of the ratio o f T:C for three measurements for each 
genomic DNA sample and six measurements o f each cDNA sample.
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Graph 6.5: Apol 4 Allelic Expression, Log scale of rs!32700 assay.
The graph shows the corrected genomic and cDNA ratios for rs 132700 plotted on a 
log scale graph. Comparison between the observed corrected genomic ratios and the 
corrected cDNA ratios assayed for APOL 4 (n=24). Data are expressed as the mean o f 
the ratio o f T:C for three measurements for each genomic DNA sample and six 
measurements of each cDNA sample. The three individuals showing evidence of 
mono-allelic expression are indicated at the top and bottom of the cDNA ratio scale.
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APOL 5:
The C>T polymorphism rs2076672 was selected for analysis. O f the 60 
subjects, 16 were heterozygous. The 16 heterozygotes yields a power of 
approximately 80% to detect the effect o f a regulatory variant present at a frequency 
o f 0.05, and a power o f 96% to detect a variant at a frequency o f 0.1. O f the 16 
heterozygous individuals, twelve showed a relative expression difference o f > 20% 
compared to the corresponding average genomic ratios (see Graph 6.6). The data 
points from each individual cDNA sample showed poor reproducibility, with an 
average SD o f the mean o f 0.57. The cDNA ratio departed from the genomic 1:1 ratio 
in both directions with the relative expression differences ranging from a 72%
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increase o f the C allele relative to the T allele, to a 108% decrease o f the C allele 
relative to the T allele.
Graph 6.6: Apol 5 Allelic Expression, rs2076672.
Corrected genomic and cDNA ratios for rs2076672. Comparison between the 
observed corrected genomic ratios and the corrected cDNA ratios assayed for APOL 5 
(n=16). Data are expressed as the mean o f the ratio o f T:C for three measurements of 
each genomic DNA sample and six measurements o f each cDNA sample.
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6.3.1.1 C orrelation  of allelic expression assay results:
Given the evidence for ds-acting sequence variants affecting the expression o f 
all five APO L genes, I analysed the data to see if  the observed relative allelic 
expression differences were correlated between assays, indicating a polymorphism in 
a master control region. To achieve this I analysed samples which were heterozygous 
for pairs o f assays and tested these for a correlation in the relative expression 
differences observed. As the phase o f the markers was unable to be established the 
allelic expression differences would not be expected in one direction. Therefore the
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analyses were performed after converting all of the relative expression differences to 
be positive. This revealed no evidence of a correlation between the relative expression 
differences observed for any combination of two assays (table 6.6). Interestingly there 
was no correlation detected between the relative expression for any of the genes 
transcribed in the same direction (for example, see graph 6.7). There was also no 
evidence revealed of any samples displaying deviation/non-deviation in allelic 
expression across all five assays.
Table 6.6 Correlation analysis of APO L allelic expression results.
The table shows the correlation between pairs of APO L assays. The table shows, the 
number of samples heterozygous in both assays, the number of heterozygotes 
displaying altered allelic expression in both assays and the corresponding Pearsons 
correlation coefficient and p-value between the two assays.
Allelic
Expression
Assay
APOL 2 APOL 3 APOL 4 APOL 5
APOL 1
4 samples Het for 
both assays.
1/4 display AE diff 
in both assays. 
corr= 0.19, p= 0.81
4 samples Het for 
both assays.
0/4 display AE diff 
in both assays. 
corr= 0.50, p=0.49
3 samples Het for 
both assays.
1/3 display AE diff 
in both assays. 
corr= 0.51, p= 0.66
3 samples Het for 
both assays.
1/3 display AE diff 
in both assays. 
corr= 0.91, p= 0.27
APOL 2
7 samples Het for 
both assays.
0/7 display AE diff 
in both assays. 
corr= 0.33, p= 0.47
9 samples Het for 
both assays.
1/9 display AE diff 
in both assays. 
corr= 0.11, p= 0.78
4 samples Het for 
both assays.
0/4 display AE diff 
in both assays. 
corr= 0.88, p= 0.12
APOL 3
8 samples Het for 
both assays.
0/8 display AE diff 
in both assays. 
corr= 0.19, p= 0.66
5 samples Het for 
both assays.
0/5 display AE diff 
in both assays. 
corr= 0.25, p= 0.69
APOL 4
9 samples Het for 
both assays.
7/9 display AE diff 
in both assays. 
corr= 0.21, p= 0.59
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Graph 6.7. APO L 2 and 4 Correlation analysis.
Graph displaying the lack o f correlation between the relative allelic expression 
differences observed for APO L genes transcribed in the same direction. Corrected 
cDNA ratios are plotted for samples heterozygous in both the APO L 2 and APO L 4 
allelic expression assays, displaying no evidence o f a correlation between assays.
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6.3.2 Ind irect genetic analysis of the A PO L gene family:
Given the results o f the allelic expression assays indicating the presence o f e x ­
acting sequence variants causing altered allelic expression in the APO L genes, I 
decided to study the gene family further by screening the genes to look for evidence 
o f association with schizophrenia. This was achieved by designing a grid o f marker 
SNPs approximately 5kb apart spanning each o f the genes (see figure 6.2) and then 
typing these SNPs in the pooled association sample to test for association with 
schizophrenia. All o f the grids were designed to include the marker SNP used in the 
allelic expression assays. As well as typing all o f the SNPs in the pooled association 
sample the SNPs were additionally typed in 96 unrelated control samples in order to
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calculate D’ and r2 values and the LD structure of all of the markers typed across the 
APO L genomic region (see figure 6.2).
APOL 1;
Six SNPs were typed in the pooled association sample across APO L 1. The 
estimated allele frequencies, allele numbers and corresponding p-values for each of 
the assayed SNPs are shown in table 6.7 below. None of the typed SNPs showed a 
significant difference between the observed case and control allele frequencies.
Table 6.7: Pooled genotvping data for APOL 1.
This table shows the estimated allele frequencies and counts for the APOL 1 
polymorphisms and the corresponding p-values.
Apol 1 SNP Data Pooled Genotyping data
SNP number. Alleles Cases (freq)
Alleles Controls 
(freq) Difference
Chi-
square P-value
rs2227089 
rs136150 
rs136154 
rs713753 
rs2239785 
rs2012928
A= 678 (0.61) 
T= 426 (0.38) 
T= 259 (0.23) 
A= 845 (0.77) 
A= 312 (0.23) 
T= 1070 (0.77) 
C= 451 (0.41) 
T= 653 (0.59) 
G= 212 (0.2) 
A= 892 (0.8) 
G= 877 (0.79) 
A= 227 (0.21)
A= 677 (0.61) 
T= 427 (0.38) 
T= 237 (0.22) 
A= 867 (0.78) 
A= 305 (0.21) 
T= 1129 (0.79) 
C= 422 (0.38) 
T= 682 (0.62) 
G= 191 (0.17) 
A= 913 (0.83) 
G= 881(0.8) 
A= 223 (0.2)
0
0.01
0.02
0.03
0.03
0.01
0.002
1.26
0.71
1.59
1.34
0.05
0.97
0.67
0.41
0.21
0.25
0.83
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APOL 2:
Seven SNPs were typed in the pooled association sample across APOL 2. The 
estimated allele frequencies and allele numbers for each of the assayed SNPs is shown 
in table 6.8 below. None of the SNPs showed a significant difference between the 
observed case and control allele frequencies.
Table 6.8: Pooled genotvping data for APOL 2.
This table shows the estimated allele frequencies and counts for the APOL 2 
polymorphisms and the corresponding p-values.
Apol 2 SNP Data Pooled Genotyping data
SNP number. Alleles Cases (freq)
Alleles Controls 
(freq) Difference
Chi-
square P-value
rs1974458 A= 819 (0.74) G= 285 (0.26)
A= 800 (0.72) 
G= 304 (0.28) 0.02 0.84 0.36
rs1557533 A= 613 (0.56) G= 491 (0.44)
A= 603 (0.55) 
G= 501 (0.45) 0.01 0.18 0.67
rs2157249 C= 404 (0.37) T= 700 (0.63)
C= 413 (0.37) 
T= 691 (0.63) 0 0.16 0.69
rs2003813 C= 711 (0.64) T= 393 (0.36)
C= 696 (0.63) 
T= 408 (0.37) 0.01 0.456 0.52
rs5995263 A= 508 (0.46) T= 596 (0.54)
A= 510(0.46) 
T= 594 (0.54) 0 0.007 0.93
rs2017689 G= 821 (0.74) A= 283 (0.26)
G= 806 (0.73) 
A= 298 (0.27) 0.01 0.53 0.47
rs2016988 C= 1016 (0.92) G= 88 (0.08)
C= 1020 (0.92) 
G= 84 (0.08) 0 0.10 0.75
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APOL 3:
Ten SNPs were typed in the pooled association sample across APOL 3. The 
estimated allele frequencies and allele numbers for each of the assayed SNPs is shown 
in table 6.9 below. None of the typed SNPs showed a significant difference between 
the observed case and control allele frequencies.
Table 6.9: Pooled genotyping data for APOL 3.
This table shows the estimated allele frequencies and counts for the APOL 3 
polymorphisms and the corresponding p-values.
Apol 3 SNP Data Pooled Genotyping data
SNP number. Alleles Cases (freq)
Alleles Controls 
(freq) Difference
Chi-
square P-value
rs132673 G= 647 (0.59) A= 457 (0.41)
G= 635 (0.58) 
A= 469 (0.42) 0.01 0.27 0.61
rs132661 A= 665 (0.6) G= 439 (0.4)
A= 688 (0.62) 
G= 416 (0.38) 0.02 1.01 0.32
rs132656 T= 579 (0.52) C= 525 (0.48)
T= 573 (0.52) 
C= 531 (0.48) 0 0.07 0.79
rs2097465 C= 943 (0.68) T= 439 (0.32
C= 946 (0.66) 
T= 488 (0.34) 0.02 1.64 0.20
rs2017329 A= 579 (0.52) T= 525 (0.48)
A= 606 (0.55) 
T= 498 (0.45) 0.03 1.33 0.25
rs132644 C= 883 (0.8) T= 221 (0.2)
C= 888 (0.8) 
T= 216 (0.2) 0 0.07 0.79
rs132635 C= 748 (0.68) T= 356 (0.32)
C= 766 (0.69) 
T= 338 (0.31) 0.01 0.68 0.41
rs80578 C= 665 (0.6) T= 439 (0.4)
C= 668 (0.6) 
T= 436 (0.4) 0 0.02 0.89
rs132618 T= 608 (0.55) A= 496 (0.45)
T= 621 (0.56) 
A= 483 (0.44) 0.01 0.31 0.58
rs132617 C= 707 (0.64) T= 397 (0.36)
C= 728 (0.66) 
T= 376 (0.34) 0.02 0.88 0.35
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APOL 4:
Twelve SNPs were typed in the pooled association sample across APOL 4. 
The estimated allele frequencies and allele numbers for each of the assayed SNPs is 
shown in table 6.10 below. None of the typed SNPs showed a significant difference 
between the observed case and control allele frequencies.
Table 6.10: Pooled genotyping data for APOL 4.
This table shows the estimated allele frequencies and counts for the APOL 4 
polymorphisms and the corresponding p-values.
Apol 4 SNP Data Pooled Genotyping data
SNP number. Alleles Cases (freq)
Alleles Controls 
(freq) Difference
Chi-
square P-value
rs132743
ii 
n
0 
o 973 (0.88) 131 (0.12) O 
O 
ii 
ii 972 (0.88) 
132 (0.12) 0 0.004 0.95
rs2005590
■I 
ii
O 
I- 778 (0.7) 326 (0.3)
C=
T=
771 (0.7) 
333 (0.3) 0 0.11 0.75
rs1812023 G=A=
886 (0.64) 
496 (0.36)
G=
A=
926 (0.65) 
508 (0.35) 0.01 0.07 0.74
rs132734 G=A=
860 (0.62) 
522 (0.38)
G=
A=
899 (0.63) 
535 (0.37) 0.01 0.06 0.8
rs6000179 A=C=
977 (0.89) 
127 (0.11)
A=
C=
966 (0.87) 
138 (0.13) 0.02 0.52 0.47
rs2007468 A=G=
558 (0.51) 
546 (0.49)
A=
G=
558 (0.51) 
546 (0.49) 0 0 1
rs132700 T=C=
793 (0.72) 
311 (0.28)
T=
C=
790 (0.28) 
314 (0.28) 0 0.02 0.89
rs2227167 A=G=
577 (0.52) 
527 (0.48)
A=
G=
574 (0.52) 
530 (0.48) 0 0.02 0.89
rs916336 C=G=
561 (0.51) 
543 (0.49)
C=
G=
560 (0.51) 
544 (0.49) 0 0.002 0.97
rs1966267 A=G=
564(0.51) 
540 (0.49)
A=
G=
569 (0.51) 
535 (0.49) 0 0.05 0.83
rs132691 C=G=
797 (0.72) 
307 (0.28)
C=
G=
792 (0.72) 
312 (0.28) 0 0.06 0.81
rs132683 A=G=
806 (0.73) 
298 (0.27)
A=
G=
809 (0.73) 
295 (0.27) 0 0.02 0.89
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APOL 5;
Eight SNPs were typed in the pooled association sample across APOL 5. The 
estimated allele frequencies and allele numbers for each of the assayed SNPs is shown 
in table 6.11 below. None of the typed SNPs showed a significant difference between 
the observed case and control allele frequencies.
Table 6.11: Pooled genotyping data for APOL 5.
This table shows the estimated allele frequencies and counts for the APOL 1 
polymorphisms and the corresponding p-values.
Apol 5 SNP Data Pooled Genotyping data
SNP number. Alleles Cases (freq)
Alleles Controls 
(freq) Difference
Chi-
square P-value
rs1540297 T=C=
679
425
(0.61)
(0.39)
T= 667 (0.6) 
C= 437 (0.4) 0.01 0.27 0.60
rs5999971 T=C=
748
356
(0.68)
(0.32)
T= 736 (0.67) 
C= 368 (0.33) 0.01 0.29 0.59
rs2009168 A=G=
752
352
(0.68)
(0.32)
A= 729 (0.66) 
G= 375 (0.34) 0.02 1.09 0.29
rs2076671 C=T=
888
494
(0.64)
(0.36)
C= 952 (0.66) 
T= 482 (0.34) 0.02 1.41 0.23
rs2076672 C=T=
801
303
(0.73)
(0.27)
C= 788 (0.71) 
T= 316(0.29) 0.02 0.38 0.54
rs2016586 G=T=
787
317
(0.71)
(0.29)
G= 760 (0.69) 
T= 344 (0.31) 0.02 1.57 0.21
rs5995165 A=G=
793
311
(0.72)
(0.28)
A= 792 (0.72) 
G= 312(0.28) 0 0.002 0.96
rs879680 C=T=
794
310
(0.72)
(0.28)
C= 768 (0.7) 
T= 336 (0.3) 0.02 1.48 0.22
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6.3.2.1 LD analysis of the APOL genomic region.
Following genotyping of all APO L markers in the 96 unrelated control 
samples the LD structure across the APO L genomic region was calculated using the 
program Haploview (http://www.broad.mit.edu/mpg/haploview/). The resultant 
Haploview LD plot is presented below (figure 6.2). The Haploview program defines 
blocks of LD using the method developed by Gabriel and colleagues (Gabriel, 
Schaffner et al. 2002).
The analysis revealed strong LD across APO L 2 and APO L 5, with a block 
of LD present in APO L 2 between markers rs2017689 and rs 1557533 and a block of 
LD in APO L 5 between markers rs5999971 and rs2016586. There was also revealed 
to be strong LD present across most of APO L 1 and modest levels of LD present 
across APO L 3 and APO L 4 (figure 6.2). The strong LD might explain why although 
43 SNPs were tested for association, none were significant, when 2 SNPs would have 
been expected to show significance by chance at the p=0.05 level. The LD may have 
reduced the number of effective SNPs being tested for association, as markers in LD 
are not independent from each other.
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6.4 Discussion;
In this chapter I have studied five of the APO L gene family members as 
potential susceptibility genes for schizophrenia. The genes were selected for study 
primarily because of the results of a previous micro-array study which reported 
altered expression of APO L genes in schizophrenia (Mimmack, Ryan et al. 2002). It 
is worth noting that the reported altered expression of APO L genes in schizophrenia 
has not been replicated in any subsequent micro-array studies. The failure of micro­
array results to replicate might be attributable to many possible confounding factors 
including methodological artefacts such as: variability in the micro-array platform 
used, differences in the specific gene probes on the array, RNA sample preparation, 
and the specific experimental conditions used to perform the assay (Katsel, Davis et 
al. 2005c). In a recent study (Hollingshead, Lewis et al. 2005) it has been reported 
that different micro-arrays may produce different results even when the same samples 
are compared across platforms. Additionally differences in the specific samples used 
to perform the experiments may impact upon the results of replication assays. For 
example differences in the agonal state, post-mortem interval, storage conditions, pH, 
age, gender and medication usage of samples may all impact upon the results of the 
expression assay (Katsel, Davis et al. 2005c).
Given the reported altered expression it was decided to initially study the 
genes by looking for evidence of altered expression caused by cis-acting sequence 
variants. I did not assay APO L 6 as there was no suitable marker available in the 
public databases at the time of study. This is still the case with the only current 
validated database markers contained within exonic sequence having a minor allele 
frequency of < 0.03, which is relatively uninformative for use in the assay.
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Of the five genes that were assayed all displayed evidence of altered allelic 
expression caused by cis-acting sequence variation. There are two general 
explanations for allelic expression differences: a) DNA sequence variant(s) in a 
region of the genomic sequence that affects the transcription, splicing or stability of 
the genes mRNA transcript, or b) Epigenetic effects (e.g Methylation etc) which result 
in the preferential transcription of one parental chromosome. The results of the 
expression assays were slightly surprising in that all five of the assayed genes 
displayed evidence of altered allelic expression. It has been previously reported that 
on average about 50% of genes display altered allelic expression attributable to 
common cis-acting variation (Bray, Buckland et al. 2003a; Pastinen, Sladek et al. 
2004). It is therefore unusual that all five of the studied APO L genes show evidence 
of differential allelic expression. Moreover the significant differences in allelic 
expression were seen in a large proportion of the samples assayed for each of the 
genes, along with variations in the magnitude of observed expression differences.
These observations might be explained by the fact that all five of the genes are 
located together on chromosome 22, where it is possible that they are all controlled by 
a common master regulatory element, which contains a c m - acting sequence variant 
responsible for the observed allelic expression differences. However, the genes are 
transcribed in different directions (figure 6.1) and it is unlikely that they are all under 
the control of a single promoter. Furthermore the extent of the altered expression 
differs both within and between the assays, ranging from the fairly minor differences 
observed for APO L 3 to what appears to be almost mono-allelic expression in some 
of the samples in the APO L 4 assay. Finally analysis of the data revealed no evidence 
of correlation between the levels of altered expression observed for the same 
individuals across the different assays (table 6.6). For instance the three individuals
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that exhibit almost mono-allelic expression in the APO L 4 assay do not display 
mono-allelic or highly altered expression in any of the other assays. Additionally, 
analysis of the expression data for the genes which are transcribed in the same 
direction (APO L 1 and 5) and (APO L 2, 3, and 4) revealed no evidence of a 
significant correlation between either the samples displaying altered expression or the 
extent of the expression differences observed in the assays (table 6.6). When taken 
together this would tend to suggest that the expression differences observed are not 
due to a common variant affecting the expression of all five genes.
The APO L 3 gene was the only assay not to show large expression 
differences. This is not explained by a relative lack of power compared to the analysis 
of the other genes, as 20 heterozygous samples were assayed compared with 11 
heterozygotes in the case of the APO L 1 assay. The subset of 20 heterozygotes 
assayed provides a power of approximately 86% to detect the affect of a regulatory 
variant present in the general population at a frequency of 0.05. The lack of large 
expression differences can also not be explained by the specific samples used to assay 
APO L 3 as several of the samples displayed large expression differences in other 
assays including one individual which displays almost mono-allelic expression for 
APOL 4.
Possibly the most interesting result from all of the assays apart from the 
existence of altered allelic expression in all of the genes is the apparent mono-allelic 
expression of three individuals in APO L 4. The individuals displayed allelic ratios of 
>1:10, which would represent a >1000% difference in the relative allelic expression. 
These results possibly suggest a cis-acting variant with a substantial effect upon the 
gene expression, or epigenetic effects such as methylation, imprinting, or histone 
acetylation etc. It has been proposed that polymorphic imprinting of certain genes
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may play a role in common mental disorders such as schizophrenia, attention deficit 
hyper-activity disorder (ADHD) and bipolar disorder given the evidence suggesting 
the disorders are inherited preferentially from one parent and/or the related 
linkage/association findings that are parent of origin dependant (Isles and Wilkinson 
2000; Davies, Isles et al. 2005; Morison, Ramsay et al. 2005). It is however worth 
noting that only about 1% of genes have been estimated to be subject to epigenetic 
modification (Sleutels, Barlow et al. 2000; Davies, Isles et al. 2005). A high 
proportion of the imprinted genes that have been discovered are highly expressed in 
the CNS, and it is thought that they might play a role in growth and development 
processes. It has also been proposed that the neurodevelopmental process may provide 
a mechanism for imprinted genes in the CNS to influence brain function (Davies, Isles 
et al. 2005).
The allelic expression assay can only measure the effects of cw-acting 
phenomena but is unable to identify either the specific functional variant or its 
genomic location. Unfortunately, in the absence of a specific causal or functional 
variant it is not possible to determine definitively whether the observed expression 
differences are the results of cis-acting sequence variants or are caused by epigenetic 
effects.
Given the evidence compatible with cis-acting effects from the allelic 
expression assays I decided to study the APO L genes genetically using an indirect 
association study design. As I had not been able to assay the allelic expression of 
APO L 6 I decided to also not screen the gene for association with schizophrenia. A 
total of forty three polymorphisms were genotyped through the pooled case-control 
association sample, spanning a total of seventy four kilobases of genomic sequence.
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None of the polymorphisms genotyped in the pools displayed any evidence of 
association with schizophrenia. These results are consistent with the findings of a 
recent study (McGhee, Morris et al. 2005) who also reported no evidence for 
association between schizophrenia and the APO L gene family. In their study they 
genotyped 51 polymorphic markers across all six of the APOL genes in a large Irish 
case-control pooled sample. Although no evidence for association was detected in my 
study or the previous study (McGhee, Morris et al. 2005) it is possible that genetic 
variants associated with schizophrenia and/or that affect the genes expression are 
located either proximal or distal to the gene, and were therefore undetected in this 
study. It is also possible that the variants might have effect sizes prohibitively small to 
allow them to have been detected with the power of this study.
One of the major drawbacks of using a pooled genotyping strategy is the 
inability to be able to perform haplotype analysis. These analyses could potentially 
increase the power of the study to detect any associated variants or haplotypes that are 
present. However, the high density of markers and the relatively high levels of LD in 
this study would suggest that any associated variants or haplotypes have a high 
chance of detection.
An alternative method to the one employed in this project would have been to 
use Tag markers selected from the HapMap. These markers are selected using 
bioinformatics programs in order to ‘tag’ the genetic information contained within a 
gene. These tags can be selected using different criteria, for example extracting the 
information from untyped markers on the basis of pairwise r2 or 2-3 marker 
haplotypes. If this technique had been applied to study APO L 1-5 based on the 
HapMap (version 2.0) using a pairwise r2 tagging method based on the parameters 
(r2=0.8, MAF=0.1) a total of 54 tags markers would need to be genotyped in order to
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capture all of the information in the APO L genes currently contained within the 
HapMap. Only seventeen of the 54 recommended tags or proxies for these markers 
have actually been typed in this study. Only two of the eight markers required to 
screen APO L 1 were typed, three of thirteen for APO L 2, four out of sixteen for 
APO L 3, and four out of thirteen for APO L 4. In the case of APO L 5 all of the tag 
markers have been genotyped.
In conclusion this study has shown strong evidence of altered allelic 
expression attributable to czs-acting sequence variation or epigenetics in five of the six 
members of the APO L gene family. However, it was not possible in this study to 
relate this altered expression directly to schizophrenia. When tested none of the 
APOL genes displayed evidence for genetic association to schizophrenia. Thus my 
study does not explain the results of the previous study which reported altered 
expression of the APO L gene family in schizophrenia (Mimmack, Ryan et al. 2002). 
This may be because for the reason of power, marker density or measurement error in 
pools, I failed to detect true effects. Alternatively, it is possible that the altered 
expression observed in that study was not directly related to the aetiology of 
schizophrenia but was attributable to artefact or secondary effects caused by 
environmental or trans-acting factors affecting the genes expression, such as diet, the 
effects of medication, or the alteration of transcription factor efficiency.
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Chapter 7. Final Discussion.
Schizophrenia is a severe psychiatric disorder with onset in adolescence or 
early adulthood, characterised by a diverse range of symptoms that have an impact on 
many areas of mental function. Although its aetiology is not well understood, it is 
widely accepted that the disorder has a significant genetic component. The mode of 
transmission is most likely complex involving a number of genetic loci with a 
variable but mostly small effect on susceptibility for the disorder. However, studies 
have shown that the risk of schizophrenia can not be explained exclusively by genetic 
factors, but also has a significant environmental component. It seems most likely that 
the disorder is ultimately caused by the co-action of multiple genetic factors together 
with interaction with various environmental factors. Thus the challenge facing the 
field of schizophrenia research is not only to detect susceptibility genes but also to 
determine how these genes interact with each other and the environment to result in 
disease susceptibility.
Numerous hypotheses have so far been formulated to explain the biological 
origins of the disorder, but schizophrenia has increasingly been viewed as a 
neurodevelopmental disorder, caused by abnormalities occurring in the brain during 
development and before the onset of schizophrenic symptoms.
Recently, and compatible with a developmental hypothesis, it has been 
proposed that oligodendrocyte and/or myelination abnormalities play a role in the 
aetiology of schizophrenia. Support for this has been provided by the results of 
several areas of research including neuropathological studies, brain imaging analysis,
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phenotypic overlap with demyelinating diseases, age related changes in myelin and 
from the results of the micro-array expression studies performed on post-mortem 
schizophrenic brain which have displayed altered expression of OMR genes in 
schizophrenia.
7.1 Mv Research.
The series of investigations described in this thesis were principally candidate 
gene studies of schizophrenia. A specific hypothesis was investigated, which 
proposed that variation in genes related to oligodendrocyte and/or myelination 
function play a role in the aetiology of schizophrenia. Genes were selected as 
candidates for study on the basis of their documented altered expression in 
schizophrenic post-mortem brain supported in many cases by their location in regions 
of the genome reported to be linked to schizophrenia.
In total I studied thirteen genes as candidates for involvement in 
schizophrenia: CNP, NOGO, NgR, OMG, NGFR, GFAP, MOG, SOX 10 and APOL 
1-5. A prior requirement for candidate gene studies is the availability of 
polymorphisms to test for association to disease. For all of the research presented in 
this thesis, except for the study of the APOL gene family, polymorphisms were 
identified through mutation detection using denaturing high performance liquid 
chromatography (DHPLC). During the investigations 147 polymorphisms were 
identified: 137 SNPs, 5 insertion/deletions, 2 VNTRs, 2 variable length poly T 
sequences and 1 variable length poly A sequence. Of the polymorphisms, 55 were 
exonic SNPs of which 10 were synonymous and 7 were non-synonymous SNPs.
291
It is notable that of the identified polymorphisms, 121 are now independently 
described in the public databases, reflecting the huge increase in the genetic 
information which has become available over the past five years. Given these 
resources now available to researchers it is becoming increasingly more appropriate to 
select SNPs from a database rather than to use extensive mutation screening to detect 
them experimentally, except perhaps in the case of the examination of rare 
susceptibility variants. Indeed it might be argued that the examination o f grids of 
markers based upon the known LD structure is more likely to detect association from 
non-coding variants than the approach utilised in the investigations presented here of 
screening all of the variation in the exonic and limited 5’-flanking sequence.
I attempted to genotype all the polymorphisms identified in these studies that 
were compatible with a primer extension assay in DNA pools. Pooled genotyping was 
attempted for 142 polymorphisms, of which, 7 had a minor allele frequency too rare 
to be genotyped in pools, resulting in pooled genotyping data for 135 polymorphisms. 
As no attempt was made to genotype by an alternative method polymorphisms that 
were either too rare or incompatible with primer extension, direct associations due to 
these variants may have gone undetected, unless being detected through LD with 
another typed marker. This potential problem might have been rectified by selecting 
additional markers from the public databases rather than relying on variants identified 
by DHPLC, although it should be noted that if the risk variant is rare, and only 
common markers are tested for association, then the difference in allele frequencies at 
the risk and marker loci will significantly reduce the power to detect association, even 
if the two markers are in complete LD (as measured by D’).
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During the series of studies presented here I detected modest evidence for 
association with three genes (CNP, NOGO and MOG) and also showed that the 
expression of these genes is under the influence of czs-acting polymorphisms. The 
genes are good candidates for study as they are differentially expressed in post­
mortem schizophrenic brain, located in reported schizophrenia linkage regions and 
functionally involved with the development of the CNS.
CNP had not been previously reported to be associated with schizophrenia and 
whilst the result is supported by both the allelic expression assay and the observations 
in a multiply affected family showing linkage to the region, the finding certainly 
requires independent replication in large suitably powered association samples. 
Several studies have previously reported NOGO to be associated with schizophrenia, 
although there have also been several negative studies published. It should also be 
noted that there are inconsistencies with the alleles and allele frequencies of the 
reported associations. These differences and the negative studies are possibly caused 
by different LD structures or alleles being responsible for association in different 
populations. The results of my association and allelic expression analysis of MOG, 
along with the findings of previous association studies are not compelling and provide 
weak evidence for the involvement of MOG in schizophrenia aetiology. However, 
further examination of the associated non-synonymous SNP is probably warranted to 
independently replicate the results. Whilst, the results for the three genes are modest, 
would not survive correction for the total number of tests performed and are awaiting 
further replication, they do provide some support for the general hypothesis that 
oligodendrocyte and/or myelination abnormalities play a role in schizophrenia 
aetiology.
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There was no evidence for association detected with the other ten genes 
studied as part of this thesis. However for the reasons I discussed earlier in chapter 4,
I cannot exclude any of these genes from playing a role in the aetiology of 
schizophrenia. To be able to do this, at a minimum requires genotyping of all the non- 
redundant variation contained within the gene in a sufficiently powerful association 
sample representative of the general population. The problems associated with 
excluding a gene from disease aetiology are not easily remedied since there is always 
an effect size that the largest available sample is unable to detect.
Since this series of investigations was undertaken, the field of molecular 
genetics has moved on at an impressive speed, meaning that many of the techniques 
utilised in these studies are no longer relevant or appropriate for use. For instance the 
use of DHPLC mutation detection has now become a very expensive and slow 
process and given the wealth of available genetic information almost obsolete. Even 
where mutation detection is still required, such as for the identification of rare 
sequence variants, new technology has been developed making the screening of 
hundreds even thousands of samples feasible (Li, Atmaca-Sonmez et al. 2006; Mailer, 
George et al. 2006). The recent advances in the bioinformatic resources available to 
molecular biologists such as the HapMap combined with tag SNP selection programs 
and higher throughput genotyping platforms have also changed the way that candidate 
gene studies are designed. Increasingly, genes and large regions of the genome are 
being examined for association in at least moderate depth using indirect methods 
relying upon linkage disequilibrium.
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Given the progress that has being made in molecular genetics, it is 
encouraging that recently molecular genetic studies of schizophrenia have started to 
produce evidence implicating several genes in the aetiology of the disorder (described 
in chapter 1). However, the majority of the genetic risk for schizophrenia still remains 
to be accounted for. In order to increase the chance of detecting the remaining 
susceptibility genes, strategies that increase the statistical power to detect small 
effects need to be employed, along with the use of other complementary solutions 
such as refined phenotype analysis to reduce heterogeneity. The power to detect novel 
loci by investigating gene-gene and gene-environment interactions while promoted by 
some, with apparent success (Caspi, Sugden et al. 2003; Thapar, Langley et al. 2005), 
remains controversial (Wang, Barratt et al. 2005; Todd 2006). However, at a 
minimum such studies based on known genetic risk factors may make significant 
contributions to our knowledge of pathogenesis. Such studies, based in part on the 
work described in this thesis, have recently provided further evidence for the 
involvement of CNP and other OMR genes in schizophrenia susceptibility 
(Georgieva, Moskvina et al. 2006) and further support the hypothesis that 
oligodendrocyte and/or myelination abnormalities play a role in the aetiology of 
schizophrenia.
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